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Executive Summary 
In an ageing Europe, where more and more citizens live with chronic diseases, telemedicine can help 
to make the difference in facing the global challenge posed to health systems by an increasingly 
heavy burden of demand for service. The European Commission realises this potential and intends to 
exercise leadership in fostering the deployment of telemedicine applications on a large scale. Acting 
in the structured framework of several policy initiatives started in 2004 with the eHealth Action Plan 
(COM 356), the Commission addressed in its Communication on Telemedicine (2008, COM 689) 
the main barriers that need to be overcome in order to facilitate greater deployment, highlighting 
three key issues: (1) increasing confidence and acceptance of telemedicine services; (2) gaining legal 
clarity; (3) overcoming unsolved technical issues and supporting market development.  
This report has been prepared within the study "Strategic Intelligence Monitor on Personal Health 
Systems" (SIMPHS) conducted by DG JRC IPTS for DG INFSO as a one of the actions devised to 
address the above issues no. (1) and (3). Focusing on Personal Health Systems (PHS)1 and, more 
specifically on Remote Patient Monitoring and Treatment (RMT),2 this report explores the current 
status of the RMT market in Europe and addresses the question of how RMT can help face some of 
the challenges standing in front of the European healthcare delivery systems. By analysing the 
reasons of the limited deployment and identified barriers, the reports provides ample evidence on the 
encouraging outcomes of early RMT deployment, while analysing the impact of the outcomes and 
briefly modelling the potential from EU-wide deployment. 
The rational of the study is based upon the following considerations: 
 Fostering a functional, reliable and affordable Health Care system in general and the 
management of chronic disease in particular has been the key goal of European policies at 
national and EU level, over a number of years. Health care expenditure as a percentage of GDP 
has seriously risen from 4.7% in 1970 to about 9% in 2007 in 19 EU countries.3 In addition, 
demographics have driven this trend: an aging European population which has doubled the 
percentage of the population over 65 between 1960 and 2008. Moreover, the ratio between 
economically inactive elderly and an active person is projected to fall from the current 1:4 to 1:2 
in 2050 and beyond, which means that one inactive elderly will eventually be supported by 2 
active people from year 2050 onwards. The resulting impact of this situation is two-fold: 
escalating care cost on the one hand, and shortages in health care delivery caused by the scarcity 
of professionals and informal carers derived from the increased demand, on the other. An 
increasing shortage of qualified health care personal is expected by 2020, both in physicians and 
nurses. This coincides with reduced potential informal carers due to increasing predominance of 
nuclear families, workforce feminisation, and workforce mobility. 
 Chronic diseases have become widespread across all age groups causing a large part of the 
disease burden in Europe and posing a major challenge for health care systems financing and 
sustainability in Member States.4 As an example, Cardio Vascular Diseases (CVD) on their own 
                                            
1  PHS – See the definition given in Table 1 at page 14. 
2  RMT – See the definition given in Table 2 at page 14. 
3  OECD 2009 Health Data. This set of data did not include: Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, and 
Slovenia. These 8 countries amount to less than 9% of the total EU27 population. 
4  Type II diabetes affects about 6.6% of the general population and is estimated at costing €29bln per year (Jönsson and B. Jönsson 
(2002). "Revealing the cost of Type II diabetes in Europe." Diabetologia 45(7): S5-S12) while CVD incure a direct cost of €109 
bln and indirect costs of approximately 83 bln in terms of direct lost productivity and that of informal care (see footnote 26) 
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carry a high responsibility for mortality causing more than half of all deaths across Europe,5 and 
heart disease or stroke represent the leading cause of death across Europe. In terms of resources 
for instance, in Denmark, it is estimated that 70–80% of health care expenses are allocated to chronic 
conditions and in the United Kingdom, 8 of the top 11 causes of hospital admissions are chronic 
conditions such as diabetes, pulmonary conditions and cardiovascular diseases. These prominent 
chronic conditions are the focal point for applications for Remote Patient Monitoring and 
Treatment (RMT) and Personal Health Systems (PHS). RMT systems contribute to confronting 
these challenges in several ways: (a) they improve health care outcomes and simultaneously help 
control costs; (b) more importantly, they can help extend the reach of the limited –and eventually 
shrinking– pool of health care professionals; and (c) they are believed to ignite entrepreneurial 
activities and innovation, which lead to consider this combination of ICT industry and health care 
services as an engine for job creation and European competitiveness.  
 There is increasing evidence that such services based on RMT/PHS reduce death rates, and avoid 
recurring hospitalisation in a cost-effective manner. However, proving beyond doubt their 
medical effectiveness, safety and reliability is of utmost importance for life critical systems; far 
more than in other realms of ICT applications. As a result of the need for further evidence, 
necessary investments are delayed and in general resistance against the use of the technology is 
reinforced. A vicious cycle is thus created leading to local champions required to provide further 
evidence, mainstream players not deciding to enter the market, limited market uptake and costs 
that remain unaffordable. The market itself is fragmented and atomised with the dominance of 
local initiatives and pilot projects that, with few exceptions, are not sustainable. In short, despite 
the positive potential for RMT and PHS a stalemate is produced. 
 A number of barriers have been identified which still hamper full deployment of RMT in Europe. 
Market players, mainly companies providing the technology, are mentioning constraints to 
market scale, the lack of reimbursement, unclear Return on Investment and business model 
choices, fragmentation of purchasers and the difficulties in obtaining approval and certification 
from health care organisations. Moreover, health care professionals are confronted with an 
unfavourable structure of incentives for introducing RMT, due to conflicting responsibilities for 
RMT within health care organisations. This is mirrored by ambiguities in different 
reimbursement schemes, in particular the allocation between those for primary, secondary, and 
social care. In addition, the lack of widespread awareness on the positive outcomes which are 
shown by many studies and meta-reviews, is considered a major bottleneck. Furthermore, the 
lack of strategic leadership for structural change hampers the natural uptake and diffusion of 
these technologies. 
This report fully analyses the above considerations and provides a number of tentative policy options 
specifically aimed at fostering the take up of RMT, for the consideration of all stakeholders 
concerned: 
• Riding the wave of policy consensus, on both sides of the Atlantic, provide governance in 
eHealth in general and "Telemedicine and Home Care" in particular as was expressed by the 
ministerial conference in Barcelona (March 2010);  
• Provide increased and sustained awareness-raising and dissemination activities, especially 
focussing on spreading the knowledge about local champions, about the increasing positive 
evidence of RMT with respect to clinical and cost-effectiveness outcomes, as well as through 
                                            
5  The data of the WHO comprises of more countries than the EU27, yet the tendency remains the same.  
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methodologically robust modelling and simulation of the potential benefits under different 
take-up scenarios; 
• Provide further financial support for studies and research aimed at further reinforcing the 
evidence on outcomes and at moving towards increasingly standardised and accepted 
evaluation methodologies; 
• Design innovative mechanisms to support networking and the emergence of hubs among 
RMT champions and innovators (i.e. creation of centres of excellence for chronic disease 
management); 
• Explore the synergies between eHealth and eInclusion policies and support instruments to 
bring about health care and social care joined up research and innovation pilots; 
• Revise the EU value chain of R&D, pilots and validation as to increase the chances of 
moving to the final stage of sustained service production and delivery; 
• Leverage the new window of opportunity that may be opened in the post i2020 framework 
with the envisaged strong investment into broadband ensuring that RMT and more in general 
PHS are the priority type of services to be supported through these new platforms; 
In sum, if the challenge for European health care systems is to increase the quantity and quality of 
care in response to higher demand pressures, at a time when various factors are putting public 
budgets at strain, then an answer to this challenge can be effectively provided with the EU-wide 
deployment of RMT/PHS systems. 
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PART ONE: EXECUTIVE REPORT 
1 Introduction 
1.1 Background 
Health care systems in Europe are facing a number of well known challenges (rising costs, ageing 
population, increasing demand, shortage of health care professionals, etc.), in an economic 
environment of cost-control and limited public expenditure. Within this context the Lead Market 
Initiative (LMI) for Europe has identified eHealth as one of its six key areas of focus, for strategic 
(improvement in competitiveness and interoperability leading to technology advances), economic 
(scale economies) and social (improvements in service level and access to health services) reasons. 
The development of Personal Health Systems (PHS) within the eHealth area looks particularly 
interesting for delivering home care and remote monitoring services to patients and contributes to the 
goals of the LMI. In particular PHS are expected to improve quality of care, quality of life and cost 
efficiency of health care processes. 
Following the adoption of the eHealth Action Plan6 the European Commission launched several 
initiatives to promote the development, use and dissemination of PHS. PHS are increasingly 
becoming the subject of conferences and dedicated events and reports, including: 
• The February 2007 conference on Personal Health Systems.7 Dealing with deployment 
opportunities and ICT research challenges. It consolidated ten-year state-of-the-art research 
results in PHS and provided  best practices; 
• The Telehealth 2007 conference.8 The conference on "Telemedicine and innovative 
technologies for chronic disease management" showed the significance of on-going 
developments for doctors and hospitals providing case studies on extramural chronic disease 
management. Regulatory and legal problems were addressed and the role of doctors in 
solving them was discussed; 
• The Tampere PHS2008 Consultation workshop.9 Addressing R&D activities on PHS from 
a broad perspective, its main focus was on recent developments in artificial organs, minimally 
invasive systems and mental health diseases, as potential areas for future PHS applications. 
Brainstorming sessions on future EU research programmes and activities were included; 
• The Telehealth 2008 conference.10 The "Telemedicine and innovative technologies for 
chronic disease management" conference presented state-of-the-art patient-oriented services 
and discussed the role of the EC in promoting the roll-out of a European PHS system; 
• TheWoHIT08-EC workshop.11 The "Procuring for health benefits" workshop stressed a 
variety of procurement models for the adoption of telemedicine services and in particular 
lessons learnt from four EU country Studies-England, Northern Ireland, Spain and Denmark; 
                                            
6  COM(2004)356, SEC(2004)539 available at:  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2004:0356:FIN:EN:PDF 
7  European Commission: Personal Health Systems: deployment opportunities and ICT research challenges. In. Brussels: European 
Commission; 2007: 25. 
8  Whitehouse D, Virtuoso S: Telehealth 2007 - Telemedicine and innovative technologies for chronic disease management. In: 
Telehealth 2007 - Telemedicine and innovative technologies for chronic disease management: 11 December 2007; Brussels; 2007: 
44. 
9  European Commission: PHS 2008 Consultation workshop. In. Tampere: European Commission; 2008: 23. 
10  Whitehouse D: Telemedicine and innovative technologies for chronic disease management. In: eHealth 2008: 2008; Portoroz, 
Slovenia: Infso; 2008: 7. 
11  Jones T: WHIT08 - EC Workshop Procuring for health benefits: Critical Factors for Beneficial Deployment of Innovative eHealth 
and Telemedicine Services. In. Copenhagen: DG Infso - ICT for Health; 2008: 28. 
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• PHS2020. This FP7 project organised several workshops and events consulting over 100 
experts and stakeholders in several European regions and recently delivered its final results in 
terms of road mapping research activities in PHS;12 
• The 2010 PHS Consultation Workshop. This workshop focused on state-of-the-art PHS 
technologies and more specifically on PHS for neurodegenerative diseases. Expert 
participants discussed the application of ICT in prevention, management and treatment of 
neurodegenerative diseases. Rising prevalence, high costs of treatment and the negative 
effects on employment and productivity pointed at the need for more R&D in this area.  
Within this context SIMPHS (Strategic Intelligence Monitor on Personal Health Systems) was 
launched at the beginning of 2009 with an expert workshop held in Brussels,13 and it is now 
delivering the findings from Phase 1 (February 2009- April 2010). SIMPHS is a three years project 
carried out by JRC-IPTS in cooperation with DG INFSO. It aims to develop a monitor in order to 
facilitate the understanding of the market and innovation dynamics of PHS in Europe. During this 
first year SIMPHS focused on the remote patient monitoring and treatment segment of PHS 
(henceforth simply RMT) in general, and on chronic diseases (i.e. chronic heart failure, diabetes, 
COPD) in particular. The objective of SIMPHS is to provide evidence on a number of research 
questions that can be applied both to PHS in general and to its different segments such as RMT: 
a) Is there among stakeholders a common understanding of PHS/RMT?  
b) Which are the main players, what is their role and goal in delivering PHS/RMT services and to 
what extent are they engaged in bringing about disruptive innovation in the delivery of care?  
c) Regarding market players (henceforth also referred to as “suppliers”):  what are their 
expectations of the future development of PHS and the corresponding strategy and course of 
actions they adopt;  
d) Regarding health care professionals and their organisations (henceforth also referred to as 
“providers”): What role do they play, what kind of disruptive activities and innovations can be 
identified in the health care systems, what future options for a reorganisation of health care 
structures do they imply, and what are the related drivers and barriers?; and finally  
e) In general, what do the various players expect from government and health care policy and 
decision-making bodies? 
1.2 Key concepts 
Two key concepts have been developed in Phase 1 of SIMPHS: “Personal Health Systems” (PHS) 
and “Remote Patient Monitoring and Treatment” (RMT), which we define and put in context below. 
eHealth is by now an umbrella term broadly used and referring to the wide range of ICT applications 
in health care. In 2007, the eHealth task force14 supporting the Lead Market Initiative provided a 
more precise definition of the components of eHealth: 
1. Clinical information systems; 
a) Specialised tools for health professionals within care institutions 
b) Tools for primary care and/or for outside the care institutions 
2. Telemedicine and homecare systems and services; 
                                            
12  See main results in C. Codagnone, (2010), Reconstructing the Whole: Present and Future of Personal Health Systems 
(http://ec.europa.eu/information_society/activities/health/docs/projects/phs2020/phs2020-book-rev16082009.pdf ), 
13  See the minutes of this workshop at http://is.jrc.es/pages/TFS/documents/090206MinutesPHSworkshopfinal.pdf. Other workshop 
material can be found at http://is.jrc.es/pages/TFS/sps.html . 
14  European Commission, Accelerating the development of the eHealth market in Europe. eHealth Taskforce report 2007: Composed 
in preparation for the Lead Market Initiative, Luxembourg: Office for Official Publications of the European Communities, 2007 
(http://ec.europa.eu/information_society/activities/health/docs/publications/lmi-report-final-2007dec.pdf ). 
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3. Integrated regional/national health information networks and distributed electronic health 
record systems and associated services; 
4. Secondary usage non-clinical systems; 
a) Systems for health education and health promotion of patients/citizens 
b) Specialised systems for researchers and public health data collection and analysis 
c) Support systems for clinical processes not used directly by patients or health care 
professionals. 
 
Figure 1 – Constituent elements of eHealth 
Remote
Patient
Monitoring &
Treatment PHS
Wellness
Telemedicine and
Home care systems
Independent 
Living
Clinical Information Systems (CIS):
Tools for Health Care Professionals
in: care institutions, primary care, &
out-of-hospital
Integrated regional/national Health
Information networks (IHIN)
distributed Electronic Health Record
Secondary usage non-clinical systems
For health education and health promotion
of patients/citizens; for researchers and
public health data collection and analysis;
support systems for clinical processes;
 
Source: Adapted from eHealth Task Force Report (see footnote 14) 
 
As illustrated in Figure 1, although PHS are not explicitly mentioned in the LMI definition, they can 
be placed in the area where telemedicine and home care systems overlap with RMT. Based on this, 
the definition of PHS and RMT adopted in the SIMPHS project are presented in Table 1. 
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Table 1 – PHS Definition 
 
Source: PHS202015 
Table 2 – RMT Definition 
 
Source: Developed by SIMPHS project 
By using RMT systems, patients keep control over their health conditions and are able live 
independently or with limited need for care. Current RMT applications are mostly used for patients 
suffering from Chronic Heart Failure (CHF), diabetes and/or COPD. As a general principle, PHS and 
RMT systems can be seen as a particular instance of doctor-to-patient services as opposed to doctor-
to-doctor applications and in this respect they differ from the broad definition of telemedicine, which 
include also several doctor-to-doctor services (e.g. tele-radiology which is the most developed and 
consolidated). The possibility of automated remote treatment and interaction with the patient (though 
mostly confined still to R&D or pilot projects and with limited practical application) also distinguish 
PHS/RMT systems from telemedicine. Using an analogy from eBusiness sources, PHS and RMT 
systems tend to, or should be, B2C services in contrast with B2B services. In practice, however, PHS 
and RMT systems can take the form of B2B2C services, when an interaction between a supplier 
(technology provider) and the health care provider takes place before the latter actually delivers the 
service to the patient. Additionally, in a futuristic scenario, PHS/RMT systems can take the form of 
entirely patient self-managed services. 
Within the RMT domain, one could actually further distinguish between two forms. Using in this 
case the analogy with the world of online services, the first form represents a “pure technology 
delivery” and the second a “multi-channel delivery” model. The first includes RMT stand-alone 
services provided only through ICT and call centres, which forward the data gathered and processed 
to the health care provider in charge.  In the second model, the ICT enabled RMT activities are one 
                                            
15  C. Codagnone, (2010), Reconstructing the Whole: Present and Future of Personal Health Systems, op. cit, pp. 8-9. 
Remote Patient Monitoring and Treatment (RMT) systems help patients with 
chronic diseases monitor vital signs (blood pressure, heart rate, blood glucose, 
weight, oxygen contents, ECG) thus improving the quality of care, the quality 
of life of the patient and enabling the prediction of aggravations and 
exacerbations of their chronic condition.  
“Personal Health Systems (PHS) assist in the provision of continuous, quality controlled and 
personalised health services to empowered individuals regardless of location. They consist 
of: 
a) Ambient and/or body (wearable, portable or implantable) devices, which acquire, 
monitor and communicate physiological parameters and other health related context 
of an individual (e.g., vital body signs, biochemical markers, activity, emotional and 
social state, environment); 
b) Intelligent processing of the acquired information and coupling of it with expert 
biomedical knowledge to derive important new insights about individual’s health 
status. 
c) Active feedback based on such new insights, either from health professionals or 
directly from the devices to the individuals, assisting in diagnosis, treatment and 
rehabilitation as well as in disease" prevention and lifestyle management.” 
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component structurally integrated into larger disease management programmes, which also entail 
other forms of face-to-face interactions with nurses and doctors in addition to those facilitated by the 
technology. In the literature this second model is also referred to as Home Based Tele-management 
(HBT) of chronic disease.16 
1.3 Scope and structure of this report 
This report is a specific deliverable of the study "Strategic Intelligence Monitor on Personal Health 
Systems" (SIMPHS) conducted by DG JRC IPTS for DG INFSO. As stated in the Technical Annex 
to the Contract regulating the initiative, this report is Deliverable D3.1, “Market Structure and 
Innovation Dynamics”, which is the main output of SIMPHS Phase I research activities. It is closely 
linked to the other three core deliverables presented separately to which we will be referring in the 
course of our exposition. These other deliverables are: 
• D1.1 “Report on the Overall Structure of the Strategic Intelligent Monitor”, containing: 
o Structure of the data gathered which will serve as a manual or guideline to browse  the 
data repository at http://is.jrc.ec.europa.eu/pages/TFS/SIMPHSdata/index.html ; 
o A framework for evaluation and measurement including around 50 measurement 
indicators; 
o Data on market indicators for the 50 companies analysed in-depth (see infra). 
• D2.3 “Report on typology/segmentation of PHS market” providing a critical review of 
currently used concepts and tags and proposing a segmentation with cases and 
exemplifications; 
• D4.2 “Report on Validation Workshop” summarising the results of the Expert Validation 
Workshop held in Brussels in November 2009, where we presented a synthetic summary of 
the findings of the first year of work in the form of a Discussion Paper17 that was fully 
validated by the experts.18 
During SIMPHS Phase 1, a number of research activities have been undertaken, basically covering 
the following three pillars and their sub-components: 
1. Desk based data gathering and analysis carried out by the IPTS team on: 
i. Market research data; 
ii. Identification and preliminary analysis of 200 companies involved in PHS/RMT 
followed by an in-depth analysis of 50 of them;  
iii. Pilots, projects and programmes financed at EC, national, regional and local level; 
2. Evidence gathered by the IPTS team field work, through interaction with experts and 
stakeholders.19 This included: 
i. A large stakeholder's workshop with 30 participants including representatives from the 
industry (suppliers), health care providers, insurers (purchasers), academia, etc.; 
ii. Three restricted workshops with 5-7 participants each; 
                                            
16  See, for instance: A. Giordano et al. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission 
of patients with chronic heart failure. International Journal of Cardiology 131 (2009) 192–199. 
17  Available at: http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHSbackgroundpaperforvalidationworkshop.pdf  
18  See the workshop minutes at:  
http://is.jrc.ec.europa.eu/pages/TFS/documents/MinutesSIMPHSValidationWSfinalforpublication.pdf  
19  The aim of this part of the work was to unearth a wide range of elements that would help us understand the activities of the 
companies represented, from a description of their role on the value chain to the perception of these experts on market growth, 
barriers and drivers, and various other elements. The qualitative data collected enabled us to sketch a number of business models 
and draw some conclusions on their key characteristics. 
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iii. A series of one-to-one meetings and phone interviews with experts  (i.e. semi-structured 
interviews); 
3. Six Self contained country case studies comprising both, desk research and field work 
(along the same lines as activity 1 and 2 above): 
i. France, Germany, Sweden and the United Kingdom outsourced to VTT; 
ii. Italy and the Netherlands carried-out by the IPTS Team; 
This report is divided in two parts. Part One (Section 1 to Section 5) provides a very selective and 
synthetic Executive Report on the evidence gathered as a result of all the above mentioned activities. 
In Part Two (Section 6 through Section 10) monographic annexes reporting in-depth details of the 
findings are available. The structure of the two parts is outlined below. 
Part One contains to a large extent a revised version of the Discussion Paper presented during the 
Expert Validation Workshop in November 2009. Given that the findings and conclusions of this 
paper were fully validated by the experts, Part One dedicates few efforts to justify our main 
conclusion: there is no consolidated RMT market and the focus should be more on what blocks the 
innovation dynamics rather than describing it. We start from this conclusion and, intend to address 
the following questions: (a) what are the health care needs and how can RMT contribute? (b) How 
much has happened so far in terms of RMT deployment? (c) Is there any evidence on whether RMT 
works and is it enough to develop a business case and convince stakeholders? (d) How does the 
above compare to the potential? And (e) what are the main barriers to achieve this potential and how 
can we overcome these barriers and what would be the impact if we do not act? The first question is 
addressed in Section 2, the second in Section 3, the third in Section 4, and the fifth in Section 5. The 
fourth question is dealt with using an scenario-based extrapolation and it has been addressed only in 
a preliminary and exemplificative fashion in this report, which would not justify treatment as a self-
standing section. Accordingly, we deal with it in §4.3of Section 4 given that it is based on some of 
the parameters extracted from the evidence on RMT outcomes. 
Part Two, as anticipated, comprises monographic annexes each addressing a specific component of 
the evidence gathered: 
• ANNEX I: Innovative activities in RMT (included as Section 6), reports on the analysis of 
innovation activities funded at local, regional, national, and EU levels (programmes, projects, 
pilots); 
• Annex II: RMT Company Analysis (included as Section 7), reports on the analysis of RMT 
market players (companies’ analysis); 
• Annex III: Summary of Country Reports (included as Section 8), contains a horizontal and 
comparative reading of the six country studies; the part of the country reports that was 
outsourced in its original form is available through the SIMPHS web site; 
• Annex IV: Health-related data and scientific evidence (included as Section 9), provides first 
an overview of the search conducted on prevalence and costs of the chronic diseases we have 
focused on in this report, followed by a synoptic overview of the findings of evaluation 
studies (randomised control trials, meta-analysis, and other sources addressing the topic of 
RMT clinical and cost-effectiveness outcomes); 
• Annex V: Patent analysis (included as Section 10), summarises the finding of the data 
gathered on patents. 
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2 Health care challenges and needs: how can RMT contribute? 
2.1 The big picture 
The challenges that European health care systems are facing and will face even more sharply in the 
future are well known and have been fully reviewed and discussed in a number of EU Public Health 
communications and white papers.20 Below, we only briefly summarise the key points from these 
and from a selection of the vast body of literature available on the topic. In short, the challenges 
consist in preserving access, equity, quality, and financial sustainability at a time when demand-side 
trends increase pressure on health care systems, while public finances are increasingly under strain. 
Since there is a wide consensus that it is hardly possible to cut health care costs, the big challenge 
can be summarised as at least “produce more and better quality output with the same level of 
input”. 
Rising expenditure  
Starting in the 1970s, when the effects of a generalised increase in national income and educational 
levels fully manifested themselves, growth in health care expenditure has almost constantly outpaced 
that of GDP. On average in OECD countries between 1995 and 2005 growth rates in health care 
expenditure outstripped GDP growth by 1.4% (1.7% considering public spending only).21 In the 19 
EU countries for which OECD data22 is available health care expenditure as a percentage of GDP has 
risen on average from 4.7% in 1970 to about 9% in 2007 (with public expenditure increasing from 
3.5% to 6.6% in the same period). Hence, it is obvious that health care remains overwhelmingly a 
matter of public expenditure. During the same period (1970-2007), the share of public financing of 
total health care expenditure on average went from 74.4% to 75.8% (with only 3 countries where the 
share of public financing is below 70%: Greece, 60%; Netherlands, 62%; and Slovak Republic, 
66.8%). Private insurance financing went down from 4.4 to 4% (except for France and the 
Netherlands with values above 10%). Out of pocket expenditure went down from 18.4% to 16.2% 
(except for Hungary, Poland, Slovak Republic, Italy, Portugal, and Spain with values above 20%).. 
Ageing of the population  
From 1960 to 2008, the percentage of population aged over 65 has doubled on average. Moreover, 
projection scenarios show that the ratio of old-age dependency compared to the overall population 
will increase from 0.25 in 2004 to at least 0.33 in 2020 and could be between 0.45 and 0,65 in 2050. 
This means that from the current ratio of 1 inactive old person for 4 active individuals (1:4), it can 
reach 1:3 in 2020 and 1:2 or even less at future stages. 
 
                                            
20  These includes: a) European Commission, The future of health care and care for the elderly: guaranteeing accessibility, quality 
and financial viability. Brussels. COM (2001) 723 final, 2001; b) European Commission, WHITE PAPER: Together for Health: A 
Strategic Approach for the EU 2008-2013. Brussels. COM (2007) 630 final, 2001; c) European Commission, Commission Staff 
Working Document, accompanying the WHITE PAPER: Together for Health: A Strategic Approach for the EU 2008-2013. 
Brussels. SEC (2007) 1376, 2007; d) European Commission, Commission Staff Working Document, Document accompanying the 
WHITE PAPER: Together for Health: A Strategic Approach for the EU 2008-2013. Impact Assessment. Brussels. SEC (2007) 
1374, 2007. 
21  OECD 2009 Health Data. We refer here and in the reminding to the database purchased as a CD Rom and from which data can be 
generated in multiple fashion, but we cannot add a specific quotation or reference to pages (we do not refer to the paper version). 
22  They exclude of the EU27: Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, and Slovenia. These 8 countries amount 
to less than 9% of the total EU27 population. 
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Figure 2 – Old age dependency, EU25, 2004-2051 (different population scenarios) 
 
Source: Eurostat, Statistics in Focus: Population and Social Conditions. 3/2006 
 
While ageing has clear consequences in terms of chronic disease burden, here we want to stress the 
impact of ageing with respect to the sustainability of health care systems. Population scenarios reflect 
that we seem to be reaching a situation where the pool of active individuals working and paying 
taxes will shrink whilst the amount of elderly population increases which in turn results on rising 
costs for health care and long-term care. This scenario overcasts a potential generational tension with 
“fewer people at working age who may be reluctant to pay the higher taxes required in order to fulfil 
all of society’s needs”.23  Therefore, rising public expenditures and decreasing tax base in the future 
are very likely to generate tremendous pressures on health care systems. We can further add that also 
European pension systems are at strain and reforms delaying the retirement age are needed. In this 
context, health care should struggle to both optimise the treatment of the elderly in chronic 
conditions and to prolong the active and health lives of “older workers” (aged 55-65 and slightly 
above, probably up to 70). 
                                            
23  J. Cleland et al. Telemonitoring for heart failure: the only feasible option for good universal care? European Journal of Heart 
Failure 2009 11(3):227. 
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Scarcity of professionals and informal carers  
According to data from the Eurostat Labour Force Survey (LFS), the expenditure caused by an 
increase of the number of people employed in the area of Health and Social Work in EU15 Member 
States has grown steadily, from 13 to 15 million in total between 1995 and 2000, rising to around 
€20.1 million in 2005 in the EU27.24 This growth, however, is running against the hard wall of 
increasing scarcity of qualified personnel.  
In OECD countries on average:  
a) The number of medical graduates per 1000 practicing physicians has steadily declined, from 
40.9 in 1990 to 33.1 in 2005. As a result the density of practicing physicians per 1,000 
population has more than doubled between 1970 and 2000 (from 1.3 to 2.8) but this growth 
has started to hover in this decade (in 2005 was only 3.1) and the density is expected to 
decline in the future;  
b) The number of nurse graduates per 1,000 practicing nurses has steadily declined and 
decreased from 59.9 to 44.8 between 1990 and 2005. As a result, the density of practicing 
nurses per 1,000 population has more than doubled between 1970 and 2000 (from 3.3 to 7.6) 
but this growth has also started to hover in this decade (in 2005 was only 8.0) and the density 
is expected to decline in the future. 
This increasing scarcity of professional carers is compounded by the increasing predominance of 
nuclear families, workforce feminisation, and workforce mobility, which reduces the pool of 
informal carers and makes the care of the chronically ill and of the elderly in general even more 
difficult, thus adding to the demand for health care and social services professionals. 
2.2 The rising chronic diseases burden 
Chronic disease management is one of the main challenges of health care; while it is easy to assess 
the overall burden and cost for supporting the patients for each disease as relatively high, especially 
among the older patients, measuring it is rather difficult. To start, the literature on chronic disease 
burden and costs is vast, and comparisons are almost impossible. We have thus decided to present for 
some chronic disease a rule-of-thumb extrapolation, which although has limited scientific validity, 
will provide an estimate of the order and magnitude of costs incurred. This will be preceded by 
comments and assumptions related to the availability and accuracy of the data used to estimate costs. 
Premise on the data available.  
Naturally, the most important trend from the health care demand side is the ageing of the population 
with the associated increase in chronic disease prevalence and cost pressures. We briefly focus below 
on diabetes, Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD, 
with a particular focus on Chronic Heart Failure – CHF), as they represent those most often targeted 
by RMT.25 Data on prevalence and costs to society of chronic diseases presented in detail in Annex 
IV (Section 9); a general premise is justified here since it explains the limit of the extrapolations 
presented in section 4.3. It may also be used to explain why further research is needed to build a 
robust forecast model from which reliable scenario-based extrapolations could be extracted. 
Internationally, comparable prevalence rates are much more difficult to gather than mortality rates 
                                            
24  European Commission, Staff Working Document, accompanying the WHITE PAPER, op. cit (point c) in footnote 20), p. 8 
SEC(2007) 1376, 2007. 
25.  General reference texts on the topic of chronic disease rising burden include reports and books published by WHO or The World 
Bank such as for instance: E. Nolte, M. McKee, (eds.), Caring for people with chronic conditions: a health system perspective. 
Maidenhead, UK: Open University Press / McGraw Hill (http://www.euro.who.int/document/E91878.pdf), 2008; and O. Adeyi, O. 
Smith, S. Robles, S. Policy and the Challenge of Chronic Noncommunicable Diseases. Washington DC: World Bank. 
(http://siteresources.worldbank.org/INTPH/Resources/PublicPolicyandNCDsWorldBank2007FullReport.pdf ), 2007. 
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for most of the diseases. For instance, for CVD, EU-wide data on prevalence26 is not routinely 
collected or updated. The reason for this difficulty is two-fold. First, national level data are not 
directly comparable due to differences in the diagnosis process and this is reflected in the statistics. 
Second, data generated from official statistics bodies and reports and in the scientific literature use 
different measures (prevalence, incidence, morbidity, DALY, etc) which makes comparison very 
difficult.  
Standardised and comparable EU-wide ready to use data are available only for Diabetes (Diabetes 
Atlas, see footnote 29). For CVD, CHF and COPD, findings resulted in a mix of data coming from 
different sources (WHO reports, scientific literature, etc) that are not comparable and even 
contradictory27 at times. Costs for each chronic disease were considered from two different angles: 
first, the calculation of aggregate costs and burden to health care and to society as a whole and 
second, the more micro level measures derived from clinical metrics of costs per patient per year, 
average costs of one hospital day and of diagnostic tests. These differences in costs add complexity 
to the situation. The literature review provided measures of aggregate costs for general CDV and for 
Diabetes (expressed in various units such as actual Euro costs, DALY burden, costs in International 
Dollars). Regarding costs per patient, very disparate and contrasting figures for the same type of 
disease in the same country were found. In addition, using different articles reporting the findings of 
Randomised Control Trials (RCT) very inconsistent (across time and space) measures of standard 
clinical costs (hospitalisation/diagnostic) were extracted. For the purpose of robust extrapolation, 
such micro level measures of costs and clinical metrics need to be collected for all countries.28 For 
CHF only, and using benchmarks derived from results of different RCT and applying them to 
prevalence data (of questionable comparability), we managed to produce a view of the order and 
magnitude of costs. 
Diabetes  
The Diabetes Atlas of the International Diabetes Federation (IDF) in 2010 (available in table 1) 
reported almost 33 million individuals affected by diabetes in Europe, a figure expected to reach 40 
million in 2025 (20% average growth).29 
                                            
26  S. Allender, European Cardiovascular Disease Statistics, 2008 edition. London: British Heart Foundation 
(http://www.heartstats.org/uploads/documents%5Cproof30NOV2007.pdf) 2008, p. 36. 
27  So as to facilitate the development of EU27 extrapolations of potential outcomes and impacts, much more time and resources 
would be needed to build and validate comparable prevalence data from disparate sources and national specific statistics. (SIMPHS 
Phase 2). 
28  For instance the eHealth for a Healthier Europe! Opportunities for a better use of health care resources, Swedish Presidency of 
the EU (http://www.se2009.eu/polopoly_fs/1.8227!menu/standard/file/eHealth%20for%20a%20Healthier%20Europe.pdf ), 
required six months of work devoted entirely to gather clinical metrics for six EU Member States, from which the several 
extrapolations were produced (but the report provides only the findings and not the clinical metrics and statistics upon which they 
were based). 
29  http://www.eatlas.idf.org/index-2.html 
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Table 3 – Diabetes prevalence in the EU27 
  
20-79 Population 
2010 (000s) 
Diabetes patients
2010 (000s)  
Crude 
prevalence 
Austria 6.301,6 708,4 11,2%
Belgium 7.643,9 610,0 8,0%
Bulgaria 5.790,2 519,5 9,0%
Cyprus 634,1 65,9 10,4%
Czech Republic 7.824,3 677,3 8,7%
Denmark 3.907,0 301,5 7,7%
Estonia 994,0 97,9 9,8%
Finland 3.863,4 319,8 8,3%
France 44.091,3 4.164,2 9,4%
Germany 62.654,4 7.494,3 12,0%
Greece 8.560,7 754,0 8,8%
Hungary 7.514,8 658,9 8,8%
Ireland 3.171,2 180,3 5,7%
Italy 44.509,9 3.926,2 8,8%
Latvia 1.719,4 169,7 9,9%
Lithuania 2.484,3 239,8 9,7%
Luxembourg 348,9 24,3 7,0%
Malta 306,8 29,9 9,7%
Netherlands 11.943,4 922,4 7,7%
Poland 28.618,0 2.674,6 9,3%
Portugal 8.033,8 997,6 12,4%
Romania 16.129,0 1.351,4 8,4%
Slovakia 4.074,6 314,0 7,7%
Slovenia 1.546,2 152,9 9,9%
Spain 33.943,8 2.939,3 8,7%
Sweden 6.618,6 484,4 7,3%
United Kingdom 44.056,1 2.139,6 4,9%
EU27 367.283,7 32.918,1 9,0%
Source: http://www.diabetesatlas.org/book/export/html/250 
 
Prevalence for all forms of diabetes among the 20-79 population ranged from 3.4% in Ireland to 12% 
in Germany and Portugal. Still the Diabetes Atlas reports that the cost of Diabetes in Europe 
amounted to 82.3 billion in International Dollar (ID)30 in 2007 and is expected to grow to 98 billion 
ID in 2025. According to the IDF, increase in prevalence may be even sharper due to rising obesity 
in the population, which is strongly associated with type II diabetes. A meta-analysis of some 
countries studies has found that the cost of diabetes ranges from 2.5% to 15% of total national health 
                                            
30  Quoting Wikipedia, the international dollar (ID), also known as the Geary-Khamis dollar, is a hypothetical unit of currency that 
has the same purchasing power that the U.S. dollar had at a given point in time. It is based on the concepts of purchasing power 
parities (PPP) of currencies and the international average prices of commodities. Figures expressed in ID cannot be converted to 
another country's currency using current market exchange rates; instead they must be converted using the country's PPP exchange 
rate.  
 22 
care expenditure depending on diabetes prevalence and the level of treatment available.31 Applying 
these percentages to total health care expenditure of 2007 in EU19 (1177 billion of Euros using 
OECD Health Data 200932), these costs can range from 29 up to 176 billion Euros. There are various 
other measures of costs per patients that vary widely depending on the country or the sources, which 
are reported in detail in Annex IV (section 9). 
Chronic Obstructive Pulmonary Diseases (COPD). Data on COPD prevalence in Europe is scarce 
(due to different diagnosis practices and classification systems) and suffers from under-estimation.33 
Figure 3 below provides a graphic snapshot provided by the European Lung White Book dated 
200334 and shows lack of data availability in many countries. The most recent data available on 
COPD prevalence (relating to different years, different country level sources, and based on different 
reference population) was compiled by WHO35 in 2007 
Figure 3 – Map of COPD prevalence in Europe 
 
Source: European lung white book (see footnote 34) 
The picture is equally fragmented but rich with different studies and estimations about the costs 
associated with COPD, which vary wildly (examples of which are reported in Table 4). The 2007 
WHO study reports direct costs only for a few European countries and with discordant figures. From 
                                            
31  M. Suhrcke, et al, The Contribution of Health to the Economy in the European Union. Brussels: European Commission, 2005 
http://ec.europa.eu/health/ph_overview/Documents/health_economy_en.pdf 
32  The data reported for 2007 is 1530 billion of US dollars (to which we applied a standard average exchange rate for that year) 
33  It is often under diagnosed as many accept breathlessness and limited exercise tolerance as features of ageing and regard smoker’s 
cough as normal. On this aspect see for instance R. Pauwels, and K. Rabe, Burden and clinical features of chronic obstructive 
pulmonary disease (COPD), Lancet, 364 (2004): 613–20. 
34  R. Loddenkemper R, et al. European lung white book - the first comprehensive survey on respiratory health in Europe. 
Huddersfield, UK European Respiratory Society, 2003. 
35  Denmark (3.7% among individuals aged 20–90 years), England (9.9% among individuals 60–75 years), Finland (11% among 
individuals 30 years and older), Italy (11% individuals of 25 years and older), Norway (4.1% among individuals of 16–70 years) 
and Spain (9.1% among individuals of 40–69 years) WHO, Global surveillance, prevention and control of Chronic Respiratory 
Diseases – A comprehensive approach, Geneva WHO (http://www.who.int/gard/publications/GARD%20Book%202007.pdf), 
2007, p. 24. 
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a different perspective the burden of COPD in Europe is estimated to be 393 DALYs per 100,000 
population (disability adjusted life-years), with particularly high rates in individuals aged 70 and 
above.36 At European level, the predicted number of deaths attributable to COPD is expected to 
increase from almost 270,000 in 2005 to over 338,000 by 2030, while the absolute burden of COPD 
is projected to fall from approximately 3,440,000 to 2,950,000 DALYs.37 
Table 4 – Examples of Cost calculations of COPD 
 
2003 International Study. Mean average 
direct cost of COPD per patient: $4,119 in 
USA, $3196 in Spain, $606 in The 
Netherlands, $ 522 in France. From 52% to 
84% of costs are due to hospitalisation.  
(Wouters, E. The burden of COPD in the Netherlands: 
results from the confronting COPD survey, 
Respiratory Medicine 97(Supplement 3): S51-S59) 
 
French scenario. Altogether 3 million French over 
45 i.e. 5-10% of the population suffer from COPD 
and 16,000 people die of COPD every year. COPD 
is responsible for 800.000 hospital stays per year 
costing €3.5 billion, out of which more than half is 
due to unexpected hospital stays in relation to 
complications (translated and adapted from 
http://bpco.ffaair.org/plan2.php?id=7&title=<p>BPCO) 
 
Source: See reference inside the box 
Cardiovascular diseases (CVD)  
Cardiovascular disease is the collective term for all diseases affecting the circulatory system (heart, 
arteries, blood vessels), which include coronary heart disease, stroke, CHF, and various others (many 
taking different forms and sub-classifications). One of the most authoritative sources on CVD 
statistics and costs is the European Cardiovascular Diseases Statistics published annually by the 
British Heart Foundation.38 As anticipated, this source concludes that there are no EU-wide 
comparable sources on CVD prevalence. As a general indirect indication in developed European 
countries CVD account for 17% of DALYs lost (the largest cause after neuropsychiatric disorders): 
every year over 12 million DALYs are lost due to CVD.39  
The same source provides, instead, more standardised and comparable data on the costs of CVD.40 
CVD costs in 2006 to EU health care systems reached €109 billion, or about 10% of total health care 
expenditure. Wide variations across countries can be observed in Table 5. 
                                            
36  E. Nolte, M. McKee, (eds.), Caring for people with chronic conditions: a health system perspective, op cit., p. 25. 
37  Ibid. 
38  S. Allender, European Cardiovascular Disease Statistics, 2008 edition. London: British Heart Foundation 
(http://www.heartstats.org/uploads/documents%5Cproof30NOV2007.pdf) 2008.  
39  Ibid., p. 37. 
40  Ibid., pp. 103-104 for the data reported year, and entire chapter 12 for a more detailed analysis. 
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Table 5 – Health care costs of cardiovascular diseases 
Countries 
Total Health care 
costs 
(000 €) 
Costs per 
capita 
% of Total Health 
care costs 
Austria 1,632,865 198 6% 
Belgium 2,030,028 193 6% 
Bulgaria 273.275 35 14% 
Cyprus 45.397 59 5% 
Czech Republic 1,097,573 107 13% 
Denmark 989,983 182 5% 
Estonia 103,753 77 15% 
Finland 1,246,204 237 10% 
France 13,003,422 207 7% 
Germany 34,029,860 413 14% 
Greece 1,921,710 173 10% 
Hungary 751,847 75 10% 
Ireland 768,777 183 6% 
Italy 13,790,198 235 10% 
Latvia 108,378 47 9% 
Lithuania 201,243 59 13% 
Luxembourg 115,605 252 5% 
Malta 29,098 72 6% 
Netherlands 4,424,508 271 9% 
Poland 2,830,204 74 17% 
Portugal 1,599,351 151 10% 
Romania 725,833 34 15% 
Slovakia 397,836 74 13% 
Slovenia 181,966 91 7% 
Spain 5,694,611 130 7% 
Sweden 2,784,356 308 10% 
United Kingdom 18,911,391 313 12% 
EU27 109,689,271 223 10% 
Source: European Cardiovascular Disease Statistics, op. cit, p. 104 
Inpatient hospital costs account for 54% of total CVD costs (which is about € 59 billion), while drugs 
represent 28% (about € 30 billion). About one fifth (€ 24 billion) of CVD expenditure is consumed 
by Coronary Heart Diseases (CHD) and 17% (about € 18 billion) by strokes. Indirect non-health care 
costs of CVD include € 41 billion in lost productivity, and € 42 billion for the cost of informal care. 
So the total burden may add up to € 192 billion per year. 
Chronic Heart Failure (CHF). This disease is of particular interest for it is one of the chronic 
diseases most commonly targeted by RMT. CHF is a syndrome, often associated with diabetes 
mellitus and hypertension, which has shown little decline in incidence since the 1980s.41 Due to 
population ageing and improved survival resulting from improved treatments, the projected burden 
of CHF is set to increase further.42 While there is consensus about this general trend, precise and 
comparable quantifications of prevalence are non-existent. Indeed, epidemiological data regarding 
                                            
41  A. Mosterd, and A. Hoes, Clinical epidemiology of heart failure, Heart, 93(2007): 1137–46. Moreover, it is possible to estimate 
that one third of death attributed to coronary heart disease may also be related to CHF. 
42  S. Stewart, et al, Heart failure and the aging population: an increasing burden in the 21st century? Heart, 89 (2003): 49–53. 
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CHF incidence, prevalence and prognosis in the population in general are scarce for a number of 
reasons.43  
It is worth reporting some illustrative examples of such variability.44 According to an article on the 
epidemiology of CHF published in the late 1990s the disease affects between 0.1% and 2% of the 
general population, whereas it goes up to 10% among those aged 75 and above.45 It is easy to note 
that the range from 0.1% and 2% is a challenging large interval if we were to apply it to the current 
500 million EU27 population: anywhere between 500,000 and 10 million! The prevalence rate for 
the elderly is difficult to apply since the data publicly available from Eurostat are broken down into 
age groups “65-79” and “80 and above”, but not “75 and above”. If we apply it to the group 80 and 
above we get a total of 2.1 million, whereas when applied to the aggregate group 65 and above it 
would give us a total of 8.5 million. Another source from 2002 reported that prevalence in Europe 
ranges from 1% to 3% of general population and may reach 10% among the very elderly46. The same 
source claims that, at the time of writing (likely to be year 2000 considering the lengthy publication 
process), there were 6.5 millions Europeans suffering from CHF (prevalence of 1.3% of EU27 
population in 2000).  
A survey-based estimation of prevalence in Portugal produced a figure of 4.36% prevalence of the 
population aged 25 and above (prevalence was 1.36% in age group 25-49; 2.93% in age group 50-59; 
7.63% in the age group 60-69; 12.67% in the age group 70-79; 16.14% in age group 80 and older).47  
Considering the UK patient data reported in Table 6, the prevalence value of the total population is 
1.6%.  
Table 6 – Chronic Heart Failure: UK Evidence on prevalence and costs 
 
Source: See reference inside the box 
CHF is estimated to absorb between 1% and 2% of health care costs in industrialised countries,48 
which applied to the OECD Health Data 2009 figure for total health care expenditure in EU19 would 
amount to between 11.7 and 23.5 billion Euros. CHF patients amount to 5% of all hospital 
                                            
43  Information is derived from different sources (hospital statistics, small surveys, clinical trials, national statistics, etc) and their 
comparability suffers from the broad definition of CHF used with an undefined level of diagnostic accuracy (see for instance F. 
Ceia et al, Prevalence of Chronic heart failure in South-western Europe: The EPICA Study, The European Journal of Heart 
Failure 4 (2002): 531. 
44  These are instrumental to the disclaimer we present later when providing our extrapolation scenario for CHF. 
45  N. Sharpe, and R Doughty, Epidemiology of heart failure and ventricular dysfunction.  Lancet 353 (Suppl. 1, 1998): 37. 
46  J. Mc Murray and S. Steward, The Burden of Heart Failure, European Heart Journal Supplements, 4 (2002, Supplement D): D50. 
47  F. Ceia et al, Prevalence of Chronic heart failure in South-Western Europe: The EPICA Study, op. cit, p. 531. 
48  A. Bundkirchen, and R. Schwinger, Epidemiology and economic burden of chronic heart failure, European Heart Journal 
Supplement (2004), 6(D): 57–60. Mc Murray and Steward in the article cite previously (The Burden of Heart Failure, op. cit., p. 
D50) report CHF to absorb 2% of total health care expenditure. 
Prevalence. It has been estimated that there are about 393,000 men aged 45 and over 
living in the UK with definite heart failure, and 314,000 women, giving a total of around 
707,000 (http://www.heartstats.org/datapage.asp?id=1125) 
 
Costs. Hospital inpatient costs take 60% of NHS expenditure for CHF against only 8% 
against outpatient home care (Source www.heartstats.org ). Yearly 86.000 CHF patients 
are hospitalised for a total costs of GBP 378 million (Department of Health, Hospital 
Episode Statistics, http://www.doh.gov.uk/hes/ ) 
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admissions and consume a lot of resources mostly for hospitalisation.49 This is because CHF patients 
are often re-hospitalised: re-hospitalisation after two weeks (from 10% to 19%),50 is as high as 50% 
after 3 months,51 and 45% after six months.52 Already more than a decade ago it has been noticed 
that many of these readmissions could be prevented53 by various means including better monitoring 
and compliance (see below). 
Non-Compliance problems. The term compliance is most often used in the clinical literature to 
refer to the degree to which patients’ behaviours coincide with clinical prescriptions (whether these 
are related to taking medication or following lifestyles guidance). The term non-compliance has a 
negative connotation related to the one-way direction and is sometimes substituted with “adherence” 
or “therapeutic concordance”. Non-compliance is the cause of additional and avoidable costs of 
chronic diseases, especially among the elderly who follow exactly and steadily clinical prescriptions. 
It has been estimated, for instance, that patients over 70 take an average of seven prescription 
medicines and three over-the-counter drugs per day.54 From a study carrying out in depth interviews 
with CHF patients, it turned out that 50% of the interviewed did not know the exact dose of 
prescribed medication and 60% could not remember the exact time for taking it.55 As a result non-
compliance is a source of cost inflation and of avoidable hospitalisation in all industrialised 
countries56. Indeed, particularly salient is the non-compliance problem among CHF patients and a 
recent meta-analysis study found that 9 out of 11 studies indicated that non-compliance was the main 
cause of worsening conditions often leading to re-hospitalisation.57 Treatment effectiveness for CHF 
has increased but so have the prescriptions and without support to patients non-compliance will 
increase and the potential improvements of more effective treatment will be lost for many patients 
who will continue to give rise to avoidable hospitalisation costs.  
In essence the burden of chronic disease on the health care systems is huge and it will only get bigger 
as prevalence of chronic disease increases with the ageing population. One may reach that 
conclusion, despite the fact that data available is not directly comparable, even within the national 
confines of one Member State, mainly due to the diversity in the definitions used, the difference in 
the diagnostic procedures as well as the different measurement characteristics.  
2.3 RMT can clearly help 
The various trends and elements illustrated in the previous two sections quite clearly provide 
compelling evidence calling for the introduction of RMT and other PHS applications. We elaborate 
                                            
49  See J. McMurray and S. Stewart, Epidemiology, aetiology and prognosis of heart failure. Heart (2000): 596–602 and .Mc Murray 
and S. Steward, The Burden of Heart Failure, op. cit. 
50  C. Ashton et al., The association between quality of inpatient care and early readmission. Annals of Internal Medicine, 122(1995): 
415–21. 
51  J. Vinson et al., Early readmission of elderly participants with congestive heart failure. Journal of American Geriatric Society, 38 
(1990): 1290–5; K. Harjaj et al. Simple clinical variables are markers of the propensity for early readmission in heart failure 
patients. Journal of Cardiac Failure 5 Supplement (1999): 80. 
52  A. Di Lenarda et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale 
of two worlds— the Temistocle study. American Heart Journal, 146(2003):E12. 
53  L. Erhardt and C. Cline. Heart failure clinics: a possible means of improving care. Heart, 80 (1998):428–9. 
54  B. Fleming, et al Medication use by home health patients. Journal of Geriatric Drug Therapy, 7 (1993): 33-45. 
55  C. Cline et al, Non-compliance and knowledge of prescribed medication in elderly patients with heart failure. European Journal of 
Heart Failure 1(1999): 145 – 9. 
56  P. Kausnik, et al, User-adaptive Reminders for Home-based Medical Tasks: A Case Study. Methods of Information. Medicine, 
47(2008): 203–207. 
57  H. Martje et al, Non-compliance in patients with heart failure: how can we manage it? European Journal of Heart Failure 7 
(2005): 5-17. 
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this need further in this section. Chronic patients can be divided into three categories, following the 
approach of the UK Department of Health, illustrated in Figure 4, as follows:58 
• Level 3: include top "hospital returners" who are heavy users of unplanned secondary care.  
• Level 2:represent patients suffering from a complex single need or multiple conditions 
• Level 1: represent individuals at an early stage of a disease or having it in less complex forms 
Figure 4 – The Health Pyramid and different categories of chronic patients 
 
Source: Authors’ elaboration (Deliverable 2.3) and adaptation from sources quoted in footnote 58 
Although the mix changes, for all three groups the management of patients requires both 
professionals’ intervention and self-care. It is probably pleonastic to stress that RMT can be at the 
same time a support to the professionals and an opportunity for enabling better self-care, as it can 
provide patients and their informal carers with knowledge, information, skills and confidence to care 
for themselves and their condition effectively. The application of RMT can avoid acute worsening of 
conditions in Level 2 patients by providing timely information to professionals and can help prevent 
avoidable hospitalisation in Level 3 patients helping them, for instance, increase their adherence to 
the clinical prescriptions. 
However, it may be unrealistic to assume that RMT and PHS or eHealth applications in general, 
could reduce health care costs; these may not necessarily decrease but can be contained. Moreover, 
the policy objectives of most actions aimed at changing the conditions of health care delivery are 
primarily aimed at improving the outcomes for citizens and patients. Cost-effectiveness can usually 
                                            
58  UK Department of Health, Supporting People with Long Term Conditions, 2007, 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_4100317); D. 
Singh and C. Ham, Improving Care For People With Long-Term Conditions: A Review of UK and International Frameworks, 
Birmingham, University of Birmingham Health Centre Management Services (HCMS) and NHS Institute for Innovation and 
Improvement, 2006 (http://www.improvingchroniccare.org/downloads/review_of_international_frameworks__chris_hamm.pdf ). 
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be the result of improvement in quality, and cost-effectiveness metrics are also a measure of 
improvement in quality. In summary, efficiency and effectiveness are sought in order to increase 
patient safety and health status, while ensuring financial sustainability. In this respect, it is worth 
noting that the eHealth for Healthier Europe study recently published by the EU Swedish Presidency 
looks primarily at goals from the perspective of the user/patient such as safety, quality, availability, 
empowerment and continuity of care and does not contain one single figure on cost reduction.59 In a 
recent editorial Cleland et al observed how “many patients do not get the basic investigations and 
treatment that they should. The point of Telehealth is that it will enable many more patients to enjoy 
the standard of care offered to only a selected few at the moment60”. 
Indeed, if RMT services can provide the same quality and safety of the traditional approach with 
fewer staff, then it is difficult to see why it should not become a preferred option. Fewer staff does 
not mean firing professionals but rather releasing resources from some routine activities and re-
deploying them for more acute matters or for clinical research and innovation, bearing in mind the 
anticipated lack of health care professionals compared to care needs in the future. Assuming all else 
remains the same, if RMT reduces avoidable hospitalisation, there will be more resources available 
to treat the foreseeable increase in the number of patients more urgently needing inpatient care. 
In brief, RMT can certainly help pursue the objective of “producing more, better, and more effective 
output with the same input”. If RMT together with other measures could, for instance, delay by five 
years the two most costly last 2 years of life and prolong the capability to work for those aged 55-65, 
it would produce exceptional benefits from all perspectives. For instance, for the patients who live 
more years in relatively less difficult conditions or can prolong their active work life. Also for the 
health care sector there are benefits, since it is well known that intensive care costs during these last 
years of life of a chronically ill person are lower if the person is already fairly old.61 In addition, this 
postponement of costs (for either care or pensions) and/or the prolongation of tax contributions 
represent important "cash flow" outcome (delayed disbursement, prolonged revenues) from the 
perspective of deeply concerned Member State Finance Ministers. RMT has a role to play in this 
context as the drivers for the seismic revolution Cleland et al envisage are all there.  
Table 7 – Telecare a seismic revolution 
Source: See footnote 60 
                                            
59 eHealth for a Healthier Europe! Opportunities for a better use of health care resources, Swedish Presidency of the EU 
(http://www.se2009.eu/polopoly_fs/1.8227!menu/standard/file/eHealth%20for%20a%20Healthier%20Europe.pdf ). 
60 J. Cleland et al. Telemonitoring for heart failure: the only feasible option for good universal care? European Journal of Heart Failure 
2009 11(3): 227-228. 
61 See European Commission, The future of health care, op. cit. p. 4. 
 “Telecare will become the preferred method for managing most long term medical conditions 
and this revolution may well be as seismic for health care as the industrial revolution was to 
Western economies 200 years ago. When and how this revolution will occur is not yet clear… 
The secret weapon of telemonitoring, as yet not deployed, is that it can actively engage the 
largest health-care workforce in the world; that is the patients and their carers. 
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3 RMT deployment: the obvious is not yet happening 
Given the compelling needs and opportunities for RMT one could have expected to find at least 
some sizeable and consolidated level of deployment. On the contrary the evidence shows that the 
“obvious is not yet happening”.62 
While we present below our own evidence about the limited development of RMT, its relative slow 
pace of adoption can be appraised indirectly looking (Figure 5) at Telemedicine adoption,63 a part of 
which is RMT, in comparison to other eHealth applications, even for countries that seem to introduce 
eHealth as a priority and despite the fact that over the last 10 years the continuing R&D efforts in this 
area have been successful.  
Figure 5 – eHealth adoption in six Member States 
 
Source: eHealth for a Healthier Europe, op. cit, p. 26 
                                            
62  This expression is taken and adapted from the analysis in E. Shortliffe, E. Strategic Action in Health Information Technology: 
Why The Obvious Has Taken So Long. Health Affairs. 24 (2005): 1222- 1233. 
63  The figure, taken from the earlier mentioned eHealth for Healthier Europe study, is based self-reported levels of adoption of 
different eHealth technologies in the six EU Member States on which the study focuses (Czech Republic, France, Netherlands, 
Spain, Sweden, and United Kingdom).  
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3.1 What do market data reveal? 
Many estimates exist in relation to the size of the RMT market, which is defined in very different 
ways (telecare, telehomecare, telemonitoring, etc). We selected the two that were more comparable 
and specifically focussed on an entity closest to the definition of RMT used in this report. 
Frost&Sullivan (F&S) 2008 report.64 According to F&S the RMT market in Europe was worth 
€127.9 million in 2007 and is expected to reach €292.3 million in 2014. This market is allegedly split 
as follows: 40% (€ 52.2 million) to equipment vendors and 60% (€ 76.4 million) to services 
providers. While what is meant by service providers was not entirely clear in the report, we were able 
to clarify with F&S that their definition of revenues for services include: "… wide range of data 
communication hubs for remote monitoring and home care applications with various connectivity 
options (wired/wireless), various remote transmission options (phone line, net and cellular) and call 
centre management coupled with rough interpretation of clinical data (summary reports). It does not 
include patient feedback or physicians/nurses work as they do not contribute to RMT market revenue 
generation".65 According to F&S data, United Kingdom is the leading country in Europe in terms of 
RMT revenues with a 25% share. Germany follows with a 20% contribution to RMT revenues. Italy 
comes third with a share of 17%, while France is fourth with 15% of total revenues. Spain represents 
5% and ranks 7th. Benelux and the Nordic countries represent 12% and 6% of RMT revenues in 
Europe respectively. 
Global Market Data (GMD) 2009 report.66 GMD data only deals with the RMT devices market, 
which in Europe is valued at €28.1 million in 2008 and forecast to grow by 2.9% annually for the 
next seven years to reach €34.5 million by 2015. It is worth noting that for 2008 the figure provided 
by GMD for the device market is only a bit more than half of the similar figure provided by F&S (€ 
28.1 million versus €52.2 million). According to GMD the increasing number of patients with 
cardiovascular diseases and the expanding use of remote patient monitoring in homecare settings for 
the older population will primarily drive the growth. From GMD data the leading European market 
appears to be France (which is only ranked as fourth in F&S). 
Market data in context.  While market reports stress good RMT CAGR and prospects for growth, 
the small almost insignificant value of the RMT market, even when the bigger number estimated by 
F&S is considered, can be appreciated in Figure 6 below, which brings this value into perspective. 
The estimated market value is about 0.9% of the total eHealth market value.  
From a different perspective the order of magnitude of the RMT market can be appreciated looking 
at the specific field of diabetes through the data provided by GMD in a separate report on global Self 
Monitoring Blood Glucose market segment:67 in 2008 globally blood glucose strips and meters 
captured 99.3% of the market, while RMT used for diabetes type I patients only 0.7%. 
 
 
                                            
64  European Remote Patient Monitoring Market M22C-56, 2008. 
65  From e-mail sent by F&S to IPTS on October 29 2009. 
66  European Remote Patient Monitoring Market: Strategic Analysis and Opportunity Assessment, August 2009. 
67  Global Self Monitoring Blood Glucose Market: increasing Adoption to Drive Growth, March 2009. 
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Figure 6 – Orders of magnitude: the “invisible” European RMT market 
 
Source: in parenthesis inside the figure   
Critical assessment of the estimated figures. There are doubts as to whether market research 
companies can actually capture all the relevant sources of data to produce reliable estimates. Even 
defining the companies that are active in the RMT/PHS market is extremely difficult due to the 
fuzziness of the market’s overall structure. Companies position themselves in different ways with 
some offering technological devices only, others monitoring and analyzing services, and only a few 
offering end-to-end services including medical services. Clear definitions of which stakeholders 
should actually be included into the RMT/PHS market are lacking.68 Also determining the active 
attitude of companies positioned in the market from “interested in the market and piloting” to “active 
in the market and doing business” is equally difficult.  
As a consequence, one is left to wonder to what extent market research data over- or under-estimate 
the overall size of the market.69 Our research has revealed that RMT is characterised by many small 
scale and very local initiatives that, we are quite confident, market research does not identify. For 
instance, during the field mission to Italy with the help of interviewed experts we produced a rule of 
thumb estimate showing that the size of the Italian market as quantified by F&S (€31 million) should 
be increased by one third in order to account for small and localised initiatives (€ 45-50 million). 
Second, while the F&S quantification of RMT services excludes the medical part, we are aware of 
companies also providing this component (and in any case the medical part is always provided by 
health care institutions/professionals). This is an important element that is apparently not counted 
when estimating the figures above. In conclusion, the size of the RMT market is very small, both as a 
proportion among other eHealth activities and as an alternative to chronic disease management 
solutions. Moreover, even if the estimates are increased by 30%, taking into account small scale local 
                                            
68  Although this data is not clearly available from market data, we have provided a detailed discussion of all major stakeholders in 
Deliverable D1.1 in the section on measurement and indicators. We are not repeating it here as it would disrupt the flow of 
narrative. 
69  Market research reports analysed were not fully transparent on how their data are estimated. 
 32 
initiatives overall Europe and despite the very positive CAGR estimated, the market will remain 
small for the next few years.  
3.2 RMT market players 
As the previous section showed, the quantification of the market is a perilous exercise. In order to 
complement the findings of market research we carried out a review of PHS/RMT market. A review 
was conducted of more than 200 companies active in eHealth likely to provide PHS/RMT services, 
out of which 50 were studied in more detail. The picture that emerges is that of an under-developed 
market, characterised by fragmentation, small-scale operations and lack of integration into health and 
social care. Each of the companies was checked for location, size, number of years in business, 
geographical focus areas, market segments targeted, type of products/services offered, and role on 
the PHS/RMT value chain. The boundaries between a company's PHS/RMT activities and other 
Health IT activities are often difficult to distinguish but the analysis helped get an overview of how 
the PHS/RMT market is developing and which actors provide what type of products and services. 
Some of the main findings will be reported below, while all findings are in Annex II, Chapter 7. 
Main characterisation in general (200+ companies). There are only few cases of pure PHS/RMT 
players of a certain dimension and success, and most players operate also in other eHealth or Health 
IT related areas. Even when such pure players could be identified, they seem to provide system 
integration, devices, and remote monitoring, but seldom in an integrated manner. The PHS/RMT 
market, thus, appears to be rather fragmented, albeit with a high level of activity at product level. 
While devices and remote monitoring are provided by a large number of companies fewer companies 
appear in the higher-end service provision, which includes the medical component of the service. 
Figure 7 – Companies’ offering (200+ companies) 
 
Source: Authors’ elaboration on collected information on companies offering RMT services 
Most of the companies offer a mix of products and services often characterised by a high degree of 
flexibility. In other words depending on the specific needs of the health care provider for whom they 
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implement the RMT solution, their offer is usually tailored to each case delivering as much or as 
little of the solution as required. For most players, the service provision ends at the point of care 
when the data gathered on the patient is handed over to a hospital or public emergency services. 
Many of the companies consulted do not provide call centre facilities, but subcontract that function if 
needed. This shows that fully integrated services are not widespread and RMT businesses are more 
often a technology-driven undertaking. 
Products for pulmonary conditions, diabetes, and heart conditions are the most common, while a 
number of players offer other devices/tools for disease management, patient databases, sensors, 
hospital information systems, teleconsultation and teleradiology, wellness devices as well as scales, 
spirometers and other monitoring/measurement devices. Large players in the health care industry 
seem to be interested into the RMT market but remain in a “wait and see” situation, possibly because 
of the high fragmentation which makes it difficult to gain significant revenues and leverage 
economies of scale. On the other hand, there is quite a large playing field for SMEs that contribute to 
PHS development with novel products, services and business models, thus helping to drive the 
market. Generalist ICT companies and Telco have entered the RMT market by expanding their 
portfolio, some offering personal health services (e.g. Ericsson, Orange), others offering hospital 
information management and system integration services (e.g. Intel, Cisco, Nokia). 
50 companies analysed in the value chain. Out of the 200+ companies identified as offering related 
services, some 50 considered to be offering Telemedicine services were selected for further analysis. 
Figure 8 below is an attempt to map this selection of 50 companies analysed in detail, situating them 
on the PHS/RMT value chain according to their main activity focus. Except for companies 
specialised in implants, many of the players mapped operate across several areas, which makes it 
difficult to draw a clear player profile.  
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Figure 8 – RMT Companies’ value chain (50 selected companies) 
Source: Authors’ elaboration on gathered companies’ information 
In Figure 8, the 50 selected companies are assigned a colour depending on relative size (red to small 
companies, blue to medium size and purple to big companies). Some companies have an integrating 
role and others provide services over two parts of the value chain or even over the whole value chain 
but this is not discernable on the graph (e.g. VITAPHONE or SALUDNOVA). More analysis on the 
characteristics of the companies can be found in Annex II (section 7) of this report. 
While, we are fully aware that the mapping presented above, does not reflect the actual position of 
many of the companies, we intentionally included it here as a picture that is indicative of market 
fragmentation and which may be used as a starting point for further analysis. At a first glance, one 
can safely conclude that there are plenty of devices on the RMT market, confirming that at least this 
most basic technology block is not an issue. However, when considering maturity of the technology 
on offer, the lack of widely accepted standards and infrastructure interoperability are still challenges 
and alliances like CONTINUA70 or associations like COCIR71 bringing together a sizable number of 
companies are attempting to reach consensus on technical issues affecting the market. 
Revenue streams, pricing, and business model.  We must stress that very limited information was 
obtained (even during interviews), on how RMT products and services are priced and how revenues 
are generated. In general market players were reluctant to provide figures on pricing and the share of 
their revenues coming from RMT, probably because of the sensitivity of such data (cost of service 
provision) considering also the likely small size of the revenues generated. The only information on 
                                            
70  http://www.continuaalliance.org/  
71  http://www.cocir.org/index.php?mode=0  
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the pricing of RMT services is what could be found in public procurement official documentation 
and/or in reimbursement guidelines for three Italian regions (see infra).  
Most activities seem to be confined to national if not regional boundaries, and the main driver for 
targeting new markets is the responsiveness of health care systems to RMT reimbursement (i.e. Pais 
Vasco, ES and Lombardy, IT). As it takes many years for RMT companies to reach a positive ROI, 
funding is a major issue for sustaining the business. For large companies, including Telco and mobile 
operators, investment decisions to participate in PHS and RMT markets are driven by socio-
economic trends and growth perspectives in the medium to long term, not by actual revenues. The 
same goes for relatively small affiliates of large multinationals which enjoy financial backing from 
long established businesses enabling them to be present on a market segment with a promising 
future. For SMEs the outlook is very different; while, sometimes surprisingly, initial funding is not a 
problem, some have to struggle to maintain operations, due to the short-term nature of health care 
providers' budgets which contrasts to the rather long time needed for RMT business profitability or 
even because reimbursement simply does not compensate the costs of providing an RMT service.  
Generally revenues may be derived from providing and installing devices, developing software, 
processing and storing data as well as carrying out technical and clinical triage for the provision of 
care services, and providing call centre services. Some companies charge a one-off fee, sometimes 
subsidised, for the device and monthly subscription fees paid by the patient privately, or reimbursed 
by an insurance company. Others negotiate contracts for a number of patients with a health care 
provider directly (at local, regional level in coordination with a local secondary care unit). Some 
mobile players propose care distribution models where the benefits of early discharge are shared 
among several of the value chain stakeholders but the sustainable implementation of such models is 
still being trialled. Even for RMT schemes led by public health care authorities the costs structure is 
not always clear, and does not reflect the actual value of the service provided. 
All companies interviewed in the field research deal with RMT for chronic disease management. 
While few deliver services over the full value chain of products and services, most companies offer 
solutions adaptable to each of the three most common chronic conditions and their co-morbidity. 
Some players indicated further interest in the wellness part of the market, offering products for 
lifestyle, home and elderly social care. Cardiac implant companies started developing RMT with new 
generation implants, a niche market within RMT. 
Business models seem to develop in an iterative, pragmatic way. Even when a company develops a 
sound business plan based on solid market forecasts and realistic reimbursement perspectives, reality 
often turns out to be different and forces changes on their initial plans (e.g. need to diversify into 
other branches of eHealth to secure stable revenues). Although more empirical data is needed to 
draw sound conclusions, the business strategy of the companies interviewed seems to be linked to the 
following elements: 
• The health care system of the country of origin of a company influences its business model 
offer, focusing on the needs of a specific stakeholder (e.g. health care rather than social care 
or private insurance); 
• A company that covers the full RMT value chain, which by including specialised call centre 
services seems to limit the focus of the activities to one chronic disease condition for example 
only cardiac disease management (i.e. HTN, Vitaphone). This may be explained by the 
complexity and costs of running an in-house medical centre with several medical specialties; 
• A further element is the orientation of a company in terms of its medical or technological 
expertise. In other words, when a company is created around a technology, its offer is likely 
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to be wider as technology can in principle be applied to various diseases while a company 
from the medical sector will concentrate on its specialty (e.g. diabetes for Roche). 
3.3 R&D, pilots and programmes 
Why look at pilots, projects, and programmes. The review of companies, both by means of desk 
research and expert interviews reveals an RMT market fraught with difficulties, characterised by 
fragmentation, small scale operations, and the availability of discrete specialised technological 
solutions, much less of integrated service provision that could contribute to the much awaited new 
models of care. Though, to integrate RMT technology into care pathways and bridge the gap between 
the promises of technology and the reality of health care and social care is the target today. To do so 
advances are needed at organisational and institutional innovation. As this is unlikely to happen 
through market forces alone, we considered that the review of market players had to be 
complemented by an analysis of what has been and is being done in R&D activities, in pilots and in 
experimental programmes at EU, national and regional level, so as to provide a more comprehensive 
picture and assess to what extent the move from R&D, through pilots and programmes, eventually to 
sustained and stable services is likely to drive the health care transformation.  
EU funded R&D and Pilots. Since 1989 EU research funding for eHealth has exceeded the €1 
billion mark spanning more than 500 eHealth projects. Within the FP5, FP6, FP7, eTen and CIP 
European Commission funded programmes,72 23 projects (see projects names in Table 11) clearly 
focus on RMT. In addition some Living Labs also tackle RMT as part of their eHealth or Active 
Ageing activities. Integrating health-monitoring tools into textiles e.g. through wearable electronics 
and body sensors, has been the focus of a number of FP5 and FP6 projects while research on new 
bio-sensors has gained importance under FP7 (e.g. for continuous monitoring of blood pressure, 
blood oxygen levels and heart function). Innovative closed-loop approaches for chronic disease 
management is another feature of FP7 projects like HeartCycle (coronary heart disease and heart 
failure), Metabo (diabetes) and Chronious (COPD and CKD – chronic kidney disease). In some cases 
the platform used even connects to electronic patient health records (Heartfaid/FP6 or 
Linkcare/eTEN). The systems developed are intended to report automatically to clinicians, who may 
adapt therapies and make lifestyle recommendations (medical loop), as well as involve the patients in 
the management of their disease (patient loop). Remote communication of data is ensured by 
wireless, mobile communications, using PDAs, mobile phones, Internet technologies, home-
interactive TV or agent technologies. The latter are promising technologies for chronic disease 
management, in the form of continuous support personal assistants in daily life allowing compliance 
support, interface with monitoring devices, real-time medical advice (e.g. PIPS, and Saphire FP6 
projects). Mobile trans-European services for chronic disease management have been researched into 
by projects like FOR-ALL and HealthService24 (eTEN). Finally, robotics is considered as having 
great potential for home patient monitoring although this may be the case in a more distant future. 
"Integrated care" services (i.e. the combination of social and health care) for effective management 
of chronic disease can be found in a large number of projects. A series of "integrated care" projects 
led by Hospital Clinic of Barcelona since 2000 shows the high potential of this approach. Further 
examples include Health-Life, Linkcare, Better Breathing FOR-ALL (eTEN) and CommonWell or 
NEXES (CIP). The CIP promotes the deployment of ICT solutions supporting integrated care 
management and home care. Most of the projects we considered have foreseen clinical trials with 
'real' patients but outcomes are often still to be assessed. In some cases results are available as for 
                                            
72  European Commission R&D funding instruments through Framework Programme 6, 7 as well as the European Community eTEN 
programme and its successor, as of 2007) the Competitive and Innovation Framework programme (CIP). 
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Heartfaid (FP6), Better Breathing (eTEN), Health-eLife (eTEN), HealthService24 (eTEN) or the 
HHH (FP5, Home or Hospital in Heart Failure) study. Observations strongly emphasise the need for 
further confirmation of findings by means of large-scale randomised intervention trials, at European 
scale, such as the one recently launched with funds from the CIP programme.73 The analysis of 
projects shows that the innovation focus is shifting from a technological to organisational innovation, 
with the increasing prominence of "integrated care" projects. At the same time, projects increasingly 
include a pilot component aimed at testing the RMT/PHS solution in real settings, with real patients 
so as to generate the much-needed evidence of RMT/PHS efficiency and effectiveness as well as to 
share the benefits produced with as many patients as possible.  
National and regional levels pilots and programmes. Like for projects, the pilot and programme 
landscape is very varied, with small, medium and large-scale initiatives at local, regional and 
national level. EU Member States further support regional and national RMT projects and pilots via 
public funding and public-private partnerships (e.g. in the UK, Italy, Germany and Spain) in addition 
to private or industry-led initiatives (e.g. in Austria, and Hungary). Projects span from monitoring to 
early prevention and home care. Chronic Heart Failure (CHF), diabetes and pulmonary conditions 
like COPD (and co-morbidity) are most addressed, followed by Chronic Kidney Disease (CKD) and 
neurodegenerative diseases. Local, regional or national pilots and projects often start from a very 
small scale (ten to fifty patients) and get scaled-up to a few hundred patients in a later stage (or not 
mainly depending on whether financing is sustained over a number of years). Very few large-scale 
RMT projects with thousands of patients (e.g. ECCH, Northern Ireland and WSD, England), have 
been launched so as to strengthen the evidence about RMT benefits and enable the transformation of 
health care delivery through RMT. A number of examples are presented below; they are only 
illustrative and do not aim to fully capture all of the activities occurring in the field. 
In Italy after some years of experimentation sustained services are being provided in three regions 
(Lombardy, Piedmont and Veneto), although under different arrangements (see Figure 9).  
                                            
73  Regions for Europe Working together in Health; RENEWING HEALTH <http://www.renewinghealth.eu> 
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Figure 9 – RMT and telecare activities in three Italian regions  
Source: Data gathered by IPTS during field mission to Italy (interviews and official documents) 
In Lombardy a number of reimbursed protocols for RMT have been formally defined and regulated 
by the regional administration and the services are currently being provided. Piedmont and Veneto, 
on the contrary, have launched procurement tenders that have been adjudicated to external suppliers 
with a fixed number of patients to be targeted by the services on offer (to be selected by local health 
authorities in collaboration with hospitals and GPs) and also a fixed price. Considering the price for 
RMT of Chronic Heart Failure patients we could establish that it ranges from 4 € per day per patient 
to up to 9 € per day per patient depending on the complexity of the services and on the amount of 
required intervention by professionals. It must be stressed that these fees are for services including 
the intervention of professionals, whereas the lower price of the Veneto case is for traditional 
telecare services for the elderly to which a very basic and limited monitoring of vital parameters has 
been added. 
The ECCH programme (Northern Ireland), the regional Telecare Development Programme (TDP, 
Scotland), Telescot (NHS Lothian) and the Whole System Demonstrator (WSD) in England are all 
large-scale RMT initiatives aimed at scaling-up deployment from a couple of hundred patients 
(Telescot) to five or six thousand patients (ECCH, WSD), with different strategies: pre-procurement 
(ECCH), randomised control trial (WSD, Telescot) and telehealth/telecare convergence (WSD, 
London). All these initiatives were recently launched (2008-2009), which shows that large scale 
RMT deployment is a new phenomenon. Further they all plan to scale-up the number of patients 
included in the RMT scheme incrementally, which points to the complexity of deploying RMT 
solutions. 
Apart from the above cases, regional and/ or local pilots tend to target small numbers of patients. 
Examples include about 300 UK telecare services provided by local authorities or housing 
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associations for various chronic diseases, the Koala study in the Netherlands scaled up from 
originally 155 patients to 1000 across the country, or the Costa del Sol pilot in Malaga started with 
15 CHF patients. Industry-led pilots include the Roche diabetes RMT initiative in Spain, the Orange 
Health care mobile pilot in Austria and the GE Health care RMT pilot in Hungary.  
The reviewed activities show that RMT technology innovation is incremental, enhancing existing 
products or devices (implants, vital sign monitoring, and communication devices), software (e.g. 
intelligent data processing, decision support software), infrastructure (telecommunication networks, 
protocols, standards) and systems (integration with EHR). Further the research and innovation focus 
is currently moving towards innovations of a different type, like process innovation (e.g. innovative 
closed-loop approaches), organisational innovation (e.g. "integrated care" models) or institutional 
innovation (reimbursement models). At its broadest, Integrated Care may encompass preventive care, 
social care, and care and support in the home, recognising that social conditions impact on health and 
vice-versa. It imposes the patient’s perspective as the organising principle of service delivery. It is 
presumed that chronic care management can be most effective when established within a wider 
system of integrated care.  
However in most European countries today social and health care are two separate entities with 
separate budgets and different infrastructures, which very often do not "talk to each other". This 
makes convergence and integrated care in Europe look like a distant dream. Major efforts are 
therefore needed to ensure that the radical innovations required and tested in some pilots and projects 
can unfold at the right pace and in the right scale. Unfortunately while RMT is thought to contribute 
best to the much praised paradigm shift towards patient-centred services and out-of-hospital care, 
which should help health care systems adapt and cope with demand in the future, not enough is being 
done at national level to push for the radical changes needed to care practices. If nothing is done at 
organisational and institutional level projects and pilots alone will not succeed in transforming health 
care at the pace that is needed. 
Slow progress from R&D to sustained services. Summing up the evidence gathered, we can 
conclude that the landscape is dominated by pilots and programmes with very few isolated cases of 
sustained long-term services. So, from a different perspective we corroborated the picture emerging 
from the analysis of companies. Additionally this analysis shows that 10 years of top level funding 
for R&D and pilots have failed to break the strong barriers that impede reasonable scale viable RMT 
service provision. One major hindrance for moving from R&D projects and from pilots to production 
seems to be the lack of funding for the transition period towards full deployment, leading many 
projects and pilots to stop after funding has dried out. Projects followed by pilots, that may be used 
to identify and correct implementation problems mostly to do with scaling up to thousands of 
patients, may be the most efficient route towards sustained service provision (as well as being a 
sound basis for building business cases). It remains to be seen whether successful pilots can lead to 
service deployment in countries not involved in the initial experiment, as this would speed up RMT 
take-up in Europe. However to date, it seems that each new initiative requires its own pilot thus 
delaying time to market. 
3.4 Europe vs. US market trends 
Having looked at detail at the RMT market size estimates, a brief comparison with equivalent 
estimates for the USA will help us understand whether the situation in Europe is particular to 
conditions in Europe or safely attributed to challenges in relation to the deployment of RMT. A 
report on mHealth and home monitoring by Berg Insight provides interesting comparison between 
market value and growth for the US vs. Europe, as summarised per segment below in Figure 10: 
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Figure 10 – Home Medical Monitoring market value by segment (world 2008-2013)  
 
Source: Berg Insight, 2009 
According to Berg Insight74 the market for home health monitoring – roughly corresponding to RMT 
– was worth USD 11 billion in 2008 (€7.84 billion)75 with diabetes monitoring by far the leading 
segment, although 90% of sales relate to strips and only 10% to actual monitors. 
On the glucose monitoring segment Europe has the lead with a share of the global market estimated 
at USD 4.9 billion (€3.5 billion76) against USD 3.3 billion (€2.35 billion) for the North American 
market, out of a global market of USD 9 billion (€6.4 billion). Interestingly, European growth rates 
are foreseen to be 10% annually for the period 2010-2014 against 6% for the US. 
The total North American market for home cardiac monitoring today is worth USD280 million (€200 
million) while the European market is only worth USD 10 million (€7.1 million). Berg Insight 
concludes on the significant potential for growth in Europe in that segment. In particular "home 
arrhythmia monitoring is likely to be adopted in Europe in a few years" in their view. For the US, 
90% of the market value comes from services with only 10% related to the sale of devices.  
According to the same study, the North American market for out-of-hospital blood pressure 
monitoring is worth USD300 million (€214 million) while the European market is estimated to 
account for USD250 million (€178 million), out of a global market of USD 800 million (€570 
million). Berg Insight foresees an annual growth rate of 8% worldwide until 2014. 
As to air flow monitoring, the market is estimated to be worth USD 50 million with an expected 
growth of 9% annually until 2014. Berg Insight foresees the sales of home spirometry devices for 
COPD patients as likely to increase, leading to the appearance of monitoring services in that 
segment. 
In conclusion Berg Insight underlines that remote monitoring has given rise to a substantial market 
only in one of the nine segments they have examined, namely the glucose monitoring segment, for 
which growth rates are expected to reach 8-10% after 2011 with a wider deployment in Europe in the 
future. Berg Insight stresses that there is a significant untapped potential for remote monitoring both 
in the US and in Europe, and estimates that 25% of the people suffering from diseases that may 
                                            
74  mHealth and Home Monitoring report, second edition 2009. 
75  Exchange rate taken from Berg Insight's conversion, e.g. p.63. 
76  As was also commented when sizing the RMT market, estimates and forecasts from various consultants differ widely: for instance 
the Berg report estimate of the 10% of European Glucose market, effectively addressing monitoring services, would be €350 
million which is of the same order of magnitude but significantly larger than the F&S estimate (see footnote 64 on page 30). This 
is only to be expected as described in detail on page 36 and 37).  
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require home monitoring would benefit from existing wireless solutions, while another 50% could 
benefit from integration of existing medical devices.   
Berg Insight also foresees a migration of cardiac monitoring towards wireless networks from existing 
solutions mostly provided over fixed lines, with added flexibility and user friendliness. For other 
segments they predict an evolution towards the consumer market with the convergence of medical 
and mobile technology. Data centres for home medical monitoring is likely to open new business 
opportunities for network providers and mobile operators. 
In summary the position of Europe vs. the US varies depending on the segment considered, as 
Europe is significantly ahead of the US market on the glucose monitoring segment but lagging 
behind dramatically on the home cardiac monitoring segment (the European market value is only 
3.5% of the US market value) and somewhat behind on blood pressure monitoring. As to COPD and 
air flow monitoring, there is no comparative data between Europe and the US so all that can be said 
is that it is the smallest segment of the above four in terms of value globally albeit with long term 
growth expectations. 
3.5 Summarising the evidence 
The key empirical findings, fully corroborated by the country studies (see Annex III, Section 8) can 
be summarised into the following three blocks: 
• Market data. Market data show that the market size is very small, in its infancy; market data 
are also of dubious reliability and raise a number of conceptual issues to be discussed; 
• An R&D and pilot subsidised market. There have been and continue to be pilots of varying 
scale and ambition. Most of them are abandoned once the funding mechanism is stopped. 
(The UK demonstrators and the CIP Pilot Renewing Health77 are the most ambitious ones.). 
A lot is still done under R&D and in form of pilots; 
• Unclear and shaky context for market players. There are small SMEs and large 
companies, which find this a high potential market but do not see ways to develop it. Setting 
up an RMT service requires a heavy upfront investment and the ROI only comes from long-
term deployment and only if this is done on a sufficiently large scale (i.e. with enough 
patients). As a result there are very few specialised companies, since business sustainability 
requires diversification. Large players are in a “wait and see” mode and keep investing to 
have a presidium on the market in case it eventually takes up. 
Further more detailed analysis on barriers justifying the various findings that we collected directly 
from stakeholders and experts will be reported on these in Section 5. 
                                            
77  A CIP funded large scale activity started in March 2010 (see details at http://www.renewinghealth.eu). 
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4 Evidence on RMT outcomes and the potential of higher deployment 
4.1 The importance of evidence on outcomes 
Considering the need for RMT and the relative absence of deployment as evidenced by the findings 
in sections 2/3, it is reasonable to wonder whether the evidence on the outcomes of the RMT services 
that are under trial exists, is positive or whether it is visible enough among the stakeholders. 
Producing evaluation and measurement indicators in a multi-stakeholders perspective is of strategic 
importance for the wider adoption of such services and the challenges of realising it in practice have 
been analysed in full depth in Section 3 of the Deliverable D1.1 “Report on the Overall Structure of 
the Strategic Intelligent Monitor”. Methodological implications for producing robust and convincing 
evidence of outcomes that can be causally attributed to RMT or any other PHS application is also 
reported in detail in Deliverable D1.1; a few important points are re-iterated here, for the sake of 
clarity. 
Evidence on positive role of ICT on clinical outcomes is required more than in other fields. 
Remote monitoring and treatment, as any other ICT enabled service in the health care sector, deals 
with the most precious of all values: life itself. It is, thus, clear that evidence on clinical outcomes 
and patient safety is a pre-condition for the acceptance of the technology by medical professionals 
and patients alike.  
Different groups of beneficiaries and stakeholders shall be convinced. Evidence on RMT should 
prove positive outcomes for different audiences:  
• Users/ patients (plus relatives and their associations/ advocates). Patients are the primary 
beneficiaries and their relatives are the secondary beneficiaries of any RMT service 
provision. First, naturally robust evidence that RMT can safely improve patients' health 
status; and second, evidence on patients improved quality of life, autonomy, control over their 
daily lives is needed to create confidence and overcome any resistance to the application of 
the technology; 
• Broadly defined health care professionals.78 Assuming RMT deployment produces the 
foreseen benefits, medical professionals will also benefit ex post as they will be required to 
concentrate their efforts to the patients that mostly need help. RMT will also provide medical 
professionals with more comprehensive data (from more regular recordings of patients' health 
status) to make more accurate decisions, thus offer better care to their patients. Ex ante, 
however, they are stakeholders in need of being convinced that RMT: (a) generates clinical 
outcomes responding to medical guidelines; (b) does not damage doctor-patient relations or 
creates risks of malpractice lawsuits79 and (c) induces improved working conditions and 
optimisation of workload and not increased workloads which in addition are not dully 
compensated by appropriate incentives); 
• Management of health care producing units (i.e. hospital, laboratory, GP practice). The 
managers of producing units as a second tier of intermediate beneficiaries (naturally taking 
for granted that they also care about patient safety and clinical outcomes) may be also 
interested in improving the efficiency of the production processes and of the allocation of 
                                            
78  This general category represent a simplification we make for the sake of brevity for it should be further broken down into nurses 
and doctors, and among the latter between primary, secondary, and tertiary level professionals. 
79  The risks often raised by professionals include: a) inappropriate treatment or delay in care (inaccurate/inappropriate information 
may confound or complicate treatment decisions and delay care); b) unintended errors; c) inappropriate use of applications or 
information or unintended diffusion of sensitive information may undermine trust and prompt conflicts and motivate consumers to 
seek care from questionable providers. 
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resources since this means that they will be able to increase the quality and quantity of output 
with the same level of input. However, also in this case, ex ante as stakeholders they have 
concerns that home care for an increasing number of chronic patients without an adequate 
alternative economic scheme or new structure of incentives may lead to a net decrease of the 
funds provided to their organisations;  
• Broadly defined institutional stakeholders/third party payers80 are interested in 
containing the rising cost of health care for chronic patients while at the same time, coping 
with increasing shortages of professionals, meeting growing demands and increasing the level 
of satisfaction and trust on the side of the citizen with respect to the European health care 
system. Naturally, though from a different perspective, also institutional stakeholders would 
like to avoid issues of malpractice, privacy violations, etc. Moreover, when deciding to invest 
public funds into such services, decision makers require proof that these funds are not wasted 
and that such services do not drain resources that may be better employed for other purposes. 
• Broadly defined industry stakeholders (suppliers)81. Naturally suppliers are not indifferent 
to clinical outcomes and patient safety, also for the simple reason that errors and malpractice 
lawsuits affect them as well. They are interested in providing quality services and 
demonstrable outcomes in order to consolidate and expand this market opportunity. Naturally 
they are interested in generating revenues and profits from such activities and, in this respect 
they may want to accelerate the process. Indeed, there are differences of opinions among the 
various stakeholders as to whether the evidence gathered so far is enough, as well as when 
and under what conditions the evidence collected will be considered sufficient82. 
State of the art. Certainly there is no dearth of RMT evaluation studies (and related meta-studies) 
that try and formally test some or all of the potential outcomes mentioned above. Such studies are 
selectively considered in the next paragraphs and systematically reviewed in summary tables 
reported in Annex IV (Section 9). More in general there are plenty of evaluation studies in 
telemedicine and others areas of eHealth; a single meta-analysis article, for instance, identified 612 
different studies focussing on the evaluation of telemedicine outcomes.83 There are also hundreds of 
case studies reporting evidence on various outcomes,84 etc. Yet, there is a lack of widely used and 
standardised approaches and particularly of institutionally approved and applied systems of 
evaluation and measurement.  
The field is still characterised by a lack of consistency between studies in terms of evaluation 
frameworks used, outcome indicators and measures available and adopted, and tools available and 
applied.85 In brief, the shortcomings of analysed evaluation studies include: (a) evaluations not based 
on standard methods, guidelines and toolkit to cope with the complexity of a multi-stakeholders and 
                                            
80  We refer here generically to policy-making and overseeing bodies, without distinguishing the various possible tiers (national, 
regional, local). We also join here together policy-making and funding bodies, which fits universal NHS models but not the 
systems where such bodies are separated (i.e. in social insurance models). This aggregation also overlooks the fact that third party 
payers can be private insurances. We assume they are broadly interested in the same outcomes as public third party payers. 
81  In this case, the treatment of industry players as a unified category simplifies the difference between those supplying strictly ICT 
services and those who, not belonging to the health care system proper, also provide the medical components of the RMT service. 
82  See minutes of SIMPHS November 2009 validation workshop, where stakeholders raised concerns on this issue: 
http://is.jrc.ec.europa.eu/pages/TFS/documents/MinutesSIMPHSValidationWSfinalforpublication.pdf 
83  P. Whitten et al, Systematic review of cost effectiveness studies of telemedicine interventions. British Medical Journal. 324 
(2002), 1434-1437. 
84  For instance 257 of such studies are reviewed in B. Chaudhry et al, Systematic review: impact of health information technology on 
quality, efficiency and costs of medical care. Annals of Internal Medicine, 144 (2006): E12-E22. 
85  R. Scott et al, Telehealth outcomes. Journal of Telemedicine and Telecare, 13 (2007, Supplement 2). 
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multi-beneficiaries domain; (b) fragmentation of evaluation and measurement approaches produced 
in different disciplines; and (c) limited resources allocated to the evaluation process.86 
A hierarchy of validity. The above difficulties are also related to the intrinsic methodological 
difficulties of causally attributing an outcome (i.e. reduced mortality) to an output (i.e. number of 
patients treated with RMT) in a scientifically and empirically robust and valid fashion. Between the 
production of an output and the realisation of the outcomes there are several intervening variables 
that must be controlled for. For this reason experimental design through Randomised Control 
Trials (RCT) with patients randomly assigned to the treated groups (receiving RMT services) and to 
the control group (not receiving RMT services but cared according to parameters ensuring they 
receive adequate quality of "usual" treatment) is considered the most valid and reliable form of 
evaluation. The random selection should control for the different individuals and socio-economic 
characteristics of the patients avoiding possible bias, as patients with particularly favourable and/or 
unfavourable parameters and conditions should be present in both the treated and the control groups. 
The settings of treatment should ensure that patients in the control group do not receive an inferior 
level of quality of treatment compared to the treated group. While RCT are placed at the top of the 
hierarchy of validity, they also present shortcomings. They are discontinuous and, between one test 
and the other, clinicians use data that can be unreliable due to their obsolescence. Moreover, they do 
not provide the continuity needed for a stable and institutionally accepted system of evaluation and 
measurement. 
Going down the hierarchy of validity we can find longitudinal studies of the same cohort of 
patients, whose parameters are steadily compared to the zero measurement (before they started the 
RMT treatment) and year-by-year. The parameters for the RMT treated cohort are also compared to 
those of patients not receiving RMT services. Yet, in this case, the equality of treatment settings is 
not ensured. Moreover, patients who are part of the cohort may over time develop very specific and 
favourable motivation and lifestyle behaviours, which would set them aside from the population of 
average patients. Due to these two characteristics the results from such studies are considered as 
providing weaker evidence as compared to that of RCT. 
At the bottom of the hierarchy we find case studies, the majority of which tend to show positive 
outcomes (here we do not refer only to RMT but to eHealth in general).  Yet, case studies do not 
allow attribution of ICT supported output to observed effects as it is not possible to apply 
randomisation or case-control design to the evaluation study. Moreover, it is difficult to generalise 
from the particular study to the broader context since in many instances the cases concern leaders 
and best practices and are much less representative of usual practice.87 
4.2 Evidence on clinical and cost-effectiveness outcomes: selected examples 
As anticipated, evaluation studies of RMT are treated more systematically in Annex IV while here 
we only selectively discuss some of them. One of the better known cases is that of the Veteran 
Health Administration (VHA)88 summarised in Table 8. 
                                            
86  E. Ammenwerth et al, (2004). Vision and Strategies to Improve Evaluation of Health Information Systems. International Journal 
of Medical Informatics. 73 (2004): 479-491. 
87  OECD, The Contribution of ICT to Health System Productivity and Efficiency: What Do We Know? Paris: OECD, 2007. 
88  A. Darkins et al. Care Coordination/Home Telehealth: The Systematic Implementation of Health Informatics, Home Tele-health, 
and Disease Management to Support the Care of Veteran Patients with Chronic Conditions. Telemedicine and e-health, 14(1) 
2008: 1118-26. Other articles discussing the VHA case include: R. Schofield et al. Early Outcomes of a Care Coordination-
Enhanced Telehome Care Program for Elderly Veterans with Chronic Heart Failure, Telemedicine and e-health, 11(3) 2005: 1118-
26. 
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Table 8 – VHA CCHT success case 
 
Source: see footnote 88 
Indeed, the results of the VHA case are impressive and solidly documented, but they may suffer from 
the earlier discussed bias that characterises longitudinal studies of the same cohort of patients. 
An RCT of a Home-based Telemanagement (HBT) programme (i.e. RMT integrated within a disease 
management programme) specifically designed to prevent hospital readmission of patients with CHF 
has been carried out by Fondazione Maugeri in four regions of Italy (Lombardy in two provinces, 
Piedmont, Campania and Apulia).89 The study documents evidence in relation to hospital 
readmission, clinical outcomes, and cost-effectiveness. All-cause90 hospital readmission in the HTB 
treated group was 36% lower than in the Usual Care (UC) group (HBT patients show likelihood of 
readmission after 1 year of 28% compared to 42% for UC patients). One-year total mortality rate was 
9% in the HBT group and 14% in UC group. Lower bound mean cost for HBT group for hospital 
readmission was €843 versus €1298 for the UC group, and the annual cost to prevent one 
readmission was €638. 
Positive outcomes have been demonstrated in another Italian randomised control trial concerning 
tele-assistance to patients with chronic respiratory failure with reduction of 36% in hospitalisation, 
65% in urgent calls to GPs, and 71% in acute exacerbations.91 On diabetes, research conducted by 
Protti in Australia shows that integrating Electronic Medical Records (EMR) with ICT enabled 
disease management could curb diabetic deaths by 32%.92 Several others single RCT can be found 
that report positive outcomes. 
A different strand of literature provides meta-analyses of single studies such as the above, where 
such a meta-analysis is not a simple review of the literature. Meta-reviews, in fact, analyse several 
studies and then select only those where the results can be aggregated and re-elaborated statistically 
                                            
89  A. Giordano et al. Multicenter randomised trial on home-based tele-management to prevent hospital re-admission of patients with 
chronic heart failure. International Journal of Cardiology 131 (2009) 192–199. 
90  This refers to re-admission to the hospital due to all possible causes and not only to CHF. It is important to stress that CHF patients 
treated with RMT may avoid re-hospitalisation for that disease but may nonetheless develop other conditions requiring inpatient 
care. 
91  M. Vitacca et al. Tele-assistance in chronic respiratory failure patients: a randomized clinical trial. European Respiratory Journal, 
33 (2009): 411-41. 
92  D. Protti, The Application of Computer Technology in GP Surgeries is Beginning To Have Positive Effects on Chronic Disease 
Management, World View Report 5, Connecting for Health: http://www.connectingforhealth.nhs.uk/newsroom/worldview/protti5  
From 2003 till 2007, VHA introduced the national home telehealth program "Care 
Coordination/Home Telehealth"(CCHT), which basically upgraded an existing disease 
management approach for non-institutional care (NIC) services with a RMT component. The 
number of patients treated increased from 2,000 to 31,750 and the diseases addressed included, 
among others, diabetes, CHF, and COPD. Data from the analysis of a cohort of 17,025 CCHT 
patients shows 19% reduction in hospital admissions, 25% reduction of bed days of care, a mean 
patients' satisfaction score of 86% with a per annum cost of $1.600, which is about half the cost 
for traditional NIC services.  
Disease-specific data include: 
• Diabetes:  20.4% decrease in utilisation of traditional NIC services; 
• CHF:   25.9% decrease in utilisation of traditional NIC services 
• COPD:  20.7% decrease in utilisation of traditional NIC services 
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to test the extent to which the outcomes documented in a single study hold when considered jointly 
with those of other comparable studies. For instance the meta-analysis by Clark et al looked at 234 
studies focussing on remote monitoring of CHF patients, of which only 14 (for a total of 4264 
patients) met the criteria for inclusion and were analysed.93 Clark et al found that remote monitoring 
of CHF patients: (a) reduces all cause mortality by 20%; (b) reduces rate of admission to hospital for 
CHF by 21%; but (c) the evidence on reduction of all causes hospitalisation is not conclusive 
(patients may be re-hospitalised not for CHF but for other morbid conditions). More recently 
Polisena et al using a similar approach analysed 21 studies (still focussing on remote monitoring of 
CHF) for a total of 3082 patients.94 Polisena et al confirm the above findings in that mortality is 
significantly lower and several studies suggest reduced hospitalisation and utilisation (but the data 
presented do not allow conclusive statements on all cause hospitalisation). 
In the earlier quoted editorial Cleland and colleagues95 comment on the findings of Clark et al and of 
two additional studies,96 that there are few doubt about the fact that telemonitoring reduces mortality 
among CHF patients but that the evidence is not conclusive as to the reduction of all cause 
hospitalisation. They add, however, the following important analysis: 
"Most patients with heart failure receive much poorer care than the patients included in 
any control group of any telemonitoring study conducted so far. Annual mortality for 
contemporary patients discharged from hospital after worsening heart failure in the real 
world is between 25% and 40%. The lack of effect on hospitalization could simply reflect 
a lack of benefit. However, timely hospitalization may have been the reason for the 
reduction in mortality and keeping patients alive means they have a chance of being 
hospitalized again. In this sense, hospitalization is a good outcome rather than evidence 
of disease progression and casts doubt on the wisdom of hospitalization as an endpoint in 
clinical trials."97 
Indeed, if we look at the results only from the perspective of clinical outcomes in terms of reduced 
mortality there is no doubt that RMT produces the desired outcomes. Moreover, although the 
evidence from RCT is not conclusive as to reduced hospitalisation (that is its cost-effectiveness), the 
implications from the above quote are two: (a) if we compare the patients treated with RMT not to 
the control group but to the average patients probably the cost-effectiveness would be evident and 
also the VHA case shows that the cost of patients treated with a combination of RMT and disease 
management is half that of those treated in a traditional manner (not totally scientific but anyway it is 
a good evidence); and (b) reduced hospitalisation should not be the main parameter to evaluate RMT 
for its contribution is to enable an increased rate of services which reach more people with the same 
level of input. 
So, going back to the key question: does RMT work? Is the evidence gathered so far enough? If not, 
what else need to be done? 
The evidence is increasingly compelling but seems not yet sufficient to convince all stakeholders and 
lead to full acceptance and deployment of RMT. Yet, we think that this is only one side of the 
                                            
93  Clark RA, Inglis SC, McAlister FA, Cleland JGF, Stewart S. Telemonitoring or structured telephone support programmes for 
patients with chronic heart failure: systematic review and meta-analysis. British, Medical Journal, 334 (2007): 942-945. 
94  A. Polisena et al, Home telemonitoring for congestive heart failure: a systematic review and meta-analysis, Journal of 
Telemedicine and Telecare, 16 (2010): 68-76. 
95  Cleland et al Telemonitoring for heart failure, op. cit. 
96  A. Mortara, et al Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). European 
Journal of Heart Failure 2009 11(3): 312-318; D. Owais, A randomized trial of home telemonitoring in a typical elderly heart 
failure population in North West London: results of the Home-HF study. European Journal of Heart Failure 11(2009): 319-325. 
97  Cleland et al Telemonitoring for heart failure, op. cit. p. 227. 
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picture. RMT does not take off not only because evidence is not entirely convincing but due to other 
sources of resistances. Having said that, naturally more can be done to better and more systematically 
collect evidence using widely shared and commonly accepted methodology and toolkit.  
4.3 Assuming evidence has convinced stakeholders: what if … 
Certainly, more work is needed to reinforce the evidence base but we can safely state that the various 
forms of RMT discussed and especially those that are integrated within a wider disease management 
approach do seem to produce important outcomes. Should this evidence be confirmed and the use of 
such approaches eventually take off on a larger scale than the current one the aggregate outcomes 
that could be achieved would be sizeable and RMT would become an important market opportunity. 
Below we first report two extrapolations of potential outcomes based on scenarios of higher level 
deployment that have been produced in the Swedish Presidency eHealth for Healthier Europe cited 
earlier for six Member States (Czech Republic, France, the Netherlands, Sweden, Spain and the 
United Kingdom). These extrapolations are based on clinical metrics gathered for each of the six 
Member States (number of admissions for chronic diseases, mortality rates, etc) to which the authors 
have applied benchmarks of benefits extracted from the literature reporting evidence on the 
application of ICT in the management of chronic patients. 
Reducing deaths from diabetes complications.98 The total number of deaths in the six countries 
that can be attributed to complications caused by diabetes are 35,000 per year. According to the 
figure reported earlier (see footnote 92), the application of EMR in combination with an ICT 
supported disease management toolkit could save up to 32% of diabetic deaths. From interviews the 
authors assessed that the deployment of such a solution (EMR plus disease management) in the six 
countries ranged from zero to 70%. Under the assumption that such technologically supported 
approach reached full adoption in all six countries, up to 11,000 deaths could be saved each year 
(35000 * 0,32). 
Reducing hospital admissions of chronic patients.99 In the six countries about 40.000.000 hospital 
admissions are reported yearly, of which it is estimated that between 75% and 85% (so up to 
30.000.000 admissions) are for chronically ill patients. From interviews the authors estimated that 
the level of adoption of Telemedicine and Home Health Monitoring in the six countries ranges from 
zero to 10%. Assuming full adoption and applying the 20% benchmark of reduced hospitalisation as 
a result of Home Health Monitoring (taken from one of the many publications about the VHA case 
seen earlier) they estimate that up to 5.6 million hospital admissions could be avoided annually in the 
six countries. 
While scientifically questionable, these estimates can nonetheless be considered good enough to at 
least reflect the order of magnitude of the potential aggregate outcomes.  
An extrapolation on CHF patients. Described below, is a set of extrapolations on the potential 
value of the market and the potential benefits from higher deployment of RMT for CHF patients 
only. In paragraph 2.2, when we presented the data available on prevalence, costs, and other 
parameters, we also cited a number of disclaimers as to the scientific validity of these extrapolations 
that apply here as well. As illustrated there, there are few standardised and comparable ready to use 
metrics. Having not had the resources to thoroughly collect clinical metrics and interview experts in 
all of the European countries for which we present the extrapolations, we relied on the following 
                                            
98  eHealth for a Healthier Europe, op. cit, p. 34. 
99  eHealth for a Healthier Europe, op. cit, p. 36. 
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available data: (a) various type of information gathered from the literature; (b) the comparable and 
standardised data contained in OECD Health Data 2009 only for EU19;100 and (c) the interviews 
conducted during the country studies (from which we extract our main hypothesis of CHF 
addressability through RMT).  
As a result, we could not find, for instance, the number of yearly admissions due to Chronic Heart 
Failure. We know from the literature that CHF patients account for 5% of yearly hospital admissions 
but we could not find anywhere (not even in the OECD 2009 Health Data) the total number of yearly 
hospital admission in EU27 or EU19 or EU15. We also could not find any reliable and comparable 
benchmark on the average cost of one hospital day for CHF patients; although we know from OECD 
Health Data 2009 that in EU19 CHF patients (once admitted) stay on average in the hospitals 10.2 
days. All limitations and assumptions that were taken into account when developing the 
extrapolations below (2 scenarios for cost and 2 for cost savings), are transparently described in 
Table 9 and the corresponding explanatory notes (see pp.54 and pp. 55).  
Considering only data for CHF, assuming a prevalence of 2% over the entire European population 
and that only 20% of the CHF patients in EU19 are able to be treated with RMT and applying a 
benchmark price to the service (4 Euros per patient, per day) we can extrapolate a growth in the 
value of the RMT market/expenditure depicted in the graph below: from only 127 M€ for all diseases 
(as was estimated by F&S) to 2.6 B€ for CHF only (see all details of estimation procedure in Table 3 
and related explanatory notes). 
 
 
 
                                            
100  As illustrated earlier the OECD EU19 do not include: Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, Slovenia. 
Total population of EU19 in 2007 (according to OECD 2009 Health Data) was 451 million, which is 91% of total EU27 
population. 
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Figure 11 – RMT market/expenditure potential growth: CHF segment only 
 
Source: estimate from F&S and authors' extrapolation see Table 9 and related explanatory notes 
We used above the expression “RMT market/expenditure” since the money for paying RMT services 
will come from third party payers or from public funding (see details in Annex I of Deliverable 
D1.1). Some of this money will go directly to pay market players and some will be used to reimburse 
the health care producing units for the work of their professionals involved in RMT service 
provisions. At any rate, regardless of whether we look at it as market or as expenditure, the value of 
€2.6 B represents the potential cost of RMT under the assumption of deployment to 20% of CHF 
patients in EU19 and must be compared to the potential benefits. 
The likely benefits. Using benchmarks for the relevant literature as reported in section 2.2 and also 
in Annex IV (section 9) we estimated the potential reduction of deaths for CHF over a year to 
amount to 90832. Assuming these patients will live only one extra year, the aggregate value we 
calculated for the corresponding QALY measure of this extra year is about €1.9 B.101 We could also 
                                            
101  Given the lack of a market price for healthcare services paid for from the public budget, governments need to find ways to measure 
the benefits associated with alternative allocations of scarce resources from the perspective of the patients ( in the market the price 
is a direct measure of consumers willingness to pay, which is assumed to reflect their appreciation of the quality of the good or 
service they decide to purchase). To obviate to this health economists have tried to measure, from the perspective of the recipients, 
the benefits associated with a possible intervention in healthcare. One solution is the development of Health-Related Quality of 
Life (HRQoL) indexes that are used to calculate Quality Adjusted Life Years (QALY). Through objective (from clinical evidence 
and surveys of clinical experts) and subjective (from patient surveys) parameters it can be measured how much having a disease 
subtract to the quality of life. Very simply this can be understood as follow: good health (both objectively and subjective) = 1 
QALY whereas death = 0 QALY. Using parameters on the disabling impact of CHF (from disability weights by disease category 
published by the WHO http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf ), thus, we can 
establish that 1 year of extra life as a results of RMT can be measured as equal to 0.7 QALY, which multiplied by the total number 
of avoided deaths (90.832) make 63.582 QALY. This is the QALY benefit in volume produced in our RMT scenario. The next 
more complicated issue is to give it a monetary value. Intuitively, one extra year of life can have a value for society (individual 
continue to work, produce, pay taxes), naturally for the patient and for his/her relatives and friends. The literature on this issue is 
vast and contains a wide range of variation in the monetary value to assign to QALY (ranging from € 10.000 up to € 100.000 
depending on the different methodologies and the corresponding assumptions). The monetary value of a QALY is of great 
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estimate that treating 20% of CHF patients with RMT could reduce/avoid 2.779.459 hospital days. 
Assigning a monetary value to these saved hospital days turned out to be more difficult (for some of 
the reasons explained earlier); so we produced two possible estimates of the cost of one hospital day 
for CHF treatment: €508 that we consider more robust, and €864 that we consider less reliable. 
Using the first estimate the total saving would amount to about €1.4 B, whereas using the second it 
would reach 2.4 B€. It is important to note here that in both cases, these more tangible (compared to 
the QALY) monetary measures of benefits would be lower than the cost (2.6 B€). In Figure 12 
below, we developed four possible scenarios crossing the two estimates of the cost of one hospital 
day (€508 versus €864), with two different pricing for one patient day of RMT: €4 per patient per 
day (used to calculate the value of €2.6 B reported above) and €2 per patient per day (assuming 
economy of scale will lead to lower cost of services).  
Figure 12 – RMT potential expenditure and benefits: CHF segment only (four scenarios) 
 
Source: authors' elaboration see Table 9 and related explanatory notes 
                                                                                                                                                  
importance for the cost-effectiveness analysis that should support decision to invest scarce resources for new treatment and/or new 
technology. In this respect it is useful to notice that in the UK the National Institute for Health and Clinical Excellence (NICE, 
NICE Guidelines to the Method of Technology Appraisal, NICE, UK, 2008) established that it is worth investing in treatment 
and/or technologies that have a cost per QALY ratio of about € 30.000. Given our scope in this extrapolation, we can reverse this 
and use it the average value of a QALY. So, we used 1 QALY= € 30.000 to estimate the monetary value of the reduced mortality 
outcome of RMT for CHF. On the other hand, it is interesting to point out that if we divide the total expenditure for RMT of 2.6 
€B(scenarios 1 and 2) by the total volume of QALY produced (63.582) we have a cost per quality ratio of € 41.714, which is 
higher than the NICE threshold. If the cost of RMT goes down (as in scenarios 3 and 4), however, we would get the much more 
favourable cost per QALY ratio of about € 20.857.  
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By comparing scenarios 3, 4 it is clearly visible that only under a reduced pricing for RMT (2 Euros 
per person per day102), the value of savings from reduced hospitalisation is higher than the costs. On 
the other hand, if we consider also the QALY value, the benefits far outset costs. Actually the value 
(benefit) of the reduced number of deaths is in itself greater than the costs incurred from applying 
RMT. 
From this and in light of what we discussed earlier in paragraph 4.2, on the non-conclusive evidence 
on reduced hospitalisation and on the assumption that this is probably not a correct measure to assess 
the contribution of RMT, our conclusion is that the cost of providing RMT should be weighted 
almost entirely against the clinical outcomes. As a matter of fact, the Swedish Presidency study cited 
earlier, reports potential benefits expressed in volume metrics and does not contain a single 
estimation of the monetary value of the reduced costs. 
We can conclude that, regardless of the scientific accuracy of such extrapolations, the order of 
magnitude clearly conveys the message that we stand to lose large potential benefits if the 
deployment of RMT remains at the current very modest level. 
In the next two pages, a table and subsequent notes explain in detail the assumptions and limitation 
of the extrapolations presented above. 
                                            
102 The price used for the extrapolation is an average based on a couple of real instances that we came across through our interviews. It 
depends on many parameters, such as the cost of the monitoring devices, the communication charges, the quality of the medical 
team monitoring as well as that of the emergency service offered. Depending on how many of the above charges are subsidized 
and/or paid out of pocket, the cost to the public Health Care sector could be even lower than the 2 Euros per patient per day used in 
the extrapolation.  
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Evidence in support of the extrapolations on CHF presented above. 
Table 9 – Data, benchmarks and assumptions used in the extrapolations 
Value of RMT expenditure/market under 20% addressability/deployment assumption for patient with CHF 
1. Total EU19 Population  454.160.000
2. Prevalence of CHF over total population 2%
3. Total CHF patients in EU19 9.083.200
4. % Of CHF considered suitable for RMT 20%
5. # Of CHF patients treated with RMT under 20% deployment 1.816.640
6. Average cost per patient per day 4€
7. Days of treatment 365
8. Value of RMT expenditure/market 2.652.294.400€
Number of reduced death at one year and QALY value applying benchmark from RCT to 20% assumption 
9. Lower bound yearly average mortality rate at one year 25%
10. Baseline deaths out 1.8M patients CHF patients at one year 454.160
11. Average reduction of mortality rates for RMT treated patients 20%
12. Reduction in number of deaths at one year 90.832
13. Assumed value of 1 Quality Adjusted Life Year 30.000€
14. Aggregate QALY value of 1 year of extra-life (assuming average 0,7 value of QALY 
for the extra year of life (CHF will not enjoy full health status) 1.907.472.000€
Value of reduced utilization applying benchmark from RCT to 20% assumption  
15. Average length of stays in hospitals for CHF patients (number of days per patient) 10.2
16. Re-hospitalisation benchmark rate at 3 months  50%
17. Baseline # of re-hospitalised patients out of the 1.8M patients 908.320
18. Hospital days occupied by re-hospitalised patients out of the 1.8M patients 9.264.864
19. Benchmark of reduction in utilization 30%
20. Reduction in hospital days from RMT treatment to 1.8M patients 2.779.459
21. Average full cost of one hospital day  508€
22. Value of reduced hospitalisation through RMT under 20% scenario 1.411.965.274€
23. Net cash benefits (without considering QALY) -1.240.329.126€
24. Net benefit considering QALY 667.142.874€
Estimation of average cost of one hospital day for CHF patient in EU19: method 1 
25. Total number of CHF patients in EU19 9.083.200
26. If 50% hospitalised at least once and stay 10.2 days, then total hospital days= 46.324.320
27. Total Health care expenditure in EU19 1.177.000.000.000
28. Total health care expenditure for CHF (2% of total health care expenditure) 23.540.000.000€
29. Cost per hospital day 508€
Estimation of average cost of one hospital day for CHF patient in EU19: method 2 
30. Yearly acute per capita bed-days in EU19 1,2
31. Total acute bed-days in EU19 544.992.000
32. CHF absorbs 5% of them 27.249.600
33. Average cost of 1 hospital day for CHF patient 864€
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Detailed explanation of the contents (source or calculation formula) of Table 3 
 
Value of RMT expenditure/market under 20% addressability/deployment assumption for 
patient with CHF 
1. OECD Health Data 2009; 
2. Average extracted from the relevant literature reported in paragraph 2.2103 and in Annex IV 
(Section 9); 
3. Row1*Row2; 
4. Obtained from interviews with physicians conducted during the case studies; 
5. Row3*Row4; 
6. Average of various pricing found during the work on companies and on 
projects/pilots/programmes; 
7. Here it is assumed that, even if the actual patients may change, in any given day of the year 
for 365 day 1.8 million patients will be under RMT treatment; 
8. Row5*Row6*Row7; 
 
Number of reduced death at one year and QALY value applying benchmark from RCT to 
20% assumption 
9. Lower bound benchmark extracted from the relevant literature reported in paragraph 2.2;104 
10. Row3*Row9. This is the baseline number of death among the 1.8M patients if they were not 
treated by RMT; 
11. Average extracted from the relevant literature reported in paragraph 2.2 and in Annex IV 
(Section 9); 
12. Row10*Row11; 
13. International benchmark of the value of one QALY in US $ converted into Euro; 
14. Row13*Row12*0.7 (to reflect that the extra year of life will not be in perfect health and that 
the disabling impact of CHF require to subtract 0.3 from each additional year of life that so 
corresponds to 0.7 QALY; 
 
Value of reduced utilization applying benchmark from RCT to 20% assumption 
15. OECD Health Data 2009; 
16. Average extracted from the relevant literature reported in paragraph 2.2 and in Annex IV 
(Section 9); 
17. Row17*Row3. This is the baseline number of re-hospitalised patients out of the 1.8M if they 
were not treated by RMT; 
18. Row17*Row16. This is the baseline number of hospital days absorbed by patients out of the 
1.8M if they were not treated by RMT; 
19. Average extracted from the relevant literature reported in paragraph 2.2 and in Annex IV 
(Section 9); 
20. Row19*Row18 
21. See 25 through 29; 
22. Row21*Row20; 
23. Row22 minus Row8 
24. Row22 plus Row14 minus Row8; 
 
                                            
103  We applied the 10% prevalence benchmark to an estimate of the population 75 and older and the lower bound of 1% prevalence to 
the rest of the total population and the total number of patients obtained is roughly equal to 2% of the total population in EU19. 
104  As reported in the editorial by Cleland et al mortality of CHF patient at one year range between 25% and 40%. On the other hand, 
mortality at 5 years can be up to 75%. To remain conservative we used only the lower bound estimate for mortality at one year. 
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Estimation of average cost of one hospital day for CHF patient in EU19: method 1 
25. Equal Row3; 
26. Our assumption based on benchmark extracted from the literature reported in paragraph 2.2 
and in Annex IV (Section 9); 
27. OECD Health Data 2009; 
28. J. Mc Murray and S. Steward, The Burden of Heart Failure, op. cit.; 
29. Row28/Row26; 
 
Estimation of average cost of one hospital day for CHF patient in EU19: method 2 
30. OECD Health Data 2009 
31. Row30*Row1; 
32. Applying by analogy to bed-days the benchmark that CHF are responsible each year for 5% 
of all admissions to hospital (the latter is also from J. Mc Murray and S. Steward, The Burden 
of Heart Failure, op. cit). 
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5 Barriers to innovation and ways to overcome them 
In this section we report on the barriers to RMT deployment as collected from the experts and 
stakeholders we interviewed during the course of our research. These barriers have been presented in 
November 2009 in the Discussion Paper105 distributed prior to the Brussels Validation workshop (see 
footnote 73). This analysis of barriers coincides to a large extent with that contained in part II of the 
latest OECD report on ICT and health care.106 This is a further confirmation of the robustness and 
validity of our findings. This is then followed by a model of Innovation dynamics that would explain 
a few of the challenges in this complex multi-stakeholder environment. A set of preliminary 
recommendations closes this section of the report.  
5.1 Barriers: views from the field 
Since this is a multi-stakeholder market, barriers are reported and prioritised differently depending 
on whether market players or medical professionals are mostly affected. The main barriers reported 
by market players are the following: 
• Lack of reimbursement.  The issue of reimbursement is one of the major roadblocks on the 
path to PHS/RMT market deployment and has been mentioned virtually by each of the 
experts and stakeholders interviewed. Some of the market players interviewed have managed 
to negotiate agreements with insurances (e.g. in Germany, Netherlands) or public health care 
(e.g. in the UK, Italy or Spain) but all these attempts are the results of longstanding, resource 
consuming individual efforts. Industry experts told us that without some clear and 
standardised financing and/or spending decisions from the relevant health care bodies the 
market will not take up (i.e. on the basis of out of pocket money or of services acquired for 
their clients by private insurances). For market players, the lack of transparency on 
reimbursement models and the complexity of national frameworks and legislation make it 
difficult to get an overview of what services may be reimbursed where and to what extent; 
• Buyers' fragmentation. The institutional set up of health care systems shapes how 
companies try to sell their products or services for RMT. For instance, in Germany, 
companies try to cooperate with social insurance, in Spain they address the local level 
providers of health and social care, in Italy they talk with the Regions for health care RMT 
but then have to talk with municipalities if they want to enter through the door of social care. 
As a result, companies were concerned of this fragmentation: both as regards the level of 
public decision-making authority and the lack of a clear procurement process. The landscape 
is, thus, populated by many local initiatives and opportunistic small companies, which usually 
die down after R&D or pilot funding money dries out; 
• Difficult to be accepted by health care organisations. Many market players encountered 
clear resistance from health care providers to accept an end-to-end RMT service provision by 
an ''outsider" supplier, even when the latter integrated state-of-the-art technology with very 
professional and well trained call centre operators and its own medical experts and nurses. 
Not surprisingly a few market players told us that they have at least one major health care 
institution among their shareholders and most often provide B2B2C services: that is they 
provide the technology, the call centre, and also partially the medical components of the 
                                            
105  Available at: http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHSbackgroundpaperforvalidationworkshop.pdf. 
106  OECD, Achieving Efficiency Improvements in the Health Sector through the Implementation of Information and Communication 
Technology, Paris: OECD, 2010, pp. 35-44. 
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service to a hospital, which in turn owns the relation with the patient and with the third party 
payers and compensates the suppliers; 
• Constraints to market scale. The fragmentation referred to earlier is also reflected in the 
lack of cross-border operations. Both SMEs and large companies operate in a "strong home 
base" before seeking to expand to other countries and generally the extent of cross-border 
operation even for larger player appears to be very limited. However, the mobility of patients 
imposes that solutions are implemented. 
In sum a number of factors contribute to create uncertainty for market players who must cope with 
unclear business models and shaky revenue streams.  
The main barriers reported either by individuals operating within health care systems (professionals 
and/or representatives of health authorities/payers) or by neutral third party experts (i.e. health 
economists, organisational scholars, and eHealth experts) are the following: 
• Unfavourable structure of incentives. Regardless of differences in EU country institutional 
public systems, both external experts and health care professionals (those involved in, and in 
favour of, RMT) are of the opinion that the structure of incentives in place in health care 
delivery and financing run against RMT. Health care reimbursement and financing oscillates 
between two models: fee for service (i.e. DRG based reimbursement) or capitation (fee for 
patients treated, regardless of activities, typical for GPs). Keeping patients out of the hospital 
through RMT reduces exactly the fee for services the hospital may receive (so it is not an 
incentive to adopt RMT). On the contrary GPs paid on a capitation basis for managing a pool 
of patients (that cannot increase) perceive the work they may have to undertake within an 
integrated pathway RMT service as an extra and unpaid load. Even if RMT would eventually 
enable them to work more efficiently it would not translate into economic gains in systems 
where the overall quota of patients that can be treated is fixed and cannot be increased. Even 
if these opportunistic considerations sound ethically inappropriate, we must realistically 
accept that health care, as any other social system, needs the correct structure of incentives in 
place to make things happen. The only other alternative would be to impose strong top-down 
mandatory obligations; however, this is not always feasible. It is thus appropriate to consider 
how to make ICT supported work attractive economically or in general beneficial in other 
ways to managers of health care institutions and to health care professionals; 
• RMT: where does it belong? RMT, especially if integrated into a HBT delivery models, is 
the quintessential form of what is called in the US NIC (Non Institutional Care) and in others 
Territorial Medicine (in brief all that happens outside of hospitals, extra muros). According to 
many of the interviewees, much talk has been made about the importance of this form of care 
delivery for the future sustainability of health care but still the issue has not been placed in a 
clear policy "box". It is not clear who the institutional sponsors really are. eHealth 
applications are successful and take off when there is a clear decision maker pushing them. In 
the field of RMT, with noticeable exceptions, it is difficult to localise where such decision 
maker might be. Interviewees reported not seeing a feeling of “urgency” to deploy RMT in 
health care since there are other more important challenges that get the attention of politicians 
and policy makers; 
• Primary, secondary, and social care. The cases of success we encountered were to a large 
extent linked to the personal motivation of actors in primary and/or secondary care – i.e. GPs 
and specialists such as cardiologists - who believe in the benefits of implementing RMT 
solutions or are forced to find solutions to service physically remote patients. Yet, some of 
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these motivated professionals told us that the fragmentation between primary and secondary 
care acts as a bottleneck; also because of the different incentives they are subject to, in their 
national health care systems. In particular professionals argued that, if hospitals are not 
always ready to launch RMT for various reasons related to incentives, the key push for it 
could and should come from the GPs. Since RMT is part of Non Institutionalised Care (NIC) 
or territorial medicine, it should be within the responsibility of GPs to identify and recruit 
patients who are more suited for RMT, especially in view of the fact that many hospitals 
especially during certain period of the year (when they face full bed occupancy) tend to early 
discharge chronically ill patients without acute conditions. These should be indentified by 
GPs as the key target for RMT, recruited, and treated through a seamless and joined up 
collaboration between GPs and institutions of secondary care. The input from GPs could 
break hospital resistance. This is not happening, not only because of lack of incentives, but 
also as a result of insufficient GPs e-Readiness and of the well-known fragmentation and 
"turf war" between primary and secondary care. Strictly related to this issue is the problem of 
identifying and selecting the appropriate target of patients to be recruited for monitoring. 
Exchange of data and information between different tiers of the health care and between the 
health care and the social care departments is crucial. The success case of Veneto (reported in 
post-it 7) confirms that a strong drive from higher-level health authorities can overcome such 
bottlenecks. Yet, according to the more pessimists among our interviewees, new systems like 
PHS/RMT add transparency and remove professional control, which is why they are met with 
resistance. According to this view, in the end the main driver will be the patient who wants 
the service. Unfortunately patient awareness of RMT solutions - let alone of their benefits - is 
still limited to say the least. 
• Lack of evidence, awareness, education. There is an increasing body of evidence 
supporting the claim that RMT can make a difference even if not fully conclusive. More work 
in this direction is certainly needed to fully ensure health care authorities/payers are aware 
about clinical outcomes and cost-effectiveness. Yet, more awareness raising activities 
targeting decision makers and insurances (social or private) should disseminate the evidence 
from journal articles that are usually not accessible in their jargon for the non experts and 
especially about "champions of success". Currently, in fact, many interviewees think that we 
are in a "chicken and egg" stalemate. Lack of standardised evidence or of awareness on 
existing evidence delays decisions on reimbursement and funding. This in turn reduces the 
numbers of treated patients available for control trials and, thus, further delays the point in 
time when more robust and conclusive evidence will be available. As a result, market players 
in turn cannot fully deploy their services and lack of market scale keep prices high. As was 
suggested before, by raising the awareness of the patients to likely benefits will put pressure 
on the system from the bottom-up. 
• Strategic leadership for structural change.  According to some of the interviewed experts, 
all of the issues reported above are very important but are of a tactical nature, in the sense that 
they could be solved if there is a strategic leadership and decision to use RMT and PHS 
within a major organisational restructuring of care delivery processes. Decision makers who 
understand that RMT and PHS can be an opportunity to introduce such changes as a way of 
making health care delivery both more effective and efficient (doing more and better while 
containing the cost) can act upon most if not all of the bottlenecks discussed so far. In other 
words the experts suggest that a longer term vision and a new strategy for how health care 
services should be organised and reimbursed is needed to take advantage of what modern 
medicine can do and ICT can enable. The linear piecemeal approach to RMT/PHS, based on 
the optimistic/deterministic assumption that sooner or later technology is adopted, may never 
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work. As one of the interviewees stated: “the mere push of technology represents a Ptolemaic 
approach not capable of producing durable and large effects. What is needed is a Copernican 
revolution where PHS are part of major institutional and organisational restructuring”. 
Finally, most stakeholders and experts affirmed that there are also some technological gaps mainly 
due to inter-operability bottlenecks. Some also thought that the RMT technology is not yet mature in 
the sense that the solutions available in the market are too basic and require still too much the 
intervention of professionals. More sophisticated approaches (i.e. ones produced by R&D efforts) are 
needed and also integrated into alternative disease management systems; however, these are either 
not yet proven in terms of reliability or are too expensive. 
5.2 Innovation dynamics within a complex ecosystem perspective 
Trying to bring together the views on barriers and of most of the empirical evidence discussed in the 
previous section, we will briefly and selectively present some insights from the literature on 
technological and institutional change and innovation. This is instrumental also to look in the end, at 
RMT as a complex ecosystem. The one depicted in Figure 13 is an S-shaped curve typically used to 
describe the dynamic of technology and innovation adoption from the perspective of diffusionist 
theories.  
Figure 13 – Traditional S-Shaped innovation and diffusion curve 
 
Source: Authors’ elaboration on literature as presented in footnote 107  
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However, such a way of looking at the diffusion of innovation107 provides a practically useful but 
merely descriptive tool, which has two clear limitations for our purpose. First, it can be used to input 
data into the underlying calculation algorithm and passively let the data speak but it does not provide 
an explanation of why a curve may be more or less steep and especially how and why a particular 
technological innovation moves from one phase to the other or simply becomes "history" as it has 
happened to many innovations that never took up. In our case we have little data to plot and 
qualitatively placing the RMT market somewhere in the graph does not help much in making sense 
of the evidence gathered and envisaging what and how could happen next. Second, it presupposes a 
sort of technological optimism that may fit well the trajectories of self-contained technological 
products but is not entirely appropriate for complex technology-driven services entailing additional 
and complex cross-complementary organisational and institutional changes as in the case of RMT. 
Clearly more directly relevant insights to facilitate the understanding of innovation dynamics in 
RMT comes from the theory of disruptive innovations developed by Christensen and colleagues,108 
which has also been specifically applied to health care.109  
Figure 14 – Disruptive innovations of health care professions and institutions 
 
Source: C. Christensen et al, Will Disruptive Innovations cure Health Care? op. cit., pp. 105-106 
                                            
107  While popularised in the marketing literature by E. Rogers, (Diffusion of Innovations, New York: The Free Press, 5th edition 2003 
– 1st edition 1965) and refined in the neo-Schumpeterian analysis of the "ICT revolution" (as presented for instance by the seminal 
work of C. Perez, Technological Revolutions and Financial Capital - The dynamics of bubbles and golden ages. Cheltenham, UK: 
Edward Elger; 2002), the curve was first plotted at the turn of the 20th century in a sociological analysis of imitation processes (see 
G. Tarde, The Laws of Imitation, trans. by E. Parsons, New York: Holt, 1903), and the - by now standard - typology going from 
early adopters to laggards comes from a 1943 article on the diffusion of "hybrid seed" among Iowa farmers (see B. Ryan, and N. 
Gross, The diffusion of hybrid seed corn in two Iowa communities. Rural Sociology, 8 (1943): 15-24). 
108  See for instance in chronological order: J. Bower and C. Christensen, Disruptive Technologies: Catching the Wave, Harvard 
Business Review, January-February 1995; C. Christensen, The Innovator’s Dilemma, Harvard Business School Press, Boston, 
1997; C. Christensen, and M. Raynor, The Innovator's Solution. Harvard Business School Press, Boston, 2003. The typical 
formulation of the Christensen model focuses on the two concepts of "overshot consumers" and "low end disruptive innovations". 
At some point market incumbents overshoot their customers, since the rate at which products improve exceeds the rate at which 
the customers can absorb the new performances. At this point, a disruptive technology may enter the market and provide a product 
which has lower performance than the incumbent’s one but which exceeds the requirements of certain segments, thereby gaining a 
foothold in the market. The disruptor can then progressively move up-market. In particular Christensen shows that powerful 
innovations disrupting industries did so by enabling a larger population of less skilled people to do more conveniently and less 
expensively things for which earlier they needed specialists in centralized locations. Minicomputers first and personal computers 
later, for instance were disruptive to mainframe producers and we no longer need to bring our punched cards to mainframe 
computer centres. 
109  C. Christensen, et al, Will Disruptive Innovations Cure Health Care? Harvard Business Review, Sept-Oct (2000), 102-112. 
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In the seminal article of 2000 Christensen et al argue that health care has devoted so many resources 
to the treatment of the most acute problems and thus to overshoot the majority of less complex needs 
many patients have. Additionally, since the system must treat also less demanding needs, very 
specialised institutions and specialists have been forced "down market". This means that they have to 
deal with problems that could instead be addressed through a combination of less expensive carers 
(nurses) and enabling technologies, in other words through disruptive innovations along the lines 
depicted in the Figure 14 above. 
We can explain the reasoning underlying the two figures above applying it to the specific case of 
RMT. As specialist physicians continue to concentrate their efforts on the most acute situations and 
on “the most incurable of illnesses for the sickest of patients”, less-skilled and less-expensive 
practitioners either employed by NHS or by market players suppliers could take on more complex 
roles and deal with ever larger numbers of chronically ill patients through RMT integrated into 
disease management programmes. This is exactly what happened in the VHA case and in other 
success cases. The same logic in parallel - still according to the Christensen model - should happen 
to health care institutions. Research clinic and large hospitals concentrate their efforts on the high-
end of the market (most acute conditions) but must also serve the lower end. In this respect they have 
tended to opportunistically use to some extent the lower end to finance the high-end segments. This, 
however, is increasingly unsustainable and signs of changes are already visible: “patients that 
occupied hospital beds 20 years ago are now being treated in more-focused care centres and 
outpatient clinics, doctors’ offices, and even at home”.110  
RMT, thus, following the logic of the Christensen model would be the final multiplier of such a 
process eventually evolving into closed loops allowing full self-caring chronic patients. Christensen 
criticised, for instance, regulation preventing nurses from taking more responsibility in the delivery 
of care and compared it to as if regulators " in the early 1980s had decreed that because 
microprocessors were inferior in computing power to wired logic circuits, all personal computers had 
to be equipped with wired logic boards, not microprocessors".111 Hence, Christensen's view in the 
end was that such processes eventually cannot be stopped even within health care. The matter of the 
fact is, however, that dealing with patients and substituting a physician with RMT plus a nurse or 
with a self-managed RMT is not exactly the same thing as substituting a wired logic circuit with a 
microprocessor. Moreover, in health care it is not easy to move resources to better serve overshot 
patients.  Apart from these objective factors, the health care system is more complex than any 
comparable industry and characterised by overlapping and conflicting incentives and vested interests. 
Change within such a system cannot be brought by disruptive technologies alone. Indeed, 
Christensen in his later work on the Innovator Solution112 done with Raynor replaced disruptive 
technology with the term disruptive innovation because he recognized that few technologies are 
intrinsically disruptive or sustaining in character. It is the strategy or business model that the 
technology enables that creates the disruptive impact. In order to understand how such innovations 
can occur within a complex ecosystem such as health care an understanding of the social, 
institutional, and economic underpinning of innovation is needed. 
 
                                            
110  Christensen, et al, Will Disruptive Innovations Cure Health Care? op. cit, p. 106. 
111  C. Christensen, et al, Will Disruptive Innovations Cure Health Care? op. cit. p. 107. 
112  C. Christensen, and M. Raynor, The Innovator's Solution, op. cit. 
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When an innovation becomes spread through such a process113 it is then incorporated into a new 
accepted institutional template of action. Networks effects and the emergence of hub of innovators 
play an important role in unleashing this mimetic innovation process. In this respect, also within 
management and organisational studies and not only within sociology, it has come to be accepted 
that innovation does not occur in isolation but within a social systems and especially within networks 
and hubs seen as loci of sharing strategies and pooling resources, with the aim of developing new 
products or of exploring new technologies.114 
The RMT field has already witnessed the emergence of champions and of a few hubs of innovator 
but no large-scale mimetic process has taken place. One possible and simple explanation is that the 
number of champions and the intensity and scope of the innovators networks is not yet sufficient to 
unleash a mimetic process. Alternatively, it is possible that awareness and dissemination about 
champions and success cases has not been spread enough or lack convincing evidence backing the 
positive results reported. These two reasons certainly provide part of the explanations to the current 
situation of RMT. Yet, there are additional elements to be considered that can be understood from 
standard and basic economic analysis of strategic and competitive behaviours and of players’ 
structure of incentives. We illustrate this reasoning hypothetically on the diffusion of innovation X 
within non-specified business-to-business market involving private firms. According to mainstream 
economic reasoning: 
• If innovation X is thought/shown to eventually increase the profitability of firms buying X 
(henceforth simply buyers) either by increasing revenues or by reducing costs, competitive 
pressures may produce mimetic processes leading to bandwagon effects among them (at least 
until the extra returns will be brought back to zero as all competitors adopt the same tools) 
and boost the market for firms producing X (henceforth simply sellers); 
• Yet, different dynamics can have negative effects stopping such bandwagon processes:  
o If sectoral dynamics tend to be characterised by an important strategic advantage for 
‘first-mover’ among buyers, this then reduces the room for adoption of X by many 
other competitors; 
o The same ‘first mover’ advantage may limit the number of sellers, which in turn slow 
down the spiral of decreasing prices and limit adoption by buyers;  
o If there is a lag time between adoption of X and increased profitability, the investments 
in X could come to be perceived as risky among buyers and bandwagon effects 
stopped; 
o Finally, specific powerful enough functional units within buyers may be threatened 
and/ or have no incentive to adopt X and succeed in resisting adoption 
• The factors above could, however, be reversed and bandwagon effects could be positively 
supported as a result for instance of:  
                                            
113  Innovations occur at micro-organisational level, also on the basis of strategic and competitive considerations captured in standard 
economic reasoning. They face institutional inertial resistance, but they spread and become mainstreamed only as a result of 
mimetic institutional processes facilitated by network effects. The way activities are carried out within a given population of 
organisations is shaped by institutionalised practice. In particular "institutional isophormism" is a process of "convergent inertia or 
change", whereby organisations do or try to do what is considered legitimate in their own institutional environment. While 
institutional inertia is strong, organisational evolutionary change occurs (On organisational evolutionary theory see for instance: R. 
Nelson, and S. Winter, An Evolutionary Theory of Economic Change, Cambridge, MA: Belknap, 1982; M. Tushman, and E. 
Romanelli, Organizational Evolution: A Metamorphosis Model of Convergence and Reorientation. Organizational Behaviour, 7 
(1985): 171-222) and is then spread through a mimetic process in which each single organisation/institution tends to imitate the 
most legitimated and/or successful players in their population of reference (a sector or an entire industry), in order to become 
legitimised too, and to reduce uncertainty about their future (see P. Di Maggio, and W. Powell, The New Institutionalism in 
Organizational Analysis. Chicago: University of Chicago Press, 1991). 
114  See for instance: L. Lengrand, and I. Chatrie, Business Networks and the Knowledge-Driven Economy, Brussels: European 
Commission, Brussels, 1999; N. Noria and R. Eccles (eds.), Networks and Organizations: Structure, Form, and Action. Boston, 
MA,: Harvard Business School Press, 1992; R. Pouder, and C. John, Hot spots and blind spots: Geographical clusters of firms and 
innovation. Academy of Management Review 21(4), 1996: 1192-1225. 
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o Selected government incentives that reduce uncertainty and risk of investments; 
o Raising awareness with patients on the benefits of out-of hospital care and cure; 
o Policy research and awareness on activities demonstrating and heralding the benefits of 
Innovation X;  
o Public discourse and hype pushing buyers to make investments even under conditions 
of uncertainty about their ROI, simply to “keep up with their neighbours”. 
The reader by now can probably already envisage how this sort of dynamic applies to the RMT seen 
as a complex socio-technical ecosystem where: a) to a large extent factors inscribed in different sub-
systems affect one another, shaping different possible outcomes and lines of development for the 
system as a whole; and b) the non-technical (broadly conveyed by the adjective ‘social’) and the 
technical elements are continually evolving on their own while continuously interacting with each 
other in ways that cannot be overtly controlled and easily predicted.115 The one depicted for RMT in 
Figure 15 below is only an impressionistic snapshot.  
Figure 15 – RMT ecosystem: snapshot 
 
Source: Authors’ elaboration 
In a more structured and aggregated fashion, also in view of the contents of the previous paragraphs 
we can identify four macro sub-systems: Users/patients (their relatives and their advocate 
organisations), Health care providers (including together both professionals and management of 
                                            
115  Rooted in classical works on socio-technical systems such as for instance: J. Forrester, Industrial Dynamics. Cambridge, MIT 
Press, 1967; J. Thompson. Organizations in Action. New York: McGraw Hill, 1967; E. Trist, The Evolution of Socio-Technical 
Systems. In: Ven, A.H., Joyce, W.F. (eds.) Perspectives on Organization Design and Behavior. New York: John Wiley, 1981. 
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producing units), Health authorities / payers, Suppliers (see discussions of different objectives and 
expectations presented earlier in section 5.1). 
The structure of incentives, interests, needs, aspirations and expectations from this complex and 
fragmented set of players and sub-systems have so far only rarely coincided to produce successful 
and self-sustained RMT service provisions. In general the reciprocal and complex interaction among 
all these sub-systems and players is producing and re-producing most of the barriers discussed above 
and hindering the kind of mimetic process whereby champions are emulated leading to progressive 
bandwagon effects and full market uptake. We can now apply to RMT the economic reasoning 
developed generically and hypothetically earlier in this section. 
Figure 16 – The vicious circle that needs to be broken 
 
Source: Authors’ elaboration 
Lack of evidence increases gap for response. RMT is not yet consensually recognised by all 
stakeholders as an application producing an increase in quality (clinical outcomes) and cost-
effectiveness of health care delivery. There is both a lack of more conclusive evidence and a lack of 
awareness about the existing evidence and the success of the increasing number of champions. In 
general the economic literature has shown that even in a less complex realm such as the adoption of 
ICT within private firms there is a time lag between the moment of investments and the time when 
productivity outcomes show up. The famous quip by Nobel Prize Robert Solow that “You can see 
the computer age everywhere but in the productivity statistics”116 also known as “productivity 
                                            
116  R Solow, We'd better watch out. New York Times, July 12, 1987, p. 36. 
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paradox”117 has reigned unchallenged for a decade before empirical evidence has started to show that 
ICT was boosting productivity but with a substantial lag time.  
This lag in RMT is compounded because: (a) Randomised Clinical Trials are time-consuming and 
additional time lag is built into it by the process of scientific publishing; and (b) Once evidence from 
RCT is available and accepted, continuous long-term services may be launched, and eventually 
concrete and tangible results may surface. This slow process has negative impacts stopping the 
potential mimetic process that can lead first to market acceleration and eventually to realisation of 
full market potential. Additionally, there is an equally negative “elective affinity” between this time 
lag generating uncertainty as to the appropriateness of RMT and the resistance springing deliberately 
and opportunistically for the defence of vested interests or in a less intentional way by mere lack of 
incentives.  
Gap contributes to uncertainty leading to low-take-up. This slow down in adoption by 
mainstream players reduces market scale and revenues, contributing to create uncertainty for market 
players. The latter in turn either leave the market or continue to “wait and see” and in this way they 
will not be able to make their product and services more affordable. Lack of affordability can 
potentially block even the more enthusiastic innovators and champions, which may further feed into 
strengthening the forces of resistance. It is a negative closed-loop that needs to be broken. 
While this explanation may seem overly pessimistic, it only provides logic and empirically backed 
understanding of how barriers block innovation dynamics. It can be looked upon from the optimistic 
perspective of how such a loop can be broken and innovation dynamics jump-started. Alternatively 
this negative loop can be mapped against best practice cases to identify the key success factors that 
prevented the barriers to reinforce each other so as to replicate them in other contexts. So such a 
stalemate can be broken down either as a result of spontaneous socio-economic and market processes 
and/or of policy actions as we discuss very briefly and tentatively in the next section.  
5.3 Conclusive recommendations 
A tentative and preliminary set of policy measures that may help break the stalemate is presented 
below. The barriers loop described earlier can be broken through policies, regulations, and 
standardisation aimed at reducing uncertainty, providing selective incentives, raising awareness, and 
supporting networks and hubs of innovation. Evidently, some of these policy and regulatory 
interventions rest with Member States and pertain more to the realm of public health than to that of 
Information Society. Some, however, are more directly actionable from the perspective of eHealth 
policies. 
Member States willing to jump-start RMT may take one of two broadly defined approaches: a) 
traditional command and control regulatory measures: make RMT mandatory; b) provide selective 
economic incentives integrated with soft measures aimed at persuading the key stakeholders 
(awareness campaign, education and training, benchmarking for “naming and shaming”, etc). 
Not considering the command and control measures, we believe that working on changing the 
incentives structure can be the most effective approach. This is so because we have to acknowledge 
that the adoption of RMT (as for other eHealth applications) is not necessarily advantageous for all 
stakeholders in the same way. Objectively under a “fee for service” payment model, leaving aside the 
question of clinical outcomes benefits, the possible economic benefit of RMT may accrue 
                                            
117  As was renamed by Brynjolfsson in his widely cited initial article Brynjolfsson, Erik "The Productivity Paradox of Information 
Technology", Communications of the ACM, December, 1993. 
 67 
overwhelmingly to the payers and only marginally to the health care provider. For instance, a 
hospital using RMT may see their funding simply reduced. A possible incentive may be that of 
allowing the hospital to retain 50% of the cost-saving produced by RMT: a hospital saving for 
instance €1 million a year in bed-occupancy costs through RMT disease management programme, 
the following year would be granted at least €500.000 to spend into innovation research in important 
clinical areas, so that a win-win situation is realised between the payer and the provider.  
The earlier mentioned 2010 OECD report has showed that incentives for the adoption of eHealth 
applications are in place in several countries, as summarised in the following table: 
Table 10 – Type of incentives adopted to boost adoption of ICT in health care 
Incentives Australia Canada Netherlands Spain Sweden United 
States 
Payment 
Differentials Yes Yes Yes No No Yes 
Grants and 
Subsidies Yes Yes Yes Yes Yes Yes 
Reimbursement No118 Yes No No No Yes 
Share 
withholds Yes No Yes No No Yes 
Source: OECD, Achieving Efficiency Improvements in the Health Sector, op. cit., p. 58 
Or in other words, the following as a direct result of the analysis of Table 10. 
• Grant programmes and subsidies are used in all six countries to encourage adoption of 
eHealth applications by GPs; 
• Bonus and add-on payment (payment differentials) are granted to reward providers for 
adopting and diffusing ICT (Australia, Canada, Netherlands) or for improved quality through 
eHealth applications (United States); 
• Reimbursement for eHealth services (Canada and United States and partly Australia); 
• Withholding payments to providers for non-compliance (Australia, Netherlands, United 
States). 
Considering all of the above and specifically aimed at fostering the take up of RMT we mention 
tentatively the following policy options: 
• Riding the wave of policy consensus, on both sides of the Atlantic on the need for governance 
in eHealth in general and Telemedicine in particular as was expressed by the ministerial 
conference in Barcelona (March 2010) 
• Increased and sustained awareness-raising and dissemination activities, especially focussing 
on spreading the knowledge about local champions, about the increasing evidence of RMT 
with respect to clinical and cost-effectiveness outcomes, as well as through methodologically 
robust modelling and simulation of the potential benefits under different take-up scenarios; 
• Further financial support to studies and research aimed at further reinforcing the evidence on 
outcomes and at moving towards increasingly standardised and accepted evaluation 
methodologies; 
                                            
118  Only in the case of Glucohealth there is reimbursement as evidenced by the OECD report mentioned as source of this table. 
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• Design innovative mechanisms to support networking and the emergence of hubs among 
RMT champions and innovators (i.e. creation of centres of excellence for chronic disease 
management); 
• Explore synergies between eHealth and eInclusion policies and supporting instruments to 
bring about health care and social care joined up research and innovation pilots; 
• Explore the potential of consumer driven policies in support of Wellness / AAL services  as a 
way to also boost healthcare and social services. For instance, conditional cash transfer to the 
elderly or to any group in need to be used to pay for such services (i.e. The Dependency Law 
in Spain will provide the elderly with 600 euro per year that can be used to buy such kind of 
services or other forms of assistance) may work as a driver for the growth of the market in 
this area. On the other hand, if economy of scale is reached in such domain this could have 
positive spill over effects in other ones (i.e. industry can bring to the market more affordable 
services that can then be acquired by the public buyer in the field of remote monitoring 
and/or social care)  
• Consider revising the EU value chain of R&D, pilots and validation as to increase the 
chances of moving to the final stage of sustained service production and delivery; 
• Leverage the new window of opportunity that may be opened in the post i2020 framework 
with the envisaged strong investment into broadband making sure that RMT and more in 
general PHS are the priority type of services to be supported through these new platforms. 
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PART TWO: ANNEXES 
6 ANNEX I: Innovative activities in RMT 
6.1 Scoping of research 
A great variety of activities can be discerned throughout Europe aiming at the creation of an RMT 
market. The starting point of our research on innovative activities was the general scanning of more 
than 200 EU-funded projects in the area of eHealth and pilots, so as to take stock of the state-of-the-
art of innovation in the field. We have identified initiatives specifically focusing on PHS or RMT, as 
well as some of their key characteristics such as the medical conditions addressed, the positioning of 
RMT innovation in relation to the RMT value chain (e.g. development of devices or systems, 
analytical tools, patient platform, medical platform, patient management system) and the scale of the 
initiative both in terms of number of patients and coverage (e.g. local, regional, national, multi-site). 
Next we selected a sub-set of projects and pilots focusing on PHS/RMT for more in-depth research 
with the objective to identify the goals, means and outcomes of these initiatives and understand how 
projects and pilots may contribute to the innovation dynamics of the RMT market as a whole. Our 
analysis is presented in this section and assesses the benefits of RMT to different user groups (such 
as patients, and medical staff including nurses) as well as the evidence on their cost/effectiveness. 
6.2 Analysis of EU-funded activities 
Since 1989 EU research funding in the area of eHealth has exceeded the €1 billion mark with more 
than 500 eHealth projects funded. Personal Health Systems and Remote Patient Monitoring and 
Treatment have been present in research activities in the area of eHealth for more than 10 years e.g. 
under Framework programmes 5, 6 and 7119 (1999 – 2013) the IST/ICT120 Thematic Priority as well 
as through policy and support to deployment activities under eTEN and its successor CIP ICT 
PSP.121 The table below gives an overview of the type and number of initiatives identified under 
various EU funding instruments. In addition Living Labs have been included in this table as some of 
them deal with eHealth and to a lesser degree with PHS and RMT. The latter focus on monitoring, 
prevention and home care, in particular within the e-Wellbeing cluster, and these Living Labs have 
started to network and scale-up, or to transfer their ICT-supported services to larger national markets. 
 
 
 
 
 
 
                                            
119  http://cordis.europa.eu/fp7/dc/index.cfm 
120  http://cordis.europa.eu/themes/home_en.html#cloud (Information and Communication Technologies). 
121  Competitiveness and Innovation Framework Programme ICT policy Support Programme. 
 70 
Table 11 – Overview of EU funded activities 
EU-funded 
activities 
FP5122 FP6123 FP7124 eTEN125 CIP126 LL 127 
No. eHealth 
projects  
133 55 9 64 7 (eHealth 
services & 
Ageing 
Well128) 
129 (23 in 
Wellbeing & 
Health cluster) 
Of which 
No. of RMT 
projects for 
CDM129 
16 5 5 10130 4 4 
RMT 
Project 
names 
@Home 
AMON 
CHRONIC 
CHS 
DIAFOOT 
E-CARE 
EPI-MEDICS 
HEALTHMATE 
HEARTS 
M2DM 
MOBIHEALTH 
TELECARE 
TeleMedicare 
TOPCARE 
U-R-SAFE 
WEALTHY 
MyHeart 
Heartfaid 
PIPS  
Saphire 
Oldes 
 
 
Chronious 
HeartCycle  
Metabo 
Perform 
Diadvisor 
 
FOR ALL     
(ICAROS) 
HealthService24
HealthWare 
iCare 
Linkcare 
Health-eLife  
(doc@Home) 
Interlife 
HealthOptimum 
 
Better Breathing 
MCC  
Dreaming 
Nexes 
CommonWell 
 
Renewing 
Health 
Laurea LL 
Skagen LL  
i-City  
Living Lab 
Salud 
Andalucía 
 
 
Source: Authors' elaboration from data available on the CORDIS server 
Health condition perspective. The analysis of the content of the selected projects shows that the 
focus spans from monitoring and early prevention to home care. Chronic Heart Failure (CHF), 
diabetes and pulmonary conditions (COPD) are the most recurrent chronic diseases addressed by the 
projects, followed by Chronic Kidney Disease (CKD), renal insufficiency and neurodegenerative 
diseases like Parkinson. In addition, co-morbidity, which refers to the condition of patients suffering 
from more than one major multiple diseases at the same time, is a thorny challenge for clinical 
medicine as one disease may affect the evolution and response to treatment of the other. Co-
morbidity is also addressed in a number of EU funded RMT initiatives such as METABO (FP7) 
which deals with chronic diseases related to metabolic disorders. 
Technology and service innovation. Most EU-funded projects address the complete value chain of 
the PHS/RMT markets. BY examining the PHS/RMT value chain, a number of technological 
advances have emerged from these projects and are briefly described below. Integration of health-
monitoring tools into textiles has been talked about for some time. The European Commission has 
invested in research efforts in this field throughout FP5 and FP6. In terms of projects that address 
these developments and focus on physiological monitoring for prevention of cardiovascular risk, is 
                                            
122  http://cordis.europa.eu/ist/ka1/health/  
123  Information available at http://ec.europa.eu/information_society/activities/health/research/fp6projects/index_en.htm  
124  http://ec.europa.eu/information_society/activities/health/research/fp7phs/index_en.htm  
125  http://ec.europa.eu/information_society/activities/eten/cf/opdb/cf/project/index.cfm  
126  http://ec.europa.eu/information_society/activities/health/cip_ict_psp/index_en.htm  
127  http://www.openlivinglabs.eu/  
128  http://ec.europa.eu/information_society/apps/projects/index.cfm?theme_id=12 
129  Chronic Disease Management (COPD, Chronic Heart Failure, Diabetes). 
130  Relatively recent projects i.e. after 2005. 
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Wealthy (FP5) and then My Heart (FP6) which have developed wearable electronics and body 
sensors to detect and measure body vital signs, as well as a signal processing algorithms used to 
extract ECG data from the wearable electronics. HeartCycle (FP7) also researches new bio-sensors 
(mainly for the continuous monitoring of blood pressure, blood oxygen levels and heart function). 
The development of innovative closed-loop approaches for chronic disease management is the focus 
of many projects: for instance, in HeartCycle (FP7) for coronary heart disease and heart failure 
patients, in Metabo (FP7) for diabetic patients, in Chronious (FP7) for Chronic Obstructive 
Pulmonary Disease (COPD) as well as Chronic Kidney Disease (CKD) and Renal Insufficiency. In 
some cases the platform connects to electronic patient health records, as is the case with Heartfaid 
(FP6) or Linkcare (eTEN). The systems developed are intended to report automatically to clinicians, 
in order for them to adapt therapies and make lifestyle recommendations (medical loop), as well as 
involve the patients themselves in the management of their disease (patient loop). 
Remote communication of data is ensured by either wireless, mobile communications including use 
of PDAs and mobile phones, internet technologies, home-interactive TV as well as agent 
technologies. One example of home-interactive TV system is the Caring TV channel, a Finnish 
innovation developed by the Laurea Living Lab131 that offers a new way of delivering health care 
and welfare services directly to the home through interactive TV. The pilot project started in 2006 
and several Caring TV projects are underway today, led by Laurea, for different user groups. Mobile 
trans-European services for chronic disease management have been researched into by a number of 
projects such as FOR-ALL or HealthService24 (eTEN). Agent technologies are promising improved 
chronic disease management systems, in the form of a personal assistant ubiquitous in the daily life 
of a patient with a continuous support for chronic disease management, allowing compliance support, 
interfacing with monitoring devices, real-time medical advice (PIPS,132 Saphire,133 FP6projects).  
Robotics is the research areas134 with most potential in home patient monitoring. However, a barrier 
in the commercialisation of robotics for care is the way health care systems are currently funded as 
well as the need for more user involvement in order to develop efficient robotic application. 
"Integrated care" services (i.e. the combination of social care and health care) for effective 
management of chronic diseases can be found in a large number of projects. A series of "integrated 
care" projects led by Hospital Clinic of Barcelona since 2000 shows135 the high potential of this 
approach. Examples are Health-Life, Linkcare, FOR-ALL, and Better Breathing (eTEN), as well as 
CommonWell and NEXES (CIP). The European CIP ICT-PSP Programme in particular promotes the 
deployment of ICT solutions supporting integrated health and home care management. The aim of 
the NEXES (Supporting Healthier and Independent Living for Chronic Patients and Elderly) project 
is to deploy, integrate and validate services targeting prevalent chronic disorders and addressing the 
areas of well-being and rehabilitation, enhanced care support of unplanned hospitalisation, home 
hospitalisation and early discharge, support of diagnostic and/or therapeutic procedures and the 
identification of strategies for the success of extensive and sustainable deployment of services. 
                                            
131  www.activelife.fi 
132   See: 
http://cordis.europa.eu/fetch?CALLER=FP6_PROJ&ACTION=D&DOC=3&CAT=PROJ&QUERY=1192711569763&RCN=712
45 
133  http://cordis.europa.eu/fetch?CALLER=PROJ_ICT&ACTION=D&CAT=PROJ&RCN=79482 
134  Dutch innovation agency, TNO, has published a ‘robo roadmap’ on the way forward for robotics in medical and health arena. The 
agency developed the roadmap as part of an EU funded study to provide policy recommendations for the application of robots in 
the future, including in health care. The study available at  http://www.tno.nl/downloads/TNOKvL_report_RoboticsforHealth 
care1.pdf  
135  http://www.betterbreathing.org/documents/Integrated%20Care%20Programmes%20at%20HCB_AlbertAlonso _HCB.ppt  
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Validation with real users. The scale of the EU projects, in terms of number of patients served as 
well as geographical coverage (local, regional or national) is diverse. Trials typically begin with tens 
of patients, then scale up to hundreds of patients and in some cases thousands of patients (large 
scale). Most of the projects considered in our review and analysis have foreseen clinical trials with 
'real' patients but outcomes are still under assessment except in the following cases: Heartfaid136 
(FP6), Better Breathing137), Health-eLife,138 and HealthService24139 (eTEN) or the HHH140 study. 
Examples of observed benefits identified in such assessments are described in. Observations made in 
these pilots strongly emphasise the need for further confirmation of findings by means of large scale 
randomised intervention (clinical) trials, at European scale, such as the one recently launched (2010) 
funded by the CIP programme (RENEWING HEALTH141). 
 
Table 12 – Multi-site trials and validations (examples) 
MyHeart (FP6) – 200 patients in 6 sites 
In October 2008 a clinical study was launched as part of the MyHeart Heart Failure Management project. The aim of the 
study was to determine if daily measurement of vital signs obtained by the MyHeart system can help predict worsening 
heart failure. Up to 200 patients at 6 clinical sites (Aachen, Madrid, Heidelberg, Malaga, Murcia and Bad-Oeynhausen) 
were included in the study, which is jointly organised by Medtronic and Philips. 
Heartfaid (FP6)  - about 20 patients 
The HEARTFAID platform prototype has been tested by the consortium clinical partners (University “Magna Graecia” 
Catanzaro (Italy), Jagiellonian University Medical College (Cracow, Poland), University Milan-Bicocca (Italy), Istituto 
Auxologico Italiano (Milan, Italy)) in two settings i.e. hospital and home settings. In home care settings, the system 
prototype transmits by means of various sensors most commonly monitored home data in heart failure patients. 
Clinical stabilization at home of the HF patients and lower incidence of acute exacerbations at home, were some of the 
benefits observed together with costs reduction. Improvement of patient’s care through an easier and better management 
of the disease. In addition, the HEARTFAID platform increased interest towards a better care and awareness of the 
disease among CHF patients improving self-control. 
Metabo (FP7) 
The validation foreseen in the Metabo project will involve patients with diabetes in Italy, Spain and Czech Republic. 
Dreaming(CIP) – 360 patients in 6 sites 
The DREAMING solution is being piloted in Denmark, Estonia, Germany, Italy, Spain and Sweden (multi-centre 
randomised trials with 60 users per site, in total over 300 users, both elderly as well as chronic patients). The aim of the 
pilots is to assess the impact of the service on the quality of life of elderly people, their formal and informal caregivers 
and their relatives and on economic and clinical indicators, verify its financial sustainability and check user satisfaction. 
NEXES (CIP) – 3000 patients in 3 sites 
Large scale randomised clinical trials (up to 5000 patients ) are foreseen through deploying four integrated care programs 
for chronic patients in three sites (Catalonia, Norway, Greece). In Catalonia, all of the Nexes services will be deployed in 
several local health areas, namely three districts of Barcelona and one medium size city in the suburbs of Barcelona. In 
each area, deployment will be coordinated by the Hospital Clinic of Barcelona. In Norway, all of the Nexes services will 
                                            
136 http://www.heartfaid.org/ 
137 Presentations of results in the final conference at http://www.betterbreathing.org/public_document.html  
138 http://ec.europa.eu/information_society/activities/eten/cf/opdb/cf/project/index.cfm?mode=detail&project_ref=ETEN_NM7 
139 http://www.healthservice24.com/Internet/external/cms/index0ed6.html?healthservice24 
140 A. Mortara, et al Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). European 
Journal of Heart Failure 2009 11(3):312-318. 
141 Also mentioned in footnotes 73 and 77 http://www.renewinghealth.eu 
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be deployed in the area of the city of Trondheim (St Olav hospital), while in Greece, the Nexes services will be deployed 
in the metropolitan area of Athens by several partners (Sotiria Hospital, Santair and ISPM). 
Better Breathing (eTEN) – 4 sites 
Four pilot sites in Better Breathing carry out market validation of the eServices for the care of chronic patients in 
Catalonia, Denmark, Norway and Wales. In Catalonia, the field trials are conducted with patients from the Hospital 
Clinic Provincial Barcelona. In Denmark, the market validation takes place at the Funen Hospital (validating eCare and 
eLearning), in Norway in the University Hospital of North Norway (eCare, eRehabilitation, eLearning and ePatient 
Community services). The patient groups consist of COPD patients. In Wales, the market validation takes place in co-
operation between the Prince Philip hospital in Llanelli, Carmarthenshire, the Carmarthenshire Trust and IHC (validation 
of eCare, eRehabilitation and eLearning). 
Evaluation of impacts on medical staff showed increased workload, but "reassuring for them to be able to monitor 
vulnerable patients remotely” . 
Health-eLife (eTEN) 
The Health-elife project is validating the Doc@Home™ service in the context of typical European hospital outpatient 
service and is also conducting a review of previous socio-economic studies in the management of chronically ill patients 
at home, undertaken in Portugal, Estonia and the UK. The study demonstrated the service competence to manage patients 
at home across a range of clinical dimensions and disease conditions 
The use of remote monitoring for COPD showed promising results for quality and cost-effectiveness .The use of remote 
monitoring also caused patients to sub-consciously adjust their life styles . 
HHH study (Home or Hospital in Heart Failure) (Action line 10.1)- 461 patients in 11 sites in 3 countries  
HHH is an EC -funded, multi-country, randomised controlled clinical trial, conducted in the UK, Poland, and Italy, to 
assess the feasibility of a new system of home telemonitoring (HT). The HT system was used to monitor clinical and 
physiological parameters, and its effectiveness (compared with usual care) in reducing cardiac events in heart failure 
(HF) patients has been evaluated. From 2002-2004, 461 HF patients were enrolled in 11 centres.  
Over a 12-month follow-up, there was not observed a significant effect of HT in reducing bed-days occupancy for HF or 
cardiac death plus HF hospitalisation (a trend towards reduction of events was observed in Italy). 
RENEWING HEALTH (REgioNs of Europe WorkINg toGether for Health) (CIP)  
A large scale pilot on Telemedicine has just been launched by Call 3 of CIP ICT-PSP programme (“ICT for patient-
centered health service”) to validate in real life settings the use of existing PHS for innovative types of Telemedicine 
services and to prepare for their wider deployment. The initiative is expected to build up the largest multi-centre clinical 
trial ever deployed in Europe to measure the effectiveness and cost effectiveness of Telemedicine solutions. 
Source: Authors' elaboration from data collected from the CORDIS database or project web-sites 
6.3 Analysis of pilots and programmes142 
Pilots and programmes are spanning from small scale (dozens of patients) to medium scale (hundreds 
of patients) to large scale (thousands) at local, regional or national levels. Most advanced countries in 
relation to RMT, in terms of scale as well as degree of integration or 'mainstreaming', are USA, 
United Kingdom, then Germany, Spain, Italy and the Netherlands. The most commonly addressed 
conditions are COPD, CHF, diabetes and combinations. Tunstall and HomMed Honeywell, Intel, 
Philips and BOSCH (Health Buddy by Health Hero, since late 2007 – see section 7.2 on companies) 
are amongst the main companies providing technologies/solutions mostly used in RMT pilots. 
                                            
142  We call “programmes” commercial activities. They may be the outcome of pilots going into "real" service production. 
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Innovative developments under so–called "integrated care" services (social/health care combinations) 
can be seen in nationwide initiatives like the Veterans Health Administration's programme in the US, 
regional initiatives like Scotland’s Telecare Development Programme (TDP programme) and 
Telescot, Connected Health & Care Northern Ireland strategy (ECCH), or the HTN Lombardy in 
Italy. Also some pilots and trials involve a combination of telecare and home telehealth applications, 
such as the KOALA study in the Netherlands.  
Large scale initiatives. Despite the fact that there is a plethora of PHS/RMT activities, there are 
only few large scale initiatives amongst them. The most integrated/mainstream example of home 
telehealth internationally is considered to be the Veterans Health Administration's Care 
Coordination/Home Telehealth programme in USA (VHA's CCHT) with more than 30,000 (mostly 
elderly) patients currently served. The medium-term implementation strategy foresees the enrolment 
of 50,000 patients with chronic Spinal Cord Injury (SCI), depression, mild dementia, multiple 
sclerosis (MS), or Parkinson's disease. Subject to the outcome of the short- and medium-term 
implementation, VHA will consider a long-term implementation programme that will support the 
41% of the chronic-disease population with low or limited activities of daily life. CCHT was 
developed as part of the VHA’s efforts to provide home care services to cater for the rising number 
of elderly veterans with chronic care needs. 
Care coordination143 has been explicitly designed to meet the changing health care needs of the 
veteran population that is ageing and coping with the limitations imposed on their lives and longevity 
by chronic diseases and conditions, e.g., diabetes, chronic heart failure (CHF), spinal cord injury 
(SCI), posttraumatic stress disorder (PTSD), depression, chronic obstructive pulmonary disease 
(COPD), stroke, multiple sclerosis (MS), and hypertension. An economic analysis of the CCHT 
outcomes by the VHA has shown reduced hospitalisations, 30% fewer emergency room visits, 30% 
reduction in the average number of bed days of care, improved health-related quality of life and 
benefits in terms of satisfaction, clinical outcomes and costs.144 
Another large-scale initiative in the US is the National Association for Home Care and Hospice 
(NAHCH) pilot. Sponsored by Philips Home Health care Solutions and co-sponsored by the 
NAHCH and Fazzi Associates, the study is considered the largest technology and telehealth study in 
the history of home care (it involved 976 Home care associations across the country). The study 
addressed four major home care technology areas, including telehealth and Remote Patient 
Monitoring Technology. Study results show145 that nearly one third of large agencies are currently 
using a telehealth system and that industry use of telehealth is expected to double over the next two 
years, mainly as a means of managing patients with chronic disease. In addition, over 88% of 
agencies report that deployment of telehealth services led to an increase in quality outcomes, as 
evidenced by the reduction in unplanned hospitalizations and Emergency Room visits, and over 71% 
report an improvement in patient satisfaction. 
In the UK, telecare and telehealth form part of a major randomised control trial across three 
demonstrator sites aiming at a recruitment target of up to 6,000 people in the three WSD pilot sites: 
Kent, Cornwall and Newham. WSD is considered the biggest single telecare/ telehealth convergence 
                                            
143  VHA defines care coordination as- the use of health informatics, telehealth, and disease management to enhance and extend care 
and case management activities to facilitate access to care and improve the health of designated individuals and populations with 
the specific intent of providing the right care in the right place at the right time http://www.va.gov/occ/ 
144  Adam Arkins , MD, Chief Consultant for Care Coordination, Department of Veterans Affairs, Changing the location of care: 
Management of patients with chronic conditions in Veterans Health Administration using care coordination/home telehealth, at 
http://www.rehab.research.va.gov/jour/06/43/4/darkins.html  
145  http://www.medical.philips.com/wpd.aspx?p=/Resources/News.wpd&id=1619&c=main  
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pilot in the Europe.146 An important aim of the Whole System Demonstrator (WSD)147 trial is to 
build the evidence base for the use of these technologies as part of integrated health and social care 
support for people with long term conditions. Criteria for enrolling patients in the WSD telehealth 
trial are those diagnosed with one or more of the long term conditions such as CHF, type 1 or type 2 
diabetes, COPD or co-morbidities, and, people that have had at least one or more unplanned events 
in the last 12 months in relation to their long term condition, such as: unplanned hospital admission, 
intermediate care, rapid response service use, treatment following call out of ambulance services or 
accident and emergency visit. The WSD Programme will run for over two years with all participants 
recruited during 2009 and results foreseen to be published in late 2010. A WSD Action Network 
(WSDAN) has been established to disseminate the lessons learned on the three sites and to become a 
source for the collected worldwide evidence on the effectiveness of telehealth and telecare (a 
database of evidence on the benefits of telehealth and telecare). 
Scotland NHS Lothian Telehealth programme (Telescot) is considered one of the largest of its kind 
in the UK and will provide in-home care for patients with COPD and other chronic conditions. The 
NHS Lothian programme is part of an ongoing collaboration between NHS Lothian and the Scottish 
Government, implemented by Intel and Tunstall (it is using the Intel Health Guide personal health 
system, launched in the UK in November 2008). It follows a small-scale pilot of 30 patients with 
COPD launched in March 2008, also using the Intel Health Guide. The large-scale programme148 
started with 200 COPD patients and will later include those with other chronic conditions including 
cardiac diseases and diabetes across Edinburgh and the Lothian regions. A number of patients 
included in the programme will be enrolled in a randomised control trial conducted by the University 
of Edinburgh. Results of this research will be available in 2010. The project149 is being evaluated 
through the TeleScot suite of randomised controlled trials; it is exploring the role of telemonitoring 
in the management of long-term conditions and whether telemonitoring of COPD affects hospital 
admissions or quality of life for people with moderate or severe COPD in comparison with usual 
care. Recruitment of patients has recently started for several randomised controlled trials, using the 
Tunstall telemonitoring technology. Telecare/telehealth convergence pilots are the focus of the 
renewed telecare strategy150 for 2008-10 implemented through the Telecare Development 
Programme (TDP). The evaluation of the first phase of implementation151 shows that a number of 
outcomes and efficiencies have been achieved.  
One of the European examples that has raised a lot of expectation, mostly because it was a combined 
shared standards and central procurement of technology, is the Northern Ireland Connected Health 
& Care strategy (ECCH).152 It represents a major investment in chronic disease management and 
public procurement of a remote telemonitoring service for 5,000 people (heart disease, COPD, 
diabetes) by 2011. ECCH was set up and funded in January 2008 by the Department of Health, 
Social services and Public Safety (DHSSPS), following a feasibility study carried out in 2007, to 
develop, procure and implement a remote monitoring service for chronic disease patients in Northern 
Ireland. This is a system-wide solution that actually goes beyond pilots. The strategic focus of the 
ECCH initiative is to embed technology in health care so as to leverage its potential to catalyse 
change, bridging the gap between market solutions that are available and which offer significant 
potential for improving the quality and efficiency of services and the lack of awareness about these 
                                            
146  http://ec.europa.eu/information_society/events/cf/document.cfm?doc_id=7253  
147  http://www.dh.gov.uk/en/Health care/Longtermconditions/wholesystemdemonstrators/DH_084255  
148  http://www.shsceventsbookings.co.uk/event_316/documents/BrianMcKinstry.pdf  
149  http://www.jitscotland.org.uk/downloads/1248342434-Newsletter%20TELESCOT%20July%202009%20FINAL.doc  
150  Telecare Strategy 2008-2010 sets out the Scottish Government's expectations of further development in telecare; 
http://www.jitscotland.org.uk/downloads/1219664870-94-Telecare%20Strategy%202008%20-%202010.pdf  
151  http://www.jitscotland.org.uk/downloads/1235404195-B59058%20Final%20Report%20low%20res.pdf  
152  http://www.eu-cch.org/  
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solutions among practitioners and policy makers. Pre-procurement for services in relation to CHF, 
COPD and diabetes patients, both home-based and mobile is currently ongoing153 and service 
implementation is planned for 2010. In the future further disease conditions may be tackled such as 
stroke prevention, hypertension, telecare services (e.g. fall detection), medicinal compliance or 
dementia, depending on the results of the evaluation of the current services. ECCH also aims to build 
an evidence base in relation to the use of remote monitoring in support of the management of chronic 
disease, which will be used to assess its operational outcome and impacts. ECCH is so far the only 
large scale, system-wide initiative with pre-procurement.  
Regional initiatives. Beyond the above mentioned large scale initiatives, many other smaller scale 
but equally regionally implemented initiatives have been identified and studied during the first phase 
of SIMPHS. The Health Telematic Network (HTN)154 in Lombardy gradually extended the initial 
telecardiology service, set up in 1998 for the Boario Home Care Project (applying new models of 
disease management and technology) to more locations in Lombardy to convert evidence from 
clinical trials and research into benefits for everyday practice.155 The Lombardy Region authorities 
have commissioned an expansion of the service from 2006 on, to cover the whole region with new 
"disease management" services. The benefits reported so far were: (a) faster and more appropriate 
access to health care for citizens who are unaware of their emerging chronic heart disease; (b) fewer 
unnecessary hospital visits; (c) faster GPs' response to changes to the therapies that are needed by 
their patients; and (d) economic benefits which were exemplified by: (i) increasing and sustainable 
net benefit to patients, GPs and hospitals; (ii) economic return (net benefits to cost ratio) over 15 
years of 230%; (iii) estimated annual cost benefit ratio 3.3 to 1 by 2012. eHealth impact project 
evaluates 31% of direct benefits are for citizens versus 69 % for health care provider 
organisations.156 
Overall, the Lombardy region is leading the process of wide diffusion of RMT services, starting 
from initial experimentation through pilots towards the introduction of reimbursement of RMT for 
CHF operationally. Early experimentation funded by either the Italian Ministry of Health or the 
European Commission, such as for instance Criteria157, Piano Urbano,158 and Radici,159 has 
eventually led to operationally reimbursed RMT services for CHF (and also for other chronic 
diseases, see infra). Even before these projects and pilots were launched, the Region had set up a 
group of clinicians to discuss what could be appropriate targets and type of diseases, the kind of 
therapeutic paths to be followed (six months versus sine die, versus various other solutions). All this 
experience has then been transformed into a self-standing programme of the Region going under the 
name of Nuove Reti Sanitarie (New Health care Networks)160 in the context of which the protocol 
for the reimbursement of RMT services for patients with CHF has been defined and is currently 
managed. The Region has introduced regional protocols (it is not formally a DRG, but it comes close 
                                            
153  There are four short listed providers selected Candidates for the Remote Telemonitoring Northern Ireland (RTNI) Managed 
Service : Robert Bosch GmbH with McElwaine Smart, British Telecommunications plc (BT) with Home Telehealth Limited, 
Hewlett Packard Limited with Honeywell HomMed, Intel and Home Telehealth Limited and TF3 consortium comprising  Tunstall 
Health care (UK) Limited (Tunstall), Fold Housing Association Limited (Fold) and Silicon and Software Systems Limited (S3); 
info at http://www.eu-cch.org/index/remote-monitoring-service.htm   
154  http://www.e-htn.it/home.htm  
155  Three different types of services are available: (a) a service to provide a rapid second opinion for general practitioners; (b) a 
service to provide home tele-nursing for chronic patients; (c) a service to provide a call centre service for hospitals. The service 
centre provides technological and organisational support, while the hospitals' cardiologists and nurses manage the health care 
activity. 
156  http://www.medetel.lu/download/2008/parallel_sessions/presentation/day2/good_ehealth.pdf  
157  http://www.cefriel.it/criteria  
158  http://www.cefriel.it/pianourbano 
159  http://www.radici.regione.lombardia.it/  
160  http://www.cefriel.it/nrs  
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to it161) for three services, managed within Nuove Reti Sanitarie. Two protocols target cardiovascular 
patients: (a) Home Telemonitoring protocol for patients with CHF; and (b) Post-cardio-chirurgic 
home-based assistance. Later, in 2008 a new protocol was launched for Home based palliative 
assistance (for terminally ill cancer patients) making use of ICT enabled solutions. The Region, 
through a number of regional level regulations,162 has identified, defined and priced the three 
protocols (see data reported earlier in Figure 9 on page 38) and subsequently authorised the health 
care structures of the region requesting the reimbursement for the provision of such services to 
implement them with another set of Regional regulatory acts.163 The reimbursed tariffs have been 
defined on the basis of a preliminary simulation of costs but will be steadily adjusted since the 
protocol mandates that the health care structures receiving reimbursement must provide detailed 
information on the usage of resources, which will serve to adjust the tariffs for reimbursement. 
Another Italian region, which has a long-standing experience of home care, European level 
experience in Telemedicine (it currently runs 19 European projects in the area of health including 
telemedicine)164 and enjoys strong leadership and vision at regional level is the Veneto Region. One 
of the recent European projects lead by the Veneto Region is HEALTHOPTIMUM (eTEN) aiming at 
deploying telemedicine services, geographically (e.g. roll-out of neurosurgical tele-counselling in all 
Local Health Authorities of the Veneto Region), and also to new specialties (e.g. the application of 
the HEALTH OPTIMUM services to stroke management where the Veneto Region has selected 
three hospitals equipped with neurology and neuro-radiology services). The region has recently 
procured a service for tele-assistance and remote monitoring of basic vital parameters ensuring for 
five years the capability of reaching everyday a total of 25,000 users. Overall, the region shows 
innovative and visionary initiatives towards the integration of health and social care. The Region 
elaborated a multidimensional fiche (known as SVAMA) where individuals are assessed along three 
dimensions: economic capabilities, social conditions, and health status. Looking at these three 
dimensions a local Committee composed by the Local Socio-Health Unit (USSL), the hospitals, and 
the local GPs will decide which patients should be enrolled in the offered tele-assistance and remote 
monitoring services and request that the provider, who cannot object to the decision, offers them a 
service. The service provision consists of a collection of a number of vital signs (ECG, blood 
pressures, and others), their automatic preliminary analysis and the transfer of the output to the 
Distretto Socio-Sanitario (an intermediate body between the USSL and the hospitals) where a 
specialist full time employee (not a cost charged by the provider) periodically looks at the data. In 
case of abnormal patterns (but not in case of full blown emergency when the patient is immediately 
brought to the hospital) the specialist may decide either for a change in the pharmacological therapy 
(she/he triggers the GP responsible for the patient) or for a short hospitalisation. The fact that all the 
health and social care human components of the services are ensured by the personnel of the USSL 
explains the lower price for the tele-assistance and remote monitoring service (see data reported 
earlier in Figure 9 at page 38), compared to those of other Italian regions. 
RMT services to treat CHF, Diabete, and COPD patients living in remote areas in the mountains has 
been recently procured by the Piedmont Region (see data reported earlier in Figure 9 at page 38). 
The services foresee, besides the standard remote monitoring activities, the periodic visit of nurses, 
the interventions of physicians and also sophisticated video-conference equipment and services. The 
level of the offered services explains the higher price per patient per day reported for this region. 
                                            
161  The detailed illustration available in the documentation received is summarised in the Country Profile Italy. 
162  DGR N. VII/20592 of 11.02.2005, DGR N. VIII/1375 of 14.12.2005, DGR N. VIII/6410 of 27.12.2007 and DGR N. VIII/7180 of 
24.04.2008. 
163  DGR N. VIII/2471 of 11.05.2006 and with DGR N.VIII/7933 of 06.08.2008 and with the recent DGR N. VIII/10072 of 7.8.2009. 
164  Presentation of Veneto Region at http://www.synthesisproject.ro/Presentation_230209_Veneto%20Region.pdf  
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In Canada, The Ontario Telemedicine Network (OTN) is one of the largest telemedicine networks 
in the world. OTN was created through the April 2006 merger of three provincially funded 
telemedicine networks: CareConnect (Eastern Ontario), NORTH Network (Central & Northern 
Ontario) and VideoCare (Southwestern Ontario). The Ontario Telehomecare Phase One Program 
(March 2007 to October 2008) provides care and monitoring to 600 patients with chronic diseases. 
Eight Family Health Teams supported phase One across Ontario in collaboration with local 
Community Care Access Centres – all of whom play key roles in chronic disease management 
activities. The Telehomecare project is currently expanding into the thousands of patients in 2009.165  
Besides the WSD programme and regional initiatives, in the UK, there are also over 300 telecare 
services provided by local authorities, housing associations, independent, voluntary and third sector 
organisations as well as commercial providers. A small number of primary health trusts have been 
testing telehealth systems that can monitor respiratory and heart conditions at home. These services 
include regular home monitoring of blood pressure, blood sugar, weight and other vital signs. If these 
measurements are outside of certain levels, health care professionals (e.g. specialist nurses, 
community matrons) are alerted and will take appropriate follow-up action. In 2008, the Commission 
for Social Care Inspection (CSCI) collected information from 150 social care authorities166 and 
reported on telecare outcomes and mainstreaming.167 For instance, a highly successful pilot employs 
telecare to deliver services to 35 people with COPD with the aim to reduce hospital admissions and 
increase self-care across Blackpool (the scheme if successful will be extended to 200 people). 
Lancashire is in the process of setting up a telehealth-monitoring pilot in partnership with East Lancs 
Primary Care Trust & Housing Pendle. Eighteen patients with long-term conditions (6 CHD, 6 
COPD & 6 Diabetes) will be identified to have vital signs monitoring in their homes. In addition to 
this, a second telehealth-monitoring pilot is under discussion in partnership with East Lancs Primary 
Care Trust & Housing Pendle. The intention is to mainstream telecare in the region by taking it up 
into a standard care package like any other treatment (2009). 
There is also a Chronic Care Management (CCM) programme (comprising three projects) 
operating across Wales – Carmarthenshire, Cardiff and North Wales – launched in 2008 and 
focused on chronic conditions such as arthritis, COPD, diabetes and CHF. Each of the three projects 
is focused on different aspects of health care and social care. The first annual report168 outlines 
improvements in care for patients with chronic conditions such as a reduction in emergency medical 
admissions in Carmarthenshire over a three year period by almost: (a) 40% for COPD; (b) 30% for 
CHF; and (c) 10% for diabetes. Admission avoidance figures attributed to the CCM team show a 
drop over 2008-2009 by 10% (to 528 patients), whilst patients have benefitted from a rapid increase 
in the number of telecare installations over 2008 – 2009 from 240 to 751, handling 1146 referrals. In 
addition, the Scottish Centre for Telehealth is supporting a number of developments.169 Some 
actual and foreseen pilots are ongoing for example in South/North East Scotland and Lanarkshire 
(hyper acute stroke care), and in Lothian, Lanarkshire, Moray (COPD). The demonstrators are also 
expected to be extended to cover a wider range of conditions, including diabetes, hypertension, 
coronary heart disease and asthma for example in Lanarkshire. Also in the UK, a major two-year 
pilot programme has been announced by the Department of Health to test and evaluate a range of 
models of integrated care. The programme which consists of 16 Integrated Care Pilots (ICP) is 
designed to explore different ways in which health and social care could be provided to help drive 
                                            
165  http://exweb.otn.ca/telehomecare/files/Telehomecare%20Fact%20Sheet%20FINAL%20Sept192007.pdf  
166  http://www.networks.csip.org.uk/telecareprofiles   
167  Telecare performance reports from social care authorities (2008) at: 
http://www.dhcarenetworks.org.uk/IndependentLivingChoices/Telecare/TelecareOutcomes/? 
168  Details of the first annual report at www.ccmdemonstrators.com 
169  http://www.sct.scot.nhs.uk/index.html  
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improvements in local health and well being. Integration refers to partnerships, public and third 
sector organisations, systems and models – crossing boundaries across primary, community, 
secondary and social care. The pilots170 vary from developing new models of long-term condition 
management to help patients choose their end-of-life care, to enable people to self-manage COPD 
care. A number of these pilots also deal with innovative approaches for chronic disease management. 
In the Netherlands171, some major regional initiatives have been launched recently (not more than 3 
years ago), such as IZIT, BHI and ZIF. The main focus of these initiatives is health care change and 
the role/position of the patient. IZIT172 is a leading regional initiative in the Twente region aiming to 
establish an information system for integrated care in Twente that facilitates the exchange of 
information between GPs in the region. IZIT has become an best case example of ICT developments 
in health and social care, for other regions. IZIT cooperates with insurer Menzis and regionally 
operating home care organisations in the successor of the KOALA project and with the regional 
Innovation Platform Twente in developing a programme, called INNOTEL, which will develop 
solutions for well-being (home care services and chronic disease management for the elderly). The 
KOALA173 project is a combination of telecare and home telehealth applications, coined as services 
for "Care en Cure" which involves about 1000 patients from all parts of the country. The first 
KOALA study involved 155 CHF patients, 25 diabetes patients and 58 COPD patients. The 
objectives were to reduce the number of visits to physicians and cardiologists. Trials will be 
continued with roughly 300 patients with CHF, diabetes and COPD and an additional 300 patients 
with intensive nursing care needs.174 Brainport Health Innovation (BHI)175 is a regional initiative, 
part of Brainport Development, around the region of Eindhoven with the aim to improve 
independent living. On the basis of a shared vision regarding the focus and orientation of BHI a 
programme has been developed, called 'Connected Client, Connected Patient'. It now consists of 
some nine projects, ranging from elderly remote care to a health service portal and a coach for 
patients with chronic diseases. BHI also participated in the Interreg IIIC project 'Telemedicine and 
Urban Planning'176 and is involved in its successor 'Healthy Workforce' (under preparation). Seven 
cities throughout Europe were connected to this initiative (Eindhoven, Den Haag, Barcelona, 
Southampton, Bologna, Genoa and Parma). Zorg Innovatie Forum (ZIF)177 is a regional innovative 
centre in the northern part of the Netherlands (province Groningen). It has formulated four 
'showcases' of which one is in the domain of RMT. The showcase 'Care for the future' will contribute 
to the successor of the KOALA project in the eastern part of Groningen. 
Local initiatives. In addition to the regional initiatives, there are obviously many more company-
driven local initiatives, three of which we report on are in Spain, Austria and Hungary. Emminens, a 
subsidiary of pharmaceutics giant Roche runs a number of initiatives in Spain. Saludnova, a spin-off 
from the University of the Basque Country and part of the Cooperativa Mondragón, is involving 
three hospitals of the Regional Health care System in the Basque country in running pilots on 
telemonitoring178 for chronic patients. In June 2009, Orange Austria and charity Arbeiter-Samariter-
Bund Österreich (Workers Samaritan Federation Austria) announced179 a trial to pilot a mobile e-
health solution for monitoring blood sugar levels and blood pressure, using Alcatel-Lucent 
                                            
170  http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098912.pdf  
171  Based on information provided for in the Dutch Country report carried out by IPTS. 
172  www.izit.nl  
173  http://www.koalaweb.nl/documents/april%202007%20Koala_En.pdf  
174  ICT&Ageing country profile at http://www.ict-ageing.eu/  
175  See http://www.brainporthealthinnovation.nl/ (download section; programme 'Connected Client, Connected Patient'.  
176  See http://www.telemedicine-europe.net/index.php?id=1 
177  See http://www.zorginnovatieforum.nl/  
178  http://www.saludnova.com/index.php?option=com_content&view=article&id=178&Itemid=146&lang=en  
179  Via http://www.ehealtheurope.net/news/4970/orange_austria_targets_mobile_e-health  
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TeleHealth Manager solution, an off-the-shelf e-health platform, in Austria. GE Health care is part 
of a consortium leading a major telemonitoring initiative, in the framework of the 3-year Hungarian 
Assisted Living Programme, initiated and majority-funded by the Hungarian government. The 
initiative (also backed up by GE Health care investment) aims to research and develop remote 
telemonitoring systems that monitor both activity levels and vital signs such as blood pressure and 
heart rate, alerting caregivers to changes that may signal potential health problems or emergency 
situations. Evidence collected will likely focus on the potential benefits of home health monitoring 
for elderly patients with chronic health problems such as stroke, depression and dementia. The 
Consortium aims to identify activity patterns and physiological symptoms that may remotely predict 
onset of disease, diagnose a condition earlier, identify problems such as a relapse or detect a 
worsening of a condition.180 
6.4 Lessons on innovative activities 
Innovative activities, mostly undertaken as projects and pilots, but also taking place in programmes, 
are spanning from small scale (dozens of patients) to medium scale (hundred of patients) to large-
scale (thousands) at local, regional or national levels. As far as EU-funded projects are concerned, 
large scale and multi-site trials and validations have been funded by the CIP and eTEN programmes. 
Most advanced countries in relation to RMT, in terms of scale as well as degree of integration or 
'mainstreaming', are the US, the United Kingdom, Germany, Spain, Italy and the Netherlands. 
Most innovative initiatives identified relate to pilots not to sustained long-term services. Instances of 
the latter supported by reimbursement models can be seen only in very few cases like in Germany 
(Vitaphone) or Italy (HTN). In Germany, a number of health insurance actors offer large-scale home 
telehealth service programmes as part of their integrated health care programmes, while other actors 
are involved in trial phases with a rather low number of participants. The experience with HTN 
Lombardy shows how reimbursement strategies might assist in moving from innovation perspectives 
to real markets – albeit with still a fraction of the possible patients being served. Recommendations 
on reimbursement of home telehealth and remote monitoring were recently made by the American 
Telemedicine Association.181 These recommendations, although not yet implemented by payers even 
in the USA, provide an insightful analysis of how Tele-homecare reimbursement can be addressed as 
part of mainstream approaches.182  
Most innovative activities studied included data collection tasks to satisfy the need to build evidence 
related to the clinical outcomes, cost effectiveness, impacts on services utilisation, and acceptance by 
health care providers.183 Since thus, telemedicine as an alternative to disease management is not 
generally accepted, there are a number of possible approaches to commissioning telecare and 
telehealth, all of which have associated risks (e.g. "Go for it – initiate major programme, phased 
implementation", "Stay with controlled pilots and projects", "Wait for the money", "Wait for the 
evidence", or "Do nothing – it's not a priority"). While a few innovators and early adopters are using 
RMT technology, a "waiting game" is taking place until the evidence on clinical outcomes and cost-
effectiveness would be available.184 The EU is trying to address this challenge by launching what is 
hoped to be the largest multi-centre clinical trial (9 countries, over 1000 patients each) ever deployed 
in Europe to measure the effectiveness and cost-effectiveness of Telemedicine solutions (CIP 
                                            
180  GE-Health care presentation during the 2009 eHealth Ministerial Conference in Prague and news at: 
http://www.ehealtheurope.net/News/4365/hungary_signs_e-health_deal_with_ge_health care  
181  Virginia and eleven other states have adopted mandates legislating that health insurers pay for telemedicine services. The other 
states are: California, Colorado, Georgia, Hawaii, Kentucky, Louisiana, Maine, New Hampshire, Oklahoma, Oregon and Texas. 
182  http://www.americantelemed.org/files/public/policy/Home_Telehealth_Policy_ver3_5.pdf 
183  Systematic Review of Home Telemonitoring for Chronic Diseases:The Evidence Base: JAmMed Inform Assoc. 2007; 14:269 –277 
184  http://www.wsdactionnetwork.org.uk/news/features/the_challenges_for.html  
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Renewing Health, see footnote 141). This pilot will produce large scale, measurable, comparable and 
statistically significant results, regarding the effectiveness of the solutions tested, using a commonly 
agreed and scientifically sound assessment methodology and develop sustainable business models. 
One of the main challenges on accessing required evidence is raising consensus on the population at 
risk, mainly as a result of difference in definitions. In the UK for instance, 5% of patients account for 
49% of in-patient bed days in hospitals (and associated costs) and just 2% of patients with long-term 
conditions account for 30% of unplanned admissions and 80% of visits to a general practitioner. 
Many hospital admissions can be prevented provided "at-risk" population can be predicted. In the 
UK, since 2005, the King’s Fund and BUPA/Health Dialog have developed predictive185 models 
such as PARR ++ (People at Risk of Readmission to Hospital). These predictive models seem to be 
more accurate when making forecasts for the future e.g. in predicting which patients will be a high 
cost in 6-12 months time as well as those patients that will have an avoidable event. Some examples 
are the PARR model used in WSD programme or in the doc@Home186 project. 
From a health condition perspective, chronic heart failure (CHF), diabetes and pulmonary conditions 
like COPD are the most important chronic diseases addressed by both EU-funded projects and pilots, 
together with co-morbidity.  
Most EU-funded projects address the whole value chain of the personal health systems and remote 
patient monitoring markets, from development of monitoring & measurement devices (sensors) 
including protocols & analysis tools to patient platforms & patient management systems (patient and 
medical loops). In some cases the platform connects to electronic patient health records.  
Funding is needed at the start of the service procurement as well as for the transition period towards 
full deployment. Most of successful implementations seem to happen when funding is made 
available by public authorities. ECCH in Northern Ireland is so far the only large scale, system-wide 
initiative with pre-procurement. Interesting cases with private funding are Saludnova (Cooperativa 
Mondragon) and Rehabitic (Telefonica) in Spain. Mixed approaches (public/private funding) can be 
seen in some cases e.g. in USA -Home Care and Hospice with Fazzi Associates and Philips, 
Hytmobile in Spain (MMC and Hospital de la Paz,  Madrid), GE Health care in Hungary. 
In conclusion, innovation in RMT is happening all over Europe. There are various models for RMT 
reimbursement that are currently being tested and USA-based recommendation that may be applied 
in the EU. A sound assessment methodology is being tested in various pilots to collect and make 
visible appropriate evidence of quality of treatment, clinical outcomes and cost-effectiveness as well 
as models for predicting patients at-risk. As a consequence the sustained funding of small or large 
pilots is required if the much needed innovative activities are to bear their much anticipated fruits. 
6.5 Role of pilots and projects in spurring innovation dynamics 
RMT pilots and projects address innovation at different levels. Based on our review of pilots and 
projects in EU member states and beyond, we have identified a number of innovation trends which 
each in their own way may contribute to RMT market uptake. These innovation trends are 
summarised in this section.  
                                            
185  Based on the DH presentation to be found at: 
http://www.aok-
gesundheitspartner.de/imperia/md/content/gesundheitspartner/bund/dmp/evaluation/konferenzberlinjuni2009/dmp_konf29_30_06_
09_goodwin_engl.pdf  
186  Docobo presentation at SIMPHS Workshop.  
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As a result of the over 10-year sustained R&D efforts, examples of incremental innovation in 
technological components, resulting in new or improved products, include devices (implants, vital 
sign monitoring, communication devices), software (e.g. intelligent data processing, decision support 
software), infrastructure (telecommunication networks, protocols, standards) and system integration 
(integration with EHR). In terms of newest developments, textile-sensing platforms for instance are 
being used to address cardiovascular diseases. These systems are cost-effective in helping physicians 
e.g. to monitor cardiac patients during periods of rehabilitation, resulting in decreased hospitalisation 
time. Finally, by providing direct feedback to the users, they improve their awareness and potentially 
allow better control of their own condition. Projects that have developed such platforms and devices 
include HealthWear, MyHeart, Wealthy and Heartcycle. 
Besides technological innovation aimed at enhancing product features, a number of projects and 
pilots increasingly address processes, an acknowledgment that there is a paradigm change towards 
patient-centred services, and out-of-hospital care, which requires a radical change with existing 
practices. Service delivery in the future will be radically different from today's care services, with its 
focus on care processes controlled and delivered by medical practitioners. Most of the EU-funded 
activities as well as pilots we studied seem to increasingly address process innovation, including 
chronic disease management systems such as intelligent closed-loop approaches. Some examples are 
provided in Figure 17 below. HeartCycle for instance tackles closed-loop management by multi-
parametric monitoring of vital signs and other parameters, physiological and statistical modelling of 
medication and lifestyle effects, motivating patients towards treatment compliance by feeding back 
the short- and long-term effects of their treatment. It provides decision support through a patient loop 
(interacting directly with the patient to support the daily treatment) and a medical loop (involving 
medical professionals, e.g. alert so as to dynamically adopt the care plan). Closing the loop towards 
integrated disease management is still to be made though and HeartCycle will use the results of the 
MyHeart project and the MyHeart clinical heart failure studies to develop a closed-loop disease 
management strategy. 
Other innovative approaches are close to reaching market deployment like Medtronic's "semi-closed 
loop" -the first diabetes technology to make automated treatment decisions in extreme situations187. 
This system, sometimes referred to as an "artificial pancreas", would emulate a healthy pancreas by 
using technology that continuously monitors glucose levels and automatically adjusts insulin delivery 
in patients with diabetes. 
                                            
187  http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1244301588079&lang=en_US  
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Figure 17 – Examples of closed loop approaches 
 
 
17a – HeartCycle closed-loop 17b – Metabo long loop 
Source: mentioned inside figure 
"Integrated Care" reflects another recent trend in projects and pilots, the goal being "seamless" care 
for patients with acute and chronic health problems at any point in the health care system. At its 
broadest, Integrated Care extends to encompass preventive care, social care, care and support in the 
home, recognising that social conditions impact on health and vice-versa. It imposes the patient 
perspective as the organising principle of service delivery. 
The term "Integrated Care" means different things to different stakeholders188 though: 
• To the user, it means a process of care that is seamless, smooth, and easy to navigate.  
• To the provider, it means working with professionals from different fields and co-ordinating 
tasks and services across traditional professional boundaries.  
• To the policymaker, it means merging budgets, and undertaking policy evaluations which 
recognise that interventions in one domain may have repercussions on those in other 
domains, and thus should be evaluated as part of a broader care package. 
Integrated Care is not yet widely implemented in any EU Member State as currently, in most EU 
countries there are separate social and health care systems with separate budgets, and different 
infrastructures that very often do not 'talk to each other'. The lack of communication between the two 
makes it difficult to reach convergence and current regulatory frameworks do not allow for instance 
medical personnel to attend medical issues in the social services area.189 However innovative 
developments under integrated care supporting the effective management of chronic disease can be 
                                            
188  Lloyd J, Wait S.; "Integrated Care. A guide for policymakers"; International Longevity Centre and the Alliance for Health & The 
Future, London: 2006.  
189  Tunstall assessment (SIMPHS WS minutes: http://is.jrc.es/pages/TFS/documents/SIMPHS16JuneWorkshopsummaryfinal.pdf).  
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seen both in EU-funded activities like the CommonWell project (CIP) as well as in national or 
regional initiatives like VHA in USA, WSD in the UK or Scotland's telehealth/telecare programmes. 
In the UK, a major two-year pilot programme has been announced by the Department of Health to 
test and evaluate a range of models of integrated care. The programme which consists of 16 
Integrated Care Pilots (ICP) is designed to explore different ways in which health and social care 
could be provided to help drive improvements in local health and well being. Integration refers to 
partnerships, systems and models as well as organisations crossing boundaries across primary, 
community, secondary and social care. The pilots190 vary from developing new models of long-term 
condition management to help patients choose their end-of-life care, to enabling people to self-
manage COPD care. Pilot sites are working across primary, secondary, community and social care 
services, public and third sector organisations to forge new partnerships, systems and care pathways. 
A number of these pilots also deal with innovative approaches for chronic disease management.  
In terms of new services for a specific disease innovation may open up new market segments or lead 
to improving existing ones. Especially with respect to ICT-driven innovation the user is able to 
influence design processes191 and plays a crucial role as a group192 in the adoption of new services. 
There are many examples of what user-centric service innovation means in RMT in particular 
stemming out of the many Living Labs projects that are being funded by the European Commission. 
For instance, the LL Skagen and maXi projects both in Denmark or the i-City in Belgium, involving 
users in testing and evaluating solutions. LL Skagen193 focuses on services for chronic patients with 
diabetes. In another example, as part of i-City in Belgium, the IM3 Interactive Mobile Medical 
Monitoring194 project, is an interesting example in relation to remote monitoring for CHF patients 
focused on the context and indirect change by using technology (a first target group of 12 patients 
with CHF, now being scaled up to 100 patients). Recent developments in the market such as the new 
"game–care" services recently launched for a specific disease may lead to opening new markets. In 
this respect, an interesting example is Bayer Didget gadget for Nintendo DS195 for telemonitoring of 
diabetes in children that was developed together with the parent of a child with type 1 diabetes.196 
There is evidence of institutional innovation in the RMT market as in reimbursement provision. In 
the US, despite strong evidence of RMT benefits, provided by the VHA programme, health care 
payers still remained resistant to providing reimbursement for remote patient monitoring.197 After a 
2005 study,198 showed that only about half of state Medicaid programs reimburse for telemedicine, 
policy options were implemented and the American Telemedicine Association recently made 
recommendations on reimbursement of home telehealth and remote monitoring (see footnote 182).  
In Europe, successful implementations of RMT with reimbursement can be seen in two cases: one in 
Germany and the other in Lombardy, Italy. In Germany, main providers include commercial 
                                            
190  http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098912.pdf  
191  Silverstone, R. & Haddon, L.; "Design and the domestication of information and communication technologies: Technical change 
and everyday life"; in R. Marshell and R. Silverstone (eds.), Communication design: The politics of Information and 
Communication Technology (pp. 44-74). Oxford: Oxford University Press (1996). 
192  Surowiecki, J. "The Wisdom of Crowds"; Anchor Books, ISBN 0-385-72170-6 New York: 2005. 
193  http://www.bth.se/hal/halsoteknik.nsf/bilagor/living_lab_Skagen_2008_pdf/$file/living_lab_Skagen_2008.pdf  
194  http://projects.ibbt.be/im3 
195  http://www.bayerdidget.co.uk/About-Didget/Didget---Diabetes-Management  
196  Paul Wessel, the parent, noticed that although his son Luke was constantly losing his blood glucose meter, he could always find his 
Nintendo Game Boy. It was this observation that inspired Paul Wessel and Bayer to work together to develop the first and only 
blood glucose meter that connects to the Nintendo DS and Nintendo DS Lite gaming systems to reward children for good testing 
habits. 
197  Report from SpyGlass Consulting  http://www.spyglass-consulting.com/press_releases/SpyglassPR_RPM_2009.pdf  
198  'Telemedicine for CSHCN: A State-by-State Comparison of Medicaid Reimbursement Policies and Title V Activities 
https://www.ichp.ufl.edu/documents/Telemedicine%20in%20Medicaid%20and%20Title%20V%20Report.pdf  
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monitoring services (for chronic diseases), non-profit organisations for chronic diseases (such as the 
Stiftung Telemedizin) and selected hospitals, clinics or GPs who provide outpatient services for 
elderly people. Vitaphone's system is an example of company –driven initiative that negotiated the 
inclusion of its system in reimbursement structures with each insurance company separately in 
Germany (Betriebskrankenkasse), however most of the subscribers to the service pay for the device 
and the service privately.199 An example of up-and-running programmes, according to a recent report 
from the ICT& Ageing project,200 is BKK Taunus201 in cooperation with PHTS Telemedizin202 that 
provides home monitoring of patients with chronic heart conditions and diabetes. The services have 
been tested in several states and are now offered nation-wide to all members of the Taunus BKK.203 
As of 2007, 2000 patients with chronic heart problems and 200 with diabetes were monitored 
through a BKK Taunus telemedicine system at home, in the German state of Hessen. 
The experience with HTN Lombardy204 shows how reimbursement strategies might assist in moving 
from innovation perspectives to real markets. Following the introduction of a testing reimbursement 
for a telemedicine service for the home telemonitoring of Chronic Heart Failure patient in 2006, in 
the next future Regione Lombardia will test a reimbursement for a second telemedicine service- the 
home telemonitoring of the Chronic Obstructive Pulmonary Disease patient. Two telemedicine 
projects (Telemaco in a rural area, and NRS in a more populated area) serve as testing grounds (500 
patients in 1st phase of Telemaco and a few hundred in NRS which will increase in the near future -5 
to 6 years to a total of 5 – 6,000). They show differences in the break-up of reimbursement cost due 
to different cost structures of hospital and telemedicine services.  
Other models are experimented in the Netherlands or Northern Ireland. According to the 
ICT&Ageing project, financial support of smart home technology was available in the Netherlands 
till the end of 2008. Afterwards, care organisations will be able to ask for reimbursement of extra 
costs for smart home technology, as far as it is within the giving budget for new housing. The 
measure will be put in place during 2009 and 2010. After 1st January 2011 smart home technology 
will be calculated within certain exploitation schemes.205 In Northern Ireland, the nursing time at 
night is being used for registering RMT services.206 
6.6 Overview of RMT-related projects and pilots in the EU 
6.6.1 EU-funded projects 
The tables presented in the following sub-section give a complete overview of EU-funded research 
projects sorted per type of activity, i.e. FP5, FP6, FP7, eTen and CIP. For each project, information is 
provided on the start and end date of the project, the health condition addressed, the main focus of 
the research, the expected outcomes and the part of the value chain covered by the research.  
In summary the following are the main findings (also described in the main part of this report: 
                                            
199  Vitaphone presentation in SIMPHS ws minutes: http://is.jrc.es/pages/TFS/documents/SIMPHS22AprilWorkshopsummaryfinal.pdf 
200  http://www.ict-ageing.eu/?page_id=403  
201  http://www.taunus-bkk.de/ 
202  http://www.phts.de/ 
203  http://www.ehealtheurope.net/news/telemedicine_growing_in_use_in_germany 
204  SIMPHS Feb.09 ws presentation at: http://is.jrc.ec.europa.eu/pages/TFS/documents/090206MinutesPHSworkshopfinal.pdf  
205  http://www.ict-ageing.eu/?page_id=509  
206  SIMPHS WS June 2009 http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHS-AIMBrux090615final.pdf  
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1. Fifteen (about 40%) of the 38 projects that we report on are dealing with the part of the value 
chain that includes monitoring of vital signs and its data transmission; that is not entering in 
the part that deals with the patient (medical platform). 
2. Fifteen (about 40%) of the 38 projects that we report on are dealing with the whole value 
chain including a medical platform in some cases also including a link to an EHR.  
3. In contrast, only 3 projects deal with the monitoring device only (a more recent one 
researches a multi-parametric monitoring device) and 5 projects with the medical loop 
without offering any particular device solution. 
4. Most of the projects deal with chronic conditions in various forms (mostly cardio-vascular) 
and only 10 projects (about 26%) deal with elderly people or rehabilitation needs. 
5. There is a recent trend to deal with neurodegenerative diseases which has not been researched 
as widely in the past.  
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Table 13 – EU-funded projects 
Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
@Home FP5 1/01-04/03 Chronic patients (cardiac 
and psychiatric)  
Development of a telemedicine 
platform for real-time, wireless, 
remote monitoring of patients 
@Home platform 
comprising wireless 
medical sensors, 
patient monitoring 
module and clinic 
monitoring module  
Monitoring, patient & medical 
platform 
AMON FP5 1/01- 04/03 - Monitoring of vital signs using a 
wearable personal health system 
A wrist monitor 
device, expert system 
that analyses and 
monitors the patients' 
condition, data link, 
multilingual interface  
Monitoring 
CHRONIC FP5 01/00  - 
01/04 
 
Chronic patients 
(respiratory, cardiac, 
neurological)  
Development of an Integrated 
care platform 
Development and 
validation of 
Integrated care 
platform in different 
settings  (hospital, 
home care, 
emergency, post-
surgery) 
Integrated  care  
CHS FP5 01/00- 
07/04 
Chronic patients (CHF Telemedicine services for home 
care 
Development and 
validation of  
telemedicine services 
for home care (clinical 
trials in 5 hospitals in 
4 countries) 
Monitoring of vital signs, data 
transmission, teleconsultation 
 88 
Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
DIAFOOT FP5 01/01- 
07/02 
Diabetes  Remote Monitoring of diabetic 
foot 
Development of a 
wireless system, for 
measuring plantar 
pressure and 
temperature for 
patients with diabetic 
foot 
Monitoring of vital signs, data 
transmission 
E-CARE FP5 01/00- 
01/03 
Recovery and long-term 
illness, elderly and people 
predisposed to diseases 
Medical expert system for 
continuity of care  
E-care Platform  Monitoring, data 
communication, patient and 
medical interfaces, link to EHR 
EPI-MEDICS FP5 01/01- 
01/04 
Cardiac patients Mobile system for early 
detection and analysis of cardio 
syndromes  
Development of a 
Personal ECG monitor 
Monitoring, data 
communication, link to EHR 
HEALTHMA
TE 
FP5 01/01- 
06/03 
Support to variety of health 
problems i.e. care of 
chronic patients, of acute 
patients and tele-assistance  
Personal health mobile system 
for telecare and tele-consultation 
Development of a 
personal health mobile 
system  
Monitoring, data communication 
via mobile  
HEARTS FP5 01/02 – 
01/04 
Heart diseases Early alarm  recognition and  
telemonitoring system 
Development and 
testing of a HEARTS 
System prototype (in a 
hospital setting) 
Monitoring, data communication 
via  mobile, alarm recognition 
M2DM FP5 01/00- 
01/03 
Diabetes Telemedicine for service care to 
residential and mobile diabetic 
patients  
Development and 
validation  of a 
M2DM telemedicine 
service in 3 sites 
Data analysis   
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
MOBIHEALT
H 
FP5 01/02 - 
07/03 
Disease prevention, 
diagnostic & management, 
remote assistance, clinical 
research 
Development of mobile services Development and 
large scale trials of 
mobile services 
Monitoring of vital signs 
TELECARE FP5 01/01- 
06/04 
At-risk citizens, post-
surgery, chronic patients 
Development of a Telecare 
service system 
Development of a 
telemonitoring service 
via mobile  
Monitoring, patient & medical 
interfaces, feedback 
TELEMEDIC
ARE 
FP5 01/00- 
06/03 
 Open Platform Telemedicine 
solution 
Development of  
telemedicine solution 
and testing of a 
prototype  
Monitoring, patient & medical 
interface , feedback 
TOPCARE FP5 01/01- 
01/04 
Patients that need infusion 
therapies, controlled 
ventilatory support and 
monitored medication 
adjustment  and adherence 
control 
Development of a telematic 
Homecare platform  
Development and 
evaluation  of a 
telematic Homecare 
platform; TOPCARE 
system has been 
evaluated in 3 home 
care scenarios (home 
ventilation, infusion 
theraphy support, 
coagulation 
monitoring) 
Vital signs monitoring, 
communication via mobile, link 
to EHR, 
U-R-SAFE FP5 01/02 – 
01/04 
Elderly patients with 
respiratory and/or cardio 
pathologies  
Universal Remote signal 
acquisition  
Development of a 
Telemedicine  service 
concept  
Vital signs monitoring, medical 
interface, feedback  
WEALTHY FP5 09/02 - 
03/05 
 Wearable health care system Remote monitoring 
using intelligent 
wearable  
Vital signs monitoring, medical 
interface, feedback 
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
MyHeart FP6 01/04 – 
12/08 
Chronically ill patients 
disease management is one 
of the four application 
concepts (more specifically 
cardiovascular disease) 
Monitoring of vital body signs 
with wearable technology.  
Intelligent clothes with an 
integrated wireless link to user 
feedback devices and to 
professional medical centers 
make up the MyHeart system.  
 
Development of 
wearable electronics 
& body sensors AND 
disease management 
system  
Prevention, monitoring of vital 
signs , patient platform  
HEARTFAID FP6 02/06 – 
01/09 
Chronic heart failure Innovative technological 
platform (HEARTFAID) that 
integrates biomedical data with 
EHR systems; provides services 
such as patient telemonitoring, 
signal and image processing, 
alert and alarm systems and 
supports clinical decision in the 
HF domain. 
Development of 
HEARTFAID 
platform 
Spanning  across whole  value 
chain (from monitoring, 
patient&medical platform, 
feedback) 
PIPS  
 
FP6 01/04 – 
12/07 
Prevention (one of the 
case-based scenarios 
involves diabetes 
management) 
Creation of a new Health and 
Life Knowledge and Services 
Support Environment, 
improving current health care 
delivery models 
New health care 
delivery model 
PIPS agents as interfaces with 
monitoring devices and for real-
time medical advice 
OLDES 
 
FP6 01/2007- 
2010 
diabetes & heart diseases User entertainment services, 
through easy-to-access thematic 
channels and special discussion 
groups supported by animators, 
as well as health care services 
based on established Internet 
and tele-care communication 
standards.  
The OLDES system 
will include wireless 
environment and 
medical sensors linked 
to health care 
providers. 
Monitoring, medical loop 
 
Saphire 
 
FP6 01/2006 – 
12/2008 
Cardiovascular diseases  Intelligent health care 
monitoring and decision support 
system  
Platform integrating 
the wireless medical 
sensor data with 
hospital information 
systems.  
 
Patient monitoring  (by using 
agent technologies) 
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
HeartCycle FP7 03/2008 – 
to 02/2012  
Cardiovascular disease 
(coronary heart disease and 
heart failure patients), as 
well as co-morbidities 
Research into new multi-
parametric bio-sensors and 
analysis of vital signs (e.g. for 
the continuous monitoring of 
blood pressure, blood oxygen 
levels and heart function; a 
closed-loop disease management 
solution serving HF and CHD 
patients, including possible co-
morbidities hypertension, 
diabetes and arrhythmias. 
New Sensors and 
closed-loop disease 
management  
Multi-parametric monitoring of 
vital signs, analysing the data , 
patient loop and medical loop 
Chronious 
 
FP7 02/2008- 
07/2011 
The Chronic Obstructive 
Pulmonary Disease 
(COPD) and Chronic 
Kidney Disease(CKD) and 
Renal Insufficiency 
Intelligent wearable platform, 
based on multi-parametric 
sensor data processing, for 
monitoring people suffering 
from chronic diseases 
Platform for chronic 
disease management 
Multi-parametric  monitoring, 
telecare (the system generates 
alerts in case of invalid medical 
data or if current activity and 
behaviour lay outside the well- 
established activity patterns )  
Metabo 
 
FP7 01/2008 - 
06/2011 
Diabetes Integrated interoperable 
platform for the continuous 
effective monitoring of 
metabolic levels and parameters, 
for the generation of predictive 
personalized models and for 
their application in care 
processes for diabetes. 
 Monitoring of vital signs, 
management platform; data 
produced by METABO will be 
integrated with the clinical data 
and the history of the patient 
Perform 
 
 
 
FP7 02/2008-
02/2011 
Neurodegenerative 
diseases (e.g. Parkinson) 
System for remote health status 
monitoring, the qualitative and 
quantitative assessment and the 
treatment personalisation for 
people with neurodegenerative 
diseases and movement 
disorders, such as Parkinson’s. 
New sensors, 
intelligent wearable 
system to be tested in 
four phases of 
experiments 
Multi-parametric monitoring  
DIAdvisor  
 
FP7 03/08-02/12 Chronic patients (diabetes, 
insulin dependent type I 
and II) 
Development of a prediction 
based tool which uses past and 
easily available information to 
optimise the therapy of type I 
improved diabetes 
control and QoL using 
control and risk 
management theory, 
Monitoring, data 
communication, patient and 
medical interfaces, system feed-
back 
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
and developed type II diabetes. 
The application is not dependent 
on specific sensor technologies 
and can be adapted to 
technologies like standard strip 
sensing, minimally-invasive 
continuous glucose sensors and 
emerging non-invasive methods. 
physiological 
modelling, 
identification theory, 
medical device 
technology, sensor 
science and user 
understanding 
FOR ALL 
 
 
eTEN 06/2006 – 
11/2007 
Heart chronic diseases Market validation of an existing 
pilot system deployed as a result 
of the eTEN ICAROS project.  
Mobile European pilot 
of ICAROS 
Monitoring,  chronic disease 
management  
HealthService
24 
 
eTEN 02/2005  
- 07/2006 
Chronic diseases (COPD , 
cardiac Patients) and 
High risk pregnancies 
Continuous Mobile  services 
(market validation of FP5 
Mobihealth)  
Mobile Monitoring 
System 
Integrated health care services 
platform 
HealthWear 
 
eTEN 11/2006 - 
04/2008 
elderly people, patients 
with chronic diseases, 
convalescent people and 
patients during their 
rehabilitation 
Remote Health Monitoring with 
wearable non-invasive mobile 
system  
Market validation of 
Wealthy prototype 
system  
Monitoring vital signs with 
wearable mobile system 
iCare eTEN 06/2006  
-02/2008 
Cystic Fibrosis , asthma, 
COPD, diabetes, chronic 
heart pathologies  
eService improving mobility 
and autonomy of patients with 
chronic disease 
Market validation of 
an eService based on 
remote auscultation 
Monitoring 
Linkcare 
 
eTEN 09/2005 – 
02/2007 
Chronic diseases Integrated health care service for 
chronic patients 
Pilot evaluation, 
platform ; a business 
case for the adoption 
of novel integrated 
care services by EU 
health care systems. 
Integrated care model  
Health-eLife 
 
eTEN 03/2005 – 
06/2006 
Chronic diseases Doc@HOME Home Based 
chronic disease Management  
Market validation of 
the Doc@Home™ 
RPM platform for chronic 
disease management  
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
service in the context 
of typical European 
hospital outpatient 
clinics 
Interlife 
 
eTEN 03/2005 – 
06/2006 
Chronic diseases New health care services, based 
on a technological platform,  for 
continuous home monitoring 
service ;the development of a 
transeuropean network for home 
care delivery 
Contact centre 
platform 
Home care delivery 
HealthOptimu
m ID 
 
eTEN 06/2007  
-05/2009 
Chronic diseases Market validation of HEALTH 
OPTIMUM services (one of 
them is tele-care) 
HEALTH OPTIMUM 
Deployment phase 1 
and preparation for 
Full Deployment  
Telecare 
Better 
Breathing 
 
eTEN 06/2007 – 
11/2008 
COPD New care model for COPD 
patients by ICT- supported 
home hospital services 
Market validation of 
eServices for the care 
of chronic patients 
New care model 
MCC 
(Medical 
Care 
Continuity) 
eTEN 02/2005  
- 05/2007 
elderly persons and 
patients suffering chronic 
diseases. 
New 
service for at-home medical care 
The market validation 
of the MCC service 
will also identify 
expected benefits, its 
acceptance by the 
users and beneficiaries 
and its effectiveness 
and efficiency. 
New Medical Care service  
Dreaming CIP 05/2008-
05/2011 
Elderly and chronic 
patients (diabetes, COPD 
and heart failure)  
Large scale pilot project to 
demonstrate new services to 
support independent living of 
elderly people 
New services for large 
scale deployment of 
Dreaming including 
health/safety 
monitoring & 
assistance at home. 
Monitoring  
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Name  Type of 
activity 
Start & 
end date 
Health Condition Focus  Expected Outcomes Part of the value chain 
addressed  
Nexes 
 
CIP 06/2008 -
06/2011 
Chronic diseases Deploying four integrated care 
programs for chronic patients 
addressing prevention, health 
care and social support and 
validating the deployed 
programmes in large scale RCT 
studies. 
Four integrated care 
programs for chronic 
patients 
Integrated care  
CommonWell 
 
CIP 01/10/2008 
-01/10/2011 
COPD & CHF (also 
independent living) 
Integrated services to provide 
independent living and improve 
the quality of life for older 
people and those with long-term 
conditions. 
Provision of 
integrated services for 
effective management 
of chronic disease 
ICT-enabled health and social 
care services 
Source: authors' elaboration from data collected on CORDIS database 
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6.6.2 Overview of pilots in European Member States 
The tables presented in the following sub-section give an overview of the pilots identified in the field 
of PHS/RMT in European Member States. For each pilot, the overview provides information on the 
type of activity, whether national, regional or local, the start and end date of the activity, the 
geographical scope, the focus and type of innovation addressed as well as the number of patients 
served. Where possible we also provide a short description of the pilot activities. 
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Table 14 – Pilots  
Name Type Start & 
end 
date 
Geo. 
scope 
Condition Focus incl. 
type of 
innovation 
Nr. of patients Short description of pilot 
Care 
Coodination/Hom
e Telehealth 
(CCHT) national 
programme 
operated by the 
Veterans Health 
Administration 
(VHA)  
national 2003-  USA The main conditions 
served are diabetes, 
hypertension, 
congestive HF and 
COPD, as well as 
smaller numbers with 
depression and post-
traumatic stress 
disorder. 
Telehealth 
monitoring 
service  
more than 30,000 
(mostly elderly) 
chronic patients 
currently served 
CCHT was developed as part of the VHA’s 
efforts to provide non-institutional care (NIC) 
services to cater for the rising number of 
elderly veterans with chronic care needs. First 
introduced in 2003, CCHT is now a routine 
NIC service that uses home telehealth and 
disease management technologies in care 
management as adjuncts to VHA’s existing 
health information technology (HIT) 
infrastructure. 
Virtually healthy: 
Chronic disease 
management in 
the home 
national 2000- 
2002 
USA COPD, CHF, diabetes 
& combinations 
Home care  790 (out of 8.704) 
veterans and control 
group of 772 patients 
set up to enable cross 
comparisons, with 
clinically similar but 
non-enrolled users. 
5 demonstration projects to test disease 
management principles, the role of the care 
coordinator and the effective use of technology 
to maintain veterans in their homes.  
NAHCH: National 
Association for 
Home Care and 
Hospice 
national 9 
months 
in 2007 
USA Chronic diseases   976 Home care 
associations  
 
Whole system 
long term 
conditions 
demonstrator 
program  (WSD)  
Regional 
Large-scale 
pilot (three 
areas : 
Cornwall, 
Kent and 
Newham) 
2008 -  UK COPD , CHF and 
diabetes 
Telehealth 
/telecare  
Over 1000 
patients/users for 
telehealth and over 
1,000 patients/users 
for telecare. 
Randomised Control Trials, focusing on 
individuals with Chronic Pulmonary Disease 
(COPD), Heart Failure and Diabetes, and 
adults with social care or health and social care 
needs at risk of hospital admission.  The 
evaluation will look at the impact on 
emergency admission rates & bed days, 
patient/carer experience and quality of life and 
the impact on Primary Care.  
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Name Type Start & 
end 
date 
Geo. 
scope 
Condition Focus incl. 
type of 
innovation 
Nr. of patients Short description of pilot 
Northern Ireland 
Connected Health 
Pilots 
Regional 
large scale 
2008- Norther
n 
Ireland  
Heart diseases, 
diabetes, COPD, 
dementia 
 5000 by 2011 As of July 2008, over 800 patients across 
Northern Ireland have benefited from 
participation in a range of eHealth pilot 
schemes including: Remote monitoring of 
implantable Cardiac Devices; Video 
conferencing for Paediatric Congenital Heart 
Disease; Remote Telemonitoring of chronic 
diseases including COPD; Diabetes and 
Dementia; and Telecare projects to support 
independent living.  
Home tele-
monitoring in HF 
patients: the HHH 
study (Home or 
Hospital in Heart 
Failure) 
EU 2002-
2005 
11 
centers 
in UK, 
PL, I 
heart failure Telehealth 
monitoring 
service 
461 European Community-funded, multinational, 
randomized control clinical trial, conducted in 
the UK, Poland, and Italy, to assess the 
feasibility of a new system of home tele-
monitoring (HT). The HT system was used to 
monitor clinical and physiological parameters, 
and its effectiveness (compared with usual 
care) in reducing cardiac events in HF patients 
was evaluated. 
NHS Lothian Local small 
scale pilot 
2008-
2011 
UK COPD and/or CHF Telehealth 
monitoring 
service  
400 patients in 
Edinburgh and 
Lothians 
Large scale (400 patients) randomised 
controlled trial conducted by Edinburgh 
University, which aims to report in 2010. 
NHS Swindon Local small 
scale pilot 
2008-
2010 
UK COPD (and diabetes if 
successful) 
Telehealth 
monitoring 
service 
 Telehealth monitoring service to support 
COPD patients following a small scale tele-
health pilot in 2007 that has shown increased 
quality of life and reduced hospital admissions 
for COPD patients. 
NHS Sheffield 
primary care trust 
Local small 
scale pilot 
2008 (5 
months) 
UK COPD  Telehealth 
monitoring 
service 
30 patients in 
Sheffield 
Telehealth monitoring service to support 
COPD patients in Sheffield  
Home-HF study  local (3 
hospitals 
North West 
London) 
 UK heart failure Tele-
monitoring  
142 patients 
discharged for follow 
up 
HOME-HF study to determine if home tele-
monitoring of typical HF patients, recently 
discharged from hospital, could reduce the risk 
of all-cause re-hospitalization, when compared 
with usual specialist care, and at what cost. 
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Name Type Start & 
end 
date 
Geo. 
scope 
Condition Focus incl. 
type of 
innovation 
Nr. of patients Short description of pilot 
HTN (Health 
Telematics 
Network) tele-
medicine project  
Regional 
large-scale 
2006 
onwards 
IT Chronic heart failure Home tele-
monitoring 
of HF 
patients 
  HTN and Regione Lombardia participated in 
several projects with the Ministry of Health, 
focused on the effects of the use of tele-
medicine in the management of chronic HF 
patients at home. As of 2006 Regione 
Lombardia introduced reimbursement for a 
telemedicine service. 
Medic4all 
telemedicine 
services  
company 
pilot 
2008  RO Chronic disease Mobile tele-
medicine for 
prevention 
 Telemedicine services launched by Orange and 
Medic4all in Romania. The Wrist Clinic, a 
health monitoring device, is monitoring health 
indicators like blood pressure information, 
pulse, EKG, temperature, breathing, blood 
oxygen levels and other medical parameters. 
Measurement results are transmitted 
automatically via Bluetooth to the customer's 
mobile and then to their online medical record, 
via the Orange network. 
Home care of 
elderly through 
tele-monitoring  
Company 
& national 
pilot  
2008-
2011 
HU elderly people & 
chronic diseases 
(stroke, dementia and 
depression) 
Integrated 
care  
 GE Health care and the Hungarian national 
Health system developed an integrated system 
for the remote monitoring of the health of 
elderly citizens, particularly those who suffer 
from neurological diseases such as stroke, 
dementia and depression.  
Roche pilot in 
Costa del  Sol  
Local small 
scale pilot 
 ES -
Malaga 
region 
diabetes type 2 
patients 
Remote 
monitoring 
for diabetes 
management 
162   
Hytmobile Local small 
scale pilot 
Hospital la 
Paz Madrid 
2009 -  ES Remote control of 
anticoagulant 
treatment (ACT) 
 13  Clinical trials started on January 2009 and have 
recruited 13 patients by now. The aim is to get 
20% of total ACT patients. 
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Name Type Start & 
end 
date 
Geo. 
scope 
Condition Focus incl. 
type of 
innovation 
Nr. of patients Short description of pilot 
Saludnova Regional 
large scale 
pilot (3 
Basque 
Region 
hospitals) 
2009 -  ES on chronic disease (in 
general)  
telemetry  Create a platform for Telemetry, (primary and 
secondary care) not focussing on any specific 
disease, but rather on chronic patients that may 
need support during the evolution of their 
disease. The sensors already connected are: 
blood pressure, oximetry, cardiac rate, weight, 
breathing rate, EKG and temperature.  
Rehabitic Local small 
scale pilot ( 
Telefónica 
with 
Hospital La 
Esperanza 
in 
Barcelona)  
 ES remote rehabilitation   Telefonica I+D is currently carrying out a 
broad-ranging clinical study with real patients 
having a knee prosthesis. A clinical evaluation 
of the platform is on-going at La Esperanza 
Hospital (IMAS), in Barcelona. It includes an 
interactive software-hardware platform 
designed to facilitate rehabilitation therapies, 
carried out remotely, for numerous pathologies 
and also include a videoconferencing function 
and access to the Electronic Clinical Record. 
Queensland trials 
telehealth project 
(AUS) 
Regional 
small scale 
pilot 
 AUS chronic diseases  100 Pilot to improve the efficiency of treatment for 
patients with chronic disease.- using HomeMed  
device (100 people in first stage in 
Queensland). It could become a regular part of 
Medicare, Australia’s health insurance 
programme.  
Health Buddy  Local small 
scale pilot 
in 4 NL 
hospitals 
 NL COPD  Tele-
monitoring 
100 COPD patients An evaluation of the effects of telemonitoring 
COPD-patients on aspects of quality of life, 
care consumption, and patient satisfaction.  
St. Lucas Andreas 
Hospital in 
Amsterdam-West  
Local small 
scale pilot 
2007 -  NL CHF Tele-
monitoring 
HF patients 
supported by 
NL health 
insurers  
100 CHF patients Tele-monitoring of HF patients at home using 
the Philips Motiva system based at the St. 
Lucas and Andreas Hospital in Amsterdam-
West; a similar pilot launched in the US as 
well. 
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Name Type Start & 
end 
date 
Geo. 
scope 
Condition Focus incl. 
type of 
innovation 
Nr. of patients Short description of pilot 
LifeStat™ 
Remote 
Monitoring and 
Health 
Management207 
Internation
al  
2008- Case 
studies 
in 
Canada, 
Austria 
and 
France 
Blood sugar levels and 
blood pressure. 
Telehealth 
monitoring 
service and 
feed-back 
n/a tele-monitoring solution combining intelligent 
end devices as well as the necessary 
infrastructure to provide remote monitoring and 
care. The application can also deliver alarms, 
notifications and reminders to patients and their 
caregivers using text messaging (SMS), e-mail 
or telephone interactive voice response (IVR) 
systems. 
Living Lab 
Skagen 208 
Local 
(experimen
tal) 
2008 The 
Skaw, 
Denmar
k 
Diabetes  Telehealth 
diabetes 
monitoring  
Eight participating 
families (30 users) 
Focuses on supporting information for the 
blood sugar level in relation to food, insulin 
and physical activity of the diabetic through a 
laptop supported software 
Source: Authors' elaboration from data collected from CORDIS database 
 
 
                                            
207  http://enterprise.alcatel-lucent.com/private/active_docs/RMK7526090608_TeleHealth_Manager_healthcare_market_EN_Brochure.pdf 
208  http://www.bth.se/hal/halsoteknik.nsf/bilagor/living_lab_Skagen_2008_pdf/$file/living_lab_Skagen_2008.pdf 
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7 Annex II: RMT Company Analysis 
Annex II focuses on the companies operating in the PHS/RMT market and describes the 
empirical evidence supporting the analysis presented in § 3.2 and Section 5 of the core part of 
this report. The Annex reports the findings of the different research activities (desk research, 
semi-structured interviews, and experts' workshop) on RMT/PHS company data that, after 
identifying a large set of 200 companies, focussed on a sample of 50+ companies. In the first 
introductory section a general illustration of how the work has been carried out is presented (§ 
7.1.1 and § 7.1.2), followed by a summary of the main findings (§ 7.1.3). Next in § 7.2 all the 
findings of the desk research activities, are presented in an integrated overview broken down 
according to several parameters. In § 7.3 we provide detailed examples from both the desk 
research analysis and the key insights from the interviews and workshops on the 50+ 
companies and thus contribute to raise evidence from the field on emerging market conditions 
and their likely impact. Finally, § 7.4 contains the list of the 50+ companies and a brief profile 
for each one of them. A set of market indicators and their value (where data were available), 
were proposed for the 50+ companies in Deliverable D1.1 (see D1.1 Annex II). 
7.1 Introduction  
7.1.1 A two step approach 
The empirical work carried out for the company analysis entailed two steps. First, we carried 
out some desk research in the first half of 2009 with the aim to identify companies active in 
the PHS/RMT market. We did so by reviewing specialised conference attendance lists, market 
reports and health IT newsletters and websites. A general review of 200 companies helped us 
identify key characteristics of the PHS market and get a better understanding of its current 
state of development. Out of these 200, we identified 50+ companies for in-depth research, in 
order to understand better the dynamics of the market, the various parameters that may define 
emerging business models, and the activities of different types of players.  
Second, in parallel to studying RMT/PHS company data, we contacted representatives of the 
selected 50+ companies, as well as other experts (e.g. health care providers, procurement etc.) 
for in-depth interviews and workshop-like discussions (between February and June 2009). 
The aim was to complement the desk research with more first hand insights from the field 
such as: a description of companies' role in the value chain, as well as the perception of 
companies' representatives and experts on market growth, barriers and drivers. Data of 
qualitative nature were thus collected which enabled us to extract the key insights that have 
been presented earlier in the core part of this report (§ 3.2 and, especially, Section 5). As parte 
of this line of activities we have organised the following events:  
a) A large stakeholder's workshop209 with ca. 30 participants from industry, health care, 
insurances, academia etc.; 
b) Three restricted workshops with 3-4 participants each;210 
c) One-to-one meetings or phone interviews with experts – i.e. semi structured interviews 
with 7 experts (note that these exclude the interviews carried out in the framework of 
country studies, see Annex III included as Section 8 for more details); 
                                            
209  See http://is.jrc.ec.europa.eu/pages/TFS/documents/090206MinutesPHSworkshopfinal.pdf  
210  See http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHS17AprilWorkshopsummaryfinalrev1.pdf 
http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHS22AprilWorkshopsummaryfinal.pdf 
http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHS16JuneWorkshopsummaryfinal.pdf  
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7.1.2 50+ companies: selection criteria, benefits, and limits of the approach 
The 50+ analysed in more detail were chosen according to the following criteria: 
• Companies playing a significant role on the PHS market; 
• Overall sample covering as many products and services as possible; 
• Companies with a clear European focus; 
• Overall sample covering all parts of the PHS value chain. 
In terms of companies playing a significant role we included in particular those with existing 
or emerging presence in the RMT/PHS market, taking into account the size of the company, 
the types of products and services offered, and the level of activity in the market. The term 
presence in the market is taken to mean that the company is directly active in the RMT/PHS 
market itself – not in markets that only support or are linked to it (i.e. companies with the 
most direct participation in the RMT/PHS market itself). We included large companies but 
also a significant number of SMEs as these play an important role in the market development.  
As to products and services, an effort has been made to select companies that offer relevant 
and economically significant products for various aspects of PHS, thus illustrating the range 
of products and services on offer. As to the level of activity, the companies chosen are the 
most active in driving the development of the RMT/PHS market through participation in 
pilots or projects, alliances, those investing large sums of money in R&D, and contributing 
generally to innovation in the market. 
As to our third criteria, the focus is on companies operating in Europe, i.e. those having their 
home base or a major part of their activities in the EU27 area. Many large companies that 
operate predominantly in the US or the Japanese market have not been included in the scope 
of this review. However, a few companies from outside Europe, e.g. from Israel and the USA, 
have been included since they have a significant level of activity in Europe besides 
representing geographical areas with the most developed PHS markets, and hence with some 
of the most innovative products and business models.  
According to our fourth criteria, a variety of companies covering as many parts of the value 
chain as possible, were included. In some parts of the value chain, many more active 
companies can be found than in others: for instance, the devices segment is well supplied by a 
large number of actors, whereas there seems to be fewer companies offering system 
integration or other high-end services, or the latter may be more difficult to identify. In spite 
of these differences, we have chosen a sample of companies that represents all the various 
parts identified. Finally, it should also be kept in mind that this list is only an attempt to 
characterise the market, and it cannot be fully representative, given the limited sample size.  
By focusing on the company location, size, number of years in business, geographical focus 
areas, the type of products and services these offer and most importantly, the market segments 
they focus in, and where in the value chain they are placed, we were able to get an overview 
of the evolution of the RMT/PHS market, the active stakeholders, and the wide variety of 
products and services on offer. 
Our approach of sampling 50+ companies for in-depth analysis has enabled us to identify and 
categorise the various types of players, and to describe the key characteristics of each 
category or cluster. The analysis also shows some of the connections that exist between the 
players and the roles played by each cluster in the PHS value chain, thereby giving us an 
overall understanding of the composition and functioning of the value chain. Moreover, the 
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analysis of companies has facilitated the description of a number of business approaches used 
in the industry, some of which focus on fulfilling the needs of a specific part of the value 
chain, others on integrating the different parts or the whole of the value chain. The analysis 
also demonstrates the possibility of utilising existing infrastructure as part of a company's 
business model: for example by using mobile phone networks for communication and transfer 
of patient data. The use of existing infrastructure enables the launch of targeted products and 
services for niche markets, by making it possible for a company to develop new products or 
services which provides them with a competitive advantage while they can use existing means 
and technologies for performing more standard functions like data transmission. We have thus 
been able to create a good overview of the EU market and its general level of development, 
and acquire an insight into the activities of the players and the industry trends / developments.  
The semi-structured interviews and restricted workshops have been useful in complementing 
the desk research analysis, providing insights into individual companies' strategies and 
business models characteristics. They have helped us understand better the variety of business 
models present in the PHS/RMT market and the current state of development of the market, 
confirming the findings emerging from the desk research and enabling further conclusions. 
The interviews have also given us insights on reasons for the slow market uptake as well as 
on drivers and barriers in general, which could not be brought to light by desk research alone. 
However, since the analysis is limited to a sample of companies, it is not possible to analyse 
the market in quantitative terms or make predictions regarding its future development. In 
addition, it should be pointed out that the availability of quantitative data is often quite 
limited. Furthermore, the analysis is limited to Europe, and as such cannot be used to make 
conclusions on a global scale, as important markets such as the USA are not within the scope 
of the study. In spite of our efforts to include companies from all EU27 Member States, we 
could only identify relevant companies from older Member States that does not make it 
possible to draw any conclusions on the new Member States, except for noting an apparent 
lack of PHS activity in this geographical area. It is obvious that, enlarging the sample of 
companies and collecting more quantitative data – if they exist – would enable us to draw 
statistically significant conclusions from the analysis, which would represent a significant 
improvement in terms of the level of insight we would be able to provide. However, it could 
be very difficult to achieve, as little data is currently available on the RMT/PHS markets.  
7.1.3 General overview of findings 
A first look at the health care industry gives the impression that a large number of companies 
operate in the RMT/PHS market; however, this is only partly true. Although the boundaries 
between companies' activities are sometimes difficult to define, many companies operate in 
an eHealth or Health IT related area, but relatively few are pure RMT/PHS market players. 
Narrowing down from Health IT to the PHS market, we have found evidence of companies 
operating in different segments such as system integration, devices, and remote monitoring, 
but there are limited signs of the market functioning as an integrated whole.  
In addition, many of the identified companies offer relatively few products or services or parts 
of services for the PHS market, while most of their activities are targeted in other areas. 
Furthermore, many companies in the market are more generic service providers, for example 
of imaging and data management solutions, and their activities cannot be classified as PHS. 
For all these reasons, the PHS market as a whole can be described as relatively immature, and 
fragmented in the sense that various companies operate in different parts of the value chain 
that are not necessarily integrated. 
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Current large players in the health care industry seem to place a 'wait and see' attitude toward 
the RMT/PHS market. This may be due to its relatively low state of development and high 
fragmentation, both of which make it difficult for large players to gain significant revenues 
and leverage economies of scale. On the other hand, the still cautious approach from larger 
players means that there is quite a large playing field for SMEs. This is confirmed by the 
significant contribution of SMEs in terms of novel products and services we have found. Even 
if the economic impact of SMEs remains somewhat limited, their activities are important for 
driving the market and preparing the ground for further developments. 
Large traditional IT and Telco companies provide "traditional" ICT services such as network 
infrastructure, connectivity and hardware in the RMT/PHS market. Moreover, several have 
entered the market by expanding their portfolio: some offering PHS (e.g. Bosch, Ericsson, 
and Orange), some offering hospital information management and system integration services 
(e.g. Intel, Cisco, Nokia). This active role, taken by ICT companies that are strong players in 
their base markets, but are newcomers in the Health IT and PHS market, represents an 
important development as it raises growth expectations. Moreover, many telco companies 
seek to find new revenue streams as their traditional markets (voice, messaging) are becoming 
saturated, and PHS represent for them the opportunity to offer new value-added services. 
7.2 Companies Review: a snapshot of the PHS market 
The evidence gathered though desk research on the 50+ companies has been structured and 
analysed according to a set of parameters that allowed us to produce several descriptive 
summary statistics. These are reported in the various graphs and charts below, which are only 
briefly commented. As anticipated, our sample does not allow deriving any quantitatively 
based generalisation and, thus, the numbers and comments below are merely indicative. 
Company Type 
Figure 18 below gives an overview of the number of companies according to their size and 
how many years they have been in business, showing that the majority of the sampled 
companies have been operating for at least 5 years whether small or large. The relative lack of 
medium-size companies in the sample could indicate that right now it is difficult for an SME 
to consolidate activities and grow in size while large companies can afford to invest in R&D 
and maintain their 'wait and see' presence in the RMT/PHS market due to their strong market 
position in other market segments (e.g. wider health IT). 
Figure 18 – Company size vs. years in business 
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Technology focus 
Figure 19 shows the type of health conditions addressed, the medical device, infrastructure, 
software and systems integration segments for the companies reviewed. As to the diseases 
addressed, these include primarily cardio-vascular, diabetes, and respiratory diseases, with a 
few instances where the co-morbidity of these three main groups of chronic diseases are 
treated. As to the devices, we can see that monitoring, medical platforms and communication 
devices are widely offered, but intervention devices are offered by less than 40% of the 
sample. Only a small part of the sampled companies offer related telecom infrastructure; with 
regard to the services offered, networks and protocols are offered by about 25%, standards by 
less than 10% of the sample. Health software, especially data processing and diagnostics, are 
offered by more than 80% of the companies, while some kind of personalised feedback is 
provided by slightly more than 60% of the sample. Finally, as many as 42 companies (84%), 
provide some form of systems integration, divided equally between value chain (though not 
necessarily all of it) and back-end integration, while education services are the least common. 
Figure 19 – RMT companies and technology focus 
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Source: authors' elaboration from collected data 
Service focus 
Figure 20 gives an overview of the various types of services provided by the companies 
reviewed. In terms of monitoring, vital signs are by far the focus of most of the services 
provided compared to implants, which seem to be a niche market. In the area of clinical 
intervention, services for hospitals or home care lead even though services to GPs and call 
centres are also common among the companies reviewed. Overall, every type of connection to 
clinical infrastructure is serviced by more than 60% of the companies. In the area of guidance 
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offered by remote PHS systems, feedback is more commonly offered than education. As to 
ICT systems' connections, the most common service is access to Hospital Information System 
followed by EHR (electronic health records including patient and clinical records), while 
PACS (Picture archiving and communications system) and billing connections are less 
common. One explanation may be that the first two are easier to integrate to new solutions, 
whereas connections to PACS and billing would require more specialised software. 
Figure 20 – RMT companies and service focus 
Services Perspective
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Source: authors' elaboration of collected data 
Full vs. partial solution 
Figure 21, displays the correlation between the size of the company and whether its solution 
offering is a full or a partial one. A full solution encompasses all parts of the value chain, 
whereas a partial solution is limited to some of them. 
Figure 21 – Company size vs. solution extent 
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As the chart shows, most of the solutions offered by SMEs are partial ones, although many 
medium-sized companies also offer full solutions. On the other hand, the majority of large 
companies seek to offer full solutions. This difference between SMEs and larger players is to 
be expected: given the larger resources (time, personnel, and finance) and product portfolios 
of the larger players, they are often better positioned to offer full solutions. Furthermore, the 
large companies may also have better visibility on the various parts of the value chain, 
making it easier for them to understand the needs of various stakeholders and thus to develop 
solutions that encompass all parts of the value chain. 
Type of solution offered 
Figure 22 summarises the types of solutions offered by companies of different sizes. This 
mapping is a relatively rough one, and only counts the companies in the segment of the value 
chain they are most active in although most companies are active in several segments. 
Figure 22 – Company size vs. solution type offered 
Company size vs. Type of solution offered
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Source: Authors' elaboration of collected data 
Large companies are visible in all the segments, with a roughly equal number of companies 
providing different types of solutions. SMEs are visible in three of the four segments, but 
offer intervention devices only to a very limited extent. As a result of this, the overall number 
of companies serving this segment is smaller than for the other ones. There may be at least 
two explanations for this: intervention devices may take more resources to develop and 
maintain than other solutions (which makes them less attractive to SMEs) and there are more 
risks (health, legal) involved with providing intervention devices (which SMEs may be less 
willing to take). 
Health conditions addressed 
The chart below, Figure 23, displays how many companies, by company size, address the 
main different disease conditions. To sum up the results, cardiac conditions are addressed by 
70% of the companies, diabetes and COPD by slightly more than 50%, and co-morbidity by 
30%. Only a small minority of the sample addresses the other conditions. If we compare 
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company size and health condition, the distribution of large, medium and small companies 
seems to be not dependent on the disease condition.  
Figure 23 – Company size vs. health condition addressed 
Company size vs. Health condition addressed
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Source: Authors' elaboration of collected data 
Solution offered vs. years in business 
The chart below, Figure 24, shows the years in business vs. the solution offering of the 
companies in the sample. More than 30 companies have been in the business for more than 5 
years, although in some cases there may be doubts as to whether they have been in an 
RMT/PHS segment during the last 5 years. If we take a closer look at the data, we can see that 
the established companies offer full solutions more often than the newly started ones. This is 
to be expected, given that the more recent market entrants have not yet had the time to 
develop more sophisticated solutions or to integrate all parts of the value chain with their 
solution. However, there may be a small bias in this result: many of the more established 
companies are large ones with more than 500 employees, which means that they have had 
more possibilities to offer full solutions in the first place. 
Figure 24 – Years in business vs. solution offered 
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Diversity of activities 
Finally one question of interest when looking at companies on the RMT/PHS market is to 
understand how diversified their activities are. We have made an attempt to get a quantifiable 
view of this by composing the following indicator. We counted the activities of a single 
company together with the conditions addressed by the products or services it offers. As a 
nominal variable each item has been scored with one point, and we took the following 10 
items to start with:  
- 4 conditions: diabetes, COPD, cardiac and co-morbidity  
- 6 technology perspectives: vital sign monitoring device, intervention device, medical 
platform, communication device, patient platform and network provision. 
The maximal score possible according to the above is 10. The actual indicator is the mean of 
the values counted for each company, sorted by either health condition or company size.  
Figure 25 – Diversity of activities indicator per health condition 
 
Source: Authors' elaboration of collected data 
The outcome, in Figure 25, shows that companies in activities related to cardiac conditions 
are the most specialised companies. The qualitative research mirrors this finding, companies 
offering tailor-made solutions for heart patients started offering remote monitoring and other 
services based on their previous experience in the medical cardiac field. One larger, non-
European example would be St Jude Medical, the US based company which strives to utilise 
its experience from cardiac rhythm management, arterial fibrillation, cardiovascular and 
neuro-modulation treatments in the development of PHS. A European company following that 
pattern is the Swiss based Schiller Medizintechnik that is specialised in cardiac conditions. On 
the other hand companies that offer support for patients suffering from co-morbidity do score 
the highest in the diversity of activities factor. Also, companies offering solutions related to 
diabetes appear to be covering a broader spectrum of activities. 
If one takes a closer look at the indicator for diversity of activities (Figure 26) one sees that 
actually small companies are the most specialised. Surprisingly medium sized companies are 
those which cover most activities, they score slightly higher in the indicator for diversity of 
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activities than large companies. The focus and specialisation of the small companies can be 
explained by the limitation in resources. This mirrors as well observations from the qualitative 
interviews with experts and stakeholders, who pursue an organic growth from one product 
before diversifying their activities. In order to gain ground and offer a broader spectrum of 
solutions larger players entering the market often purchase small or medium sized companies. 
Figure 26 – Diversity of activities indicator vs. company size 
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7.3 Analysis of the evidence from the field on company strategies, the 
RMT/PHS market conditions and their likely impacts 
This sub-section analyses the data collected by the desk research and in the field, aiming at 
highlighting evidence that shapes stakeholders decisions mainly in relation to prospective 
market conditions and foreseeable implications. 
Company size and presence 
In terms of company size and presence, the interviews revealed that small and medium-sized 
companies, such as for instance Vitaphone, Docobo, and HeartLinkOnline, are generally 
rather open about their current areas of operation, their actual plans for expanding their 
geographical base and their market share, if not always in terms of revenues at least in terms 
of patients served, i.e. number of patients connected to their systems.  
As to larger companies like Philips, Honeywell, Bosch etc. while it is much more difficult to 
obtain a clear picture of where their activities start and stop on the RMT/PHS value chain, it is 
also more difficult to assess the extent of their presence across Europe as well as get even a 
rough estimate of their market share. This is likely due to: (a) the confidentiality of the 
information type, especially in a market that is far from being well established; and/or (b) the 
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reluctance to give access to market figures that show a very immature stage of development. 
The situation is similar for telcos or mobile operators active in the PHS market: while some 
companies have developed clear business cases the extent of their market presence is less 
obvious. For instance, Ericsson seems to be at the forefront among mobile or telco operators; 
its mHealth solution was planned (in 2009) to be provided in Belgium, Netherlands, Spain, 
Portugal, Switzerland, Italy and Singapore. 
SMEs are often only active in the country in which they were established and seek to first 
establish a sound business case in their home base before seeking expansion into further 
regions. Three examples follow: (a) Docobo, a UK start-up in 2006, is an SME with 14 
employees which very recently opened a sales representation in the Baltic, Portugal being 
next in line; (b) Saludnova, a small company that came into existence at the end of 2008, has 
established its operation in the Basque Country region of Spain and intends to extend to other 
Spanish regions before crossing the national boundaries; and (c) HeartLinkOnline, a Belgian 
start-up created in September 2007, is also working on establishing its business operations in 
its home base first as is the Belgium based Niko group which acquired both Vitalsys and 
Vitaltronic, indicating a move into the digital assisted living and home care market. 
With slightly different objectives in mind, the multinational pharmaceutical company Roche 
also started offering remote monitoring solutions in Spain, the country in which it acquired 
Carpe Diem, an SME that had already started providing remote monitoring services in Spain. 
In that sense the Roche subsidiary Emminens that resulted from Roche's move into this 
market is also mainly active in Spain, its home market, for remote monitoring solutions, while 
expansion into other countries is in the pipeline. 
Tunstall with over 1000 employees is a large company that has had long established business 
in the UK and expanded into telecare solution from its social care activities. Its main market 
is the UK but it is also active in countries like Spain, Netherlands etc. Its expansion to other 
countries is closely linked to the health care/social care institutional set-up in these countries.  
The relative lack of cross border operation from an SME perspective shows that the market is 
far from being developed. Besides, most of the SMEs, that we came across, have been created 
in the last couple of years which confirms the nascent nature of the remote monitoring market. 
While this may seem in contradiction with the fact that remote monitoring and telemedicine 
technologies have been available for at least the last 15 years, it shows that it takes a long 
time for mature technologies to make the step into full market deployment.  
In terms of larger companies, as mentioned before, the extent of their geographical coverage 
is somewhat difficult to assess. For instance, Bosch acquired the well established and widely 
used Health Hero network serving mainly Veterans of the United States with the rebranded 
Health Buddy which has the highest installed patient base of the companies in the sample. 
However the discussions with representative of large multinationals indicate that their market 
presence is not as developed as they would wish and they are more or less in a waiting 
position, whereby they may withdraw from the market altogether if revenues do not start to 
flow as the investment made in RMT/PHS solutions are rather high and may become 
increasingly difficult to justify in light of weak market sales. 
Finally, both with regard to the 50+ companies sample and the companies interviewed, it 
should be noted that most companies are from Western Europe or USA, with the exception of 
some key global players originating from Israel (e.g. Aerotel, SHL Telemedicine). There is 
scarce evidence of companies from prospective EU Member States, except for Vamstec 
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(Croatia), not only in the RMT/PHS market studied, but in the Health IT sector in general. 
This seems to indicate that these countries are just a market for PHS and remote monitoring 
systems implementation rather than PHS innovation centres, though the situation could 
change. 
Role of SMEs vs. large players in the value chain 
Looking at the SMEs, we can see that some of them (MeTeDa, SHL Telemedicine, Docobo) 
provide full solutions, but that most focus on one part of the PHS value chain. This is quite 
natural, given the more limited resources, technical capabilities and number of staff SMEs 
have. SMEs therefore typically aim to fulfil the needs of one part of the value chain as well as 
possible, often based on a novel technological solution or business model, and connect their 
solution to other parts of the value chain. Furthermore, SMEs often have one key product or 
set of products, which forms the cornerstone of their business, and which can be modified or 
tailored to suit different sets of requirements that arise in various use cases and environments. 
SMEs, such as Vitaphone, often cooperate with larger companies, which enter the e-health 
market without prior medical knowledge. 
We can also see that quite a few of the SMEs utilise existing infrastructure as part of their 
service offering. For example, companies such as Kiwok, T+ Medical and SHL Telemedicine 
make use of existing mobile networks as part of their business model. Further, many 
companies use existing IT infrastructure and hospital information systems as building blocks 
in their system. 
In contrast to the SMEs, large medical companies tend to cover a much wider spectrum of 
products and services. Some of those (e.g. Boston Scientific, GE Health care, Philips 
Medical) are able to leverage their existing product offerings to cover all parts of the PHS 
value chain. What's more, large players not only offer products in all or most of the segments, 
but often actively seek to connect the various parts of the value chain and make the entire 
chain more efficient, thus functioning as system integrators. Within larger companies the units 
responsible for e-health can appear to conduct their business rather like an independent 
medium sized company, HomMed/Honeywell, for instance, only employs around 100 people; 
nevertheless such a business unit has the opportunity to tap into the resources of the parent 
company. 
Funding 
The main difference in funding approaches is linked to the size of the company. In general, 
for larger companies, funding is less an issue from the outset as engaging in PHS/RMT are 
investment decisions based on market returns expectations, like in other domains, but the time 
it takes for PHS/RMT revenues to start flowing may endanger these investments, as stressed 
by the larger players interviewed. For example, for a large company like Bosch or Intel or for 
telcos and mobile operators investment decisions, to participate in telemedicine markets in 
general and RMT/PHS markets in particular, are made based on market growth perspectives 
at medium to long term and may be seen as market diversification opportunities. Smaller 
companies belonging to large multinationals like HomMed/Honeywell, Emminens/Roche or 
Tunstall a medium-sized company, also enjoy the financial backing from long established 
businesses and can draw into the R&D resources from the mother company that makes the 
issue of, initial or ongoing, funding less critical. At the same time, decisions to withdraw 
funding for such activities may happen at short notice if different priorities appear to be more 
promising to management and/or shareholders. It is therefore crucial for the PHS/RMT 
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market that barriers are removed fast if one does not want to risk losing larger players, as 
some expert put it. This could delay market growth even further or even kill the market, as 
both small and large companies are required for a healthy, competitive market and PHS/RMT 
ecosystem to develop. What currently motivates both small and large players to remain active 
in the market in spite of slow uptake is the societal and economic trends, i.e. projections on 
the exponential growth of chronic diseases, ageing of EU population and depleting public 
health care resources (both human and financial).  
The situation is very different for SMEs. Some of the SMEs, we talked to, have not come 
across too many difficulties in securing funding to start or pilot run their activities: Vitaphone 
for instance, has received the financial backing from one of the co-founders of SAP, which 
allowed for the initial investment in infrastructure and operation or HeartLinkOnline which 
also managed to convince initial investors. Docobo, on the other hand, reported having had to 
struggle to secure funding, surviving on EU Framework programme funding in addition to its 
CEO having had to renounce any form of emolument for the first year or two of operation. 
The case of HTN in Italy, a company born in 1998 out of the Boario Home Care project, a 
regionally-funded project, is also typical of the way SMEs or young spin-offs have to struggle 
to get their activities off the ground. HTN needed significant funding at the start to develop its 
IT Platform and had to rely on cash flow from pilot and projects for some years. Today cash 
flows from projects still finance a large amount of its operating activities and this situation 
may be reversed in 5 years from now, according to its CFO depending on the pace of 
reimbursement uptake as well as type and number of services reimbursed. In other words, by 
then R&D and operation would be funded mostly by reimbursement. Saludnova, a spin-off 
from the University of the Basque Country mentioned earlier, is part of Cooperativa 
Mondragón, a group of 264 companies from various sectors whose promotion centre aims to 
support the development of new locally based businesses in different areas. Although its 
funding is currently secured, Saludnova reported having to work hard on convincing its 
counterparts to plan funding for the following years so as to ensure continuity of its operation.   
Eventually larger players foresee a consolidation process on the PHS market with a few large 
players and a number of small players. Big players are needed as small companies would not 
be able to scale up to the same extent. The picture may look like that of the automotive 
industry, with large players and a myriad of local/smaller providers and funding may not be a 
problem in this case. As a result, the decisions for either a large multinational, a well 
established mother company, a venture capital firm or a private investor to financially commit 
to the creation of business operations in the RMT/PHS market is linked to the availability of 
evidence as well as to the general health and demographic trends in Europe: 
- The projected increase in chronic disease occurrence across Europe (and worldwide)  
- The financial burden this will impose on health care systems 
- The proof of concept that remote monitoring technology works 
These have all been mentioned as reasons for going into business in that market segment. 
Health conditions addressed 
While directly addressing various health conditions, almost all companies operating in the 
market also offer services for the management of chronic diseases. This can be explained by 
the fact that these conditions are becoming increasingly common due to aging populations 
and lifestyle issues, are predicted to increase exponentially over the coming decade and as 
such represent significant market opportunities.  
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The chronic disease management systems are often linked to hospital information systems, 
and to the patient data clinicians and general practitioners have access to. These services 
generally focus on long-term patient management and care, often through specialised disease 
management software and patient information databases. Another type of service, from a 
health condition perspective, is the broad spectrum of tele-consultation, tele-nursing, tele-
radiology, and other remote treatment or consultation services. They are enabled by new 
telecommunication services, which make it possible to efficiently transmit and process patient 
data. Remote consultation services in the case of limited patient mobility are very valuable. 
When considering remote monitoring and management of chronic conditions, companies like 
Vitaphone focus on delivering the full value chain of products and services for chronic heart 
failure. But, most others, including both SMEs and larger companies offer solutions that can 
be applied to a varying degree to each of the three most common chronic conditions, namely 
CHF, diabetes and COPD, with asthma, mental disease and co-morbidity rapidly becoming 
important segments. Some market players further indicated interest in the weight management 
or wellness part of the market: Ericsson is one example. Their product offer is targeted at 
lifestyle as well as chronic diseases and besides applications for hospitals (mobile discharge), 
home and elderly care and public health care (mobile disease management), it also addresses 
pharmaceutical companies with solutions for mobile clinical trials. Companies like St Jude 
Medical that operate on the cardiac implant market are for logical reasons starting to develop 
remote monitoring solutions with implants on the cardiac segment, which they see as a niche 
market at the moment. On the other hand Medtronic, a leader with cardiac implants, which 
has a long experience with insulin pumps and diabetes monitoring targets both heart and 
diabetes remote monitoring. 
Moreover, interviews revealed, the interest of PHS/RMT players in the wellness part of the 
market (not obvious from the desk research). Some of the products available on the market 
may already be marketed with this broader target customer group in mind. However the bulk 
of the companies interviewed have not tackled this segment yet, focusing on getting their 
business case right with RMT of chronic conditions first. What may happen in the future 
though, as stressed by some players, is that the RMT market gets a push from the consumer 
side, i.e. from the more general wellness and prevention market which is in a much better 
position to become a mass market than RMT. 
Targeted segments in the value chain 
Both small and large companies interviewed seem to be capable of covering the full value 
chain of PHS/RMT in terms of offered services (see Figure 8 on page 34 of this report). The 
interviews revealed that most if not all companies considered, provide full and adaptable 
solutions, i.e. from providing patient devices to ensuring connection from the home to the 
medical platform and the various clinical systems. Only in few exceptions RMT providers run 
their own call centre, a function which is normally outsourced. The data communications 
happens through existing infrastructures, and partnerships with specific operators, especially 
in case of mobile applications, are not uncommon. Where the offer from the various 
companies differs most is probably in the service provision segment. Companies in the RMT 
market seek to provide distinctive features so as to gain a competitive edge e.g. by offering 
more and more sophisticated analytical tools, user-friendly patient or medical platforms, or 
putting the stress on the mobility features of their offer. 
Looking more precisely at the type of products and services available in the PHS market, 
based on the 50+ company sample, we can point out several "clusters" of companies. First of 
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all, many companies focus on the remote monitoring segment (e.g. Aerotel, Biotronik, 
Bmeye, CardGuard, IEM, Kiwok, SHL Telemedicine), providing systems that include various 
measurement devices as well as vital signs processing and analysis tools. Some of their 
products only process and transmit the patient data and vital signs, but more often these 
products also enable some kind of vital signs analysis, usually taking place at the clinic or the 
hospital. The key health segments addressed by the remote monitoring devices, and the wider 
personal health systems sector, are the cardiac, diabetes, and COPD conditions. Furthermore, 
many vital sign monitoring products can be used to monitor several of the chronic diseases 
(only the niche market of implantable cardiac devices is a truly separate market). Overall, the 
level of competition in the remote monitoring market is already quite significant, but there 
seems to be potential for further growth, as there are no signs of saturation. 
A second cluster of companies consists of those that offer different patient data management 
solutions (e.g. Docobo, GoodIT, T+ Medical, Viterion). Most commonly these solutions 
consist of a software package that can be linked to hospital information systems; in some 
cases the software also connects to electronic patient health records. There is less direct 
evidence of connections to PACS (image management) and billing systems, though many 
products either enable this connection or can be tailored to include it. Nearly all companies 
that offer data management solutions seek to improve the current information management 
process by making it more efficient, allowing for better updating and/or consolidation of 
patient data thus improving the overall patient data management process.  
A third, related cluster is made up of more conventional ICT providers. Several companies 
(e.g. InterComponentWare, ISPro, Vamstec) offer ICT and communications solutions 
specifically for the medical industries, consolidating data from various sources and enabling a 
more efficient flow of information. In some cases, the dividing line between patient data 
management and ICT infrastructure provision is blurred; this is understandable, given that 
consolidating patient related information involves both the management of clinical data and 
improving the communications infrastructure. 
Finally, we can also identify a cluster of telecommunication companies that have entered the 
PHS market. Some of them have developed new business models, whereas others merely 
bring in their communications capabilities (which are not analysed in this report). 
Organisations such as Orange are an example of the former: they act as a service provider that 
offers turn-key communications solutions for the lower layers of the network. This is a new 
business for telecommunications companies that require new knowledge and expertise. 
Moreover, some communications companies (Ericsson, Intel) are becoming active in the PHS 
market itself by offering information consolidation and data management services. These are 
aimed both at professionals (clinicians, general practitioners, hospitals) and patients, with 
specific features tailored to both segments. As for Nokia, one of the main reasons for its 
interest in the PHS market seems to be the fact that its smartphones offer a platform for 
transmitting patient data. For the moment, we have not been able to find evidence of Nokia 
directly offering health related products or services. However, Nokia has been very active in 
financing small companies in PHS (eHIT, LifeChart). Nokia is also a promoting member of 
Continua Health Alliance.  
Products, services and technical solution 
Most of the companies studied offer a mix of products and services that are often 
characterised by a high degree of flexibility. In other words depending on the specific needs 
of the health care provider for whom they implement the remote monitoring system, their 
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offer will be tailored to each case delivering as much or as little of their solution as required. 
This is the case for both SMEs and large multinationals.  
One exception may be Vitaphone that provides all elements of the value chain from the 
equipment on the patient's side to the call centre manned by their own cardiologists. Their 
service provision ends at the point of care when the patient is handed over e.g. to a hospital or 
when emergency services have to be involved. Most companies consulted do not provide call 
centre facilities, but subcontract that function if needed. Their service offer therefore stops a 
little earlier on the value chain.  
Patient devices 
All the companies provide one or several devices to be used by the patient. These devices can 
take different shapes depending on the condition to be monitored and whether they measure 
vital signs or collect qualitative information. Examples include: 
- ECG belt (from 2 to 12 points) for cardiac signs measurement (e.g. HeartLinkOnline) 
- ECG card worn around the neck for registering ECG (e.g. Vitaphone) 
- Peripheral devices such as weight scale, blood pressure cuff, blood glucose meter, 
pulse oximeter, peak flow meter, and PT/INR211 (e.g. HomMed, Saludnova, Tunstall, 
Ericsson), packaged per chronic condition and connected to a monitor (HomMed, 
Tunstall) or mobile phone/PDA (Saludnova, Ericsson) 
- Handheld monitor capable of reading vital signs (Docobo), through the use of built in 
sensors, which for example record twenty-second rhythm strips of ECG, as well as 
capable of collecting other qualitative data 
- Handheld or laptop style monitors which: (a) enable a qualitative assessment of the 
patient health status, by for instance displaying questions which patients can answer 
by pressing buttons or using a touchscreen; (b) may be equipped with audio/video 
capabilities allowing for educational content to be diffused; and (c) may be capable of 
connecting to vital signs measurement devices. 
While the above are proprietary solutions, some companies like HTN use devices from 
manufacturers like Aerotel or CardGuard; Docobo also provides a connection to third party 
devices alongside its HealthHub. Together with the measurement of vital signs, most devices 
facilitate the collection of qualitative information, whereby questions are displayed to the 
patient who can key in simple answers (e.g. yes/no). Qualitative data collection modules are 
generally based on decision-trees that constitute the intelligence of the system. This goes both 
for devices offered by small companies (e.g. Saludnova or Docobo) and large ones like (e.g. 
HomMed's monitor, Bosch's Healthbuddy, Intel's Health guide). The systems typically draw 
on a vast pool of questions that can be tailored to the needs of a specific condition in a 
specific health care setting and in the required language. 
Processing/Communications 
Once the measurements are registered on the patient's device, they need to be transmitted to a 
server for further processing. In some cases like for Saludnova the data is processed in a 
mobile device or PDA locally, thanks to the intelligence built in the software with which the 
                                            
211  PT/INR is the prothrombin time (PT) measured as prothrombin ratio (PR) over international normalized ratio (INR). 
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mobile phone or PDA is equipped. In the case of HeartLinkOnline, a smartphone gateway is 
used which has a GPS function so as to locate the patient while the intelligence is built-in in 
the measuring device i.e. the chipset on the ECG belt has an algorithm which cardiologists 
can pre-program by indicating which ECG exception of the patient should be immediately 
transmitted to the clinic’s permanent cardio-monitoring centre. 
The data transfer from the measurement device to a mobile, PDA or gateway is often done via 
Bluetooth212, but also via cable, infrared and increasingly through Near Field Communication, 
which does not require power like Bluetooth and is faster/easier to set-up. Further 
transmission from the gateway to a server or central database happens via fixed line, Internet 
or mobile networks. From then on, the data may be routed into clinical information systems, 
connected to EHR or other applications. In case the data transmitted exceeds given thresholds, 
an alarm is triggered and emergency services are alerted. 
A number of companies in the remote monitoring market team up with Telco or mobile 
operators, as is the case for Saludnova that works exclusively with Vodafone. Telefonica is 
another example of a Telco cooperating with remote monitoring solution providers (e.g. Costa 
del Sol remote monitoring project). Roche originally worked on exclusive terms with 
Vodafone in Spain but opened up to all Telco in 2005. Orange recently launched a remote 
monitoring initiative in Austria in partnership with remote monitoring solution providers 
while Ericsson's mHealth solution has been tested in a number of trials since 2001.   
Service provision 
Services provided generally include the storage/processing of data, the provision of decision 
support tools and applications as well as some form of technical support and training. Docobo 
does so through its clinical database Doc@HOME that can be accessed by clinicians via a 
web interface. It is based on open standards and is fully interoperable so that it can connect to 
EHR. Saludnova's offer includes service maintenance of the system e.g. web services, alarms 
management, medical personalization, ontology in real time. Tunstall provides similar types 
of services. Roche also provides access to its database via web interface that allows the 
viewing of patient data and generation of graphical representations of the data. Bosch's 
HealthBuddy system also enables clinicians to create trend charts and patient reports. The 
Intel® Health Care Management Data Services and Application Suite enables the clients' IT 
departments to deploy/manage the telehealth programme within the health care organisation. 
HomMed/Honeywell provides different level of service depending on clients' requirements. 
Except for Vitaphone and HTN that run their own call centres staffed with specialists, most 
companies outsource the medical/specialised part of the service provision or cooperate with a 
university clinic or hospital. This is the case of HeartLinkOnline that works with the Belgian 
Imelda (Bonheiden) hospital (a renowned hospital in the domain of cardiac diseases), which 
staffs a medical call centre, located in the cardio centre of the clinic, that has been monitoring 
heart patients for over 10 years. That cardio centre receives alarm data from HeartLinkOnline 
patients. Saludnova can provide access to a medical call centre and add further services upon 
request through the involvement of external parties. Intel in contrast has set up a team of 
clinical experts to provide professional services to health care organisations, facilitating the 
integration of the PHS into their current disease management programs and care settings. 
                                            
212  Bluetooth is also the first connectivity standard accepted by the Continua Health Alliance. 
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Market focus, market size 
Different strategies are being followed depending on the company offering and the country 
concerned. Specifically the health and social care set up play an important role for companies 
when defining their strategy to deploy remote monitoring services in a given country. 
In Germany, Vitaphone focuses on cooperating with insurers (Betriebskrankenkasse) but also 
targets private patients who pay for the service from their own pocket. In Spain, Roche works 
with hospitals i.e. the public Health care. Roche actually uses remote monitoring services as a 
marketing tool to increase its market share of diabetes strips; the sales representatives for 
diabetes strips promote the remote monitoring solutions towards hospital managers. 
Saludnova also built its business model around its close cooperation with public hospitals, but 
deliberately does not address private insurances. Tunstall, a company with a long history of 
social care/telecare, works closely with social care providers in the UK and has started 
establishing similar connections with social care services in Spain.  
The strategy from larger companies like Intel, HomMed/Honeywell or Bosch is, however, 
less clear. Both the health care and consumer markets seem to be within their possible focus. 
Nevertheless, as reimbursement is mentioned as a key issue by some of these players, i.e. a 
condition for market uptake, they are likely to pursue negotiation with health and social care 
actors as well. On the other hand such players also foresee a market push from the consumer 
side. Their product offering seems to be capable of fitting both types of market segments. 
While some companies focus on one condition only, such as heart for Vitaphone or HTN, 
diabetes for Roche (since Roche is a market leader in diabetes diagnostics), others like 
Saludnova, Intel, Bosch, HomMed and others cater for any of the most common chronic 
diseases. Although more empirical data would be desirable in order to draw sound 
conclusions, at first sight it seems that the market focus of a company is closely linked to the 
following elements: 
- The country of origin of the company seems to influence the way a company develops 
its business model focusing on some specific stakeholders e.g. health care vs. social 
care vs. private insurance 
- Whether a company covers the full value chain including manning a specialised call 
centre seems to limit the focus of the activities to one particular condition e.g. only 
cardiac disease management (HTN, Vitaphone). This can be explained by the 
complexity and costs of running an in-house medical centre with several specialties. 
- A further element explaining the business choices made by companies on the remote 
monitoring market is the origin of the company in terms of medical vs. technology 
development. In other words, when a company is created around a technology, its 
offer is likely to be wider as technology can in principle be applied to various diseases. 
On the other hand when a company originates from the medical sector, (e.g. 
Vitaphone is co-founded by a cardiologist), or the company was specialised in one 
condition before providing remote monitoring applications (e.g. St Jude Medical, 
Roche), then its offer will logically concentrate on that one condition.  
In terms of market size, it is very difficult to access reliable and comparable data. Smaller 
companies tend to be more open about the number of patients they serve, as well as on 
revenues or service pricing in some cases. For example, Vitaphone declares to have more than 
30,000 users in at least 3 countries, HTN serves some 500 patients from 12 hospitals in 
Regione Lombardia and SaludNova have an annual budget of 150,000 Euros for as many 
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patients (70 currently, 2009) as possible served by 2 hospitals in the Spanish Basque region. 
For larger companies, it is both unclear which EU countries they actually operate in and how 
many patients they serve through remote monitoring services, as opposed to other telehealth 
services they may run. For example HomMed declares to serve 40,000 patients worldwide. IN 
general, small and very small companies especially those which started operating a year or 
two ago generally have small-scale activities. Large companies or those that started earlier on 
the remote monitoring segment tend to have a wider customer base as could be expected.  
Business models 
Most of the evidence presented in this section, are relevant for defining emerging business 
models. A separate EC funded study, the Rand/Cap Gemini report on "Business Models for 
eHealth",213 dealt with this topic and elaborated a conceptual and theoretical framework for 
defining business models in this area. From this report we can recall that, although "a 
common definition on the notion of business models" is lacking, their key elements include: 
- "Description of key components defining a specific business idea", 
- "Roles and relationships among a firm's customers, allies and suppliers, major flows 
of product, information and benefit for all participants", 
- "Tools that links the technical potentials of an organisation to the realisation of full 
economic value". 
In addition, the Rand/Cap Gemini report stresses that the current approaches to the analysis of 
business models are inward looking, not taking account the dynamics of factors outside of an 
organisation. The report considers these approaches nevertheless interesting in the area of 
eHealth where a business model is required to orchestrate the interests of the various 
stakeholders involved in pursuing a specific strategy. The report concludes by underlining the 
difference between strategy and business model where a strategy is about why an eHealth 
system should be implemented by a health care provider, while a business model is about how 
the system is to be implemented. 
All the supporting evidence presented here can be compared against the model presented by 
the Rand/Cap Gemini report, and while we have not provided a full analysis of business 
models according to one or the other definition, we have sought to identify the various 
dimensions that characterise the companies interviewed and the determining factors for 
success or failure. 
Revenue streams 
Very little information could be gathered on how remote monitoring products and services are 
priced and how revenues are generated. Further information can be found in the country 
studies (see Annex III, Section 8). 
Some companies seem to offer devices for a lump sum and services for an affordable monthly 
subscription, thus also enabling private patients to use the services along side those that are 
members of insurance schemes. Other companies have concluded agreements with certain 
hospitals and costs are borne by the public health care system. Vitaphone indicated that 
revenues come from: (a) the device provided to the patient for a cost of approx. 200 Euro and 
                                            
213  "Business Models for eHealth", Rand/Cap Gemini, June 2010, published by European Commission, last accessed at: 
http://ec.europa.eu/information_society/activities/health/docs/studies/business_model/business_models_eHealth_report.p
df 
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a monthly subscription fee of 10 Euro which covers the service provision consisting of 
connecting the patient to a central registration centre. The patient sometimes pays this 
privately, in other cases this cost is reimbursed by an insurance company. 
Ericsson's model is based on sharing the benefits of early discharge along the value chain, as 
is the case with the German Red Cross Hospital Group, Munich. The hospital bears the 
investment (and optionally the running costs), as it will save on each early discharged patient 
and distributes parts of the savings to members of the value chain (i.e. doctor, Ericsson, health 
service provider, operator). Furthermore, Ericsson has developed a process for identifying the 
business case for m-health (mobile health) solutions; it identifies quantifiable business case 
variables, measures them, puts them into scenarios, and develops a cost calculation and a 
model to distribute the costs and benefits over the value chain stakeholders. This last step is 
essential to a fair distribution of costs and benefits (i.e. it prevent that some parties bear the 
costs but do not get the benefits while others receive benefits even though they bear no costs). 
Saludnova negotiates yearly contracts for providing services for a given number of users with 
each hospital in the public health care system. Dependency on health budgets makes it 
difficult to secure steady revenue streams. 
While no figures were given by most companies, their revenues may be derived from 
comparing the cost of providing and installing devices, developing software, processing and 
storing data as well as carrying out technical and clinical triage for the provision of care 
services, and providing call centre services. 
Reimbursement 
Reimbursement is a teething issue for market players on the PHS/RMT market. The 
difficulties encountered in relation to having products and services taken up in a 
reimbursement scheme are one of the most important factors slowing market uptake. Only 
one company (Vitaphone) mentioned having private patients paying themselves for the RMT 
services although this is not the main bulk of its client base. All companies interviewed 
mentioned having agreements with public health care authorities or with health insurances. 
However the level of reimbursement is often not sufficient to sustain a business as underlined 
by SMEs like HTN and Docobo. The extent of and modalities for reimbursement of remote 
monitoring depends on the country where the services are deployed and the health care and 
social care settings. (see Annex III: Section 8 on Countries study for more details). The lack 
of trust in or awareness about evidence on the benefits of PHS/RMT solutions on the side of 
payers contributes to this state of play. In addition even when there is a will to implement 
PHS/RMT solutions in e.g. a public health or social care settings, the inadequacy of the legal 
framework makes it either impossible to implement these solutions, or requires to circumvent 
the system until a permanent solution is found.   
Evidence 
While there seems to be a lack of awareness about evidence among payers and health care 
providers on the benefits of PHS/RMT, many of the companies interviewed stressed that there 
is more than sufficient scientific evidence of the benefits of remote monitoring around. These 
companies have often commissioned their own study to prove the benefits of their solution or 
have cooperated with research institutes to bring evidence about the benefits of remote 
monitoring solutions (see paragraphs 9.3 to 9.6 on scientific evidence for more details). 
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However, there is very little being done from the companies' side to raise awareness on the 
bulk of evidence to the medical professionals (usually the primary care medical professionals) 
and even less towards the patient. The issue is clearly about disseminating scientific results 
and making such results more comparable, promoting a common approach in that field. 
Certification 
A couple of companies referred to certification as an important tool to convince insurance 
companies and other parties of the benefits and quality of remote monitoring systems. In 
particular Vitaphone has invested in setting up a quality infrastructure for the managed care 
model with the German VDE (Verband der Elektrotechnik, Elektronik and 
Informationstechnik) that resulted in the production of a Quality Handbook of more than 900 
pages (2007) which details the set-up and quality assurance regulations for such a 
Teleservice214 centre. Any system fulfilling the requirements of the Handbook will be 
acknowledged as VDE Certified Management System. Saludnova also reported carrying out a 
pilot at the Hospital de San Sebastian, to demonstrate that the technology requirements of the 
Regional Health System (Osakidetza) are fulfilled so as to obtain certification from the 
Basque government. 
Research and innovation activities 
Larger companies like Roche, HomMed, Intel and Bosch can draw on their own R&D 
resources and facilities to pursue innovation in the RMT field. Both, small and large are 
engaged in local, regional or national projects as well as EU projects. Besides the obvious 
R&D goals pursued with these activities, in particular larger players underlined that their 
interest in being involved in innovative developments and EU projects is not only about 
getting research funding but is also a means to keep up with market evolution and be aware of 
potential new business opportunities. 
This is confirmed by a recent statement from the German Minister for research and education 
commenting on Germany's participation in EU projects:  
"Apart from the plain numbers this level of engagement offers other 
advantages for German researchers,” said Annette Schavan, the German 
minister for research and education. “The value of participating in 
European projects lies in building networks, exchanging knowledge and 
reaching out into new markets.”215 
As to smaller companies, they often use EU projects as a means of funding both research 
activities and business operation. This shows how difficult it is currently for smaller 
companies to sustain a viable business model based on revenues/reimbursement only.  
 
 
                                            
214  http://www1.vde.com/WBB/PMM/Publikationen/Anwendungsempf+TeleMonitoring.htm 
215  See http://www.bmbf.de/press/2661.php  - English Translation of the statement in Research Day Europe Issue 3266 08 
Sep 09.  
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The following examples illustrate the type of research and innovation activities the companies 
interviewed participate in:  
1. Vitaphone is involved in a number of national and international research projects like:  
- EasyCare,216 dealing with nurse call services for care at home and Motivation60+217 
for Sports and activities, two national projects focusing on the consumer market; 
- EmotionAAL218 (diabetes) and AMICA219 (for patients with COPD, two international 
projects focusing on managed care models). 
2. Tunstall participates in various projects and pilots including the UK Whole System 
Demonstrator, regional projects like NHS Lothian, NHS Sheffield and NHS Swindon, and 
the EU funded CommonWell project, a large-scale project aiming at delivering integrated 
care services for COPD and CHF patients as well as in the context of Independent living. 
3. HTN was born out of an Italian project, the Boario Home Care project (1998-2003). It still 
participates in national and international projects in the Telemedicine area in order to be 
able to fund and pursue its own innovation activities.  
4. Docobo was also born out of EU FP projects. It is currently involved in a 2007 - 2010 EU 
FP 6 project called ‘ENABLE’ dealing with the development of wearable systems. It also 
participates in the 2008-11 TSB ALIP project ‘PEACE’ (Personal Care Environments) 
and the 2009-12 TSB ALIP project ‘PEACE EVERYWHERE’ Community. 
Partnerships 
There are examples of partnerships at different levels on the RMT market. Telco and mobile 
operators seek partnerships with technology solution providers in order to enter the market. 
Vodafone is an example in Spain as shown by the Saludnova and Roche cases. Beyond the 
companies that are reviewed in this section, Orange has recently announced a partnership with 
Alcatel Lucent in Austria for mobile eHealth service provision.   
For companies capable of providing full solutions, or with already established services, 
insurance companies are interesting candidates, giving access to large bases of patients. 
Vitaphone recently announced that they signed a partnership agreement with ADAC thus 
aiming to address their services (telemedicine-supported prevention programme) to 16 million 
insured members and 8200 employees. Vitaphone also announced in July 2009 its 
cooperation with Biotronik – a market leader in the cardiac implant segment – for the 
monitoring of patients with heart failure in Germany.  
On a scientific level, companies also seek cooperation with research organisations so as to 
validate the efficiency and benefits provided by their solutions. 
 
       
                                            
216  http://partner.vde.com/bmbf-aal/AAL-Steckbriefe/Documents/BMBF%20Förderprojekte/easycare.pdf 
217  http://partner.vde.com/bmbf-aal/AAL-Steckbriefe/Documents/BMBF%20Förderprojekte/motivation60plus.pdf 
218  http://www.aal-europe.eu/calls/funded-projects-call-1/copy_of_ecaalyx 
219  http://www.amica-aal.com/index.php 
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7.4 50+ company list and company profiles 
Table 15 – List of the 50+ companies 
Implants Service providers/Product vendors/SMEs 
Biotronik Aerotel 
Boston Scientific Vitalsys 
Medtronic Aipermon 
St Jude Medical Tunstall 
Sorin Group Docobo 
Large players Vitaphone 
Philips Saludnova 
GE Health care Heart Online 
Agfa Health care E-HTN (Lombardy) 
Honeywell Bmeye (cardiovascular) 
Bosch IEM (blood pressure) 
Newcomers in the PHS market Goodit (diabetes, other remote monitoring) 
Intel Kiwok (ECG) 
ICT providers T+ Medical (disease management systems) 
Nokia Vamstec Croatia (image and data 
management systems) 
Ericsson eHIT (system integration) 
Vodafone GEM-MED (measuring and monitoring, 
patient platforms) 
Orange Schiller Medizintechnik (telemonitoring, 
medical platforms) 
Telefonica Vitaltronic (vital data real-time 
management) 
Cisco SHL Telemedicine (cardiac monitoring, 
other remote monitoring) 
DGN Service (hospital information 
systems) 
MeTeDa (teleanalysis and outpatient 
management) 
InterComponentWare (electronic personal 
health records, other data systems) 
TMA Medical (mobile care unit: multi-
device examination system designed for 
mobile and stationary operation) 
ISPro (ICT and telematic solutions for 
hospitals) 
 
Frost & Sullivan report Pharma 
Omron Roche 
Cardguard Bayer 
Viterion Other 
Healthhero Institut fur Angewandte Telemedizin 
(implementation of telemedicine systems) 
Bodytel Scientific  
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Brief description of 50+ company profiles  
Aerotel is an Israel-based, medium-sized company with activities throughout the world. They mostly 
operate as a product vendor, with devices for the measuring of blood pressure, ECG, blood glucose, 
weight, SPO2, respiratory peak line via telemonitoring, wearable alarms, and remote monitoring 
software. They provide full-service solutions for telehealth applications, offering an inpatient 
monitoring system that consists of a medical call centre software and monitoring devices that transfer 
vital, medical or lifestyle data over the telephone, the Internet or wireless networks. The patient 
information and the transmitted data can be viewed locally or via the Internet. Their most important 
product is the Heartlink ECG monitoring system, which is specifically designed for various 
diagnostic, emergency and monitoring applications. It consists of a range of personal 1 to 12 lead 
transtelephonic or digital ECG devices for remote diagnostics. The recorded data can be transmitted 
through the phone to Aerotel's Heartlink Receiving Station (HRS) for immediate diagnosis. 
Agfa Health care offers solutions such as Hospital Information Systems (HIS), Clinical Information 
Systems (CIS), Radiology Information Systems (RIS), Picture Archiving and Communications 
Systems (PACS), Laboratory Information Systems (LIS), Cardiology Information and Image 
Management Systems (CVIS), solutions for reporting, enterprise scheduling, decision support, and 
data storage as well as Digital Radiography, Computed Radiography, print solutions, film and 
associated products. According to discussions with experts from the company Agfa Health care 
wishes to apply this knowledge as a hub for eHealth and telecare solutions.  
The Luxemburg-based Aipermon GmbH & Co. KG is active in the field of telemedicine and 
monitoring of physical activity. The AiperCoach Home system enables the patient to transmit vital 
data such as blood pressure, physical activity and weight conveniently from home to the doctor, to 
the hospital or to a telemedical centre. Furthermore the company offers devices with a display to 
monitor the energy intake and physical activity level of patients, who are as well guided for the 
change in behaviour. The company cooperates with the Charité University clinics in Berlin and 
various distributors, their products are available mainly in EU countries and other developed nations.  
Bayer Health care is the subsidiary of the Germany based Bayer AG. Bayer Health care operates 
through four divisions: Animal Health (veterinary drugs); Consumer Care (OTC meds); Diabetes 
Care; and Pharmaceuticals (represented by Bayer-Schering Pharma and Bayer Health care 
Pharmaceuticals). Diabetes Care's Viterion 200 telehealth monitor transmits patients' vital signs 
taken at home, saves the measurements and transmits them to the General Practitioner. Bayer offers 
analytical software to analyse the data both for patients and health care professionals. Note that 
Bayer through its subsidiary MEDRAD offers products including vascular injection systems, 
magnetic resonance scanner coils, and computed tomography injection systems, as well as syringes 
and disposable tubing.  
Biotronik is a large German company that focuses on cardiac monitoring devices and systems. They 
concentrate on two distinct business areas, electrotherapy and vascular intervention. In 
electrotherapy, they offer diagnostic tools and options for treating arrhythmias. The products offer a 
range of diagnostic features for remote processing and analysis of data from implanted cardiac 
rhythm management devices. In this way, the implants provide access to relevant technical and 
clinical data, while allowing systematic and continuous patient surveillance. The implanted 
defibrillators and pacemakers transmit encrypted messages, which can be automatically analysed in 
Biotronik Home Monitoring Service Centre and sent to the physician. In the field of vascular 
intervention, Biotronik offers guide wires, balloon catheters, and stents, but these are less relevant for 
the purposes of PHS. 
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Bmeye is a small Dutch company that offers products for monitoring cardiac and pulmonary 
conditions. Their main product in the remote monitoring field is the BMEYE monitor, available in 
two basic configurations: Nexfin Continuous Blood Pressure Monitor, and Nexfin HD Continuous 
Cardiac Output and Blood Pressure monitor with Real-time Hemodynamics. Their product enables a 
full patient analysis including stroke volume, cardiac output, systemic vascular resistance, and 
various blood pressure metrics. 
BodyTel is a German based company that specialises in comprehensive telemedical monitoring and 
management systems for chronic diseases, particularly diabetes, obesity and blood pressure. On the 
patient site its products are designed to simplify home monitoring for patients and to enable 
communication of measured body values between patients, health care professionals and caregivers. 
Their products can send alarms to caretakers in case of hyperglycaemic or hypoglycaemic episodes, 
mobile phones are used for the communication.  
Bosch Health care is a subsidiary and umbrella brand of the Bosch Group. It encompasses a full 
range of telehealth products and services. This newly established subsidiary built around Health 
Buddy, a monitoring device made by Health Hero Network, which was acquired by Bosch in 2007, 
includes all international operating units in the area of telehealth, which aims to extend health care 
outside the traditional institutional walls of health care systems, and into individuals' homes and 
lives. It incorporates ViTelNet telehealth systems, which produce robust telehealth hardware, 
including touch screen-based systems. The ViTelNet telehealth system also offers flexible 
integration with customer systems. In Germany, a first pilot study has been launched with the 
hospital operator Asklepios. The objective of this project is to use telehealth solutions to monitor 
patients suffering from chronic obstructive pulmonary disease (COPD), type 2 diabetes and 
Parkinson. For more than two years, Bosch has been involved in the "Partnership for the Heart" 
project, together with the Charité Medical School in Berlin and the Robert Bosch Hospital in 
Stuttgart. This study - the most extensive of its kind, encompassing more than 600 congestive heart 
failure (CHF) patients - hopes to scientifically substantiate the benefits of telehealth for this 
condition. Additional cooperation projects in the U.K., the Netherlands, and the Middle East are 
currently also in the pipeline. Practical application of the Bosch telehealth system has so far been 
highly successful. Last January, the U.S. Department of Veterans Affairs published an analysis of 
data from over 17,000 patients whose care was coordinated using telehealth systems, particularly the 
Health Buddy System and ViTelNet's product offerings, from 2004 to 2007. The study showed an 
average 20 percent reduction in hospital admissions across a wide variety of conditions. 
Boston Scientific is a large US-based medical company with an annual global turnover of $8.3 
billion. This revenue is generated over multiple product lines and services, and does not represent 
PHS alone. In the area of PHS, they are nonetheless a major player, with offerings in all the major 
product categories (cardiac, COPD, blood pressure, co-morbidity, and so on). Additionally, they are 
a major provider of implants and associated monitoring systems. Their services aim to connect the 
various kinds of personal health systems, and they can thus be described as a value chain integrator, 
even if most of their products and services can also be used on a stand-alone basis. 
CardGuard(renamed LifeWatch in May 2009) is a Swiss company focusing on vital signs 
monitoring and data analysis. They have an extensive product portfolio that covers the cardiac, 
COPD and blood pressure segments, and also offer devices for transferring information between the 
patient and a call centre. Remote monitoring remains their most important market, with revenues of 
$12.82 million in the fourth quarter of 2007.220 They have also signed a long-term agreement in 2004 
                                            
220  Europe Remote Patient Monitoring Markets, Frost & Sullivan, June 2008. 
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for a strategic alliance with Samsung Electronics Co., Ltd. in Korea. According to the terms of this 
agreement, Card Guard will develop, manufacture and sell to Samsung Electronics various medical 
software applications and devices, which will be used in Samsung mobile handsets.  
The United States based Company Cisco is a market leader worldwide for IP-based networking 
equipment, the company provides routers and switches used to direct data, voice, and video traffic. It 
uses its expertise in these fields to expand into the eHealth market. In cooperation with the 
UnitedHealth Group the company is building United States-wide network, which will give patients 
access to physicians and specialists when in-person visits are not possible. It will be called 
"Connected Care" and will combine audio and video technology and health resources to greatly 
expand physicians' reach into rural, urban and other underserved areas. Cisco's products are 
furthermore used to build responsive support communities for patients with different conditions. The 
company is active as well in the field of medical images.  
The Germany based DGN Service GmbH specialises in medical intranets; it runs the health network 
for doctors Deutsche Gesundheitsnetz D/G/N, the network for pharmacists aponet Professional and 
the network for dentists DZN. The company is one of the systems integrators in Germany providing 
the technical infrastructure for telehealth solutions, including trusted computing for RMT/PHS. 
Docobo is a small UK-based company specialising in medical platforms. Their main product is 
called doc@Home, which is an integrated telehealth solution for the remote management of patients 
with a range of long term conditions. Through doc@Home, essential patient related data is collected 
and analysed, which permits the management of chronic conditions through interaction between 
clinicians and patients at home. To complement the doc@Home patient management system, 
Docobo offers the HealthHUB product, which is similar to a PDA and, using the principle of “store 
and forward”, records and transfers vital signs measurements, changes in symptoms, side effects, and 
quality of life indicators to the centre of care. 
The Finland based company eHIT(bought by Mega Electronics Ltd in October 2009) specialises in 
the field of mobile solutions within the health care and wellness industries. It provides software 
products and implements customer projects dealing with integration of eHealth solutions. Its 
products and services consist of eHealth and eWellness solutions in which the end users actively 
participate in the maintenance of their own health. eHIT's products focus on  self care, home care, 
and occupational health. The products offered by this SME include the seamless integration of real-
time patient-doctor communications with the patient’s medical record, vital sign monitoring and 
nursing support via a mobile device which acts as a gateway for different sensors, as well as a 
medical platform for data analysis. 
HTN is an Italian company that was established by a small group of cardiologists, who, through the 
Boario Home Care project, started providing 24 hours a day telemonitoring for patients with 
cardiovascular diseases, using a mobile electrocardiographer. The project took place in the Boario 
region of northern Italy. The successful results led to expanding the project to other northern Italian 
regions and HTN subsequently participated in several projects of the Ministry of Health and the 
Lombardy region, which were focused on the effects of using telemedicine in the management of 
chronic heart failure patients at home. The projects helped demonstrate the positive impacts of 
telemedicine, in terms of diagnostic accuracy, quality of life and spending optimisation. As a 
consequence, in 2006 the Lombardy region introduced reimbursement for the home telemonitoring 
of Chronic Heart Failure patients on a test basis. HTN offers medical platform and communication 
services, specialised teleconsulting, medical assistance over communication networks, personalised 
monitoring and vital signs monitoring. They also provide teleconsulting and ECG referrals, 
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multispecialty second opinion for general practitioners, home telenursing for chronic cardiac 
diseases, telediagnosis for arrhythmia, and call centres for hospitals.  
Ericsson is a global Swedish telecommunications company that has recently entered the personal 
health systems industry. Their main product in the PHS market is Ericsson Mobile Health, a hosted 
solution for remote monitoring and patient follow-up. The system has been designed to be as easy to 
use as possible, with no manuals for the patient to read and a single button to push to transmit the 
medical information relevant to the patient. The system also enables mobile monitoring and follow-
up of large numbers patients, and has a fixed monthly fee for the hospitals and clinics that choose to 
use it. The system works as an information hub, integrating information from patients, clinicians and 
insurance companies.  
GE Health care is a major US-based player in the medical industry with a global turnover of $17 
billion, of which only a minor part comes from PHS products and services. GE Health care offers a 
variety of remote monitoring, medical information, and vital signs collection and analysis systems. 
GE health systems are also connected to hospital information systems, PACS imaging systems and 
billing solutions. As they offer a full service package to connect the different parts of the value chain, 
GE Health care can be considered a system integrator from the PHS point of view. As announced in 
April 2009, GE Health care and Intel have also signed an alliance to deliver personal health care 
products and services to patients in their homes. Both companies will invest $250 million in the 
products and research over the next five years. GE Health care is also a promoting member of the 
Continua Health Alliance. 
Gem-med is a Spain-based company working at the crossroads of ehealth and cardiology. gem-med 
designs, develops and sells eHealth equipment, it offers telemedical services and diagnosis through 
the net. Its products focus mainly on health services in a professional environment and are 
specialised in the field of electrocardiography. The company designs and develops diagnostic 
equipment for cardiology and carries out research on the use of medical methods and protocols of 
prognosis and diagnosis for interpreting cardiologic tests. The products and services are offered in 
two lines of complementary business. One line consists of electrocardiographic diagnostic 
equipment, which includes a range of electrocardiographs and Holter. The other is a line of 
telemedicine services which includes virtual diagnosis, the renting of equipment, and the 
development of customised projects and specialised training. 
IEM is a small German product vendor focusing on COPD treatment. They offer various blood 
pressure measurement products as well as educational content related to COPD and blood pressure 
issues in general. Their products enable both the measurement and analysis of patient data. 
GoodIT is a Finnish SME whose main focus is diabetes. They offer ICT solutions for management 
of diabetes, alongside remote management of mobile medical devices, accounting and billing 
systems for mobile medical services, and medical and health care process models and platforms. In 
addition, they offer a significant amount of educational content, both for hospitals and patients. 
Health Buddy System is a United States Based company that serves as the interface between 
patients at home and care providers, facilitating communication of historical patient data of and self-
management support for patients with chronic conditions. Originally developed in California by 
Health Hero Network, the Health Buddy System was acquired by the Bosch Group in Dec.07 (now 
part of Bosch Health care). The Health Buddy Appliance connects patients in their homes to their 
care providers. The health management programmes within the Health Buddy system cover more 
than 30 health conditions and provide interactive scripted content based on standard practice 
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guidelines. A web-based patient management tool enables care managers to analyse the data and take 
appropriate actions. 
Heartlink Online (HLO) is a Belgium based start-up whose offering currently consists of a belt 
equipped with a two point ECG device used to remotely monitor ECG’s for emergency and routine 
monitoring. Furthermore it offers accompanying service for the arrangement to transmit the data to 
the cardio centre of the patient’s clinic, via a Smartphone gateway equipped with GPS facilities. The 
belt that can be pre-programmed contains an algorithm which enables specialists to define exceptions 
that should trigger an alarm. HLO also provides data storage facilities and connection to EPHR using 
Secured Software as a Service. Next to cardio-data which is HLO's current focus, a variety of other 
vital sign data can be transmitted through the Smartphone gateway and into the EPHR, such as 
glucose data, spyrometry, combined blood pressure and heart rhythm, oxygen saturation of the blood, 
weight and other measurement.  
Honeywell HomMed is a United States medium sized company and part of Honeywell's Life Safety 
business unit. It is active in telehealth and remote patient monitoring. It has a large home health 
customer base serving over half a million patients globally. Within the EU the company serves over 
40,000 patients in the UK (1,400 patients per WSD site). HomMed is also active in Italy, Germany 
and in the Netherlands. Its biggest customer in the US, Kaiser Permanente (a closed system run by a 
centrally funded health insurer) represents over 60,000 monitors, and 600 customers, serving over 
600,000 patients. Its products measure vital signals, support and remind in-home user in taking care 
of them selves, HomMed also provides software to analyse the data.  
The Institut für Angewandte Telemedizin is part of the Heart and Diabetes Center North Rhine-
Westphalia in Germany. It is active in the fields of cardiac, circulatory and metabolic diseases. A 
device enables the patients to monitor their vital parameters. Patients can record their ECG and call 
the Medical Service Centre in case of symptoms. After an anamnesis an ECG is transmitted. The 
situation is then evaluated by medical personnel with special training, supervised by experienced 
cardiologists from the Clinic for Thoracic and Cardiovascular Surgery.  
Intel is a global ICT company that has recently entered the PHS market. Their main product in the 
PHS market is the Intel Health Guide, which is intended to be a powerful care management tool for 
health care professionals who manage patients with long-term (chronic) conditions. The Intel Health 
Guide seeks to provide a higher level of patient engagement and more efficient care management by 
enabling communications between patients and health care professionals, and providing clinicians 
with access to the most current, actionable data. This personal health system combines an in-home 
patient device – the Intel Health Guide PHS6000 – as well as an online interface – the Intel Health 
Care Management Suite – allowing clinicians to monitor patients and remotely manage care. Intel 
and GE Health care have also agreed on a €183 million technological alliance to develop and 
promote new products and services for personal health. 
InterComponentWare is a German company that provides ICT solutions for the medical industry. 
Their product range encompasses electronic personal health records, data systems, and technology 
platforms. Their business model is about integrating stand-alone IT systems through hardware and 
software products, making information flows more efficient and consolidating data from various 
sources. Some of their key products include the LifeSensor personal health record, solutions from 
ICW Professional Suite, and the ICW eHealth Framework as a development environment and base 
technology. They are also actively involved in standardisation activities. 
ISPro is a small German ICT provider for hospitals and clinics. Their most important products 
include the Jesaja.net Zuweiserportal, a user portal for clinicians and general practitioners, and the 
 129 
Cordoba communications platform for networks of clinicians. These can also be coupled with remote 
monitoring systems. At the moment, more than 200 hospitals in Germany and elsewhere are using 
ISPro systems. 
Kiwok is a Swedish company focusing on cardiovascular measurement and transmission of ECG 
data over mobile phone networks. Their product portfolio is built around the BodyKom Series ECG 
solution, which enables doctors and care personnel to receive the ECG of heart patients via an ECG 
sensor and a cellular phone. The system operates in all locations worldwide, as long as there is 
mobile phone service coverage. The caregiver receives diagnosis data as soon as the patient registers 
abnormality in his monitoring. Customised measures (e.g. sending of notification to doctor and 
relatives) can be deployed automatically. With added functionalities, the BodyKom Series can also 
be applied in other areas which require monitoring, such as diabetes and blood pressure. 
Medtronic is a large US-based company with a global turnover of $13.5 billion. In common with 
other global medical companies, only a small share of their revenue comes from PHS and remote 
monitoring businesses. Nevertheless, they are a very active player and leader in the PHS market, 
where their key activities are focused on new-generation implants with remote connection 
capabilities. They also offer a range of other remote monitoring and homecare devices. The health 
conditions they address in the PHS and remote monitoring markets include cardiac rhythm disease 
management, cardiovascular conditions, and diabetes. 
MeTeDa is a medium-sized Italian company that focuses on vital signs monitoring and analysis. The 
core of their activity is the production of managerial medical software, with an emphasis on clinical 
data elaboration and the development of innovative technologies of telemedicine and 
teleconsultation. Managing and analysing clinical data, especially the data provided by remote 
monitoring systems, is their main focus area in the PHS market. 
Nokia is a Finnish telecommunications company with a total turnover of over 50 billion Euros. 
Recently they have become active in the personal health systems and remote monitoring markets. 
One of the main strategic advantages for Nokia's presence in the PHS markets is their ability to 
provide patient platforms (or communication platforms) which enable the transfer of patient data. 
With a smartphone they can evaluate and assess the data before sending it towards a medical 
platform. Nokia also actively supports and finances smaller companies in the area, such as the 
Finnish company eHIT and the e-Health company LifeChart (jointly funded by Nokia and Johnson & 
Johnson), which monitors and manages patients with chronic heart conditions. In addition, Nokia is 
an active member of Continua.  
Omron is a large Japanese hospital equipment manufacturer with global revenues of 60 billion Yen. 
They are also active in the PHS and remote monitoring markets, for which they supply products such 
as blood pressure monitors, non-invasive vascular monitors, and portable ECGs. In these markets, 
they can be characterised as a device manufacturer, though the company as a whole works more as a 
system integrator whose products and services encompass the whole value chain. 
Orange Health care is the health care division within the France Telecom group. It focuses around 3 
priority areas, at the hospital, at the doctor’s office and at the patient’s home. It enables and 
facilitates hospitalisation and care at home by connecting health care professionals and their patients. 
The company cooperates with partners for the provision of medical and care knowledge, the 
exchange of medical information, the coordination of action and diagnosis, and the provision of a 
kind of "working area on the move". Furthermore Orange strives to offer electronic payment, 
electronic transmission and data storage services. It targets remote assistance of patients suffering 
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from chronic disease and the provision of data systems and intelligent software adapted to specific 
conditions. 
Philips Medical is a global medical systems provider whose product offering includes diagnostic 
imaging systems, health care information technology solutions, patient monitoring and cardiac 
devices. In the PHS market, they address the cardiac, diabetes, COPD as well as co-morbidity 
conditions. As a company that connects the different parts of the value chain through a 
comprehensive product and service portfolio, they can be considered a systems integrator for PHS. 
Philips is also a member of Continua. 
Roche is a large Swiss company with an annual turnover of 46 million Swiss francs. Their main 
interests are in the pharmaceutical market, but they also operate as a provider of diagnostic products 
for the PHS market. Roche has been one of the first companies to offer tailored products for different 
patient groups. Roche also has a subsidiary called Emminens, which offers telemedicine services 
(teleconsultation, processing patient data, monitoring patient status) for diabetes patients in Spain 
and other parts of Europe. Roche is a member of Continua. 
The Spain based Saludnova is a young start-up within the Cooperative Mondragon Group, which 
originated at the University of Bilbao. It provides ubiquitous solutions for monitoring of biometric 
variables and the real-time detection of alarm situations, triggering the necessary medical care 
measures. Saludnova offers two distinct  streams of solutions in the remote monitoring market, the 
Careline Home, more focussed on preventive medicine and  social care and Careline Pro focusing 
on monitoring of in-out patients e.g. by hospitals. The product targeted at professional users 
comprises additional functions compared to the standard one such as transmission of graphics, 
photos and comments. It contains automatic sensors for measuring hypertension, respiratory, heart 
and co-morbidity vital signs, and transmission is via Bluetooth. In addition qualitative questions 
allow capturing data manually about the person's condition (e.g. how they slept etc.) and a manual 
sensor is used for transmitting temperature and glucose levels. The Saludnova products and services 
are targeted at chronic patients. Saludnova sees clear opportunities in this market, as technology will 
be needed to face the sheer volume of chronic diseases, which will require more efficient health care 
in the future. 
The Swiss based Company Schiller manufactures and supplies electrocardiographs, long-term 
pocket sized ECG and blood pressure recorders, spirometers, medical IT solutions, patient monitors 
and external defibrillators. The company portfolio also comprises small portable vital signs 
monitoring devices to be used in PHS, which they produce themselves. Even though the Schiller's 
product are predominantly used within hospitals, the company is an example of a larger group of 
highly specialised SMEs active in the field of medical devices for patient monitoring, which have the 
potential to enter the PHS market.  
SHL Telemedicine is an Israeli company that focuses on cardiac monitoring and its integration in 
the PHS value chain. They concentrate on developing and marketing advanced personal telemedicine 
systems as well as providing their end-users a comprehensive telemedicine solution that includes 
medical call centre services. Their solution includes the transmission of medical data by an 
individual, from a remote location to a medical call centre via communication networks. Using 
computer systems, the medical call centre staff uses the data to diagnose and monitor patient health 
and to respond to their needs. 
St. Jude Medical, Inc. is incorporated in the United States and is also present in Europe. The 
company develops, manufactures and distributes cardiovascular medical devices for global cardiac 
rhythm management, cardiology and cardiac surgery, arterial fibrillation therapy as well as 
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implantable neurostimulation devices for the management of chronic pain. St. Jude Medical markets 
a wireless transmitter called Merlin@home, which has been introduced in Europe in 2008 at pilot 
centres. This system communicates automatically by radiofrequency with the implantable device, 
sends data to the physician using an analogue landline system and alerts if necessary the physician or 
the patient. The latest version of the Merlin.net Patient Care Network (PCN) gathers and stores data 
from the implant procedure, in-clinic follow-up visits and from subsequent remote transmissions sent 
from a patient’s home. Remote transmissions can include both patient-initiated and automatic follow-
ups and monitoring transmissions sent via the Merlin@home remote transmitter. The system gives 
doctors more timely access to important patient and device data, allowing them to get a more 
complete patient record by easily transferring cardiac device data into EHR systems. 
T+ Medical is a medium-sized UK based company with large-scale operations also in the USA. 
They specialise in remote monitoring and health care management over mobile networks. Their 
telemedicine solutions utilises existing network infrastructures, mobile phone and web technologies 
for ubiquitous access and direct communication to people with chronic diseases. T+ Medical's 
service offering consists of disease management, remote monitoring and wellness solutions for 
disease management organisations, hospitals, group practices, health plans, employers and 
government organizations. The company cooperates with Vodafone in providing them medical 
know-how and services 
The Spain-based company Telefonica provides fixed and mobile telecommunications services across 
Europe and Latin America. The company has set up a special division called eHealth that will 
develop and implement proposals specifically related to health and welfare. In Spain, the Ministry of 
Health of the regional government of Castilla and León trusted automation of its first level care 
appointments to Telefónica, through which patients can make an appointment through different 
channels: phone, SMS and internet. USP Hospitales and Telefónica signed a strategic alliance to 
work together on developing eHealth, telemedicine and tele-radiology solutions. Furthermore the 
pilot project Remote Service Platform (Plataforma de Teleasistencia) is a platform intended to 
facilitate the care of dependent people, reducing the number of trips needed to check their health 
status. Telefonica is also participating in the Home Telecare project together with the Hospital Costa 
del Sol. In this project that started in December 2008 and is targeted at heart patients and terminal 
patients, It is designing the communication platform in cooperation with health care professionals.  
TMA Medical is an Austrian SME whose main product in the PHS market is called the Mobile Care 
Unit (MCU). Designed for stationary or portable use within telemedicine applications, the MCU is a 
stand-alone multi-device examination system operated and controlled by a dedicated personal 
computer. The MCU enables a wide range of examinations. A homogeneous electronic medical 
record is created and will be transmitted using various Internet connectivity methods (Lan, WLan, 
3G, WiFi, PSTN, satellite). The MCU can be customised and interfaced with existing telemedicine 
platforms. In addition, by using video-conferences, the MCU can be used as a medical tool for 
remote areas, emergency and prevention. 
Tunstall is a UK based company which is one of the world's leading providers of telecare and 
telemedicine solutions, with a global turnover of more than €180 million. Tunstall has a number of 
different devices in its product portfolio for PHS. These include RTX monitors and peripherals with 
disease specific packages and clinical systems organisers (CSO). Over 2,500 monitors and CSO's are 
deployed and used by over 65 NHS partners in the UK. The objective of the technology is to reduce 
the amount of time doctor/nurse needs to spend with patients: measuring is done at home, an alarm is 
triggered and medical intervention is arranged only when certain parameters are exceeded which 
saves patient visits. The information transmitted is stored in servers, and medical experts can access 
the database for trend analysis purposes.  
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Vamstec is a small Croatian company that specialises in image and data management systems. They 
process and distribute medical images in electronic form, and combine them with patient 
examination data, thereby aiming to make existing health care services more efficient and more 
attuned to patient needs. Their products provide scalable, secure, and relatively economical patient 
management systems for day-to-day use in clinics and hospitals. 
The Belgium based Start-up VITALTRONICS is a subsidiary of the telemedicine specialist Vita, it 
develops medical technologies in order to allow doctors to follow the vital parameters of their 
patients in real time. In this context, VITALTRONICS has already developed prototypes of 
telemonitoring devices, in collaboration with various technological partners like CETIC and Verhaert 
New Products & Services. It sub-contracts the technical design and the production to other 
companies. Its products include an automated external defibrillator (CardiAid) and a fall detector.  
Vitalsys is a Belgium based company specialised in Telemedicine Integration systems and services 
for Telemedicine combined with the distribution of medical technologies in the Benelux Region. The 
company promotes existing validated medical vital sign monitoring systems for hypertension, heart 
diseases, respiratory problems, diabetes and other conditions. The core of these systems is the 
Vitalsys telemedicine platform named VitalCare for processing of medical data. The company 
belongs to the Niko Group together with Vitaltronics. 
The German based company Vitaphone offers integrated systems for the acquisition and 
transmission of biological signals with the help of modern communication devices. These are part of 
telemedicine monitoring and care systems. The telemedical concepts encompass both top of the line 
technology and a medical service centre, which is staffed with physicians, and is available around the 
clock. Vitaphone provides comprehensive patient care solutions to care suppliers and health care 
insurers and targets patients suffering from chronic heart failure. 
Vodafone, a leading mobile communications operator, is directly active in the field of e-health in 
cooperation with the Rockefeller Foundation and the United Nations Foundation, offering mobile 
health solutions for developing countries. Furthermore, the company is cooperating with T+Medical 
(see above), a provider of mobile phone-based technology, and focuses on transferring biometric data 
of patients with chronic diseases, recording details about their condition and treatment, using mobile 
phones. Vodafone Spain has developed a service that enables people with diabetes to effectively 
control their sugar levels. A monitoring device measures the level of sugar in their blood, displays 
the reading on their mobile phone and transmits this information to their doctors. With the support of 
the Vodafone Portugal Foundation, a system has been developed to remotely monitor epilepsy in 
children. Neurologists and paediatricians at the West Lisbon Hospital Centre use mobiles and 
specially developed software to monitor medical diagnostics remotely via the Internet. The Vodafone 
Care service in Germany, offered in partnership with Vitaphone, provides elderly people with instant 
access to the Vitaphone Service Centre (24-hour support by doctors and health care specialists), 
enabling health care specialists to make decisions quickly in an emergency. Vodafone is also a 
partner of Saludnova (see above) for the provision of telemonitoring services in the Basque Country.  
Viterion is a German SME owned by Bayer Health care (see above). They work as a system 
integrator, combining and consolidating different types of patient data and managing it over 
communications networks. Their products offer features such as patient specific alerts, 
communication between health care providers, a library of disease management protocols, 
streamlined clinician workflow and management of patient data, managing access to patient data 
(e.g. according to its confidentiality), and the ability to integrate with other hospital information 
systems. 
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8 Annex III: Summary of Country Reports 
8.1 Study design and reliability 
The SIMPHS activity, in fulfilling its objective to get field data, planned to carry out country studies. 
VTT Technical Research Centre of Finland was subcontracted by IPTS to help build a picture of the 
RMT/PHS market and provide an analysis of the roles and strategies of the market stakeholders in 
France, Germany, Sweden and United Kingdom, by interviewing key stakeholders and experts from 
the field in these four EU countries. Furthermore, IPTS elaborated two additional country studies for 
the Netherlands and Italy. 
Stakeholder interviews were used as the means to gather both qualitative and quantitative data from 
various key stakeholders in each respective country, so as to fill the “knowledge gap” that currently 
exists, since there is little public data about the RMT/PHS market in most European countries. Filling 
the gap is the first step in determining: (i) how innovation in RMT/PHS emerges and impacts market 
growth; (ii) whether innovation and changes take place top-down through health care systems and 
GPs, bottom-up through industry players or through health care policy at national, regional or local 
level. Different stakeholders’ interests were covered such as policy makers, payers, health service 
providers, users, large-scale procurement, technology and IT service providers.  
A total of 68 interviews were conducted in the six countries (7 in France, 10 in Germany, 13 in Italy, 
18 in the Netherlands, 7 in Sweden and 13 in the UK). The number of persons interviewed per 
country could have been larger and was only limited by the strict timeframe and available resources. 
Stakeholder's willingness to participate in the survey and provide expert information varied by 
country; participants willing to provide evidence were found rather easily in Germany and the UK, 
while it turned out a bit more challenging to awake the stakeholders' interest in France and Sweden, 
for instance. Interviews were conducted both face-to-face and by telephone and were structured 
using sub-sets of the questions presented in § 8.6. Before the interview, additional material and the 
questionnaire were sent to each interviewee to enable preparation for the interview. The list of the 
interviewed experts can be found in § 8.7. Most of the experts and stakeholders interviewed were 
working in the RMT/PHS domain; on the one hand this meant that they were well versed into this 
domain, however on the other hand, it meant that there could be some bias in their responses. To 
balance this we also interviewed stakeholders that were not directly involved in the domain. 
The data collected via interviews was complemented with data from other sources to build the most 
comprehensive picture of the RMT/PHS market as possible in each respective country. The study 
results were presented and validated at the SIMPHS Validation Workshop in Brussels on 17-18 
November 2009. A full report presenting a detailed country report for each of France, Germany, 
Italy, the Netherlands, Sweden and the UK is provided separately.221 Each country report gives an 
account of the overall health care system, its funding, the policy context in which it is set, the 
management of chronic conditions and the RMT/PHS market situation. Each report also includes a 
discussion chapter addressing issues like RMT in a social care context and patient empowerment, 
and includes a concluding section summarising the main findings of the respective country study. 
In the following sections we discuss the key findings of the country studies and compare the state of 
development in the six countries. But before going into this we first introduce two concepts as a 
frame of reference that will allow us to assess the position of the countries and the RMT market. 
                                            
221  http://is.jrc.ec.europa.eu/pages/TFS/documents/VTTcountryreps 
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8.2 Chronic Care Model and disruptive innovation 
The widely accepted "golden standard" in disease management is the Chronic Care Model (CCM) 
developed by Wagner and colleagues.222 It comprises six interacting components (see Figure 27 – 
Overview of the Chronic Care Model) that are needed to provide high-quality care for chronic health 
problems:  
(1) the community with the resources and policies,  
(2) the health care system, which is organized to enable the interaction of its four components:  
a) self-management support,  
b) delivery system design,  
c) decision support, and  
d) clinical information systems. 
Figure 27 – Overview of the Chronic Care Model 
 
Source: Developed by the MacColl Institute – ACP-ASIM Journals and Books (see footnote 134) 
The core idea of the CCM is the facilitation of the interaction between the informed and activated 
patient and the prepared care team. Patients have the motivation, information, skills, and confidence 
necessary to effectively make decisions about their health and manage it. Similarly, the care team has 
the patient information, decision support, and resources necessary to deliver high quality care. In the 
CC Model the patient is no longer an object that is being cared for but an active participant of the 
care process, a co-producer of care. Another term that is often used to illustrate the role of the patient 
is patient empowerment.  
The role of the clinical information systems is to: 
• Provide reminders for providers and patients.  
• Identify relevant patient subpopulations for proactive care. 
                                            
222  Chronic care model: http://www.improvingchroniccare.org/  
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• Facilitate individual patient care planning. 
• Share information with providers and patients. 
• Monitor performance of team and system. 
Note that the CCM although it emphasises the interactions between patients and care teams does not 
include any remote monitoring technologies as such. RMT is a recent add-on to the model and the 
value added by RMT has yet to be demonstrated in clinical trials.  
Although the model has been shown to provide improved health (functional and clinical) outcomes 
its implementation in clinical routine has been difficult. The main barrier for successful disease 
management programs is the current reimbursement incentive framework and integration of 
independent providers when providing care. Most health care systems are organized in a way that do 
not reward practitioners, care teams and providers if they manage the health of their patients better 
and thus reduce the workload and/or visits to care facilities. A well-documented example of 
successful disease management systems comes from the USA, where Kaiser Permanente and the 
Veterans Health Administration have provided incentives for disease management by rewarding 
health outcomes, not number of transactions (fee for service) or capitation. In this case, another key 
enabler is that both are integrated providers not a group of interacting but separate providers. 
The difficulties in implementing disease management programs are just one example of the problems 
of current health care systems. National health care systems have developed in a piecewise fashion 
over tens of years. Although enormous progress has been made in medical knowledge and medical 
technologies, health care systems are still based on the same, original principles. Michael Porter from 
Harvard Business School when speaking on a report done on the Finnish health care system223 
summarized his view of the current state of national health care systems with the following sentence: 
“Today, 21st century medical technology is delivered with 19th century organization structures, 
management practices, and pricing models”. Clayton Christensen (also from Harvard Business 
School) has elaborated the above statement and proposes to reorganize health care based on four 
service models:224  
• Coherent solution shops (to sort out disorders that are still in the realm of intuitive medicine);  
• Retail clinics (to care for our everyday rules-based disorders); 
• Value adding process clinics (to process needs after a definitive diagnosis has been made);  
• Facilitated user networks (to help patients service their behaviour-dependent chronic ailments). 
Each service model needs to have its own set of incentives in order for the business models to work 
and produce the desired outcomes. Christensen’s argument in putting forward this proposal is that the 
current health care systems need to be disrupted in ways similar to what we have come to witness in 
most other industry and business domains. The problem of the current health care systems is that the 
four service models co-exist as an entangled mesh. They need to be separated and for each an 
incentive scheme has to be set up that rewards "correct behaviour". In the case of the CCM the two 
last mentioned service models need to be implemented: facilitated user networks as the treatment in 
most chronic diseases is to change the patient’s behaviour and value adding process clinics for the 
care teams to interact with the patients. 
                                            
223  Juha Teperi, Michael E. Porter, Lauri Vuorenkoski and Jennifer F. Baron. The Finnish Health Care System: A Value-Based 
Perspective, 2009 (PDF: http://www.sitra.fi). 
224  Clayton Christensen et al. The Innovator’s Prescription – A disruptive solution for health care. McGrawHill, 2008. 
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8.3 National frameworks for RMT 
8.3.1 Health reforms are the norm – not the exception 
The health care systems in the six countries are complex. All provide health services to all citizens. 
But underneath, there are a myriad of policies, agencies and interacting incentives and disincentives 
that make it nearly impossible to understand how the system actually works225 (see Christensen’s 
argument on the need to disrupt the Health care systems, on page 135). In the country reports we 
provided an overview of the respective systems; however, the overviews are "biased" towards RMT 
systems within the health care environment.  
Coinciding with OECD and WHO report findings, the 6-country study results identify that EU health 
care systems are fighting several concurrent and interdependent challenges such as: cost 
containment, innovation in medicine, life sciences and technology and demographic change due to 
ageing populations. Consequently, continuous health reforms have become common place in almost 
all EU countries. As such, RMT/PHS is competing for the attention of policymakers and other key 
stakeholders in this environment. It should not come as a surprise that RMT is not accepted as a 
central means to tackle the challenges that health care systems are facing; as one of the interviewed 
experts put it “there is no urgency for RMT”. 
8.3.2 Reimbursing health outcomes – incentives for integrated care 
To make a justified case for RMT/PHS one would need to convince policymakers that what is 
needed is policy that sets incentives for providers to offer integrated services in chronic care and that 
rewards providers for the improved health outcomes. With that in place, we would only need to 
demonstrate that the deployment of RMT in CCM does indeed improve health outcomes.  
With current lifestyles projected to further increase the incidence of certain chronic diseases, such as 
cardiovascular diseases, diabetes and certain cancers, the need for the deployment of the CCM is 
more than clear, as it has been estimated that up to 70% of health care expenditure derives directly 
and indirectly from chronic diseases. All six countries have recognised this challenge and have 
designed policies that address the management of chronic diseases. However, while the approach is 
according to the golden CCM standard, most countries are not making it attractive for providers and 
general practitioners to work for improved functional and clinical outcomes.  
More explicitly, the health care systems of the countries we studied do not reward services that keep 
patients away from doctors' offices or hospitals; instead providers are reimbursed based on fee for 
service and/or capitation.226 Neither mechanism encourages providers to keep patients away from 
hospitals or outpatient clinics. Moreover, in most systems there are no incentives that reward 
providers and GPs for improved functional and clinical outcomes when treating patients with chronic 
diseases. As a result, DM programs, which are facilitated by RMT and offered by service providers 
(ICT, triage centre and health care), have to: (a) be adjusted to reward improved outcomes in general; 
and (b) find a formula that enables the sharing of rewards among providers in a way that also 
encourages all value chain members to strive for better performance i.e. functional and clinical 
outcomes. 
                                            
225  More information and detail on how the EU health care systems are organized, health reforms implemented and topical themes, 
such as chronic care management are reported by OECD www.oecd.org and WHO Observatory 
http://www.euro.who.int/observatory.  
226  In Germany physician practices get a (small) bonus for deployment of the DM programs but this not connected to health outcomes. 
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The important thing to notice is that it is not enough to reward providers for results; what is also 
needed is that the patients are provided with truly integrated care. Otherwise providers can shift 
work and cost between themselves at the cost of the patients. In other words, the focus of the service 
provision should be on the patient and not the disease and health outcomes should be appropriately 
measured on this. The findings of the 6-country study demonstrate that incentives for integrated care 
outcomes are not yet in place. 
With DM programs based on best practice and appropriate incentives in place, the next step is to 
determine the best way to deploy RMT in disease management. RMT services could add value to 
DM programs by providing a better connection between the patients and care providers. Returning to 
the urgency comment referred to above the challenge is "to connect the dots between DM programs 
and RMT". In other words, provide evidence that RMT adds value to disease management and set up 
incentive systems that reward health outcomes over capitation and fee-for-service. One clear finding 
in the 6-country study is that the relevant stakeholders have not yet made this connection. 
8.3.3 RMT/PHS market – Innovation dynamics 
The RMT market is still in a formation stage; evidenced by the RMT activities (projects) that are 
currently ongoing in the six countries. The countries differ quite a lot in this respect. France seems to 
be most behind, as we couldn’t identify any push for RMT. In Germany DM programs have been 
recognized and physician practices are encouraged to apply a CM model. The role of RMT in this, 
however, is not widely recognized. The same more or less applies to Sweden, that is DM 
programmes are considered important but RMT is not part of the recognized solution. In Italy, 
eHealth, as health care in general, is regionalised, and as a result RMT deployment is emerging only 
in the richest regions (Lombardia, Emilia-Romagna, Toscana, Veneto and Piemonte). In the 
Netherlands, where important reforms encourage market developments in health care, RMT still 
remains a niche market. Of the six countries the UK is the only one where there are large-scale 
Randomized Clinical Trial (RCT) pilots in Telehealth and advanced Telecare (i.e. in RMT). In the 
other countries there are many local projects but their level of ambition is much lower than for those 
in the UK. 
Although the 6-country study did not supply us with any hard market data, the market projections 
(done by consultancy companies and others) which were collected seem to be based on statistics on 
disease prevalence provided among others by OECD Health Data. As an example, in the UK report 
the number of people with Long Term Conditions (LTCs) and the percentages that could benefit 
from RMT services are estimated. The former is derived from the relatively recently introduced 
Quality of Outcomes Framework (QOF) as part of the remuneration system for GPs in the UK but 
the latter are subjective estimates reflecting a wide range of awareness across the medical 
community. The low reliability of market data is a barrier to 'connecting the dots' which has serious 
negative implications for the sustainability of market mechanisms. 
The problem of embedding the technology into a service that will improve health outcomes is central 
to the creation of sustainable business models in this area. Even then, the organisational changes 
needed to deliver ICT support for DM programs are practically not defined. Firstly, any such changes 
should only positively impact the patient/doctor relationship (i.e. by improving and facilitating it). 
Secondly, the cost of the initial investment in setting up an RMT service, which will deliver and 
install the RMT system at the patient’s location (home a/o mobile patient), as well as the required 
further investment for the education and training in using the system require logistics support that 
needs to be built-in into RMT systems. Also, a help-desk would be needed to troubleshoot usage 
problems both trivial and complex. All this means that an RMT service needs a lot of users (patients 
and health care providers) in order to deliver services at an affordable cost. The suggestion made by 
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several interviewees was that a virtual Care Management Centre be set-up, one which runs 24/7 and 
provides clinical triage and the basic logistical services. The question that arises from this is whether 
the centre should be in-house (with respect to the RMT service provider) or provided externally; and 
the question thereafter is whether the services could be provided by extending the existing Call 
(Contact) Centres that are quite common place today even in health care. 
Moreover, governance of any RMT solution proposed is not clear. For example, clinicians may not 
easily accept (as initial evidence seems to indicate) that an intermediary (Contact Centre/Care 
Manager) runs the regular service and only exceptional cases (patients whose clinical condition is not 
within the preset boundaries) are brought to their attention. Secondly, and more importantly, 
clinicians are less likely to trust vital signs monitoring and reporting done by the patients on their 
own. For example, blood pressure readings are highly dependent on whether the patient is standing 
or sitting, or has been exercising etc. Similarly blood glucose readings are quite different before and 
after meals. It is highly important that patients are trained and understand how and when the vital 
signs measurements are to be taken. Another concern that was expressed is that patients may 
knowingly feed erroneous readings of their vital signs.  
Within the countries studied, innovation seems to be applied on different levels. For instance, 
through participation in EU or national or regional programmes, projects and initiatives as well as 
through company related innovation activities. The problem, though, is that (the UK being the 
exception) there does not seem to be an overall vision of what RMT could offer. Indeed, some 
experts pointed out the need to develop a longer term vision of how health care services should be 
organised and reimbursed to take advantage of what modern medicine can do and how ICT can 
enable this. Their point was that it is not enough to push RMT/PHS or eHealth but rather push for a 
systemic change across the health system227 as it has happened in other business domains where ICT 
has disrupted existing business models and created new opportunities.  
The traditional route for larger diffusion of new technologies in health care has been for the industry 
to engage medical opinion leaders as first users and through them convince and gradually provide 
evidence that the new technology can be used to provide improved services to patients. In the case of 
RMT (and any ICT system in health care for that matter) the problem is that there are few opinion 
leaders to be found in the medical profession. The purpose of the technology is to facilitate 
interaction across the whole care team that includes the patient as a co-producer. In spite of the 
difficulty in identifying a business owner on the health care side technology industry should work to 
engage relevant stakeholders in order to produce success stories that ultimately will lead to diffusion. 
The basic rule in medicine is that you need to show that it works. The large-scale demonstrators in 
UK and elsewhere are in that respect highly important for the development of the RMT/PHS market. 
8.3.4 Embedding RMT into care processes – integrating patient data 
The 6-country study has revealed a somewhat lukewarm demand for RMT/PHS services although 
there was overall consensus on its potential. In essence, this evidence sheds light on why a mix of 
market (creation of new markets), organisational (creation of new ways of doing the same job), and 
institutional innovations (creation of new norms, rules, habits) is required, beyond the already 
available product (new goods, medicines and devices, new services) and process innovation (new 
ways of using products), if the transition (or disruption) of health care to a system with a stronger 
emphasis on DM, long-term care, home care and prevention is to materialise. It is also for this reason 
that extensive experiments and pilots are required before RMT can be embedded in the day-to-day 
                                            
227  The ideas put forward by Michael Porter, Clayton Christensen and Regina Hertzlinger (all from Harvard Business School) are 
good examples of how current health care systems should be disrupted. 
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structure of health and social care organisation and practice. Experiments and pilots, testing new 
ways of delivering health care, play a vital role in this.  
The countries studied each have an ongoing infrastructure development programme that seeks to 
provide an integrated electronic medical record (EMR) that care providers and citizens (patients and 
family, informal carers) can access and use. The implementation of the national EMR programs, 
however, has turned out to be more challenging than originally anticipated. Sweden and the UK are 
implementing a nation-wide care summary record system. In Spain a similar system is being 
implemented in a strongly regionalised institutional environment. In Germany the EMR program 
seems to be delayed because of privacy/security concerns. In France a program was underway but 
was stopped and is being refocused. In Italy, electronic Health Records (EHR) is one of the four 
priorities of an ambitious eGov 2012 Action Plan, but progress toward its implementation has been 
slow. Many proof-of-concepts are running in the Netherlands in relation to the large-scale 
implementation of at least parts of a national EHR, but they have also been affected by many delays. 
Several interviewees considered that the delays in these EMR programs form one barrier for RMT 
diffusion, as an integrated EMR/EHR is a necessary prerequisite for RMT services.  
Patient acceptance of RMT is however, essential. Acceptance relies on whether patients will be 
willing and able to use RMT to their benefit (there is emerging positive evidence from UK pilots). 
Patients are expected to take vital signs measurements with the devices and transmit the results to the 
clinicians. Some parts of this can be automated but not all (at least not today).228 Yet another, 
essential part of the trust chain is the privacy of personal health data exchanged during RMT 
processes. It is of high importance that industry takes a proactive role in this issue and respects the 
relevant legislation and rules concerning the privacy of confidential personal health data in 
implementing RMT/PHS systems. 
The interviews revealed also that the readiness to re-evaluate the role of the patient and to shift 
towards the co-producer approach is not yet there. Service providers are more comfortable in their 
current roles of managing patients that comply with their instructions. Overall, there are justified 
concerns about the co-producer model; in an ideal world, the patient is willing to take on the 
responsibility for his own care and has the tools and abilities to be an active member of his own care 
team. In a real world, care must be exercised to build and maintain trust across the whole value chain 
for the co-producer model to work. 
8.3.5 Creating awareness and evidence 
The 6-country study identified evidence that the relevant stakeholders (policy makers, industry, 
professional groups etc.) do not know what RMT/PHS is or what it can enable. Also as already 
revealed "there is also no feeling of urgency" to deploy RMT in health care (see sub-section 8.3.1) 
since other more important challenges get the attention of stakeholders. Whether these are more 
important or whether RMT really is the technology, that when deployed appropriately 
(disruptively!), can bring savings while at the same time improve health outcomes, is an issue that 
the RMT stakeholders themselves need to address. They need to showcase: (a) scientific proof of the 
improved outcomes of the application of the technology; (b) the added value of the technology 
towards all stakeholder groups; (c) the likely benefits of the application of the new vision of health 
care to society as a whole; and (d) the contribution to jobs and growth for the EU. Most of all they 
need to bring the evidence closer to the patient so that 'demand pull' can be in effect exercised. 
                                            
228  Remote monitoring of intelligent implanted cardiac pacemakers is an example of RMT that exists today and is found to be useful. 
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Although RMT pilots are being carried out only a few of them are done at a level where scientific 
proof can be obtained and reported. Major improvements in clinical status and decrease in use of 
hospital and outpatient clinic services, have been reported in pilot deliverables published. The 
problem though is that turning these into cost savings would require re-organisation in health care 
services in the style suggested by Christensen’s value-added process clinics and user facilitated 
networks. This means that in addition to working towards producing evidence of benefits, effort is 
needed in educating decision makers and other key stakeholders (including patients). In conclusion, 
there is ongoing some degree of awareness but as stated above this does not translate into action. 
The full country report lists the activities that were identified during the study. There must be many 
more that did not come up in the interviews or from the material collected for the study. The problem 
with most of these is that their ambition level reaches only to a “proof-of-concept” level. 
Implementing many small proof-of-concept projects is counterproductive. It spreads limited 
resources into small projects that will not produce hard evidence that can move the market forward. 
Proof-of-concept projects are also the result of the fact that public funding agencies seem to be 
overly focused on technology and rely on the fact that market mechanisms will carry good ideas 
forward. Again UK stands out as a good example of what the other countries should follow, i.e. fund 
large-scale pilots that can produce hard evidence. In general, for EU health care systems, the 
requirement that RMT satisfies is implicit or latent. Working with large-scale pilots and publishing 
scientific evidence is necessary to create and justify this need.  
8.3.6 Standards, innovation cycles and need for integration 
Although several interviewees were aware of international standards development organizations 
(SDOs) for technical and semantic interoperability of RMT systems, it was a bit surprising to note 
that this was not more common. This finding is aggravated by the fact that most of the persons that 
were interviewed were experts and stakeholders in this domain and therefore one would have 
expected that almost all would know of for instance, the Continua Health Alliance and Integrating 
the Health care Enterprise initiatives.229 This finding is indicative of the need of sharing information. 
The 6-country study shows that the RMT/PHS market is still being defined. The first generation of 
RMT products and services are being tested and piloted to gather evidence of value. One could 
compare this with the situation with the first CT and MRI scanners and minimally invasive surgery 
in the early 80’s. It took several innovation cycles with intensive interplay between the technology 
developers and the users (clinicians and surgeons) to transform (disrupt) medical imaging and 
surgery into what they are today. We need to get the cycle of innovation into motion also for RMT. 
In the above examples the key innovators were industry and medical opinion leaders. In the case of 
RMT a much larger network of innovators is required as argued by Christensen. 
One possible route to speed up these cycles is if the needs of the elderly both in terms of staying 
independent and coping with their environment (Ambient Assisted Living, Advanced TeleCare in 
UK terminology) and RMT/PHS (TeleHealth in UK terminology) can be served through one 
integrated channel. Integration of the service channels makes sense not only from the patient 
perspective but also from the service perspective. The interviews showed that there is awareness of 
the integration need in the four countries. In reality, though, wheels are turning slowly. 
 
                                            
229  www.continuaalliance.org and www.ihe.net  
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8.4 Summary of country findings 
8.4.1 French RMT market summary 
Table 16 – France country study, main findings 
• No RMT market to date. There is a growing interest and awareness about market possibilities, 
but development has been slow. Market growth is anticipated to happen in the future, but prior 
estimates of growth rates have been recently toned down. A strong shift of interest from devices 
to services has also occurred. 
• In France market actors tend to partner, since they believe that value chains amongst various 
providers are the best way to attain results and awareness that no actor alone can achieve. 
• The availability of market data is very limited. Also, scattered data is difficult to find and 
analysing its reliability is often difficult. There is a strong need for better data, with data 
concerning evidence on RMT benefits and potential contacts interested in partnering, especially 
needed. Also information of reimbursement possibilities and success stories of RMT are needed. 
• The RMT market barriers heavily outweigh current drivers. Main drivers include an ageing 
population, increasing prevalence of chronic conditions and the uneven distribution of medical 
professionals. The most important stakeholders driving change are policy makers, medical 
professionals and citizens themselves. Also, interviewees expressed the need for both bottom-up 
and top-down diffusion of RMT. 
• There was some information on a newly formed agency called CNR, which according to initial 
limited information may have great potential in driving the market forward.  
• On a general level it seems RMT is hard to implement into current health care structures. Many 
potential market barriers were identified such as on organizational, cultural, social and financial 
aspects. Technology is not seen as a barrier although certain technological advances could 
facilitate market growth (interoperability & EPR). Main barriers included lack of education, lack 
of reimbursement possibilities and lack of aligned incentives. Also the role of medical doctors 
was seen as problematic due to possible fear of loss of power if RMT is implemented. 
• The potential for RMT in a social care setting is clearly recognised but organizational boundaries 
are major barriers for implementation. There is a need for inter-organizational co-operation and 
continuum of care.  
• Patient empowerment seen as very important, but actual empowerment is still rare. Patients 
generally are more interested in health information, but this has not realized into demand for 
RMT services. Education about RMT is needed. 
 
Conclusions 
The main finding from the French RMT market could be summarized as: there currently is no RMT 
market. Although RMT is receiving more and more attention, projects in general do not seem to pass 
the project phase and pilots remain as pilots due to a number of barriers that hinder growth. For 
sustainable business opportunities to arise, the following major barriers would have to be overcome: 
lack of reimbursement possibilities and incentives to adopt RMT. Although estimates concerning 
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RMT growth in the number of years it would take until market reaches a more mature phase were 
mostly missing, all French stakeholders felt that the market would grow in the future.  
Generally speaking RMT does not seem to fit the current health care system in France. As a 
consequence, market growth has not materialised and current barriers remain unresolved. Until the 
"rules of the market" are set stakeholders will find it hard to deploy RMT and find their place in the 
new value chains RMT services would enable. 
8.4.2 German RMT market summary 
Table 17 – Germany country study, main findings 
• No real market has yet materialized and supply-side success stories are very rare. Since action 
remains mostly project-based pilot studies, the critical mass to make things happen is still 
missing. Partnering has become more common among actors, but market consolidation is still 
strongly needed. 
• The estimates about when the RMT market will be mature were usually in the range of 2 to 3 
years, but interviewees said it could take up to 10 years before the market became mature. 
• Availability of market data is currently low. Data is also extremely scattered with quantitative 
data almost unavailable and its reliability questionable. There is a clear need for more data 
concerning many areas of RMT that the SIMPHS could facilitate. Success stories and evidence-
based proof of concepts were most needed; however, turning data into action should be the focus. 
• Main market drivers include an ageing population, increase in chronic diseases, and increase of 
rural areas with scarce services. Technology is not a market driver – it could offer possibilities, 
but it is not being adopted.  
• Current barriers heavily outweigh market drivers as on a policy maker level RMT does not need 
to happen now; in other words there is no long term strategy on RMT on a political level and the 
market is "on hold" until the German elections with stakeholders waiting to see where the next 
round of possible reform points. The whole concept of RMT and how it should be integrated in 
current health care structures is fuzzy which has led to unresolved roles and responsibilities 
amongst key stakeholders. Finally, the innovation process, from innovation to reimbursement and 
market, concerning RMT is unclear. 
• Other main barriers include lack of leadership, lack of industry consolidation, RMT services that 
do not fit the current health care structure, lack of reimbursement possibilities, organizational 
boundaries that make implementing services difficult, a physician culture that is not used to RMT 
services (loss of power), lack of patient interest due to lack of knowledge about RMT.  
Conclusions 
Talking about an RMT market in Germany seems to be optimistic at the moment. Although progress 
is happening in the form of pilot projects and partnering among interested stakeholders and actors, 
many of the key issues hindering growth are still unresolved. Although some actors have managed to 
create business through their RMT services, the scale of business is still very small. There is a 
general interest towards RMT and even acceptance that it could be a possible solution for creating a 
sustainable health care system in the long term in light of acknowledged pressures the current system 
is facing. However, action and leadership are currently missing. The whole field of RMT is fuzzy, 
and the perceptions of various stakeholders on the roles and responsibilities of others are unclear. 
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The rules of the market seem to be missing with no clarity in who is responsible in making them. 
Also the urge to tackle RMT is not as acute as many other problems currently on the table.  
The ongoing reforms of the German health care system have not targeted RMT issues. Neither have 
these reforms changed the structure of the system drastically which is difficult to do in practice. The 
key question is whether widely adopted RMT services can be moulded to fit the current structure of 
the German health care system in a manner that enables wide scale adoption of RMT services or will 
the system itself have to change. If it is down to the latter, it is still unclear who will take the first 
step in making this happen and how long this change would take. Stakeholder views were mainly 
quite optimistic, believing the market would be ready in 2 to 3 years. With the German national 
election round the corner key stakeholders are eagerly waiting to see what comes next with regard to 
RMT. Although RMT has not as of yet found its place in the German health care system, Germany’s 
DM programs can prove to be a potential platform where RMT solutions could be implemented if 
suitable business models are found to justify the initial up-front investment cost and adequate 
incentives between physicians and health insurance funds are met. 
8.4.3 Italian RMT market summary 
Table 18 – Italy country study, main findings 
• In Italy, the RMT market does not exist and RMT is not an integrated part of care pathways. But, 
there are successful cases of RMT deployment (Lombardy/Veneto), albeit with a slow uptake. 
• The RMT market in Italy is characterised by: (a) a few large companies, a minority of which has 
RMT as their core business, most making revenues from other eHealth services or services like 
tele-surveillance or telecare; (b) a few medium sized companies structurally positioned to take 
advantage of RMT market; (c) many small localised and opportunistic companies whose lifespan 
is short; (d) a handful of insurance companies providing RMT as part of added value services.  
• Strong regional disparities with some of the richest regions providing RMT activities, with a push 
from regional authorities and public procurement initiatives, but little to no RMT activities in 
significant parts of the country.  
• RMT solutions offered today are very simple (e.g. static measurements) and require significant 
involvement of health care professionals since more complex RMT solutions may be met with 
resistance by users and may be too costly. 
• Main barriers to RMT deployment include: (a) lack of a favourable incentive framework which 
means that until RMT is included for reimbursement at national level no take up of the market 
can be expected; (b) lack of awareness, culture and capacity to introduce a "Structured Tele-
medicine" approach which may only be achieved through major institutional and organisational 
restructuring; (c) closed regional systems with some regions like Lombardia, Toscana, and 
Emilia-Romagna having invested into their own broadband network to inter-connect health care 
units and players, making it difficult for new players to get into the market; (d) lack of evidence 
on and of awareness of potential benefits of RMT; and (e) resistance of practitioners (both GPs 
and specialists) and hospitals, mainly for financial reasons. 
Conclusions 
The RMT market in Italy remains a niche market, with some examples of successful undertakings 
albeit limited in scale. The lack of political push and of a specific strategy for RMT combined with 
the strong regional differences in terms of health care organisation and financing make it a difficult 
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market for industry players. Most of them try to be present in the market, drawing revenues from 
other eHealth activities, to be in good position should RMT take up in the future; however, in the 
past few years, even those have had to revise their business plans and scale down their expectations, 
and have diversified their activities to be able to survive. 
One of the main barriers to RMT uptake is the lack of a clear incentive framework that would 
encourage the implementation of RMT services. Instead, GPs, specialists and hospitals alike resist 
the introduction of RMT that undermines their existing revenues streams. The lack of awareness 
about what RMT offers and the perceived lack of evidence on its benefits also play against market 
uptake. The fragmentation of the health care organisation combined with the funding mechanisms 
organised at regional level contributes to the fragmentation of the RMT market itself. There is a trend 
towards moving the competence for eHealth away from the Regional Innovation Department into the 
Health Department but only few regions are sufficiently active in the eHealth domain to give RMT 
market players confidence in future growth. 
In other words in spite of a number of successful projects and large scale pilots, particularly at 
regional level, and despite the emergence of successful Italian companies on the local /regional RMT 
markets, the prospects for growth do not lead to much optimism as the current health and social care 
framework is not adapted to the specificities of RMT. 
8.4.4 Dutch RMT market summary 
Table 19 – Netherlands country study, main findings 
• There is evidence of some 'viable-business-model' market developments in the Netherlands with 
RMT services embedded in home care or offered as stand alone, either reimbursed by insurance 
schemes or paid out of pocket. However, there are a limited number of companies active in the 
RMT field, which is still a niche market. 
• There are several experiments and pilots on new ways of delivering health and social care funded 
via EU, national and regional programmes and projects, as well as by industry actors (e.g. on 
remote care, long term care, home care, independent living etc.). 
• Patient empowerment, although still in its infancy, is increasingly seen as one of the main drivers 
of innovation in the health care system.  
• There is scarce availability of both qualitative and quantitative data about the RMT market. Most 
actors have no comprehensive view of the RMT field, and in addition, there is limited exchange 
of information among actors.  
• Main market drivers include an increasing elderly population, the forecasted lack of health care 
professionals, and the need for new models for care of chronic diseases in the future. 
• In spite of profound reforms calling for new models of care, the role of RMT is still limited 
although it is believed to have the potential to help in the transformation process. 
• Main barriers are those of financial nature: lack of incentives for GPs (paid per visit and not per 
outcome), difficulties with budget reallocation between primary and secondary care, as well as 
between health and social care. 
• There is increasing awareness on a political level of likely benefits of RMT deployment, but 
there is no short term strategy for RMT. The increasing importance of regions in the health care 
organisation may help push RMT services introduction. 
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Conclusions 
The market for RMT services is still limited in the Netherlands which appears to be a young, niche 
market with only few active players. However ongoing reforms and power given to insurers and to 
the regions could become important drivers for RMT diffusion. Different approaches adopted to date 
include the cooperation between health and social care organisations in projects and pilots, the stand-
alone services offered as a market product and the embedding of RMT services in existing insurance 
packages. The next generation of projects (Koala, CommonWell, Health Buddy) with a larger 
number of patients involved (up to a few hundred per project) is underway. This could lead to the 
elaboration of the evidence needed to prove the added value of RMT services. Evidence on benefits 
is so far scattered but points in the direction of patient satisfaction, enhanced self-management by 
patients, enhanced autonomy and independent living as well as beneficial impact on hospital re-
admissions and bed days of care (BDOCs). Coordination and co-operation at national level to help 
combine the efforts undertaken in the various projects could mean a quantum leap in terms of 
producing evidence which is statistically significant. Meanwhile, the market will continue to grow by 
absorbing further RMT solutions but growth will be sub-optimal in view of the absence of clearly 
defined and shared evidence. Since the new projects have an international component results may 
also be used for international comparison. 
Finally, the patient is often mentioned as the single actor who can promote the diffusion of RMT, by 
demanding access to RMT services. In reality patients or patient organisations are not sufficiently 
organised in that field but working on their mobilisation would help foster dissemination of RMT 
systems. Raising patient awareness by organising national campaigns might be one option; media 
attention for RMT systems another.  
8.4.5 Swedish RMT market summary 
Table 20 – Sweden country study, main findings 
• The Swedish RMT market does not exist, and successful business cases are very rare. There is 
growing activity, mostly project-based pilot studies with an increasing trend for partnering 
among stakeholders but with insufficient critical mass despite the very advanced IT infrastructure 
in Sweden. The market is seen as possessing all the potential to grow during the next 2-5 years. 
• There is increasing awareness towards the need for new services to support health and social care 
and collaboration among different organizations. Integration of RMT into the health care system 
seen as possible and desirable. 
• Patient empowerment is increasingly happening and is the focus of the national health strategy. 
• Market data are extremely scattered, and qualitative and quantitative data are scarce. There is a 
need for more data concerning successful examples and evidence-based proof of concepts.  
• Main market drivers include increasing elderly population and need for new models for care of 
chronic diseases in the future. 
• There are currently more barriers than drivers for market development: (a) lack of funding and 
changes in the current reimbursement mechanisms; (b) lack of leadership; (c) lack of information 
and knowledge about RMT; (d) users and patients are not aware of the possibilities of RMT. 
• While eHealth in general, is seen as one of the lead markets for Sweden, and there is increasing 
awareness on a political level of the importance of RMT, there is no specific strategy yet. 
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Conclusions 
There seems to be widespread interest among different stakeholders in the development of RMT. 
However, action requires clear leadership, which is still missing among stakeholders.  As a result, 
developments are embryonic and a lot still needs to be done to enable market growth in spite of the 
common vision of and belief in the potential the RMT market holds. Establishment of the market 
also requires government action to involve county councils and municipalities in its development; the 
government, as the guiding actor, would need to set up common rules and regulations while the 
implementation itself will be the responsibility of the county councils and municipalities. The roles 
in general are still not defined between different stakeholders. There is also need to change the 
current reimbursement mechanisms, which are likely to not give further incentives to the 
development of new RMT applications. Progress is currently happening in the form of increasing 
discussions, pilot studies and projects but also in partnering among interested stakeholders and actors 
in the field. However, several key issues remain unsolved. Although some companies have managed 
to stay in the market and create business for their RMT services, success stories are rare. 
8.4.6 The UK RMT Market 
Table 21 - United Kingdom country study, main findings 
• The market is currently very small (well below 5% penetration) and still being defined.  
• There is growth potential during the next 5 years in the market. 
• This growth is dependent on positive outcomes from current major trials, pilots and demonstrator 
projects and from the clinical acceptance of RMT and related services for a wider range of ‘long 
term conditions’. 
• Strong evidence of long-term ‘infrastructural’ actions to enable growth but some concerns 
regarding adequacy of future broadband local access networks. 
• An increasing focus on the convergence of health care and social care delivery with considerable 
attention being given to underlying process management and organisational models. 
• Further supplier development required in technical and clinical triage processes at RMT hubs. 
• Significant investment in health care informatics and vastly improved demand data flowing from 
the (Primary Care) Quality and Outcomes Framework. 
• Patient empowerment beyond service choice will benefit from imminent implementation of 
Summary Health care Records.  
• Market drivers include demographic trends, chronic care management costs, growth of life-style-
related conditions, citizen expectations (early adopters), strong policy leadership and a 
combination of economic and sustainability pressures.    
• Market barriers include a perceived lack of evidence-based investment rationale (clinical and 
economic), uncertainties around information governance, challenges for procurement processes 
and a generally low level of citizen/media awareness of the scale of required health care 
transformation. 
• Good and growing awareness across all Administrations within the UK in terms of policy 
development.  Legislation is planned to expand remote home-care services for the elderly. 
Conclusions 
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After more than three decades of debate, infrastructure evolution and cautious experimentation, the 
UK market for Personal Health Systems and Remote Monitoring & Treatment is still at a formative 
stage. There is, as yet, no commonly agreed or widely understood nomenclature to describe this 
emergent market and its segments.  The words Health, Medicine and Care are variably prefixed by, 
‘e’, ‘Tele’ and ‘digital’, and used together (e.g. TeleHealth care) or with other descriptors to 
differentiate between segments (e.g. social/community care), or, alternatively, to provide all-
embracing ‘umbrella’ descriptions such as ‘Connected Health’ and ‘Assistive Technologies’ – this 
latter term being preferred by informatics specialists at the UK Government’s Department of Health. 
There is an increasing recognition across the Primary Health care and the Social Care professional 
communities of a ‘continuum’ that stretches from reactive medical interventions to individual 
attention to wellbeing. This recognition reflects a realisation that many of the same, or similar, 
technology-based care delivery systems and techniques can be applied across disciplines that have, 
for most of the UK, been developed over the past 60 years under distinct budgetary and management 
regimes, each with their own culture and customer relationships.    
There is, within these professional communities, a growing realisation that current practice is 
unsustainable in the context of demographic trends and the exponential growth of life-style-induced 
Long-Term-Chronic (LTC) conditions. Professionals to be yet fully embedded in public 
consciousness to the same extent as, say, do, not believe this general realisation, and its direct 
implications for citizens and the UK economy, climate change.230 
The scale of the future challenge (and thus potential market for Assistive Technology solutions) is 
directly related to population size, age-demographic trends and the emergence of new and 
conveniently deployed technologies.231 Of the UK’s 61.4million citizens approximately 30% are 
known to have one or more ‘Long Term Conditions’ (>16 million in England alone) and this is 
expected to grow by a further 20% in the period to 2025.  The average age of the UK population (in 
2008) is now 40 – two years higher than a decade previously – with around 20% over age 65.  There 
are regional variations in age demographics with the Northern Ireland (population 1.77 million) 
having a higher than UK average proportion of older citizens.232 
Evidence to support the clinical and economic cases for investment remains limited but is expected 
to be clarified (in 2010 and 2011) by results from demonstrator projects in England and Wales, by 
the eHealth programme in Scotland and the major procurement exercise in Northern Ireland.   
The economic case for process changes and services innovation may expect to gain further support 
from a recognition of complimentary values – particularly in areas of environmental sustainability 
(‘green NHS’) and a ‘systems view’ that can embrace secondary and tertiary impacts such as anxiety 
reduction amongst carers.  The speed with which process changes and services innovation are 
accepted and taken forward by clinicians and other stakeholders (in what are large and sometimes 
cumbersome organisations) will reflect the success of engagement and knowledge transfer 
programmes. 
                                            
230  The recent report that more than half of all children born in the UK this year may survive beyond 100 years was treated by the 
media as ‘a good news story’ celebrating advances in medical practice.  There was correspondingly little comment that over the 
period 1950-2050 the ratio of those below age 65 to those above (the ‘potential support ratio’) will have fallen from 12:1 to 2:1.  
231  As an indicator of growth, the global market for wearable wireless body sensors for health (not sports/fitness) applications is 
predicted (ABI Research) to grow from near zero to 60 million units per annum by 2014.  
232  The relatively higher proportion of elderly citizens in Northern Ireland is attributed to past phases of emigration and lower recent 
rates of immigration. 
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8.5 Final conclusions 
PHS/RMT market 
• There is no market today. It is still being defined. The available market data are based on 
projections from statistics on prevalence of e.g. chronic diseases and ageing populations. 
• There have been and continue to be pilots of varying scale and ambition. Most of which are 
abandoned once the pilot project is over. The UK Whole System Demonstrators are the most 
ambitious ones and have faced a lot of problems getting started but are now ongoing. 
• There are small SMEs and large companies who understand the market potential but are still 
defining ways to develop the market. Consequently, a lot is still done under R&D and as pilots. 
Lack of incentives and viable business models  
• One major barrier holding RMT / PHS back is the current incentive framework that does not 
reward services that keep patients away from doctor’s offices or hospitals. What is needed is 
large-scale deployment of the Chronic Care Model and financial incentives that reward 
functional and clinical outcomes. 
• The other major barrier is lack of evidence of clinical benefits and cost savings. Although pilots 
are ongoing only a few are done at a level where evidence can be obtained and reported 
scientifically. Pilots that have published their evidence have reported major improvements in 
clinical status and decrease in use of hospital and outpatient clinical services. However, turning 
these into cost savings would require reorganization of health care services. 
• In order to facilitate deployment, a new service provider between the patient and the health care 
system that runs the service 24/7 and acts as an intermediary triage centre is proposed. In 
addition, a longer term vision of how health care services should be organized and reimbursed to 
take advantage of what modern medicine can do and what ICT can enable, ought to be 
developed. 
• Yet another barrier refers to knowledge of what PHS/RMT is and can enable. Education of 
stakeholders is an issue that needs to be addressed. There is awareness but it does not translate 
into action. There is no feeling of “urgency” to deploy RMT in health care. There are other more 
important challenges that get the attention of politicians and health policy makers. 
The way forward 
• Provide leadership and as the first priority develop a strategy that addresses the barriers to market 
development. A good starting point would be the “Manifesto for Connected Health” that was 
written by the 1st Leadership Summit of the European Connected Health Campus in May 2009 in 
Belfast.233 
• The European eHealth Action Plan should more clearly address the need for countries to develop 
a long-term vision of how health care should be organized in view of what we know today. The 
current health care environment needs to be disrupted in order for PHS/RMT to work 
                                            
233  Manifesto for Connected Health (www.echcampus.com). 
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• Create a clearing-house that collects evidence from PHS/RMT pilots and creates awareness of 
progress in the domain.  
In closing, the need for collaboration and engagement cannot be overemphasized. No company can 
succeed alone. They need to work close to the patients and health care providers. They need to 
cooperate with other players in the market, including the social and professional organizations, and 
users as well as intermediate users. They need to combine resources, competencies and create 
dynamic capabilities. 
8.6 Interview questionnaire 
Facts on PHS/RMT market: 
1. Main perspective of the stakeholder on the market of PHS/Remote monitoring, now and in 
the near future.  
2. Type of market data or business information the stakeholder is aware of and/or uses with the 
aim of supporting activities in the PHS market, and accessibility of such data.  
3. Type of qualitative data the stakeholder is aware of and/or uses with the aim of supporting 
activities in the PHS market and accessibility of such data.  
4. Type of activities, products and/or services deployed in the market on PHS/Remote Patient 
Monitoring.  
5. Role of the stakeholder in the health care delivery chain with regard to PHS/ Remote Patient 
Monitoring implementation.  
6. Established or planned partnerships among actors.  
Analysis of stakeholders' roles and strategies: 
7. Key factors for successful PHS implementation according to the stakeholder, including 
known examples of successful business approaches or business cases.  
8. Factors (demographics, economics, disease occurrence, technology etc.) influencing the 
stakeholder's PHS procurement/deployment decisions.  
9. Stakeholder's strategy in getting its activities running (business as usual, seizing new 
opportunities, allying with other businesses/public authorities, etc.).  
10. Business models behind the stakeholder's activities and funding models for PHS.  
11. Drivers (business, political, social) as perceived by the stakeholder as key for the realisation 
of a full-fledged PHS-market.  
12. Barriers perceived as impeding the realisation of a full-fledged PHS-market.  
Stakeholders' views and perceptions: 
13. Successful innovation models and perceived role of the various actors within these models 
(medical practitioners, public authorities, industry, patients, etc.). 
14. Kind of activities, initiatives, measures etc. seen as necessary to realise a full-fledged PHS-
market.  
15. Role the stakeholder thinks he/she should have in such activities, initiatives, measures etc.  
16. Lessons to be learned from the introduction of PHS in other markets (for instance the US-
market).  
17. Lessons to be learnt from other health markets (e.g. the pharmaceuticals market). 
18. Views on usefulness of the Strategic Intelligence Monitor and focus it should have.  
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8.7 Stakeholders interviewed 
Table 22 – List of stakeholders interviewed in the six countries 
FRANCE (7) 
Stakeholder segment Name Role/Organisation 
Policy makers Laurent 
Debenedetti 
International Relations Director, Agence pour les Systèmes d’ Information 
de santé Partagés (Agency for shared health Information systems) 
ASIP/GIP-DMP 
Payers Yves Masson CEO, AXA Assistance 
Health service providers Norbert Noury Professeur, University of Lyon, Institute of Nanotechnology, INSA Lyon 
Health service providers Michel Amiel President, Association pour la Télésanté en Région Rhône Alpes (ASTRHA) 
PHS/RMT integration 
aspects 
Alain Franco Professor, Université & CHU de Nice 
Technology and service 
providers/PHS/RMT 
integration aspects 
Charles Parisot & 
Berzsenyi Agnes 
General Manager Home Health & Manager, Interoperability Standards and 
Testing, GE Health care 
Technology and service 
providers 
Lyse Brillouet, Marketing director, Orange Health care / France Telecom 
GERMANY (10) 
Stakeholder segment Name Role/Organisation 
Policy makers Mathias Perleth i. A. PD Dr. med., The German Health Care System and the Federal Joint 
Committee, G-BA 
Policy makers Kirsten 
Steinhausen 
Federal Ministry of Education and Research (BMBF, Ref. 615) 
Payers Christoph Gries Geschäftsbereich Produktmanagement, Deutsche Angestellten-Krankenkasse 
(DAK ) 
PHS/RMT integration 
aspects 
Prof. Dr. Hans-
Jochen Brauns 
Chairperson, DGTelemed - Deutsche Gesellschaft für Telemedizin e. V. / 
alpheios 
PHS/RMT integration 
aspects 
Thomas Norgall Senior Engineer, Fraunhofer Institut fuer Integrierte Schaltungen - BMT 
Health service 
providers/ PHS/RMT 
integration aspects 
Prof. Otto 
Rienhoff 
Arzt, Med. Informatiker, The German University Medicine/ Verband der 
Universitätsklinika Deutschlands e.V. (VUD) 
Technology and service 
providers 
Stefan Schraps Managing Director, Founder, Bodytel GmbH 
Technology and service 
providers 
Stefan Jentsch Product manager, Weinmann GmbH 
Technology and service 
providers 
Florian Herrmann Medical Sales, StollmannEntwicklungs- und Vertriebs-GmbH 
Technology and service 
providers 
Michael Bruhnke Business Development Manager, Aipermon GmbH & Co. KG 
ITALY (13) 
Stakeholder segment Name Role/Organisation 
Policy makers Paola Tarquini Department for Digitalisation and Innovation, Italian Ministry of Public 
Administration, Head of eHealth Sector 
Policy makers Claudia di Minco Department of Health, Italian Ministry of Welfare, Head of SIS (Health 
Information Systems) 
Technology and service 
providers 
Marco Romani Project and Market Developer, TELBIOS SpA (Telemedicine company) 
Health service providers Professor Mariano 
Corso 
Milan Polytechnic University, Department of Management Engineer, Head 
of Observatory on ICT in the Health Sector 
Health service providers Gabriella Borghi Lombardia Regional Administration, Department of Health, Coordinator of 
Programme Nuove Reti Sanitarie (New Health Networks) 
Health service providers Professor Cristina 
Masella 
Milan Polytechnic University, Department of Management Engineer, Head 
of eHealth Sector 
Technology and service 
providers 
Prof Simonetta 
Scalvini (founder) 
Health Telematic Network (telemedicine company) 
Technology and service 
providers 
Prof Paolo 
Glisenti (founder) 
Health Telematic Network (telemedicine company) 
 151 
Technology and service 
providers 
Maurizio Nardi 
(CFO) 
Health Telematic Network (telemedicine company) 
Policy makers Giancarlo Ruscitti Secretary General, Department of Health, Veneto Regional Administration 
Health service providers Dr. Angelo Rossi 
Mori 
National Research Centre (CNR), Institute of biomedical technologies,  
Head of eHealth Sector 
Technology and service 
providers 
Marco Mena Director, Between Spa (Market research company), responsible for Between 
observatory on eHealth deployment 
Policy makers Professor Roberto 
Landi 
Luiss University of Rome, Management School, head of eHealth sector 
THE NETHERLANDS (18) 
Stakeholder segment Name Role/Organisation 
Policy makers Annemarie van 
Hout 
Aveant 
Policy makers Walter Salzmann CVZ 
Technology and service 
provider 
Daan Dohmen Founder, Focus Cura 
Professional 
organisation 
Marijke van Hees; 
Aart Leferink 
IZIT (ICT in Health care in Twente) 
 
Health service provider Rolien de Jong MeaVita,  Former head of Innovation 
Insurer Harry Nienhuis Menzis, Head of the Knowledge Centre on innovation 
Policy makers Hans Haveman Min VWS, Department of Health, Wellbeing and Sport 
Policy makers Johan Bruin NICTIZ 
Interest organisation Marita 
Meulmeester 
NPCF, Patient association promoting the interest of patients within care 
Consultancy Herman Pieterse Managing Director, Profess Medical Consultancy 
Technology and service 
providers 
Jan Ramaekers Founder, Sananet 
Consultancy Willem 
Schroeijers 
Syntens 
Technology and service 
providers 
Pim Ketelaar Chairman of the Dutch Association of eHealth (NVeH) and CEO of 
Telecom4Care (TeleHealth consultancy) 
Research institute Hermie Hermens; 
Mirjam 
Vollenbroek 
Cluster Manager, Roessingh R&D and Chair in telemedicine at University of 
Twente /head of RMT group. Cluster Manager at RRD & part time professor 
University of Twente, Clinical research and feedback in telemedicine. 
Technology and service 
providers 
Ed Mos TNO 
Technology and service 
providers 
Jelle van der 
Weijden 
Tunstall 
Health service providers Victor Pop Universiteit van Tilburg, Chair in primary care and GP 
Technology and service 
provider/Health service 
provider 
André van Oort Vitaphone Nederland 
SWEDEN (7) 
Stakeholder segment Name Role/Organisation 
Policy makers Jonas Gumbel & 
Michael 
Bergström 
Swedish Association of Local Authorities and Regions (SALAR) 
Policy 
makers/PHS/RMT 
integration aspects 
Monica Winge In charge of eHealth issues at VINNOVA, the Swedish Governmental 
Agency for Innovation Systems 
Payers Björn-Erik 
Erlandsson 
Senior Advisor, Stockholm County Council 
Health service providers Sabine Koch Professor, Karolinska Hospital 
Large scale 
procurement 
Mats Larsson Senior Partner at Caritea AB, The Swedish Association of Local Authorities 
and Regions (SALAR) 
Users Christer Neleryd District Manager, The Swedish National Board of Health and Welfare 
Technology and service 
providers 
Björn Söderberg Sales and Marketing Director, Fouder, Kiwok AB 
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UK (13) 
Stakeholder segment Name Role/Organisation 
Technology and service 
providers 
Ivan Harrow Senior product Strategist,  Intel Corp. 
Technology and service 
providers 
Paul Gee Chief Executive, Telecare Services Association 
Technology and service 
providers, PHS/RMT 
Integration Aspects 
Nat Billington Managing Director, MapofMedicine 
Technology and service 
providers 
David Kelly Managing Director, Tunstall ltd 
Health Service 
Providers 
Paul Duffy Chief Technology Officer, Belfast HSS Trust 
Policy Makers George McGinnis Senior advisor, NHS England 
Large Scale 
Procurement 
Tim Ellis Project Leader, NHS, Whole System Demonstrators 
PHS/RMT Integration 
Aspects 
Dr. Mike 
Bainbridge 
Clinical Architect, Technology Office, DH Informatics Directorate 
Policy Makers Sir Muir Gray Director Budgetary office, Department of Health 
Users Dr. Peter Short NHS General Practitioner, Buxton, Yorkshire. 
PHS/RMT Integration 
Aspects 
Dr Michael Wilks Senior Advisor, British medical Association 
Large Scale 
Procurement 
Eddie Ritson Procurement project leader, DHSS, Public health Agency, Northern Ireland 
Large-scale 
procurement 
Dr. Hubert Curran Senior Advisor, PHA, Northern Ireland 
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9 Annex IV: Health-related data and scientific evidence 
9.1 Prevalence data  
9.1.1 Cardiovascular diseases 
Cardiovascular diseases (CVD) are characterised by pathological changes in the circulatory 
system of the body, i.e. the heart muscle and the blood vessels. This group of diseases 
includes hypertension (elevated blood pressure); ischaemic heart disease, including 
myocardial infraction; cerebrovascular disease, including stroke; peripheral vascular disease; 
rheumatic heart disease; congenital heart disease; and cardiomyopathies. 
Cardiovascular diseases (CVD) are among of the leading causes of death and hospitalization 
in both genders in nearly all countries of Europe. The most frequent CVD are those of 
atherosclerotic origin, meaning the hardening and fatty degeneration of the arteries, mainly 
ischemic heart disease (IHD) and stroke. CVD clinically manifest itself in middle life and 
older age, after many years of exposure to unhealthy lifestyles, such as unhealthy diet, 
physical inactivity, and smoking habit and risk factors, such as high blood pressure, high 
cholesterolemia, diabetes, and obesity.234 
9.1.1.1 Chronic Heart Failure (CHF) 
In medical terminology the expression chronic refers to conditions with a long duration, 
whereas the term "acute" indicates a rapid onset, hence Chronic Heart Failure(CHF) is a long 
term condition, usually with stable treated symptomatology, the combined symptoms of a 
particular disease.  
Due to lack of a comparable and comprehensive gathering of prevalence data for chronic 
heart failure, different estimations deriving from a variety of sources are to be taken into 
consideration. The estimated overall prevalence of clinically identified CHF is based upon 
population studies. The variability of the estimates on CHF prevalence has already been 
discussed in par. 2.2 and will not be repeated here. 
According to several studies CHF puts a greater burden on the patients than any other chronic 
medical condition. It is a fatal condition; approximately 60% of patients diagnosed with CHF 
will die within 5 years of diagnosis. The self-reported quality of life is impaired by heart 
failure significantly and affects all dimensions of quality of life. According to the European 
Society of Cardiology only a minority of these patients are cared for by a cardiologist, which 
can lead to a higher rate of incidences and the corresponding costs.235 
The economic costs and personal burden of chronic heart failure are significant. Direct costs 
due to heart failure were (in million € per one million population in 2004 values) 26 in the 
UK, 37 in Germany, 39 in France and 70 in the US, respectively. For the United States the 
expenditures dedicated to heart failure were higher than that for the treatment of cancer and 
myocardial infarction in 1991. Overall, chronic heart failure consumes 1–2% of the total 
health care resources in the developed countries. Medication is only responsible for a small 
part of the costs. Bund economic burden of heart failure may become unmanageable in the 
                                            
234  EUPHIX and EUphact. (2009). "Cardiovascular diseases." Retrieved 26 October 2009, from 
http://www.euphix.org/object_class/euph_cardiovascular_diseases.html. European Commission (2007). Major and 
Chronic Diseases REPORT 2007. Luxembourg: .European Commission (2007). Major and Chronic Diseases REPORT 
2007. Luxembourg. 2007: pp.  18 et seq., 117 et seq., 291 et seq. 
235  Ibid.: D52 et seq. 
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setting of an ageing population indicating the need for cost-effective treatment options and 
preventive strategies.236  
9.1.1.2 Causes for CVD 
Although CVD prevalence is very high, its occurrence is largely preventable maintaining risk 
factors at favourable level during life span. Epidemiological studies have demonstrated that 
cardiovascular risk is ‘reversible’, that means that by lowering the level of risk factors it is 
possible to reduce the number and severity of events, or delay the event occurrence.237  
Even though the clinical onset is mainly acute, CVD often evolve gradually, causing 
substantial loss of quality of life, disability, and life long dependence on health services and 
medications. They also result in premature deaths. Based on a prospective cohort studies 
CVD are associated with adverse outcomes in the elderly people, including cognitive 
impairment, dementia and decreased physical performance.238  
9.1.1.3 Morbidity and Years of Life lost in disability due to CVD 
Uniform data on the prevalence of CVD and quantifiable data on how this condition is 
affecting the different populations is hard to obtain. One source is the WHO Burden of 
Disease project,239 which compiles data from their Member states. It uses the disability-
adjusted life year (DALY240) measures health gaps as opposed to health expectancies. It 
measures the difference between a current situation and an ideal situation where everyone 
lives up to the age of the standard life expectancy, and in perfect health in this way it one 
measure the time lived with disability and the time lost due to the condition.  
                                            
236  Berry, C., D. R. Murdoch, et al. (2001). "Economics of chronic heart failure." European Journal of Heart Failure 3(3): 
283-291. p. 285 et seq.; Bundkirchen, A. and R. H. G. Schwinger (2004). "Epidemiology and economic burden of 
chronic heart failure." Eur Heart J Suppl 6(suppl_D): D57-60.: p. D58. 
237  Tunstall-Pedoe, H., K. Kuulasmaa, et al. (1999). "Contribution of trends in survival and coronar y-event rates to changes 
in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations." The Lancet 
353(9164): 1547-1557.: pp. 1547 et seq. 
238  Hofman, A., M. Breteler, et al. (2007). "The Rotterdam Study: objectives and design update." European Journal of 
Epidemiology 22(11): 819-829.:pp. 820-821. 
239 http://www.who.int/healthinfo/global_burden_disease/en/index.html 
240 DALY = YLL + YLD where: (YLL = years of life lost due to premature mortality; YLD = years lived with disability). 
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Figure 28 – Age-standardised DALYs rate for CHD, stroke and other CVD by EU 
country, 2002 
 
  Age-standardised DALYs lost per 100,000 
  CHD Stroke Other CVD
Austria  579  349  431
Belgium   512  356  321
Bulgaria  1.344  1.188  1.485
Cyprus   638  289  832
Czech Republic 945  629  452
Denmark   478  401  359
Estonia  1.449  819  714
Finland   687  411  299
France  259  271  360
Germany   574  338  481
Greece  620  592  454
Hungary   1.137  731  654
Ireland  671  361  359
Italy   409  335  363
Latvia  1.606  1.102  803
Lithuania   1.444  620  608
Luxembourg 403  420  397
Malta   709  365  235
Netherlands 460  329  411
Poland   949  598  657
Portugal  431  836  301
Romania   1.176  1.162  793
Slovakia  1.037  387  795
Slovenia   552  524  492
Spain  368  294  274
Sweden   506  300  284
United Kingdom 657  359  298
Source: World Health Organization (2004) The World Health Report 2004. WHO: Geneva241 
9.1.2 Diabetes  
Diabetes is a chronic condition that occurs when the pancreas does not produce enough 
insulin, or alternatively, when the body cannot effectively use the insulin it produces. 
Diabetes prevalence increases with age. It is a common disease and its prevalence is expected 
to increase in the future, especially in developing countries. The majority of these diabetic 
patients (over 90%) suffer from Type II (non-insulin-dependent) diabetes mellitus, which is 
by nature, a progressive disorder with a slow and insidious onset. As a consequence, the 
condition is frequently under reported. Most common complications include blindness, heart 
and blood vessel disease, stroke, kidney failure, amputations, and nerve damage.242  
Data on the occurrence of Diabetes is usually collected in special, often regional, surveys and 
not by routine monitoring. The international Diabetes Foundation estimated in 2010 that 8.9% 
                                            
241  World Health Organization (2004). The World health report : 2004 : changing history. Geneva, WHO. 
242  Jonsson, P. M., L.-Å. Marké, et al. (2000). "Excess costs of medical care 1 and 8 years after diagnosis of diabetes: 
estimates from young and middle-aged incidence cohorts in Sweden." Diabetes Research and Clinical Practice 50(1): 35-
47.: pp. 42-46 ; Jönsson and B. Jönsson (2002). "Revealing the cost of Type II diabetes in Europe." Diabetologia 45(7): 
S5-S12. 
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of the adult (20-79 years) EU-27 population is suffering from diabetes, the prevalence ranges 
from 4.9% in the United Kingdom to 12% in Germany.243  
 
 
 
 
 
 
                                            
243 International Diabetes Federation (2006). The Diabetes Atlas 2006. T. Edition. Brussels, International Diabetes 
Federation. International Diabetes Federation. (2009). "IDF Diabetes Atlas." IDF Diabetes Atlas  Retrieved 7 January 
2010, from:  
http://www.diabetesatlas.org/content/diabetes-mortality   
http://www.diabetesatlas.org/content/europe-0 
http://www.diabetesatlas.org/sites/default/files/DM%202010_7%20regions.xls 
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Figure 29 – Diabetes Mellitus by country 
Country/ 
Territory 
2010 
Population 
(20-79 years) 
(000's) 
2010 DM 
National 
prevalence 
(%) 
2010 DM 
Comparative 
prevalence 
(%) 
2010 DM 
Total 
numbers 
(000's) 
2010 Type 
1 
incidence 
(000's) 
2010 IGT 
National 
prevalence
244 (%) 
2010 IGT 
Comparative 
prevalence 
(%) 
2010 IGT 
Total 
numbers 
(000's) 
NUMBER 
OF 
DEATHS 
ATTRIBUTABLE 
TO DIABETES 
(20-79 YEARS) 
Males 
NUMBER OF 
DEATHS 
ATTRIBUTABLE 
TO DIABETES (20-
79 YEARS) 
Females 
National 
Diabetes 
Program
me** 
EU Total    367,283.70            8.87   
 
32,918.10 
 
441.10      10.69  
 
8.81 
 
32,374 
 
140,182 
  
137,718            -  
Austria 6,301.6 11.2 8.9 708.4 13.3 6 4.1 377.8 2300 2,225 YES 
Belgium 7,643.9 8 5.3 610 15.4 6.5 4.8 494.5 2697 2,869 NO 
Bulgaria 5,790.2 9 6.5 519.5 9.4 6 5 344.7 3999 4,125 NA 
Cyprus 634.1 10.4 9.1 65.9 14.9 6.7 5.9 42.8 218 171 YES 
Czech 
Republic 7,824.3 8.7 6.4 677.3 17.2 17.4 15.3 1,360.9 3414 4,129 NO 
Denmark 3,907 7.7 5.6 301.5 22.2 15.2 12.4 594.4 1226 1,518 YES 
Estonia 994 9.9 7.6 97.9 15.3 17.4 15.3 173.2 645 685 NA 
Finland 3,863.4 8.3 5.7 319.8 57.4 8.8 5.9 339.2 1469 1,139 YES 
France 44,091.3 9.4 6.7 4,164.2 12.2 7.6 6.6 3,339.6 18443 11,984 YES 
Germany 62,654.4 12 8.9 7,494.3 18 6.6 4.1 4,132.6 27585 26,994 NO 
Greece 8,560.7 8.8 6 754 9.9 7.4 5.9 634.5 2957 3,585 YES 
Hungary 7,514.8 8.8 6.4 658.9 11.3 17.5 15.3 1,315.3 4279 5,545 NO 
Ireland 3171.2 5.7 5.2 180.3 16.3 1.9 1.7 61.3 608 589 NO 
Italy 44,509.9 8.8 5.9 3,926.2 8.4 6 4.7 2,654.7 13427 13,966 YES 
Latvia 1,719.4 9.9 7.6 169.7 7.5 17.4 15.3 299.7 1028 988 NO 
Lithuania 2,484.3 9.7 7.6 239.8 7.8 17.3 15.3 428.9 1759 1,784 NA 
Luxembo
urg 348.9 7 5.3 24.3 15.5 5.9 4.8 20.4 104 107 NO 
Malta 306.8 9.8 6.8 29.9 15.6 7.7 6.1 23.8 93 141 NA 
                                            
244  All comparisons should be done using the comparative prevalence which is adjusted to the world population. The national prevalence indicates the percentage of each country's population that has 
diabetes; it is ideal of assessing the burden of diabetes in each country. 
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Netherla
nds 11,943.4 7.7 5.3 922.4 18.8 6.3 4.8 748 3675 4,108 YES 
Poland 28,618 9.3 7.6 2,674.6 12.9 16.9 15.3 4,843.3 14150 15,126 NO 
Portugal 8,033.8 12.4 9.7 997.6 13.2 13.3 4.7 1,071.6 2825 3,136 YES 
Romania 16,129 8.4 6.9 1,351.4 5.4 17 15.3 2,743.4 8985 9,083 YES 
Slovakia 40,74.6 7.7 6.4 314 13.6 16.6 15.3 676.2 1822 2,256 NA 
Slovenia 1,546.2 9.9 7.7 152.9 11.1 17.5 15.3 271.2 618 427 NO 
Spain 33,943.8 8.7 6.6 2,939.3 13 7.5 6.6 2,533.8 10969 9,581 YES 
Sweden 6,618.6 7.3 5.2 484.4 41 9 7.3 597.7 1406 2,231 YES 
United 
Kingdom 44,056.1 4.9 3.6 2,139.6 24.5 5.1 4.7 2,250.5 9481 9,226 YES 
Non EU            
Iceland 210.5 2.1 1.6 4.4 14.7 7.3 5.9 15.5 15 19 NO 
Norway 3,356.7 4.7 3.6 159.3 27.9 8.6 7.3 287.1 595 567 YES 
Switzerla
nd 5,569.1 11.3 8.9 629.9 9 6.1 4.1 339.2 1640 1,710 NO 
Israel 4,495.9 7.1 6.5 318.8 10.4 5.5 5.1 248.2 1029 918 NA 
Source: based on the Diabetes Atlas by the IDFs245  
 
                                            
245  http://www.diabetesatlas.org/book/export/html/250 (accessed on the 7 Jan 2010). 
 159 
9.1.3 COPD 
9.1.3.1 Prevalence of COPD 
Chronic obstructive pulmonary disease is a smoking-related condition of progressive airflow 
obstruction, with disabling symptoms of chronic dyspnoea, cough and sputum production. The 
amount of patients suffering from this condition is hard to estimate due to a paucity of well-designed 
epidemiologic studies on COPD from most regions in the world including both EU15 and EU12. 
This makes it hard to estimate the number of patients in the EU27. The estimates of prevalence rates 
vary widely, from 0.2% to 18.3%, partly as a result of real differences in prevalence among countries 
and regions, and partly because of other factors. These factors include the method by which the 
prevalence is estimated (expert opinion, patient-reported diagnosis, symptom-based or spirometry-
based), the definition of COPD that was used, age and smoking status of the population included, etc. 
Based upon comparison between well-designed studies and samples prevalence of COPD in Europe 
is estimated to rank between 4% and 10% of adults in the Member States.246 Due to different 
categorisation and no uniform system to collect the data, data on prevalence at the level of individual 
countries is not included in this report. 
According to Halbert, Isonaka et al.247 COPD is "a leading cause of chronic morbidity and mortality 
and should be a major public health concern." and " Reliable COPD prevalence data are lacking for 
many parts of the world, despite the frequency of major risk factors for COPD, such as cigarette 
smoking, use of biomass fuels, and air pollution. Approximately 15% of smokers will acquire COPD. 
" 
9.1.3.2 Mortality of COPD 
The Global Burden of Disease Study estimates that by the year 2020, COPD will move from the 
sixth to the third-leading cause of death worldwide. The rates of mortality by COPD vary from less 
than 25 to more than 75 per 100,000 inhabitants in various European countries.248  
 
 
 
 
 
 
                                            
246  Halbert, R. J., S. Isonaka, et al. (2003). Interpreting COPD Prevalence Estimates* What Is the True Burden of Disease?, Am Coll 
Chest Phys. 123: 1684-1692. 
247  Ibid. pp. 1684-1685. 
248  Ibid, Loddenkemper, G. GJ, et al., Eds. (2003). European Lung White Book. TThe first comprehensive survey on respiratory 
health in Europe. Brussels, European Lung foundation. Wouters, E. F. M. (2003). "The burden of COPD in the Netherlands: results 
from the confronting COPD survey." Respiratory Medicine 97(Supplement 3): S51-S59, Buist, A. S., M. A. McBurnie, et al. 
(2007). "International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study." The Lancet 
370(9589): 741-750. 
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Figure 29 – Mortality (SDR) from COPD per 100,000, total in EU-27 in 2003 
 
Source: based upon Kaiser, S. (2007). "Mortality (SDR) from COPD"249 
9.2 Clinical metrics (costs) 
9.2.1 Cost of CVD 
The data revealing the cost of cardiovascular diseases is using research gathered by the British Heart 
Foundation Health Promotion Research Group (BHF HPRG) based at the University of Oxford. 
According to British Heart Foundation's statistics the normal procedure of looking only at the health 
care costs of CVD grossly underestimates the total cost of CVD in the UK. Loss of years of 
productive life from death and illness in those of working age and from impact of the informal care 
of people with the disease contribute greatly to the overall financial burden. Furthermore the costs 
are also linked to illness benefits and retirement. Their research took a societal perspective to enable 
a wider analysis, in which all costs are considered, irrespective of who bears them or where they are 
incurred. It is not restricted to health care costs but also includes those costs falling outside the health 
care sector, such as the opportunity costs associated with unpaid (i.e. informal) care to CVD patients, 
or productivity losses associated with premature death or morbidity. For this analysis, a societal 
perspective was adopted.250 
                                            
249  Kaiser, S. (2007). "Mortality (SDR) from COPD." EUPHIX, 2010, from http://www.euphix.org/object_map/o26n27163.html. The 
graphic is based on Data taken from the Eurostat database. It represents mortality from chronic lower respiratory diseases (ICD-10 
code J40-J47) only. Mortality from asthma (ICD-10 code J45-J46) has been subtracted. 
250  Allender, S., Scarborough, et al. (2008). Methods for the EU cost of CVD study. Oxford, British Heart Foundation Health 
Promotion Research Group Department of Public Health. 
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From 1970 to 2000 for the age-range 45-74 years mortality has been decreasing in the majority of 
Western European countries but increasing in Central and Eastern Europe; during recent years 
mortality has also been decreasing in some Central and Eastern European countries. Those early 
declines could be due to changes in environmental risk factors, such as diet and lifestyle risks 
described above factors; more recent declines to improvements in modern cardiovascular treatments, 
responsible of both decreasing morbidity and increasing survival.251 
9.2.1.1 Cost structure for CVD 
The Cost structure for CVD are based on data collected by the British Heart Foundation, expressed in 
2003 prices according to their country. The categories of CVD direct health care service included 
were, primary care, accident and emergency care, hospital inpatient care (including day cases and 
cardiac rehabilitation services), outpatient care, medications.252 
Other categories of health service were not included, such as school/community based prevention 
and health education activities, and out-of-pocket expenses incurred by patients in purchasing over 
the counter medications, consulting private practitioners, etc. These were not included in the study 
due to the difficulties of identifying them in the majority of countries. These excluded categories are 
likely to represent a very small proportion of the total costs identified. Categories of non-health care 
expenditure included in the study were the following: 
• Informal care, 
• Productivity costs due to mortality, 
• Productivity costs due to morbidity. 
Overall CVD is estimated to cost the EU Economy €192 Billion a year. This translates into a total 
annual cost per capita of €391. A great variety in prices can be found over different Member States 
from around €60 per capita per Year in Bulgaria to over 600 per capita per year in Germany and the 
UK. Of the Total cost of CVD in the EU, around 57% are due to direct health costs, 21% to 
productivity losses and 22% to the informal care of people with CVD. 
9.2.1.2 Health care cost of CVD in EU 27
                                            
251  Kesteloot, H., S. Sans, et al. (2006). "Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 
1970 and 2000." Eur Heart J 27(1): 107-113.: pp. 107-110.  
252  Allender, S., Scarborough, et al. (2008). Methods for the EU cost of CVD study. Oxford, British Heart Foundation Health 
Promotion Research Group Department of Public Health;  Allender, S., Scarborough, et al. (2009). European cardiovascular 
disease statistics 2008. Oxford, British Heart Foundation Health Promotion Research Group Department of Public Health. 
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Figure 30 – Health care costs of CVD, by country, 2006, EU  
 Primary  care  
Outpatient 
care A&E
Inpatient 
care Medications  
Total health 
care costs
Cost 
per capita
Percentage of total 
health care expenditure 
 € (thousands) 
€ 
(thousands)
€ 
(thousands)
€ 
(thousands)
€ 
(thousands)  
€ 
(thousands) € % 
Austria 109,234 96,853 17,518 875,423 533,837   1,632.865 198 6 
Belgium 156.909 60.976 63.622 1.000.875 747.646  2.030.028 193 6 
Bulgaria 32,042 32,051 5,607 132,270 71,305   273,275 35 14 
Cyprus  4,321 6,608 3,182 10,559 20,727  45,397 59 5 
Czech Republic 29,511 132,145 70,159 410,907 454,851   1,097,573 107 13 
Denmark 55,495 63,335 13,576 619,399 238,178  989,983 182 5 
Estonia 8,219 21,365 1,526 41,371 31,272   103,753 77 15 
Finland 24,626 26,839 9,609 771,812 413,318  1,246,204 237 10 
France  1,146,635 876,855 259,123 6,513,404 4,207,406   13,003,422 207 7 
Germany 5,418,746 2,276,990 1,300,678 17,777,334 7,256,111  34,029,860 413 14 
Greece 27,645 25,735 67,819 810,342 990,169   1,921,710 173 10 
Hungary 48,213 73,963 6,169 174,053 449,449  751,847 75 10 
Ireland 70,264 40,178 21,934 311,279 325,122   768,777 183 6 
Italy 1,081,033 322,548 98,093 7,022,524 5,266,000  13,790,198 235 10 
Latvia 5,694 9,793 2,242 57,460 33,189   108,378 47 9 
Lithuania 19,057 13,612 2,263 94,984 71,327  201,243 59 13 
Luxembourg 4,795 5,294 3,073 69,797 32,647   115,605 252 5 
Malta 562 628 522 5,629 21,757  29,098 72 6 
Netherlands 176,796 211,340 78,017 3,052,690 905,666   4,424,508 271 9 
Poland  243,757 334,862 18,353 1,086,026 1,147,205  2,830,204 74 17 
Portugal 173,348 82,802 136,535 547,579 659,087   1,599,351 151 10 
Romania 24,833 115,071 9,653 366,838 209,437  725,833 34 15 
Slovakia 42,314 59,617 3,475 131,791 160,639   397,836 74 13 
Slovenia 12,441 12,195 6,579 65,130 85,620  181,966 91 7 
Spain 439,422 579,507 259,513 1,849,545 2,566,623   5,694,611 130 7 
Sweden 167,011 499,558 94,566 1,661,298 361,923  2,784,356 308 10 
United Kingdom 1,098,629 390,487 88,760 13,635,293 3,698,222   18,911,391 313 12 
EU 10,621,552 6,371,208 2,642,166 59,095,613 30,958,732   109,689,271 223 10 
Source: www.heartstats.org op. cit. op 
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Figures 31 and 32– Cost of Cardiovascular diseases  
 
Source: www.heartstats.org op. cit. op. 
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9.2.2 Cost for Diabetes 
Cost related to Diabetes Type II are primarily based on the study Revealing The Cost Of Type II 
Diabetes In Europe253 which is an attempt to estimate the costs for Type II diabetes, which affects 
90% of the patients suffering from diabetes related conditions.254 It compares the costs in eight 
countries - Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United 
Kingdom. The total direct medical costs of Type II diabetes in the eight European countries was 
estimated at EUR 29 billion a year (1999 values).  
Based on a Swedish study the cost profile during the natural history of diabetes is assumed to follow 
a 'U' or 'J' shape with relatively high costs immediately after diagnosis due to incidents during the 
adjustment and incidents leading to the diagnosis of the illness. This is preceded by a fall of costs and 
a raise with the onset of complications in the later stage of the disease.255 (Jonsson, Marké et al. 
2000) 
In the early stage adjustments of the medication and incidents lead to higher costs, part of this cost 
can be reduced by interventions prior to the necessity of hospital admissions. According to a study by 
the U.S. Department of Veterans Affairs, continuously monitoring of chronically ill can reduce the 
bed days of care (BDOC) for Diabetes Mellitus by 20.4%.256  
The estimated average yearly cost per patient was EUR 2,834 a year in Europe. Of these costs, 
hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 
billion for the eight countries.257 
                                            
253  Jönsson and B. Jönsson (2002). "Revealing the cost of Type II diabetes in Europe." Diabetologia 45(7): S5-S12. 
254  World Health Organisation. (2008). "Diabetes Factsheet." Fact sheet Fact sheet N°312. Retrieved 7th January 2010, 2010, from 
http://www.who.int/mediacentre/factsheets/fs312/en/index.html. 
255  Jonsson, P. M., L.-Å. Marké, et al. (2000). "Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from 
young and middle-aged incidence cohorts in Sweden." Diabetes Research and Clinical Practice 50(1): 35-47. 
256  Darkins, A., P. Ryan, et al. (2008). "Care Coordination/Home Telehealth:The Systematic Implementation of Health Informatics, 
Home Telehealth, and Disease Management to Support the Care of Veteran Patients with Chronic Conditions." TELEMEDICINE 
and e-HEALTH: 1118-1126.  
257  Jönsson and B. Jönsson (2002). "Revealing the cost of Type II diabetes in Europe." Diabetologia 45(7): S5-S12. 
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Figures 33 – Cost for ambulatory care in selected European countries related to Diabetes 
 
Graphic: Currency €, based on op. cit258  
                                            
258  Ibid. p. S9. 
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Figures 34 – Cost for hospitalisation in selected European countries related to Diabetes 
 
Graphic: Currency €, based on op. cit. p. S9259  
As seen in Figures 34 the highest mean cost for hospitalisation occurs in Germany €2,173 (data for 
1999, the lowest standard deviation with €755), while the lowest mean cost for hospitalisation occurs 
in Italy with €1,787, but Italy had the highest standard deviation of €8,778.  
9.2.3 Cost of COPD 
Wouters260 (2003) conducted an economic analysis of data from a large-scale international survey, 
Confronting COPD in North America and Europe, which covers seven countries (Canada, France, 
Italy, The Netherlands, Spain, the U.K and the U.SA.) for investigating the burden of chronic 
obstructive pulmonary disease (COPD).The results demonstrated the high economic impact of 
COPD on the health care system and society in each country. The mean annual direct costs of the 
disease were particularly high in the U.S.A. (US dollar 4,119 [€3,647261] per patient) and Spain (US 
dollar 3,196 [€2,830] per patient) but relatively low in the Netherlands (US dollar 606 [€536]) and 
France (US dollar 522[€460]). Lost productivity due to COPD had a particularly high impact on the 
economy in France, The Netherlands and the U.K, accounting for 67%, 50% and 41% of overall 
costs, respectively.262 
                                            
259  Ibid. 
260  Wouters, E. F. M. (2003). "The burden of COPD in the Netherlands: results from the confronting COPD survey." Respiratory 
Medicine 97(Supplement 3): S51-S59: pp. S51-S52. 
261  The € values in brackets are based on the interbank exchange rate for the whole year 2003, please note that some of the numbers 
date back earlier. 
262  Wouters, E. F. M. (2003). "The burden of COPD in the Netherlands: results from the confronting COPD survey." Respiratory 
Medicine 97(Supplement 3): S51-S59. 
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The total societal cost of COPD per patient ranged from over US dollar 5,646 [€4,999] in the U.S.A. 
to US dollar 1,023 [€906] in the Netherlands. In five out of seven countries, the majority (52-84%) of 
direct costs associated with COPD were due to inpatient hospitalizations. As acute exacerbations of 
COPD are a key driver of secondary care costs, interventions aimed at preventing and treating 
exacerbations effectively could significantly reduce the economic impact of this disease. In all of the 
participating counties, COPD was underdiagnosed and undertreated. Between 9% and 30% of 
patients were undiagnosed despite having symptoms consistent with COPD, and up to 65% of 
patients did not receive regular prescribed medication. Patients reported poor symptom control and 
considerable use of health care resources. Therefore, reducing the burden of COPD will involve 
better evaluation and diagnosis of patients with COPD, as well as improved management of chronic 
COPD symptoms by health care professionals. The survey also demonstrated that the societal costs 
of COPD were 4-17 times higher in patients with severe COPD than in patients with mild COPD. 
Patients with comorbid conditions (accounting for 30-57% of patients in each country) were also 
particularly costly to society. These results suggest that a high priority should be given to 
interventions aimed at delaying the progression of disease, preventing exacerbations and reducing the 
risk of comorbidities, in order to alleviate the clinical and economic burden of COPD in North 
America and Europe.263  
9.3 Scientific Evidence on RMT for Heart Conditions 
The following tables present a summary of the scientific evidence found on the impact of RMT used 
for patients with heart conditions, providing details on the type of study, the authors or sponsors of 
the study, the start and end date, the focus of the study e.g. cost/benefit analysis, clinical trial etc., the 
outcomes and a link to the website of the research organisation or the study itself. 
                                            
263  Ibid. 
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Table 23 – Scientific Evidence on RMT for Heart conditions 
Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
Boario Home 
Care Project  
R
e
g
i
o
n
a
l
 
i
n
i
t
i
a
t
i
v
e
 
e
-
H
T
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n
e
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s
 
Started 
1998, 
ongoing 
Italy, Lombardy region. Contains 
service description, stats on use of 
telecardiology, review of benefits of 
the project, costs and impact of 
telecardiology in the region 
Telecardiology in Italy: benefits from a telemedicine 
network connecting chronic patients, general 
practitioners and health care provider organisations 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\2006 - 
Scalvini_Boario_assessment.pdf 
TEN-HMS Study 
Demonstrates 
Clinical and 
Financial Efficacy 
of Home 
Telemonitoring 
T
E
N
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t
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t
i
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e
 
P
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l
i
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,
 
C
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e
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d
…
 
2003 World's first large-scale, randomized 
prospective telemonitoring trial, 
covering 426 Heart failure patients 
randomised into three groups (usual 
care, telephone nurse support and 
home telemonitoring) during 2000-
2002 period 
 showed that homebased telemonitoring reduced 
the number of days spent in hospital by 26% and 
led to an overall 10% cost savings compared to 
nurse telephone support. Home Telemonitoring also 
significantly improved survival rates relative to usual 
care and led to high levels of patient satisfaction 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\2003 - TEN-
HMS_Telemonitoring evidence - 
FINAL.pdf 
Remote 
monitoring 
systems for 
patients implanted 
with cardiac 
devices 
(cardioverter 
defibrillators and 
pacemakers). 
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e
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2006 Reviews the use of remote monitoring 
systems for patients with pacemakers 
and implantable cardioverter 
defibrillators. Three of the more 
prominent systems are examined; the 
Carelink® Network by Medtronic, the 
Home Monitoring® System by 
Biotronik and the Housecall Plus™ 
Remote Patient Monitoring System by 
St. Jude Medical 
While the remote monitoring of implantable cardiac 
devices offers a number of potential benefits for 
patients and medical practitioners, a number of 
questions remain unanswered. At present, it is not 
clear whether these systems will be financially 
viable in Australia, to what extent they will reduce 
practitioner workload and whether or not problems 
in the transmission of data will result in serious 
negative health outcomes. Large scale randomised 
trials involving control groups are required to further 
assess the financial and clinical effectiveness of 
remote monitoring systems. 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\2006 - 
ANZHSN - RMT of ICD - 
overview of evidence.pdf 
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Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
HARTMOTIEF 
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2006 Randomised trial, intervention group 
used MOTIVA system and were 
equipped with automated devices for 
daily measurements of blood pressure 
and weight (those who had had heart 
failure treatment before) 
Hartmotief study protocol : 
randomized Control (50%), T1(30%), 
T2(20%) 
•216 Patients 
•8 participating hospitals 
•Ended 31st of December 2006 
•Principal investigator : dr. AHMM 
Balk of Erasmus MC Rotterdam 
Presents results in terms of Days in hospital, Mean 
number of hosp. days per patient Days in study, 
Days in hospital  per day in study, Number of 
hospital admissions (and range pp), Mean duration 
of hospitalization (days), Mean number of 
hospitalizations per patient. Concludes on positive 
impact of the system on educating patients in their 
disease management and on care improvement 
 
Review of 
published 
evidence-based 
applications of 
telemonitoring for 
the surveillance of 
cardiac rhythm 
management 
devices 
S
t
u
d
y
 
E
u
c
o
m
e
d
 
/
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h
r
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s
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M
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e
n
t
 
Aug-08 Present the current evidence 
pertaining to the clinical and cost-
effectiveness of remote surveillance of 
CRM devices, and highlight the most 
relevant studies conducted in the 
broad field of remote monitoring. 
clinical efficacy and patient safety was 
examined in 6 studies, including 888 
patients 
All 10 studies confirmed feasibility and reliability of 
RMT; clinical effectiveness and patient safety of the 
remote patient management systems were 
reported in 7 of the 15 publications; Two studies 
examined the characteristics of an optimal standard 
follow-up programme; 6 included financial analyses 
combined with the clinical study (not comparable). 
One study underlined the burden imposed on 
physicians, allied professionals and medical 
institutions, by the large number of devices that are 
being implanted. The authors recommend a more 
intensive use of Internet-based technologies to 
monitor the devices, and new means of patient data 
management and sharing. They recommend the 
recognition of the importance of device follow up, 
and urge the development of appropriate 
reimbursement 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\2008 - 
EUCOMED - 
CRM_Telemonitoring - lit survey 
remote device checks - final.ppt 
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Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
Remote 
Physiological 
Monitoring 
U
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R
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? 2008 Cost-effectiveness analysis using the 
expanding evidence base for RPM, 
status of barriers to adoption, also 
looks at coverage and reimbursement 
options. 
Shows a 60 percent reduction in hospital 
readmissions compared to standard care and a 50 
percent reduction in hospital readmissions 
compared to disease management programs 
without remote monitoring. • Remote patient 
monitoring has the potential to prevent between 
460,000 and 627,000 heart failure-related hospital 
readmissions each year.• Based on this reduction in 
hospital readmissions, NEHI estimates an annual 
national cost savings of up to $6.4 billion dollars.• 
Based on this reduction in hospital readmissions, 
NEHI estimates an annual national cost savings of 
up to $6.4 billion dollars. Also highlights three main 
barriers (reimbursement, lack of user awareness 
and providers' concerns 
 
Einfluss einer 
telemedizinischen 
Lanzeitbetreuung 
auf 
Hospitalisation 
und 
Krankenhausverw
eildauer bei 
chronischer 
Herzinsuffizienz - 
eine Fall-Kontroll-
Studie 
C
o
s
t
 
b
e
n
e
f
i
t
 
a
n
a
l
y
s
i
s
 
-
 
A
u
t
h
o
r
s
:
 
Z
u
c
c
a
 
e
t
 
a
l
 
-
 
C
o
m
m
i
s
s
i
o
n
e
d
 
b
y
 
T
a
u
n
u
s
 
B
K
K
 
a
n
d
 
P
H
T
S
 
T
e
l
e
m
e
d
i
z
i
n
 
Publishe
d April 
2009 
The objective of the study was to 
determine whether a telemedicine 
monitoring of an unselected and wide 
group of insured patients would lead 
to a decrease in morbidity. 
A group of 650 insured patients from the Taunus 
BKK who had at least one previous hospital stay 
because of heart failure were given telemedicine 
monitoring on top of their medical treatment which 
included transmission of weight, heart frequency 
and blood pressure data. A control group followed 
the traditional medical treatment. The patients 
groups were comparable in terms of age, sex and 
underlying condition. 
After a 12 month period, rehospitalisation, hospital 
stay length and hospital costs decreased 
significantly. 
www.phts.de 
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Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
HTA Report - 
Monitoring heart 
functions using 
telemetry 
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b
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2006 The following research questions are 
addressed in this HTA report: 
• What is the efficacy of 
Telemonitoring for monitoring heart 
functions? 
• Is it possible to prevent cardiac 
events with Telemonitoring? 
• Could Telemetry be useful in 
secondary prevention of myocardial 
infarction? 
• What are the pros and cons of 
Telemonitoring for the patients 
regarding diagnosis, prevention 
of cardiac events, treatment, and 
quality of life? 
• Does Telemonitoring have an impact 
on the treatment strategy of 
physicians? Is it possible 
that in certain cases less medication 
could be necessary. 
• Do patients accept Telemonitoring? 
• Where does the implementation of 
Telemonitoring make more sense: 
primary or secondary 
prevention, or treatment? 
• Does Telemedicine have an impact 
on the treatment strategy, medical 
therapy and compliance of the 
patients? 
• Is Telemonitoring more cost-effective 
in comparison to conventional 
treatment? 
Telemedicine is well accepted by the patients. It has 
been indicated that the implementation of 
telemedicine reduces both the number of 
hospitalisations and the duration of hospitalisation. 
Treatment costs are accordingly reduced. With an 
early diagnosis, the therapy can be optimised 
precociously. Considering acute medical care, a 
diagnosis prior to hospitalisation can lead to a 
reduction in the time interval between admittance 
and the start of therapy. Considering preventive 
medical care, the continuous surveillance enables a 
timely diagnosis. The quality of life of the patient is 
hereby significantly enhanced. 
Conclusion 
Telemetric monitoring can be applied in many areas 
of health care and be of positive assistance, within 
the single therapeutic strategies, to patients with 
acute and chronic cardiac illnesses. The integration 
of information- and communication systems 
available for the health sector can significantly 
support patient orientated medical care. This has 
been indicated in numerous studies/trials. 
Telemedicine supports the renunciation of a 
centralised medical care system, where the patient 
has to seek for consultancy, towards a patient 
orientated system, where expert advice (by means 
of caretaking networks) is transferred to the patient. 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\21 
IFEG_HTA Bericht 
2006_Kurzfassung.pdf 
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Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
Remote 
monitoring of 
implantable 
cardiac devices 
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i
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2006 Results of the first European multi-
centre trial have been presented in 
abstract2. 124 patients with a 
pacemaker had an implanted 
transmission chip that was set up to 
automatically send daily messages. 
They were followed up for three 
months. Patients were classified as 
‘not successfully monitored’ if more 
than three contacts to the patient were 
necessary to maintain home 
monitoring or if the longest interval 
without a message was six days. Six 
patients were excluded from the study 
because home monitoring could not 
besuccessfully established, and a 
further 21 patients were not 
successfully monitored. In the 
remaining 95 patients, successful 
transmission occurred for 92% of the 
messages. Additional abstracts have 
focused on the use of home 
monitoring for effects of medication3 
and on detecting atrial 
tachyarrhythmia4. 
The potential advantages of remote monitoring of 
implantable devices could include timely monitoring 
of clinical events and symptoms, a reduction in 
routine patient follow-up, closer monitoring of device 
longevity that may extend usage, and reduced 
patient transport costs. 
Staff time may also be saved, in both primary and 
secondary care, with electronic transmission of data 
improving data quality. This may lead to greater 
patient throughput in specialist clinics. However, 
there are few studies published with sufficient detail 
for a full evaluation of the systems’ potential impact 
on NHS services, NHS costs, patient outcomes and 
quality of life. 
..\SIMPHS data 
collection\Evaluation and 
assessment studies\2006 - 
NHSC-UK - RemoteMonitoring of 
ICD - overview of evidence.pdf 
Telemonitoring or 
structured 
telephone support 
programmes for 
patients with 
chronic heart 
failure: systematic 
review and meta-
analysis 
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,
 
S
.
 
 
2007 
 
To determine whether remote 
monitoring (structured telephone 
support or telemonitoring) without 
regular clinic or home visits improves 
outcomes for patients with chronic 
heart failure. 15 electronic databases, 
hand searches of previous studies, 
and contact with authors and experts.  
Programmes for chronic heart failure that include 
remote monitoring have a positive effect on clinical 
outcomes in community dwelling patients with 
chronic heart failure. 
 
http://eprints.gla.ac.uk/26124/ 
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Name Type Partners/ 
Authors 
Start & 
end date 
Focus Outcome Website 
Home 
telemonitoring for 
congestive heart 
failure: a 
systematic review 
and meta-analysis 
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2010 An electronic literature search was 
conducted to identify studies of home 
telemonitoring use in congestive heart 
failure (CHF) patients. Twenty-one 
original studies on home 
telemonitoring for patients with CHF 
were included (3082 patients). 
Several studies suggested that home telemonitoring 
also helped to lower the number of hospitalizations 
and the use of other health services. Patient quality 
of life and satisfaction with home telemonitoring 
were similar or better than with usual care. More 
studies of higher methodological quality are 
required to give more precise information about the 
potential clinical effectiveness of home telehealth 
interventions. 
http://jtt.rsmjournals.com/cgi/cont
ent/abstract/16/2/68 
Home 
telemonitoring in 
heart failure 
patients: the HHH 
study (Home or 
Hospital in Heart 
Failure). 
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2009 The Home or Hospital in Heart failure 
(HHH) study was a European 
Community-funded, multinational, 
randomized controlled clinical trial, 
conducted in the UK, Poland, and 
Italy, to assess the feasibility of a new 
system of home telemonitoring (HT). 
The HT system was used to monitor 
clinical and physiological parameters, 
and its effectiveness (compared with 
usual care) in reducing cardiac events 
in heart failure (HF) patients was 
evaluated 
Home or Hospital in Heart failure indicates that self-
managed HT of clinical and physiological 
parameters is feasible in HF patients, with 
surprisingly high compliance. Whether HT 
contributes to a reduction of cardiac events requires 
further investigation. 
http://www.ncbi.nlm.nih.gov/pub
med/19228800 
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9.4 Scientific evidence on RMT for Diabetes 
The following tables present a summary of the scientific evidence found on the impact of RMT used 
for patients suffering from diabetes, providing details on the type of study, the authors or sponsors of 
the study, the start and end date, the focus of the study e.g. cost/benefit analysis, clinical trial etc., the 
outcomes and a link to the website of the research organisation or to the study itself. 
 175 
Table 24 – Scientific Evidence on RMT for Diabetes 
Name Type Partners/ 
Authors 
Start & end 
date 
Focus Objectives Outcome  
Telemedicine 
for monitoring 
chronic 
diseases 
(Diabetes) 
R
e
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e
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2006 Diabetes 
Mellitus, 
metabolic 
control, 
literature 
review of 
experiments 
(40 studies 
selected) 
Efficiency, efficacy, and 
user satisfaction of 
telemedicine in 
metabolic control, 
through literature review 
Better control of glycemic levels, improved 
self management, improved education 
..\SIMPHS data 
collection\Evalua
tion and 
assessment 
studies\2008 - 
AETSA_2006-
20_Telediabetes
.pdf 
Evaluation of a 
mobile phone 
telemonitoring 
system for 
glycaemic 
control in 
patients with 
diabetes 
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Trial done 
in 2006-
2007, 
published 
2009 
Type 2 
diabetes 
patients. 
Evaluation of 
mHealth impact 
on HbA1c 
levels 
RCT using mobile health 
technology, 137 patients 
72 in intervention group, 
65 in control group, over 
9 months in 2006-2007, 
impact on HbA1c levels 
Higher default rate in intervention group 
(32/70 completed the trial) due to technical 
problems. No difference in HbA1c levels in 
telemonitoring vs control group. Conclusion 
is that beneficial effect of telemonitoring on 
long term diabetes control is likely to be 
small. Lack of human contact may be 
weakness of the study as other qualitative 
studies show that using telemedicine 
requires supportive interactions with health 
care providers. 
..\SIMPHS data 
collection\Evalua
tion and 
assessment 
studies\2009 - 
JTT RCT 
Evaluation 
mobile 
telemonitoring 
diabetes.pdf 
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Name Type Partners/ 
Authors 
Start & end 
date 
Focus Objectives Outcome  
The effect of 
telemedicine 
on outcome 
and quality of 
life in pregnant 
women with 
diabetes 
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Published 
2009 
Type 1 
diabetes, 
pregnant 
women. To 
evaluate the 
effect of a 
telemedicine 
system on 
maternal and 
fetal outcome 
in women with 
diabetes. 
Evaluation of 
depression, 
health-related 
quality of life 
(QoL), Stress 
and Distress for 
the impact of 
diabetes. 
276 pregnant women 
with gestational diabetes 
were enrolled in the 
study and sequentially 
assigned to a 
telemedicine or a control 
group, 88 in the 
telemedicine group and 
115 in the control group; 
there were 17 women 
with type 1 diabetes in 
the telemedicine group 
and 15 in the control 
group.  
Women in telemedicine groups were asked 
to submit their blood glucose data every 
week, and had a medical examination at 
the diabetes clinic once a month. Women in 
the control groups had a medical 
examination every two weeks. Subjective 
outcomes were investigated using the 
following questionnaires: CES-D for 
depression, SF-36 for health-related quality 
of life (QoL), Stress and Distress for the 
impact of diabetes. Clinical variables and 
pregnancy outcomes were no different 
between the two telemedicine groups, 
whereas women with gestational diabetes 
in the telemedicine group had a better 
metabolic control in the 3rd trimester and a 
lower rate of caesarean sections and 
macrosomia. As for QoL, women in the 
telemedicine groups showed lower levels of 
frustration and concerns about their 
diabetes, and a better acceptance of their 
diabetic condition. A questionnaire on the 
use of the telemedicine system showed a 
high degree of acceptance (85%). Both 
telemedicine groups had fewer check-ups 
at the diabetes clinics. The use of a 
telemedicine system for glucose monitoring 
improved pregnancy outcome in women 
with gestational diabetes and improved 
QoL in all diabetic pregnancies.  
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Name Type Partners/ 
Authors 
Start & end 
date 
Focus Objectives Outcome  
Telemedicina 
en el 
seguimiento 
de 
enfermedades 
crónicas: 
Diabetes 
Mellitus 
Revisión 
Sistemática de 
Literatura y 
Evaluación 
Económica 
Telemedicine 
for monitoring 
of chronic 
diseases: 
Diabetes 
mellitus 
Executive 
abstract 
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2008 Diabetes 
Mellitus 
The main objective of 
the review is to know 
whether the use of ITC 
in Medicine can improve 
effectiveness, efficiency 
and satisfaction aspects 
in DM patients’ 
metabolic control. 
Moreover, two specific 
aims have been 
included: one of them 
concerns educational 
aspects, and the other 
one deals with the 
possibility to early detect 
diabetic retinopathy 
through 
teleophthalmology 
techniques both of them 
due to the importance 
they get in this 
pathology. 
Conclusions: 
1. Concerning the effectiveness and 
combining all the measure groups, there 
can be said that telemedicine applied to 
monitoring diabetic patients is effective with 
an evidence of high quality. 
2. With a level of evidence from high to 
mid, we can state that telemedicine is 
efficient for glycemic control of patients. 
3. With high quality evidence, there can be 
said that telemedicine systems for 
metabolic control reach high satisfaction 
level for users. 
4. Considering sensitivity, specificity 
aspects, there can be affirmed that 
telemedicine techniques get results very 
similar to those from traditional techniques 
with high level of evidence. Taking into 
account other aspects such as the number 
of adjustable images, satisfaction, 
transmission time and costs, we can say 
that telemedicine is appropriate for the 
early diagnosis of RD with a low level of 
evidence. 
5. From the economic assessment carried 
out in a parallel way to the present review, 
there can be enhanced the conclusion, 
which deals with the decrease in the cost of 
detection tests of diabetic retinopathy using 
telemedicine. However, the effectiveness is 
slightly lower to that of traditional system. 
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Name Type Partners/ 
Authors 
Start & end 
date 
Focus Objectives Outcome  
A Ubiquitous 
Chronic 
Disease Care 
system using 
cellular 
phones and 
the internet  
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Published 
June 2009 
Diabetes Type 
2 and 
Hypertension 
To improve the quality 
and efficiency of chronic 
disease care, the 
authors investigated the 
effectiveness and 
applicability of the 
Ubiquitous Chronic 
Disease Care (UCDC) 
system using cellular 
phones and the internet 
for overweight patients 
with both Type 2 
diabetes and 
hypertension. Patients 
were given a modular 
blood glucose measuring 
device, strips, lancets 
and an automatic blood 
pressure measuring 
device. Patients received 
advice and feedback 
depending on 
measurements sent. 
After 12 weeks, there were significant 
improvements in HbA1c in the intervention 
group (7.6 ± 0.9% to 7.1 ± 0.8%, P < 0.001) 
compared with the control group (7.4 ± 0.9% 
to 7.6 ± 1.0%, P=0.03). Furthermore, a 
significant reduction in systolic and diastolic 
blood pressure was observed, as well as 
improvements in total cholesterol, low-
density lipoprotein-cholesterol and 
triglyceride levels in the intervention group. 
Furthermore, there was a significant 
increase in adiponectin levels in the 
intervention group compared with the 
control group, although high-sensitivity C-
reactive protein and interleukin-6 levels did 
not change in either group.  
Conclusions: the novel UCDC system 
presented in this paper improved multiple 
metabolic parameters simultaneously in 
overweight patients with both Type 2 
diabetes and hypertension.  
..\SIMPHS data 
collection\Evalua
tion and 
assessment 
studies\2009 - 
Diabetes 
ubiquitous care 
system.TIF 
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Name Type Partners/ 
Authors 
Start & end 
date 
Focus Objectives Outcome  
Home 
telemonitoring 
of patients with 
diabetes: a 
systematic 
assessment of 
observed 
effects 
R
e
v
i
e
w
 
M
i
r
o
u
 
J
a
a
n
a
 
a
n
d
 
G
u
y
 
P
a
r
é
 
 
P
o
s
t
 
D
o
c
 
a
n
d
 
C
h
a
i
r
h
o
l
d
e
r
 
i
n
 
I
n
f
o
r
m
a
t
i
o
n
 
T
e
c
h
n
o
l
o
g
y
 
i
n
 
H
e
a
l
t
h
 
C
a
r
e
,
 
 
C
h
e
m
i
n
 
d
e
 
l
a
 
C
ô
t
e
-
S
t
e
-
C
a
t
h
e
r
i
n
e
,
 
M
o
n
t
r
e
a
l
 
Q
C
,
 
C
a
n
a
d
a
 
2006 A 
comprehensive 
literature 
review was 
conducted on 
Medline and 
Cochrane 
Library  The 
objective of the 
study is provide 
a systematic 
and 
comprehensive 
review of  all 
aspects of 
diabetes ‘home 
telemonitoring’ 
and its effect at 
the 
informational, 
clinical, 
behavioural, 
structural and 
economical 
level 
Close management of 
diabetic patients through 
telemonitoring showed 
significant reduction in 
HbA 1c and 
complications, good 
receptiveness by 
patients and patient 
empowerment and 
education. Yet, the 
magnitude of its effects 
remains debatable, 
especially with the 
variation in patients’ 
characteristics (e.g. 
background, ability for 
self-management, 
medical condition), 
samples selection and 
approach for treatment 
of control groups. 
Close management of diabetic patients 
through telemonitoring showed significant 
reduction in HbA 1c and complications, 
good receptiveness by patients and patient 
empowerment and education. Yet, the 
magnitude of its effects remains debatable, 
especially with the variation in patients’ 
characteristics (e.g. background, ability for 
self-management, medical condition), 
samples selection and approach for 
treatment of control groups 
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9.5 Scientific evidence on RMT for COPD 
The following table presents a summary of the scientific evidence found on the impact of 
RMT used for patients suffering of COPD, providing details on the type of study, the authors 
or sponsors of the study, the start and end date, the focus of the study e.g. cost/benefit 
analysis, clinical trial etc., the outcomes and a link to the website of the research organisation 
or to the study itself. 
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Table 25 – Scientific evidence on RMT for COPD 
Name Type Partners/ Authors Start & end 
date 
Focus Outcome  
Website 
Telemedicine / 
Telemonitoring in 
Respiratory 
Medicine & COPD 
- COPD and (Tele) 
Rehabilitation  
Review study 
/ Evidence 
Scottish Centre for 
Telemedicine 
TeleRespiratory_CO
PD 
15-Sep-08 Review of a 19 COPD 
telemonitoring trials or 
studies 
Summary of results for each study www.sct.scot.nhs.uk/document
s/TeleRespiratory_COPD.doc 
Home 
Telemonitoring for 
Respiratory 
Conditions: A 
Systematic 
Review  
Review Mirou Jaana and 
Guy Paré  Post Doc 
and Chairholder in 
Information 
Technology in 
Health Care, Chemin 
de la Côte-Ste-
Catherine, Montreal 
QC, Canada 
2009 A comprehensive 
literature review was 
conducted on Medline to 
provide a systematic 
review of home 
telemonitoring for 
respiratory conditionsand 
to present evidence on its 
effects in relation to data 
quality, patient medical 
condition, utilization of 
health services, feasibility 
and use, and economic 
viability. 
Home telemonitoring of 
respiratory conditions results in 
early identification of 
deteriorations in patient condition 
and symptom control. Positive 
patient attitude and receptiveness 
of this approach are promising. 
However, evidence on the 
magnitude of clinical and 
structural effects remains 
preliminary, with variations in 
study approaches and an absence 
of robust study designs and formal 
evaluations 
http://www.ncbi.nlm.nih.gov/pm
c/articles/PMC2244878/ 
Systematic 
Review of Home 
Telemonitoring for 
Chronic Diseases: 
The Evidence 
Base 
Review Guy Paré,  
Mirou Jaana,  
Claude Sicotte  
1990- 2006 A systematic review of the 
nature and magnitude of 
outcomes associated with 
telemonitoring chronic 
illnesses: including 
pulmonary conditions, 
diabetes,. 
Telemonitoring effects on clinical 
effectiveness outcomes (e.g., 
decrease in the emergency visits, 
hospital admissions, average 
hospital length of stay) are more 
consistent in pulmonary and 
cardiac studies than diabetes and 
hypertension. Lastly, economic 
viability of telemonitoring was 
observed in very few studies and, 
in most cases, no in-depth cost-
minimization analyses were 
performed 
http://www.ncbi.nlm.nih.gov/pub
med/17329725 
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Tele-assistance in 
chronic respiratory 
failure patients: a 
randomised 
clinical trial 
Randomised 
trail 
M. Vitacca,  
L. Bianchi,  
A. Guerra,  
C. Fracchia,  
A. Spanevello,  
B. Balbi and  
S. Scalvini 
2008 The aim of the present 
study was to primarily 
evaluate reduction in 
hospitalisations and, 
secondly, exacerbations, 
general practitioner (GP) 
calls and related cost-
effectiveness of tele-
assistance (TA) for these 
patients. A total of 240 
patients (101 with chronic 
obstructive pulmonary 
disease (COPD)) were 
randomised to two 
groups: an intervention 
group entered a 1-yr TA 
programme while controls 
received traditional care.  
In chronic respiratory failure 
patients on oxygen or home 
mechanical ventilation, a nurse-
centred tele-assistance prevents 
hospitalisations while it is cost-
effective. The chronic obstructive 
pulmonary disease group seems 
to have a greater advantage from 
tele-assistance. 
http://erj.ersjournals.com/cgi/co
ntent/abstract/33/2/411 
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9.6 Scientific Evidence on RMT for Multi-disease Conditions 
The following tables present a summary of the scientific evidence found on the impact of RMT used 
for patients with multiple chronic conditions, providing details on the type of study, the authors or 
sponsors of the study, the start and end date, the focus of the study e.g. cost/benefit analysis, clinical 
trial etc., the outcomes and a link to the website of the research organisation or to the study itself. 
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Table 26 – Scientific Evidence on RMT for Multi-disease Conditions 
Name Type Partners/ Authors Start 
& end 
date 
Focus Outcome  
Website 
Remote 
Monitoring 
Review 
S
t
u
d
y
/
R
e
v
i
e
w
,
 
D
i
a
b
e
t
e
s
,
 
H
e
a
r
t
,
 
C
O
P
D
 
D
r
 
M
a
r
g
a
r
e
t
 
O
’
B
r
i
e
n
,
 
G
P
 
C
l
i
n
i
c
a
l
 
A
d
v
i
s
e
r
,
 
E
C
C
H
,
 
N
o
r
t
h
e
r
n
 
I
r
e
l
a
n
d
 
Jun-
08 
Review to ascertain if the current 
evidence base supports the use of 
remote tele-monitoring in the 
management of diabetes mellitus, 
chronic heart failure and chronic 
obstructive pulmonary disease. 21 
systematic reviews summarised. 
Evidence strongest for use of home tele-monitoring in 
management of chronic disease, in particular 
monitoring of vital signs. Lack of studies of large size 
and the relatively short duration of a number of the 
interventions. To date insufficient economic appraisal of 
telemedicine interventions. RMT acceptable to patients 
and HC professionals, no adverse events, improved 
quality of life, reduced hospital admissions, reduction in 
mortality, empowerment of patients and altered patient 
attitudes towards their condition. 
 
Stratego 
Consortium 
C
o
n
f
e
r
e
n
c
e
 
r
e
p
o
r
t
 
D
i
a
n
e
 
W
h
i
t
e
h
o
u
s
e
 
a
n
d
 
S
a
l
v
a
t
o
r
e
 
V
i
r
t
u
o
s
o
 
 Conference aimed to highlight good 
practice and use cases in 
telemedicine in Europe, but also to 
identify the various, possible barriers 
to the broad deployment of 
telemedicine 
initiatives. Content includes: 
Background to telemedicine 
(including challenges, problems, and 
weaknesses): Definition(s); 
Telemedicine examples with a 
particular focus on tele-radiology; The 
organisational context; Legal, 
regulatory, and professional issues; 
Issues relating to professional 
conduct 
Examples of projects and pilots and country initiatives 
already known to us 
 
Implementati
on of Care 
Coordination
/Home 
Telehealth in 
US 
U
S
 
R
e
v
i
e
w
 
o
f
 
R
M
T
 
i
m
p
l
e
m
e
n
t
a
t
i
o
n
 
w
i
t
h
 
a
g
e
i
n
g
 
t
i
t
V
H
A
 
2008 
report 
on 
2002-
2007 
period 
Implementation of RMT for ageing 
patients for diabetes mellitus (DM), 
congestive heart failure (CHF), 
hypertension (HTN), posttraumatic 
stress disorder (PTSD), chronic 
obstructive pulmonary disease 
(COPD), and depression. 
Describes implementation process, issues encountered, 
how the HC was organised and assesses benefits. 
40000+ patients. Reports on benefits (reduced 
hospitals stays etc.). Also highlight important issues like 
educating the patient, need for clinical process re-
engineering etc. 
 
 185 
Name Type Partners/ Authors Start 
& end 
date 
Focus Outcome  
Website 
Virtually 
healthy: 
Chronic 
disease 
managemen
t in the 
home 
A
r
t
i
c
l
e
 
i
n
 
D
i
s
e
a
s
e
 
M
a
n
a
g
e
m
e
n
t
,
 
J
u
n
e
 
2
0
0
2
,
 
v
o
l
.
 
5
,
 
n
o
 
2
,
 
8
7
-
9
4
 
M
a
r
l
i
s
 
M
e
y
e
r
,
 
R
i
t
a
 
K
o
b
b
,
 
P
a
t
r
i
c
i
a
 
R
y
a
n
 
2000-
2002 
From April 2000 and over 2 years, 
five of eight clinical demonstration 
projects were funded within the 
Sunshine Networks of the Veterans 
Health Administration (VHA) to test 
disease management principles, the 
role of the care coordinator and the 
effective use of technology to 
maintain veterans in their homes, 
focusing on CDM (CHF, COPD, 
Diabetes and Hypertension and 
combinations). 791 out of 8.704 
veterans were enrolled (identified as 
high risk, high costs, high use 
patients). A control group of 772 
patients was set up to enable cross 
comparisons, with clinically similar 
but non-enrolled veterans. The 
motivation of the projects was to 
improve health status, increase 
program efficiency, and decrease 
resource utilization.  
Evaluation after the first year showed:  
- 40% reduction in emergency room visits 
- 63% reduction in hospital admissions 
- 60% reduction in hospital bed days of care, 64% 
reduction in VHA nursing home admission, and 88% 
reduction in nursing home bed days of care.  
Only clinic visits went up, but showed a sharp decline at 
the fourth quartile. In the control group most parameters 
went down as well (except for nurse home admission 
which showed a steep rise), but less sharply.   
All indicators measuring quality of life and functional 
ability improved as well. These were measured using 
the SV 36V questionnaire, a standardized, scientifically 
validated questionnaire, which is generally regarded as 
a reliable measure of quality of life and functional ability.
Significant improvements were recorded in Role 
Physical (p<0.003), Bodily Pain (p<0.000), Social 
Functioning (p<0.004), Role Emotional (p<0.000) and 
Mental Composite (p<0.011). 
 
Supporting 
Self Care a 
practical 
option 
U
K
 
r
e
v
i
e
w
 
r
e
p
o
r
t
 
U
K
 
D
e
p
a
r
t
m
e
n
t
 
o
f
 
H
e
a
l
t
h
 
 Review of Diagnostic, Monitoring and 
Assistive Tools, Devices, 
Technologies and Equipment to 
Support Self Care (includes list of 
devices) 
Best benefit to cost ratio for devices will result from 
deployment of the most appropriate solution for 
individual needs. Rather than 'technology-driven', all 
solutions must be 'needs-led'. Scope for improved 
health outcomes at modest investment (cheap devices, 
mobile technology). Devices that require central 
monitoring services entail more complexity and hidden 
costs to implement. Lack of inter-operability and 
standards across devices. Continuous monitoring 
devices appear promising, but further research needed 
to assess effectiveness. Research evidence for the 
effectiveness of self care devices is not yet available for 
all the various devices currently in use. Often small 
scale pilot research studies have been conducted. 
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Name Type Partners/ Authors Start 
& end 
date 
Focus Outcome  
Website 
Systematic 
Review: 
Impact of 
Health 
Information 
Technology 
on Quality, 
Efficiency, 
and Costs of 
Medical 
Care. 
L
i
t
e
r
a
t
u
r
e
 
r
e
v
i
e
w
 
C
h
a
u
d
h
r
y
 
B
,
 
W
a
n
g
 
J
,
 
W
u
 
S
,
 
M
a
g
l
i
o
n
e
 
M
,
 
M
o
j
i
c
a
 
W
,
 
R
o
t
h
 
E
,
 
M
o
r
t
o
n
 
S
C
,
 
S
h
e
k
e
l
l
e
 
P
G
 
2006 A systematically review evidence on 
the effect of health information 
technology on quality, efficiency, and 
costs of health care. 
Four benchmark institutions have demonstrated the 
efficacy of health information technologies in improving 
quality and efficiency. Whether and how other 
institutions can achieve similar benefits, and at what 
costs, are unclear. 
http://www.rand.
org/cgi-
bin/health/show
ab.cgi?key=200
6_114 
EU: eHealth 
is Worth it 
C
a
s
e
 
s
t
u
d
y
 
K
 
A
.
 
S
t
r
o
e
t
m
a
n
n
:
 
T
 
J
 
A
 
D
o
b
r
e
v
 
V
 
B
 
S
t
r
o
e
t
m
a
n
n
 
2006 A study shows across a wide range 
of eHealth applications to show 
evidence on the benefits of 
information and communication 
technology in routine healthcare 
settings 
The benefits range from improvements in quality and 
better access of all citizens to care, to avoidance of 
unnecessary cost to the public purse. 
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Name Type Partners/ Authors Start 
& end 
date 
Focus Outcome  
Website 
The socio-
economic 
impact of 
telehealth: a 
systematic 
review 
r
e
v
i
e
w
 
J
e
n
n
e
t
t
,
 
P
 
A
;
 
L
 
A
f
f
l
e
c
k
 
H
a
l
l
;
 
R
 
E
 
S
c
o
t
t
 
H
e
a
l
t
h
 
T
e
l
e
m
a
t
i
c
s
 
U
n
i
t
,
 
F
a
c
u
l
t
y
 
o
f
 
M
e
d
i
c
i
n
e
,
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
C
a
l
g
a
r
y
,
 
C
a
l
g
a
r
y
,
 
A
l
b
e
r
t
a
;
 
 
 
D
 
H
a
i
l
e
;
 
A
 
O
h
i
n
m
a
a
 
{
D
e
p
a
r
t
m
e
n
t
 
o
f
 
P
u
b
l
i
c
 
H
e
a
l
t
h
 
S
c
i
e
n
c
e
s
,
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
A
l
b
e
r
t
a
,
 
E
d
m
o
n
t
o
n
,
 
A
l
b
e
r
t
a
 
C
 
A
n
d
e
r
s
o
n
;
 
C
 
A
 
C
o
n
s
u
l
t
i
n
g
,
 
W
e
t
a
s
k
i
w
i
n
,
 
A
l
b
e
r
t
a
;
R
 
T
h
o
m
a
s
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
C
a
l
g
a
r
y
,
 
C
a
l
g
a
r
y
,
 
A
l
b
e
r
t
a
;
B
 
Y
o
u
n
g
,
 
M
c
G
i
l
l
 
U
n
i
v
e
r
s
i
t
y
,
 
M
o
n
t
r
e
a
l
,
 
Q
u
e
b
e
c
;
D
 
L
o
r
e
n
z
e
t
t
i
;
 
I
n
s
t
i
t
u
t
e
 
o
f
 
H
e
a
l
t
h
 
E
c
o
n
o
m
i
c
s
/
C
e
n
t
r
e
 
f
o
r
 
H
e
a
l
t
h
 
a
n
d
 
P
o
l
i
c
y
 
S
t
u
d
i
e
s
,
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
C
a
l
g
a
r
y
,
 
A
l
b
e
r
t
a
,
 
C
a
n
a
d
a
 
2003 Literature search on telehealth and 
socio economic indicators 
Telehealth studies till the year 2003 have not used 
socioeconomic indicators consistently. However, 
specific telehealth applications have been shown to 
offer significant socio-economic benefit, to patients and 
families, health-care providers and the health-care 
system. The main benefits identified were: increased 
access to health services, cost-effectiveness, enhanced 
educational opportunities, improved health outcomes, 
better quality of care, better quality of life and enhanced 
social support. 
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Name Type Partners/ Authors Start 
& end 
date 
Focus Outcome  
Website 
Telehomeca
re and 
Remote 
Monitoring: 
An 
Outcomes 
Overview 
U
S
 
R
e
v
i
e
w
 
-
 
A
u
t
h
o
r
s
:
 
M
a
x
 
E
.
 
S
t
a
c
h
u
r
a
 
e
t
 
a
l
A
d
V
a
M
e
d
 
 
-
 
C
o
m
m
i
s
s
i
o
n
e
d
 
b
y
 
A
d
V
a
M
e
d
 
-
 
A
d
v
a
n
c
e
d
 
M
e
d
i
c
a
l
 
T
e
c
h
n
o
l
o
g
y
 
A
s
s
o
c
i
a
t
i
o
n
 
2007 Focus on diabetes mellitus (DM), 
congestive heart failure (CHF), and 
chronic obstructive pulmonary 
disease (COPD). 
Review of outcomes in terms of :  
- Improvements in clinical care 
- Costs, cost benefits and avoidance 
- Potential for growth 
Includes three case studies 
The results of studies to date are promising and show 
clear value in remote monitoring and telehomecare. But 
they also point to technology, infrastructure, access and 
reimbursement issues that must be addressed for 
maximal care quality improvement and cost savings. 
These are multi-faceted issues that will require careful 
and coordinated evaluation by payors (Medicare, 
Medicaid and private insurers), government (federal, 
state and local), care providers (physicians and nurses, 
hospitals, home health agencies, and nursing facilities), 
and employers, as well as an assessment of technology 
needs (medical technology, infrastructure, and 
telecommunications). While most published studies are 
small, some are contradictory, and the need for large 
well-controlled trials remains, evidence supporting the 
value and the potential of telehomecare is clear and 
growing. 
 
Care 
Coordination
/Home 
Telehealth: 
the 
systematic 
implementati
on of health 
informatics, 
home 
telehealth, 
and disease 
managemen
t to support 
the care of 
veteran 
patients with 
chronic 
conditions. 
C
a
s
e
 
r
e
p
o
r
t
 
D
a
r
k
i
n
s
 
A
,
 
R
y
a
n
 
P
,
 
K
o
b
b
 
R
,
 
F
o
s
t
e
r
 
L
,
 
E
d
m
o
n
s
o
n
 
E
,
 
W
a
k
e
f
i
e
l
d
 
B
,
 
L
a
n
c
a
s
t
e
r
 
A
E
.
 
2003 
- 
2007 
Between July 2003 and December 
2007, the Veterans Health 
Administration (VHA) introduced a 
national home telehealth program, 
Care Coordination/Home Telehealth 
(CCHT). Its purpose was to 
coordinate the care of veteran 
patients with chronic conditions and 
avoid their unnecessary admission to 
long-term institutional care. 
Routine analysis of data obtained for quality and 
performance purposes from a cohort of 17,025 CCHT 
patients shows the benefits of a 25% reduction in 
numbers of bed days of care, 19% reduction in 
numbers of hospital admissions, and mean satisfaction 
score rating of 86% after enrolment into the program. 
The cost of CCHT is $1,600 per patient per annum, 
substantially less than other NIC programs and nursing 
home care. VHA’s experience is that an enterprise-wide 
home telehealth implementation is an appropriate and 
cost-effective way of managing chronic care patients in 
both urban and rural settings. 
http://www.lieber
tonline.com/doi/
abs/10.1089/tmj.
2008.0021 
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10 Annex V: Patent analysis 
10.1 Introduction 
Companies use patents to protect information they consider vital to their businesses. To get this 
protection they need to publish crucial information concerning the invention they have made, which is 
an interesting source for researchers who study innovation dynamics. Over the years patent statistics 
has developed as a field of research which enables the analysis of behaviour of companies, of 
emerging fields, and of developments over time. Although exploring patent statistics is full with 
methodological problems, it is generally accepted as a sensible approach to improve understanding of 
emerging and on-going technological developments on the basis of quantitative data. 
A patent analysis was carried out, aiming at uncovering dynamic patterns of innovation in the field of 
PHS/RMT. Standardised procedures to arrive at an overview of patents available in this specific 
domain were followed but did not produce reliable results. We therefore developed a method based on 
a less structured approach, in our case a query of free text keywords. We tried several queries and 
used the one which produced the best results for our purposes. The results reported in this section 
should only be considered as a first exploration of the field.  
10.2 Methodology 
Patent offices gather and make available data on individual patent applications, presenting the 
information in a systematic manner. Such data includes the names of the inventor, the company, the 
invention, earlier patents, and classifiers (used to organise patents in classes). One way to search 
patent databases is by using the classification criteria to check which patents are within a specific 
class, thus finding about developments within this specific class. Another approach is searching for all 
patents filed by specific companies, thus discovering developments about companies and their 
competitive edges. A third approach is using queries of keywords relating to the invention to study the 
development of a specific invention. Each approach should be precise (relevant patents should be 
found) and specific (no patents outside the scope should be found) which is a challenge. 
We opted for using the WIPO database and the PATSTAT databases, but the latter did not deliver any 
reliable results. We therefore concentrated on the patents filed at WIPO (60% of the European patents 
filed at EPO originate from WIPO). It should be noted however that many inventions do not get 
patented at all, and that registering with WIPO is costly, a potential deterrent for SMEs, which may 
opt for national patent procedures instead and may therefore be sub-represented in the WIPO results. 
We searched the WIPO database, via its Patentccope interface, with a number of keywords (e.g. 
chronic disease, telemedicine, remote monitoring, and telehomecare) in a kind of trial and error 
process, until we concluded that the best search string was: 
Table 27 – Search string for RMT-systems in WIPO database 
"remote patient monitoring" AND (COPD OR CHF OR diabetes OR "chronic heart failure") OR 
"remote monitoring" AND patient AND (COPD OR CHF OR diabetes OR "chronic heart failure") 
OR 
"home monitoring" AND (COPD OR CHF OR diabetes OR "chronic heart failure"). 
 
The results were a total of 357 patents, out of which 48 were not relevant (i.e. 13.4% "recall" rate). 
One unknown factor is the number of patents we have not found but which exists, thus making it 
impossible to define the degree of precision of our results. 
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10.3 Patent analysis – main findings 
The results delivered by Patent@Scope enabled the analysis of a number of trends and distributions. It 
also enabled a more qualitative analysis on the basis of the abstracts provided.  
10.3.1 Main trends 
Evolution over time 
Since 2000 the number of RMT patents filed yearly at WIPO exceeds 10, to reach 70 patents in 2008 
showing a steady increase, with the exception of the period 2004-2005 (which may be due to the 
internet bubble). There are many more patents dealing with technologies than with services.264 Since 
2005, the number of patents filed per year has grown considerably, which might indicate a rising 
interest in RMT, although this may be countered by the 2008-2009 economic and financial crisis.  
Geographical distribution 
The US lead in terms of numbers of patents filed over the years, with 80% of all patent applications, 
Europe representing only 15%, with UK and Germany leading (resp. 4% and 3% of worldwide 
patents). Europe is therefore apparently lagging behind in terms of high-value patents filed through 
WIPO since Europe.  
Distribution over firms 
The table below shows companies with more than 5 RMT patents: 
Table 28 – Distribution of application by firms (> 5 hits) 
First applicant/assignee International applications 
Medtronic, Inc 46 
Cardiac Pacemakers, Inc 18 
Dexcom, Inc 11 
Roche Diagnostics GmbH 10 
Health Hero Networks, Inc 9 
St. Jude Medical AB 6 
Medapps, Inc 6 
Cardiocom, LLC 6 
Source: WIPO-Patent@scope, 2009 
Three out of the above eight companies deal with cardiac devices (Medtronic, Cardiac Pacemakers, St 
Jude Medical) which appears to be a high value domain while there isno company dealing with 
devices monitoring vital signs (blood glucose meters, spirometers and even ECG monitors) in this list. 
The list shows that high value patents are part of high value, established markets (cardiac implants, 
biomedical diagnostics). Companies on the high value segment own about 30% of all patents, the 
remaining 70% being distributed over a myriad of firms with only one or a few patents. Our method 
shows some limitation though, as companies like Philips do not appear here while they do when 
searching "remote patient monitoring" only. 
Distribution over IPC keywords 
                                            
264  Also in services the patent itself usually relates to some kind of technological element, such as a software programme, an algorithm, 
a decision support system, or the development of educational content. 
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The WIPO search enables to check the keywords (IPC) most commonly used to describe inventions. 
The largest part of patents is covered by keywords representing "Diagnosis, surgery and 
identification", followed by "Electrical data processing", then "Vital Sign Analysis". Unfortunately 
this is too general to enable drawing any relevant conclusion on the type of invention. 
Distribution of patents over diseases 
Patents either relate to one specific disease (CHF, COPD or diabetes), at least two diseases (all 
combinations possible) or cover all three diseases. As shown in Figure 35, the majority of the patents 
are in the field of diabetes. COPD only accounts for a minor fraction of the patents found, while CHF 
is more or less on an equal footing with diabetes (almost half of all patents). 
Figure 35 – Distribution of patents over chronic diseases 
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Source: WIPO-Patent@scope, 2009 
10.3.2 Content analysis of the patents 
The main technology and service categories we defined for our 50+ company review (See Section 7) 
have been used here to analyse the content of patients, namely: 
- Technologies: Medical User Devices (MUD), Information and Communication Infrastructure (ICI), 
Health Related Software (HRS) and System Integration (SI)  
- Services: Monitoring Health Conditions (MHC), Clinical Intervention (CI), Guidance and Education 
(GE), and Clinical Information Services (CI). 
The figure below shows that 80% of all patents relate to technologies while 20% relate to services.  
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Figure 36 – Distribution of patents over services and technologies 
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Source: WIPO – Patent@Scope; processing: JRC-IPTS 2009) 
As may be clear from the above, patents we categorise under "service" usually have a technology 
component as well such as a software package. Since patents need to have a technological dimension, 
the number of patents that are fully service oriented will be (very) limited if not inexistent.   
Technologies 
Medical user devices (MUD) are the technology that evokes the most patents, while the information 
and communication infrastructure (ICI) and system integration (SI) are each responsible for slightly 
less than 20% of all patents. Inventions in medical user devices cover a broad array of activities, from 
implantable devices to sensors to dispensers. They cover all diseases studied and can be very limited 
(just a sensor measuring a vital sign) or encompassing (a full device including measuring equipment) 
in scale. The information and communication infrastructure covers inventions such as wireless 
processing systems and methods for medical device monitoring, or systems and methods for 
processing and transmittal of medical data. An example of an invention in systems integration is a 
remote health care diagnostic tool that includes the device, the measurement and the communication 
system. Health related software (HRS) still captures 15% of patents. An example of HRS patents is a 
web-based integrated information system for sharing patient medical information across an 
organisation.  
Services 
On the service side, patents in the field of Guidance and Education (GE) almost cover half of all 
service-oriented patents. The core of these patents is a software package, steering the interaction with 
the patient and storing medical data. An example of a patent in the domain of Monitoring Health 
Condition (MHC) is an invention dealing with monitoring physiological signs from a subject to 
determine the subject's susceptibility for a seizure. This is monitoring which requires some software 
package to make sense of the monitoring data. An example of a Clinical Intervention (CI) service is 
an application for an enhanced acoustic monitoring and alarm response, which sends an alarm on the 
basis of monitoring health parameters back via the Internet. Patent applications in the field of Clinical 
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Information Services (CIS) are almost absent. This is mainly due to the choice of keywords that 
focused on the remote monitoring part and not on the interconnection with back-end systems.  
One set of patent applications has been neglected in the figure Figure 36 above. Several patents 
covered inventions that were difficult to classify under each of the four technology categories (or the 
service categories). These inventions dealt mainly with bio-medical, bio-chemical and bio-
physiological processes, offering analytical tools to measure specific dimensions within these 
processes. They are disease-related rather than remote monitoring related which is why we have 
excluded them from the above figure. The number of inventions in this domain (which we may label 
"Vital Sign Analysis") lies between the numbers found for "Information and Communication 
Infrastructure" inventions and "medical user devices".  
 Evolution over time 
Figure 37 – Patent applications in RMT technology and RMT services 
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As could be expected, both figures show the same dip in 2001-2002 and 2003-2006. As to 
technologies, one can notice the growth of "medical user devices" and the decline of "systems 
integration" over time. Specialisation seems to have become more prominent in the later years. Focus 
on technological infrastructure (communication protocols and networks) for monitoring solutions is 
clearly visible in the years 2001-2003 (in combination with systems integration) but declining 
thereafter. This might indicate that technological issues for communication networks somehow have 
been settled and are no major area for further investigations. "Health related software" has 
experienced varying growth figures over the years with a steady increase over the last four years. It is 
however difficult to indicate a precise focus in HRS as the number of patent applications is limited. 
The descriptions of patent applications in HRS vary from image normalisation techniques to 
techniques to monitor progression of heart failure, to systems for remote patient monitoring 
communication and command execution and a portable programmer for providing patient status 
information.  
The picture of services-related patents is more difficult to interpret as the figures per category are very 
low (a few per year), as seen earlier. The most prominent category is "Guidance and Education" (GE), 
which deals with content issues offered through various media (e.g. questionnaires, educational 
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content). Except for one of the GE patent applications in 1998, all patents in this domain between 
1998 and 2000 are from a single company, Health Hero Networks, which developed a strong position 
through advanced questionnaire and feedback systems to remotely check the health condition of 
patients.265 
10.4 Limitations of our approach 
Our pilot study on patents brought to light a number of issues relating to the usefulness of the 
methodology and to insights patent analysis can deliver about innovation and market dynamics.  
10.4.1 Conclusions on content 
The search strategy used delivered a limited set of patents, which is inherent to the database used 
(WIPO) and companies strategy with patents. The WIPO is a relatively expensive route to patent. 
This may lead to an overestimation of high value patents and of large firms who are able and willing 
to pay the high costs. During workshops and interviews representatives of small firms indicated that 
they opt for national patent databases. 
A few companies own many patents, especially in the high-end RMT market segments, i.e. 
(implantable) cardiac devices and bio-diagnostics, but there is a long tail of companies with one or a 
few patents only. They cover all segments of the value chain.  
The number of RMT patents seems to have taken off over the past few years, as the number of patents 
per year quadrupled over the last four years. This may be due to low numbers in 2004-2005. It would 
be interesting to see if this trend will continue and at what pace. 
The US are clearly leading, both in terms of high-end companies (with many patents) and lower end 
companies (with fewer patents). Europe is lagging behind together with the rest of the world. 
As to content, most patents relate to technology and within technology to medical user devices. 
Health related software and patents on information and communication infrastructure are well placed 
as well. Service related patents are less visible with the notable exception of services on guidance and 
education. Furthermore, service-related patents have an IT component that is usually software based.  
10.4.2 Conclusions on the methodology 
The methodology followed is sensitive to the keywords used. Keywords were chosen based on limited 
insight in the field. Although we checked the query for robustness, the method is difficult to validate. 
It would be better to use an automated method based on text analysis, revealing specific keywords or 
to set up an expert panel to elicit a set of keywords to validate the field under research. 
The database used (Patent@Scope of WIPO) has its limitations as it does not offer a full overview of 
all patents which might relate to RMT/PHS since patents filed at national offices are not included. To 
get a proper picture of the contribution of SMEs to the knowledge base other sources should be used, 
although PATSTAT is not an appropriate one. Search in EPO and national patent offices data might 
offer an alternative. 
The content analysis that has been done manually has not been validated and the allocation of patents 
to the specific categories has been done on the basis of the information provided in patent abstracts. 
                                            
265  See http://is.jrc.ec.europa.eu/pages/TFS/documents/SIMPHS17AprilWorkshopsummaryfinalrev1.pdf 
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The categorisation we used is probably too fine-grained but it is consistent with the different 
components we identified in the PHS/RMT value chain. There may be suitable alternatives we did not 
explore.  
The same goes for the distinction between products and services. We found very few patents dealing 
with services, which is explained by the fact that all patents need to have a technological invention. 
The usefulness of the distinction between services and technologies is therefore questionable. 
10.4.3 Next steps 
Patent analysis is a useful tool to follow PHS/RMT growth and "discover" new, emerging fields. It 
can be used as one of the monitoring tools of the SIM as it enables the quantitative analysis of the 
growth in number of patents, of the distribution of patents per region, per company and per disease.  
The approach used in this pilot is just a first attempt. A more sophisticated approach, whose results 
can be validated more readily, is needed. Three possible strategies can be followed: 
- Start with a textual analysis on abstracts to reveal keywords and keyword combinations and 
extend it to other patents as well (e.g. EPO). Use the set of keywords to search for additional 
patents in PATSTAT and/or EPO database and/or a subset of national databases. Outsource the 
activities to an organisation that has the appropriate tools to tackle such databases. 
- Start with selecting a number of representative companies and search for their patents. Then 
perform the analysis as suggested above.  
- Repeat the approach of this pilot a year later on the WIPO database to check what has changed.  
10.5 Full description of the methodology used for the patent analysis 
Patent offices gather data on individual patent applications. They present this information in a 
systematic manner. Information on the inventor, the firm, and the invention itself is stored, as well as 
additional information such as the patents which preceded this invention and classifiers which 
organise the patents in specific classes. The information stored about patents may be used to search 
for patents that meet specific criteria. One approach is using the classification criteria to check which 
patents are within a specific class. This will reveal developments within this specific class. Another 
approach is searching for all patents of a number of specific firms. This might be used to study the 
development of firms and the competitive edge of these firms. A third approach is using queries of 
keywords relating to the invention to study the development of a specific invention.  
Each approach will have to obey two constraints: it should be precise, and it should be specific. 
´Precise´ means that all patents that are produced on the field under study will be found. ´Specific´ 
means that no patents are found which are outside the scope of the study. Meeting both criteria at the 
same time means that one has defined a search strategy that delivers only those patents that are within 
the scope of the search strategy. This is the basic challenge of each patent search strategy. It is the 
problem of 'precision' and 'recall'. One should strive to high precision, i.e. all patents that are within 
the scope of what one wants to study are indeed found. And one should simultaneously strive to low 
recall, i.e. only few patents that are outside the scope are found as well.  
In constructing our search strategy, we opted for a start through the user-friendly interface of WIPO 
(see http://www.wipo.int/pctdb/en/) which enables user guided searches on the basis of multiple 
entries (inventors, firms, IPC,266 abstract, title, description). This first stage was meant to be 
                                            
266  International Patent Classification, a structured (but not hierarchical) set of keywords used to delineate patents. See 
http://www.wipo.int/classifications/ipc/en/ for an overview and an in-depth presentation of the IPC. 
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exploratory only. The second stage was intended to using the experience of the first stage for 
performing a more intensive search in the PATSTAT database.267 We tried the second stage, but it 
showed that the PATSTAT database is not yet sufficiently well accessible to deliver reliable results. 
For one, it lacks a user-friendly interface. Search strings have to be created 'by hand'. This was not a 
problem, since we already had constructed a query that was initially tested in the WIPO database. For 
another, it only allows for searching in titles and abstracts. The full text of the patents (including the 
description of the invention) is not yet available for searching purposes. And thirdly, while WIPO 
returns results 'immediately' (i.e. within a few tens of seconds) the PATSTAT database needs 
considerable more time to process the requested data (up to several hours and even days). We tried a 
search on the basis of the query we produced for WIPO. This hardly delivered any results. Key words 
(such as 'remote patient monitoring') apparently are seldom used in titles or abstracts of patents.    
We tried to circumvent this problem by checking the IPC codes used in the patents we found in the 
first WIPO search. This might offer an alternative to be used for PATSTAT as well. This route 
showed however to be highly problematic. No set of IPC keywords realised any kind of high 
precision and low recall. Though many RMT patents fall in one specific category (the category of 
medical diagnostic tools: 'A61B') this category still is much too broad to have any significant meaning 
in identifying patents on Remote Patient Monitoring. Using much more detailed classifiers (such as 
'A61B 05/02' which relates to patents measuring pulse, heart rate, blood pressure or blood flow) did 
not alleviate the problem. Combinations of IPC keywords (such as 'A61B 05/02' with 'G06F' – 
electrical digital data processing, see also Table 2) neither did produce better results. The keywords 
showed to be disjoint; no patents were categorised with both classifiers. The conclusion to be drawn 
with respect to the usefulness of IPC in identifying patents in the domain of Remote Patient 
Monitoring unfortunately thus must be that IPC does not offer the proper classification structure to do 
so.268 The overall conclusion at this stage was that the PATSTAT database was problematic to use at 
this stage. 
To continue the pilot study we concentrated on the patents that are filed at the WIPO. This implied we 
would focus on a subset of all patents, namely those that are filed at WIPO. Firms have different 
options to file a patent. They can use national patent offices, regional ones or the WIPO. Many 
inventions will not be patented at all (given the figures known, this will probably be at least 50%). 
The majority of European patents (over 60% of EPO patents269) originate however from WIPO. This 
makes WIPO an interesting starting point. For firms, WIPO has the advantage of introducing a longer 
lead time before publishing information about the patent; it has the disadvantage that it is more costly. 
The last aspect may rule out patents by SMEs that are not able to cover the costs associated to the 
WIPO procedure. They most probably will start with protecting their intellectual property through 
national patent offices (or regional ones, which in case of European SMEs is the EPO270). Patent 
applications in WIPO will thus be patents of firms who presume to have an economically 
advantageous invention. For getting a view on the innovation dynamics within a specific sector 
focusing on this subset, this limitation appears to be reasonable.   
                                            
267  PATSTAT is a database which collects information of all distinct databases of the different European Patent Offices. It is however, 
yet under construction and not fully operational.  
268  We tested several subsets of IPC keywords. No set delivered any reliable data, neither in terms of precision, nor in terms of recall. 
The process of attributing classifiers to patents apparently is not done with the aim of retrieval in mind. 
269  OECD, 2009. EPO is the European Patent Office; EPO enables firms to file a patent directly at European level and offers the 
opportunity to decide later in which specific European countries the patent will be registered. 
270  During the workshops we have held we have asked the participants what patent strategies they used. These were very wide-ranging 
and interesting. But all in all, whenever small firms file a patent, they will do so at the national office and use a description which is 
sufficiently large to cover a wide array of possible applications.  
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From a pragmatic perspective WIPO offers an interesting starting point as well. As indicted above, it 
offers its database for free through Internet and has produced a user friendly interface which enables 
searching on various dimensions at once (see extract in Figure 38). The various entries present the 
various information categories that are collected of each patent.  
Figure 38 – User interface for patent search at Patentscope 
 
Source: http://www.wipo.int/pctdb/en/ 
Inserting a specific search string delivers an overview with all patents attached. Next to yielding basic 
information over each patent (title, WIPO number; date of filing, firm filing and full abstract), the 
WIPO patent service Patent@Scope provides four different forms of analysis: 
1. It delivers a breakdown of patents relative to the keywords used. 
2. It delivers a breakdown over the years. 
3. It delivers a breakdown over companies involved. 
4. It delivers a breakdown per category of the IPC terms involved. 
The development of the query to be used was done in a heuristic manner, by trying and improving, 
meanwhile checking for robustness of results. We did this for a series of keywords, ending up with 
the following combination of keywords: 
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Table 29 – Search string for RMT-systems in WIPO database 
"Remote patient monitoring" AND (COPD OR CHF OR diabetes OR "chronic heart failure") OR 
"remote monitoring" AND patient AND (COPD OR CHF OR diabetes OR "chronic heart failure") 
OR 
"home monitoring" AND (COPD OR CHF OR diabetes OR "chronic heart failure"). 
The keywords on chronic diseases restricted the patents in the subclasses found through remote 
patient monitoring and home monitoring to those patents which indeed dealt with RMT for chronic 
diseases. Other terms that are frequently used in literature, such as 'telehomecare' and 'chronic disease' 
showed to deliver few additional – if any – patents on top of those found by the query indicated 
above.  
This query delivered a total of 357 patents of which 48 could not be classified as being relevant for 
RMT systems (recall of 13.4%). Regarding the degree of precision we have realised, unfortunately 
this is impossible to determine by this method. We know what we have found, but we do not know 
what we have not found. We optimised the query heuristically, but patents that do not have a specific 
combination of keywords in one of their fields will not be found.271 We relied on the fact that by 
adding new keywords to the search string (within the limits posed by the WIPO interface, i.e. no more 
than ten different entries) the sample did not grow, implying that we already had included the most 
relevant keywords. 
 
                                            
271  As indicated during the workshops, firms have different strategies in patenting. One of them is to use an open formulation so that 
the patent can be used in several circumstances. 
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